<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C341426C-6B7F-40C3-BA31-A7169D241484"><gtr:id>C341426C-6B7F-40C3-BA31-A7169D241484</gtr:id><gtr:name>Cardiovascular Research Foundation of Southern California</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/15E25A93-2757-436A-AEDC-23749AFD09FA"><gtr:id>15E25A93-2757-436A-AEDC-23749AFD09FA</gtr:id><gtr:name>Oshawa Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/184FBFFE-8C68-4375-90C9-752F090AFE82"><gtr:id>184FBFFE-8C68-4375-90C9-752F090AFE82</gtr:id><gtr:name>Academic Clinical Hospital, Wroclaw</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1B2084F-4E44-45FB-8C5B-9A2A14B28E3D"><gtr:id>A1B2084F-4E44-45FB-8C5B-9A2A14B28E3D</gtr:id><gtr:name>Nordsj?llands Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/428B1B7D-9F67-498E-9162-8D72AE08A98A"><gtr:id>428B1B7D-9F67-498E-9162-8D72AE08A98A</gtr:id><gtr:name>Eastern Suffolk Cardiology (ESC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/429724C1-8CD5-48CE-9539-C80FEBC262A0"><gtr:id>429724C1-8CD5-48CE-9539-C80FEBC262A0</gtr:id><gtr:name>Hospital Umum Sarawak</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A601437-2EFC-42F2-9E23-3B4D475CF80D"><gtr:id>7A601437-2EFC-42F2-9E23-3B4D475CF80D</gtr:id><gtr:name>Gloucestershire Royal Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0B428F6C-54DE-4BB6-B163-6FA0BD5B2368"><gtr:id>0B428F6C-54DE-4BB6-B163-6FA0BD5B2368</gtr:id><gtr:name>Hospital Kuala Terengganu</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19AE95AA-578C-40C4-907B-A3274DFFDAEB"><gtr:id>19AE95AA-578C-40C4-907B-A3274DFFDAEB</gtr:id><gtr:name>St Mark's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36E11EE6-DAC1-4D73-BCDE-158C1EF0B6C5"><gtr:id>36E11EE6-DAC1-4D73-BCDE-158C1EF0B6C5</gtr:id><gtr:name>Xuzhou Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/234BEB95-6825-49BA-ACB4-7871147654FA"><gtr:id>234BEB95-6825-49BA-ACB4-7871147654FA</gtr:id><gtr:name>UNLISTED</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/493210C7-4207-4BEA-B889-6BB88179AA95"><gtr:id>493210C7-4207-4BEA-B889-6BB88179AA95</gtr:id><gtr:name>KfH Nierenzentrum Coburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A941DC9-348C-4F6B-A556-8144215A3517"><gtr:id>0A941DC9-348C-4F6B-A556-8144215A3517</gtr:id><gtr:name>Tallahassee Research Institute Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7780E7DB-CA07-4C70-9022-F6ACAD15B202"><gtr:id>7780E7DB-CA07-4C70-9022-F6ACAD15B202</gtr:id><gtr:name>Sahlgrenska University Hospital</gtr:name><gtr:address><gtr:line1>Sahlgrenska Universitetssjukhuset</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4F5629D4-145B-4F79-8D78-D7195EE2194A"><gtr:id>4F5629D4-145B-4F79-8D78-D7195EE2194A</gtr:id><gtr:name>Sydney Adventist Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3F38B91-A101-4885-AEF9-6BF7AE89A119"><gtr:id>C3F38B91-A101-4885-AEF9-6BF7AE89A119</gtr:id><gtr:name>Newmarket Cardiology Research Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/861ACCDE-0C5F-4548-A744-3332BC51C690"><gtr:id>861ACCDE-0C5F-4548-A744-3332BC51C690</gtr:id><gtr:name>PHV-Dialysezentrum Hildesheim</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78CA1442-F154-40E7-964B-12FE667ADBE0"><gtr:id>78CA1442-F154-40E7-964B-12FE667ADBE0</gtr:id><gtr:name>Hvidovre Hospital</gtr:name><gtr:address><gtr:line1>Hvidovre Hospital</gtr:line1><gtr:line2>Kettegard Alle 30</gtr:line2><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3BDF7A0F-6392-4C06-B9E2-DB17082FFDFB"><gtr:id>3BDF7A0F-6392-4C06-B9E2-DB17082FFDFB</gtr:id><gtr:name>Charite Campus Virchow-Klinikum</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/51DBAC33-45DC-4304-9ACF-DDA2EB4B8482"><gtr:id>51DBAC33-45DC-4304-9ACF-DDA2EB4B8482</gtr:id><gtr:name>Cardiology Associates of Bellin Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/81897883-DBCF-400F-9BD9-6F1431971F60"><gtr:id>81897883-DBCF-400F-9BD9-6F1431971F60</gtr:id><gtr:name>Xuzhou No.1 People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FD8C7CE-7881-4D70-82C8-51E52071441B"><gtr:id>9FD8C7CE-7881-4D70-82C8-51E52071441B</gtr:id><gtr:name>Queen Margaret Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/73466115-4CD0-4CBE-B90D-28B8273E9FCC"><gtr:id>73466115-4CD0-4CBE-B90D-28B8273E9FCC</gtr:id><gtr:name>Strakonice Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D7A1300-F3AB-4A93-92E3-8EAD59F57EBF"><gtr:id>8D7A1300-F3AB-4A93-92E3-8EAD59F57EBF</gtr:id><gtr:name>Queen's University Canada</gtr:name><gtr:address><gtr:line1>99 University Avenue</gtr:line1><gtr:postCode>K7L 3N6</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9F3F5F5-C649-4720-933F-A3B567DEC3C1"><gtr:id>B9F3F5F5-C649-4720-933F-A3B567DEC3C1</gtr:id><gtr:name>Inner Mongolia Electrical Power Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BBA4B6D4-2D92-486A-9BC4-F93F0C462C0F"><gtr:id>BBA4B6D4-2D92-486A-9BC4-F93F0C462C0F</gtr:id><gtr:name>Qingdao Municipal Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E2587143-F6DB-4C96-981F-254B4BEED2C9"><gtr:id>E2587143-F6DB-4C96-981F-254B4BEED2C9</gtr:id><gtr:name>Oskarshamns Sjukhus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E62586E-7DE8-46E6-B59A-07EFD834F600"><gtr:id>4E62586E-7DE8-46E6-B59A-07EFD834F600</gtr:id><gtr:name>Saint Martin Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B769156F-CDD4-47AE-9115-AEA20000B692"><gtr:id>B769156F-CDD4-47AE-9115-AEA20000B692</gtr:id><gtr:name>Huddersfield Royal Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23CDF2CB-26A6-4301-9CD7-083C046041DA"><gtr:id>23CDF2CB-26A6-4301-9CD7-083C046041DA</gtr:id><gtr:name>Grosshadern Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8CA6AF58-E9E2-4F5A-81B8-D97AC4638AD8"><gtr:id>8CA6AF58-E9E2-4F5A-81B8-D97AC4638AD8</gtr:id><gtr:name>Carient Heart and Vascular</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/62FDAC6F-3C5B-4F15-91A8-8BA72D02E149"><gtr:id>62FDAC6F-3C5B-4F15-91A8-8BA72D02E149</gtr:id><gtr:name>County Hospital, Stafford</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A8E1777-C962-47BC-8187-36ECBD3BB367"><gtr:id>4A8E1777-C962-47BC-8187-36ECBD3BB367</gtr:id><gtr:name>Francesco Ferrari Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/08631715-C842-4B84-834E-9FB33307A34D"><gtr:id>08631715-C842-4B84-834E-9FB33307A34D</gtr:id><gtr:name>Norra ?lvsborgs L?nssjukhus, Trollh?ttan</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/69A8FD70-D16D-44F5-A887-6FCB239928C9"><gtr:id>69A8FD70-D16D-44F5-A887-6FCB239928C9</gtr:id><gtr:name>Rhode Island Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5FEA3988-CC47-43A0-82AB-48EBD2208B97"><gtr:id>5FEA3988-CC47-43A0-82AB-48EBD2208B97</gtr:id><gtr:name>Gotham Cardiovascular Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BEB6090A-3F57-441D-8D5A-794933DDC910"><gtr:id>BEB6090A-3F57-441D-8D5A-794933DDC910</gtr:id><gtr:name>Gentofte Sygehus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F1B962EA-3976-46C4-B486-A2AA3F1D4D8D"><gtr:id>F1B962EA-3976-46C4-B486-A2AA3F1D4D8D</gtr:id><gtr:name>Internistische Praxisklinik Kempten</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1DFD7952-2BAA-414D-AA15-F46D43D4EB55"><gtr:id>1DFD7952-2BAA-414D-AA15-F46D43D4EB55</gtr:id><gtr:name>Martin Luther University</gtr:name><gtr:address><gtr:line1>Universit?tsplatz 11</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E7F92D8-7E39-4756-AF1F-9D507C1F0098"><gtr:id>4E7F92D8-7E39-4756-AF1F-9D507C1F0098</gtr:id><gtr:name>Herning Regional Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9AB04997-6718-42F7-BA19-0AE17BBA50F1"><gtr:id>9AB04997-6718-42F7-BA19-0AE17BBA50F1</gtr:id><gtr:name>Blekinge Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80ABD8F4-FC22-47D8-BAFE-6F8D1114D2CC"><gtr:id>80ABD8F4-FC22-47D8-BAFE-6F8D1114D2CC</gtr:id><gtr:name>West Middlesex University Hospital</gtr:name><gtr:address><gtr:line1>University of Middlesex</gtr:line1><gtr:line2>Twickenham Road</gtr:line2><gtr:postCode>TW7 6AF</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C63F917E-007D-4CCB-995C-29711A966551"><gtr:id>C63F917E-007D-4CCB-995C-29711A966551</gtr:id><gtr:name>Second Affiliated Hospital of Dalian Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0EB1D5E7-E11B-4097-8AE4-7B2A41174360"><gtr:id>0EB1D5E7-E11B-4097-8AE4-7B2A41174360</gtr:id><gtr:name>Dialysepraxis Seehausen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E210CF35-6FAB-4850-90AE-9F74E7AA02AC"><gtr:id>E210CF35-6FAB-4850-90AE-9F74E7AA02AC</gtr:id><gtr:name>Royal Berkshire Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6DDF29AE-71F3-4D4B-9397-2D5E925CF93D"><gtr:id>6DDF29AE-71F3-4D4B-9397-2D5E925CF93D</gtr:id><gtr:name>Baogang Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F8EFCD07-7E2C-4F75-9E17-02C1D6A05DF4"><gtr:id>F8EFCD07-7E2C-4F75-9E17-02C1D6A05DF4</gtr:id><gtr:name>Gubbio - Ospedale Gubbio Gualdo Tadino</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8EE0E790-5A03-483D-9513-C7A090219006"><gtr:id>8EE0E790-5A03-483D-9513-C7A090219006</gtr:id><gtr:name>Vestfold Hjertesenter AS</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2593B548-FB87-4E1D-854E-2723C93D7921"><gtr:id>2593B548-FB87-4E1D-854E-2723C93D7921</gtr:id><gtr:name>Buffalo Cardiology and Pulmonary Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90586AE8-B1B4-4D85-B7CC-B9130F248E5C"><gtr:id>90586AE8-B1B4-4D85-B7CC-B9130F248E5C</gtr:id><gtr:name>University of Nebraska-Lincoln</gtr:name><gtr:address><gtr:line1>University of Nebraska-Lincoln</gtr:line1><gtr:line4>Lincoln</gtr:line4><gtr:line5>Nebraska</gtr:line5><gtr:postCode>68588-0340</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61346E56-180E-481C-B5F9-E022D99A6627"><gtr:id>61346E56-180E-481C-B5F9-E022D99A6627</gtr:id><gtr:name>Gemeinschaftspraxis Dr. Haggenmiller und Dr. Jeserich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/924D623F-7DCE-49AA-AF73-DB079B2FDE0E"><gtr:id>924D623F-7DCE-49AA-AF73-DB079B2FDE0E</gtr:id><gtr:name>Ocala Research Institute Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/701E3F4D-96E2-4A83-81E6-9605FDE69B25"><gtr:id>701E3F4D-96E2-4A83-81E6-9605FDE69B25</gtr:id><gtr:name>University Hospital of Erlangen</gtr:name><gtr:address><gtr:line1>Schwabachanlage 6</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BA04C796-8B9C-4FB5-BFE8-8B441176AC70"><gtr:id>BA04C796-8B9C-4FB5-BFE8-8B441176AC70</gtr:id><gtr:name>Oulu University Hospital</gtr:name><gtr:address><gtr:line1>Oulu University Hospital and University</gtr:line1><gtr:line2>PO Box 23</gtr:line2><gtr:postCode>90029 OYS</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECFCCC8C-325C-450F-82A7-F7B615FA1FAA"><gtr:id>ECFCCC8C-325C-450F-82A7-F7B615FA1FAA</gtr:id><gtr:name>Charlotte Heart Group Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/356FD650-5A2E-4C7B-A687-1BDEFF85C2FD"><gtr:id>356FD650-5A2E-4C7B-A687-1BDEFF85C2FD</gtr:id><gtr:name>National Clinical Research, Richmond</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A335403-97CB-467D-8557-1D6574E7270D"><gtr:id>3A335403-97CB-467D-8557-1D6574E7270D</gtr:id><gtr:name>Fu Wai Hospital</gtr:name><gtr:address><gtr:line1>167 Beilishi Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63D5DC2E-86DA-494B-AAE3-CA630ED82427"><gtr:id>63D5DC2E-86DA-494B-AAE3-CA630ED82427</gtr:id><gtr:name>MultiCare Health System</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECD366A1-8F9A-43CA-B58D-E5CDB32B1725"><gtr:id>ECD366A1-8F9A-43CA-B58D-E5CDB32B1725</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Hope Hospital</gtr:line1><gtr:line2>Stott Lane</gtr:line2><gtr:line4>Salford</gtr:line4><gtr:postCode>M6 8HD</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11BA1C71-9597-40ED-A8A0-615CE5C4E243"><gtr:id>11BA1C71-9597-40ED-A8A0-615CE5C4E243</gtr:id><gtr:name>Westmead Hospital</gtr:name><gtr:address><gtr:line1>Westmead Hospital</gtr:line1><gtr:line2>Cnr Hawkesbury and Darcy Roads</gtr:line2><gtr:postCode>NSW 2145</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F0DE12EC-900B-4C67-BB76-67A5C13B8ADC"><gtr:id>F0DE12EC-900B-4C67-BB76-67A5C13B8ADC</gtr:id><gtr:name>Frenchay Hospital</gtr:name><gtr:address><gtr:line1>Frenchay Hospital</gtr:line1><gtr:line2>Frenchay Park Road</gtr:line2><gtr:line3>Frenchay</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:postCode>BS16 1LE</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CC9E0DD3-10E2-4892-9974-F5952DB8AF8B"><gtr:id>CC9E0DD3-10E2-4892-9974-F5952DB8AF8B</gtr:id><gtr:name>Third Xiangya Hospital of Central South University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99883644-5867-461D-9568-962C7596135D"><gtr:id>99883644-5867-461D-9568-962C7596135D</gtr:id><gtr:name>KfH Nierenzentrum Bamberg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F213414-B66E-454F-9F35-596138E443BD"><gtr:id>5F213414-B66E-454F-9F35-596138E443BD</gtr:id><gtr:name>The People's Hospital Of Liaoning Province</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8FE6FBD6-F011-47BA-90EE-39494C496CB3"><gtr:id>8FE6FBD6-F011-47BA-90EE-39494C496CB3</gtr:id><gtr:name>Southwest University</gtr:name><gtr:address><gtr:line1>2 Road Tiansheng</gtr:line1><gtr:postCode>400715</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/132225E8-29CD-4330-8185-C1A2A3699111"><gtr:id>132225E8-29CD-4330-8185-C1A2A3699111</gtr:id><gtr:name>Raigmore Hospital</gtr:name><gtr:address><gtr:line1>Old Perth Road</gtr:line1><gtr:postCode>IV2 3UJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/14BF88C8-470C-4093-B258-6BDF91FA5614"><gtr:id>14BF88C8-470C-4093-B258-6BDF91FA5614</gtr:id><gtr:name>Viborg Regional Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A3632DE8-BAC1-432B-B6AE-6D0AC367C94B"><gtr:id>A3632DE8-BAC1-432B-B6AE-6D0AC367C94B</gtr:id><gtr:name>Halmstads Sjukhus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/098DBCCE-4144-4026-9B7E-6A5EE41CF563"><gtr:id>098DBCCE-4144-4026-9B7E-6A5EE41CF563</gtr:id><gtr:name>Northampton General Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Cliftonville</gtr:line1><gtr:postCode>NN1 5BD</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/62C09B8D-45DC-4EE0-93D7-03764D8D098B"><gtr:id>62C09B8D-45DC-4EE0-93D7-03764D8D098B</gtr:id><gtr:name>Gentofte Hospital 2</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8DFF6A88-08FC-405F-9C16-08057322BD26"><gtr:id>8DFF6A88-08FC-405F-9C16-08057322BD26</gtr:id><gtr:name>Zhengzhou Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30A555B-E689-4D06-8E68-3358E55788BE"><gtr:id>E30A555B-E689-4D06-8E68-3358E55788BE</gtr:id><gtr:name>Maharaj Nakorn Chiang Mai Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37099067-27C9-43AA-8AFD-84FF45326287"><gtr:id>37099067-27C9-43AA-8AFD-84FF45326287</gtr:id><gtr:name>Hjerteklinikken i Harstad AS, Norway</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3350DC58-5D48-4A46-86F2-4D31450BA798"><gtr:id>3350DC58-5D48-4A46-86F2-4D31450BA798</gtr:id><gtr:name>Harlem Hospital Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/92F81743-12CA-4C06-9CDF-5AB4B09B6F38"><gtr:id>92F81743-12CA-4C06-9CDF-5AB4B09B6F38</gtr:id><gtr:name>Sir Charles Gairdner Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/69D8A011-CBF3-4EB5-8ECE-63B5E70F6416"><gtr:id>69D8A011-CBF3-4EB5-8ECE-63B5E70F6416</gtr:id><gtr:name>Hopital Maisonneuve-Rosemont</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7C2010AB-D714-4749-BBF3-59C9C137056E"><gtr:id>7C2010AB-D714-4749-BBF3-59C9C137056E</gtr:id><gtr:name>Avera Research Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9CC28215-42C0-4D9B-A6AB-3E26FCAF5951"><gtr:id>9CC28215-42C0-4D9B-A6AB-3E26FCAF5951</gtr:id><gtr:name>Hjarthuset AB, Varberg, Sweden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD6EF798-1631-4DB7-AD11-DD9BD00568B1"><gtr:id>DD6EF798-1631-4DB7-AD11-DD9BD00568B1</gtr:id><gtr:name>Hospital del Mar</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/662BF024-62D0-4EA2-B0EA-9A6EB07C704B"><gtr:id>662BF024-62D0-4EA2-B0EA-9A6EB07C704B</gtr:id><gtr:name>Memorial Hospital, Darlington</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1474FDAB-9358-4F6C-BA8F-A1D1F01B4617"><gtr:id>1474FDAB-9358-4F6C-BA8F-A1D1F01B4617</gtr:id><gtr:name>Klinikum Coburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E26C4939-F3A1-4655-A5E0-550A46380128"><gtr:id>E26C4939-F3A1-4655-A5E0-550A46380128</gtr:id><gtr:name>Klinikum Frankfurt H?chst</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D0580610-2CED-4B40-98FA-EC2311C94F96"><gtr:id>D0580610-2CED-4B40-98FA-EC2311C94F96</gtr:id><gtr:name>Shenyang Fourth People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1388E354-AFFA-4C1C-BC1F-2B09B644BA28"><gtr:id>1388E354-AFFA-4C1C-BC1F-2B09B644BA28</gtr:id><gtr:name>Ospedali Riuniti</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B81D5AE-90EB-42E6-855F-A0F582DA5820"><gtr:id>1B81D5AE-90EB-42E6-855F-A0F582DA5820</gtr:id><gtr:name>Royal North Shore Hospital</gtr:name><gtr:address><gtr:line1>St Lenards</gtr:line1><gtr:postCode>2065</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A6F1C95E-7B55-4CE1-8FA3-35E3267C5473"><gtr:id>A6F1C95E-7B55-4CE1-8FA3-35E3267C5473</gtr:id><gtr:name>InterMed</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30EB6540-762D-4FCA-8243-E7BE23908390"><gtr:id>30EB6540-762D-4FCA-8243-E7BE23908390</gtr:id><gtr:name>Nepean Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29"><gtr:id>7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29</gtr:id><gtr:name>Royal Preston Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BCD054BE-CBB2-4E2A-BF44-28547B2E9891"><gtr:id>BCD054BE-CBB2-4E2A-BF44-28547B2E9891</gtr:id><gtr:name>Novant Health Heart and Vascular Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/303E2392-4064-48A4-99F4-4ADB9D75C377"><gtr:id>303E2392-4064-48A4-99F4-4ADB9D75C377</gtr:id><gtr:name>St George's Hospital</gtr:name><gtr:address><gtr:line1>Blackshaw Road</gtr:line1><gtr:line2>Tooting</gtr:line2><gtr:postCode>SW17 0QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F835191-AA04-4F96-8432-277EFB3D9475"><gtr:id>1F835191-AA04-4F96-8432-277EFB3D9475</gtr:id><gtr:name>NYU Hudson Valley Cardiology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/468B44E5-2D7A-46BE-907F-426A83CDCB9C"><gtr:id>468B44E5-2D7A-46BE-907F-426A83CDCB9C</gtr:id><gtr:name>Ninewells Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CC884DBE-E63D-416D-8328-48CB16276834"><gtr:id>CC884DBE-E63D-416D-8328-48CB16276834</gtr:id><gtr:name>Manchester Royal Infirmary</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A040EC9D-77F3-4B52-8379-7621F3632C7E"><gtr:id>A040EC9D-77F3-4B52-8379-7621F3632C7E</gtr:id><gtr:name>G&amp;G Research Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F8E5752-68D3-477B-9E86-D7C9968C5560"><gtr:id>6F8E5752-68D3-477B-9E86-D7C9968C5560</gtr:id><gtr:name>North Ohio Research Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EF372E2-3083-4984-A0FA-AF78EB0C7E64"><gtr:id>9EF372E2-3083-4984-A0FA-AF78EB0C7E64</gtr:id><gtr:name>St. Josefs Hospital Cloppenburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CBBBC327-11B9-4689-A4F7-762CCB65DA26"><gtr:id>CBBBC327-11B9-4689-A4F7-762CCB65DA26</gtr:id><gtr:name>Discovery Clinical Services Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2B4890EC-5704-4F99-AE13-CC1371378CBB"><gtr:id>2B4890EC-5704-4F99-AE13-CC1371378CBB</gtr:id><gtr:name>Copenhagen University Hospital</gtr:name><gtr:address><gtr:line1>Kettegaard Alle 30</gtr:line1><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A643A122-531B-44C9-BE5F-7408FD89C354"><gtr:id>A643A122-531B-44C9-BE5F-7408FD89C354</gtr:id><gtr:name>North Karelia Project Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/79D90120-8141-469E-83F6-46828ABB0C89"><gtr:id>79D90120-8141-469E-83F6-46828ABB0C89</gtr:id><gtr:name>Zhuzhou No.1 Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77B70E31-12F7-45F4-B979-2F9951F0A344"><gtr:id>77B70E31-12F7-45F4-B979-2F9951F0A344</gtr:id><gtr:name>Affiliated Hospital of Xuzhou Medical College</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A6A4BD71-2EF8-4D38-80D0-0E5F9378688A"><gtr:id>A6A4BD71-2EF8-4D38-80D0-0E5F9378688A</gtr:id><gtr:name>Ministry of Justice (Brazil)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DA279075-4AF6-4948-8034-C98867EE3B27"><gtr:id>DA279075-4AF6-4948-8034-C98867EE3B27</gtr:id><gtr:name>H?pital du Sacr?-Coeur de Montr?al</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F94A5B13-041B-41FC-A2C4-F8ECF0A2F373"><gtr:id>F94A5B13-041B-41FC-A2C4-F8ECF0A2F373</gtr:id><gtr:name>Royal United Hospital NHS</gtr:name><gtr:address><gtr:line1>Royal United Hospital</gtr:line1><gtr:line2>Combe Park</gtr:line2><gtr:postCode>BA1 3NG</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/500AD7E2-35EF-4C02-AF6F-719636D6ADFD"><gtr:id>500AD7E2-35EF-4C02-AF6F-719636D6ADFD</gtr:id><gtr:name>Fourth Affiliated Hospital Of China Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6D82075A-731A-4ACD-994A-7C070DBD5FD0"><gtr:id>6D82075A-731A-4ACD-994A-7C070DBD5FD0</gtr:id><gtr:name>Hillingdon Hospital, Uxbridge</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4688C4BE-4DA7-44F6-B33C-8B701BCFEE33"><gtr:id>4688C4BE-4DA7-44F6-B33C-8B701BCFEE33</gtr:id><gtr:name>Heritage Medical Research Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1179BA2-D96B-48F9-8DEA-35D0E9F7427B"><gtr:id>A1179BA2-D96B-48F9-8DEA-35D0E9F7427B</gtr:id><gtr:name>Satakunta Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AF29214D-A1C5-45E9-81A8-831E2A50ECA0"><gtr:id>AF29214D-A1C5-45E9-81A8-831E2A50ECA0</gtr:id><gtr:name>Jacksonville Centre for Clinical Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4489F2C4-061B-49A9-9E72-9ACC7ECCA2AF"><gtr:id>4489F2C4-061B-49A9-9E72-9ACC7ECCA2AF</gtr:id><gtr:name>Derriford Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE2E996-FB8F-4404-B8AD-8380898F8850"><gtr:id>5EE2E996-FB8F-4404-B8AD-8380898F8850</gtr:id><gtr:name>Sint Lucas Andreas Ziekenhuis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8AC941F7-8CF0-43F9-88AA-278632E6A962"><gtr:id>8AC941F7-8CF0-43F9-88AA-278632E6A962</gtr:id><gtr:name>First Hospital of Jilin University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC47A4DF-0946-4222-BDE6-982898A32DD1"><gtr:id>FC47A4DF-0946-4222-BDE6-982898A32DD1</gtr:id><gtr:name>Marshfield Clinic Research Foundation</gtr:name><gtr:address><gtr:line1>Center for Human Genetics, MLR</gtr:line1><gtr:line2>Marshfield Clinic</gtr:line2><gtr:line3>1000 North Oak Ave</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CDE11331-8129-4BDC-9AA9-09B828DC99EB"><gtr:id>CDE11331-8129-4BDC-9AA9-09B828DC99EB</gtr:id><gtr:name>Leighton Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BDA71A8B-3A0A-45A6-884C-C267316CEDF6"><gtr:id>BDA71A8B-3A0A-45A6-884C-C267316CEDF6</gtr:id><gtr:name>Charles LeMoyne Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7A72D78-3889-48F8-BD20-1C70ED5D6A3E"><gtr:id>C7A72D78-3889-48F8-BD20-1C70ED5D6A3E</gtr:id><gtr:name>Q &amp; T Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF788313-87E6-4237-B2DD-B1E70FB4DD58"><gtr:id>FF788313-87E6-4237-B2DD-B1E70FB4DD58</gtr:id><gtr:name>University Medical Center G?ttingen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7E12A8CD-0F83-4A1D-BE8B-BE9189E0A54F"><gtr:id>7E12A8CD-0F83-4A1D-BE8B-BE9189E0A54F</gtr:id><gtr:name>Cairns Base Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/65CBBD28-0111-4C62-A98F-8CE7C8084C67"><gtr:id>65CBBD28-0111-4C62-A98F-8CE7C8084C67</gtr:id><gtr:name>Laurentius Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/07150914-4974-462F-8854-095C7E7D8655"><gtr:id>07150914-4974-462F-8854-095C7E7D8655</gtr:id><gtr:name>Premier Healthcare, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3344C704-70F4-4171-A461-83CC376CC533"><gtr:id>3344C704-70F4-4171-A461-83CC376CC533</gtr:id><gtr:name>Danderyd Hospital (Danderyds sjukhus)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE8B9EF4-AA3E-40BF-9C34-9203544CE129"><gtr:id>FE8B9EF4-AA3E-40BF-9C34-9203544CE129</gtr:id><gtr:name>China-Japan Union Hospital of Jilin University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3FABD0D8-DAEC-44D8-9072-2FD22B5BF2C6"><gtr:id>3FABD0D8-DAEC-44D8-9072-2FD22B5BF2C6</gtr:id><gtr:name>The First Affiliated Hospital of Baotou Medical College</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D7054AD-21D8-4F59-A4B0-824DB85B8741"><gtr:id>8D7054AD-21D8-4F59-A4B0-824DB85B8741</gtr:id><gtr:name>Liaoning Provincial People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C0EB6B5-6CC4-4FCE-A7B3-686186B00CDD"><gtr:id>2C0EB6B5-6CC4-4FCE-A7B3-686186B00CDD</gtr:id><gtr:name>Renal Research Institute RRI</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5418652-2386-4D9F-A0CC-463787258ABD"><gtr:id>F5418652-2386-4D9F-A0CC-463787258ABD</gtr:id><gtr:name>Alfred Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47AB0710-E78B-4799-8346-770708E44A0A"><gtr:id>47AB0710-E78B-4799-8346-770708E44A0A</gtr:id><gtr:name>Helse Forde HF</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D4B99A3F-3131-4DB7-94FA-25856BDD1B20"><gtr:id>D4B99A3F-3131-4DB7-94FA-25856BDD1B20</gtr:id><gtr:name>Ospedale Maggiore</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB478ACF-F8F9-40E4-BB10-E1DC69A6A75E"><gtr:id>BB478ACF-F8F9-40E4-BB10-E1DC69A6A75E</gtr:id><gtr:name>Heart Research UK</gtr:name><gtr:address><gtr:line1>Suite 12D</gtr:line1><gtr:line2>Josephs Well</gtr:line2><gtr:postCode>LS3 1AB</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8516D1B6-37AA-4051-A58C-59EB501A16E9"><gtr:id>8516D1B6-37AA-4051-A58C-59EB501A16E9</gtr:id><gtr:name>Taiyuan City Centre Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5157264D-6981-4EBC-97E0-9DACD40D3DEC"><gtr:id>5157264D-6981-4EBC-97E0-9DACD40D3DEC</gtr:id><gtr:name>Fana Hjertesenter AS</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/18189AC3-F58B-4875-B612-3E6DFECC63CA"><gtr:id>18189AC3-F58B-4875-B612-3E6DFECC63CA</gtr:id><gtr:name>Kidney Associates, PLLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1A4EA0D0-69DB-4E7F-A621-CC2BAA3550E2"><gtr:id>1A4EA0D0-69DB-4E7F-A621-CC2BAA3550E2</gtr:id><gtr:name>Associated Research Partners LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/166BBB5A-BE49-4AD7-9F54-6256F059C802"><gtr:id>166BBB5A-BE49-4AD7-9F54-6256F059C802</gtr:id><gtr:name>The Wallace-Kelsey Research Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80E0171B-8C2E-4229-A9F3-041CCB348217"><gtr:id>80E0171B-8C2E-4229-A9F3-041CCB348217</gtr:id><gtr:name>St Luke's Hospital, Dublin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4EBF298-A6F7-4512-8612-770C8233F31A"><gtr:id>F4EBF298-A6F7-4512-8612-770C8233F31A</gtr:id><gtr:name>Wollongong Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75E7FC4F-8F59-4D32-9008-5976FFFFF12D"><gtr:id>75E7FC4F-8F59-4D32-9008-5976FFFFF12D</gtr:id><gtr:name>Tenon Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8ACE27BB-E375-48BA-9F43-EB264C0BCF04"><gtr:id>8ACE27BB-E375-48BA-9F43-EB264C0BCF04</gtr:id><gtr:name>Dalecarlia Clinical Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AF8E13-A8FB-4FB6-8E64-CDD23B65A006"><gtr:id>75AF8E13-A8FB-4FB6-8E64-CDD23B65A006</gtr:id><gtr:name>Permian Research Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0CEB4460-F06F-4F94-A663-33125D59655F"><gtr:id>0CEB4460-F06F-4F94-A663-33125D59655F</gtr:id><gtr:name>Provincial Specialist Hospital No 5. St. Barbara</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B7F99893-CCBE-456F-B252-698F8A130EF9"><gtr:id>B7F99893-CCBE-456F-B252-698F8A130EF9</gtr:id><gtr:name>PHV-Dialysezentrum Wilhelmshaven</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F4D3582-0B23-4B99-A6F9-921D48A3935A"><gtr:id>6F4D3582-0B23-4B99-A6F9-921D48A3935A</gtr:id><gtr:name>Milano - Ospedale Niguarda</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95FB2B17-31DC-4679-9388-DA58B9CC7917"><gtr:id>95FB2B17-31DC-4679-9388-DA58B9CC7917</gtr:id><gtr:name>David M. Kates Medical Services Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4847D437-2655-4B81-8F64-C8426072D914"><gtr:id>4847D437-2655-4B81-8F64-C8426072D914</gtr:id><gtr:name>KfH Nierenzentrum Marl</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8DFDF247-A072-43F9-BEC8-F171E33182BB"><gtr:id>8DFDF247-A072-43F9-BEC8-F171E33182BB</gtr:id><gtr:name>Universit?tsklinik f?r Innere Medizin Innsbruck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4C0E103C-B16F-4556-8152-5BAAD1BAC79C"><gtr:id>4C0E103C-B16F-4556-8152-5BAAD1BAC79C</gtr:id><gtr:name>Santa Rosa Cardiology Medical Group, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2AAEC2E2-EAC7-4AAE-8496-5231A5D18AEB"><gtr:id>2AAEC2E2-EAC7-4AAE-8496-5231A5D18AEB</gtr:id><gtr:name>DRK Kliniken Berlin Westend</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/21DC7FA1-CCE0-4E14-9708-B2AC7026E58A"><gtr:id>21DC7FA1-CCE0-4E14-9708-B2AC7026E58A</gtr:id><gtr:name>S?nderborg Sygehus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/00FF9FA9-F966-4D0D-80A6-A11BE7C2CFE6"><gtr:id>00FF9FA9-F966-4D0D-80A6-A11BE7C2CFE6</gtr:id><gtr:name>Louisville Metabolic and Atherosclerosis Research Centre (L-MARC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8E5E2AD5-89D3-4388-A262-CFB545B5ABDD"><gtr:id>8E5E2AD5-89D3-4388-A262-CFB545B5ABDD</gtr:id><gtr:name>Tianjin Chest Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F294D2A2-D662-4307-9966-020275C7F6F7"><gtr:id>F294D2A2-D662-4307-9966-020275C7F6F7</gtr:id><gtr:name>The Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFE4BBFC-F5BB-4312-8DD8-B8741BE3B856"><gtr:id>AFE4BBFC-F5BB-4312-8DD8-B8741BE3B856</gtr:id><gtr:name>Whiston Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B5E4682-9906-4E2B-9B5A-FE53A302974E"><gtr:id>4B5E4682-9906-4E2B-9B5A-FE53A302974E</gtr:id><gtr:name>Ospedale di Jalmicco di Palmanova</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E8E15A6C-B983-40C3-9EA5-64ABDD6EB216"><gtr:id>E8E15A6C-B983-40C3-9EA5-64ABDD6EB216</gtr:id><gtr:name>King's Mill Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B15331A-48F1-49FC-9B5D-B2578070359B"><gtr:id>3B15331A-48F1-49FC-9B5D-B2578070359B</gtr:id><gtr:name>East and North Hertfordshire NHS Trust</gtr:name><gtr:address><gtr:line1>R &amp; D, LC357D</gtr:line1><gtr:line2>Clinical Governance</gtr:line2><gtr:line3>Anritsu House</gtr:line3><gtr:postCode>SG1 4AB</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/44FD3240-3F57-4563-8656-1BE32246E2A6"><gtr:id>44FD3240-3F57-4563-8656-1BE32246E2A6</gtr:id><gtr:name>Nephrology Practice and Dialysis Oldenburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B0511743-88C0-483B-A46D-AFE931364B77"><gtr:id>B0511743-88C0-483B-A46D-AFE931364B77</gtr:id><gtr:name>Royal Adelaide Hospital</gtr:name><gtr:address><gtr:line1>Royal Adelaide Hospital</gtr:line1><gtr:line2>North Terrace</gtr:line2><gtr:postCode>SA 5000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E6ADDEA8-D0AE-4CA2-8C9F-42AAE8E6ECCC"><gtr:id>E6ADDEA8-D0AE-4CA2-8C9F-42AAE8E6ECCC</gtr:id><gtr:name>East Lancashire Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Midtherm Estate</gtr:line1><gtr:line2>New Road</gtr:line2><gtr:line3>Netherton</gtr:line3><gtr:postCode>DY2 8SY</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/21E92A8C-1B13-4E25-97C2-F0248458657B"><gtr:id>21E92A8C-1B13-4E25-97C2-F0248458657B</gtr:id><gtr:name>San Giuseppe E Melorio Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EE63160B-D70B-48E2-B58D-A1EEA035E9A5"><gtr:id>EE63160B-D70B-48E2-B58D-A1EEA035E9A5</gtr:id><gtr:name>Victoria Hospital</gtr:name><gtr:address><gtr:line1>Victoria Hospital</gtr:line1><gtr:line2>Avon &amp; Wilts Mental Health Partnership</gtr:line2><gtr:line3>Okus Road</gtr:line3><gtr:postCode>SN1 4HZ</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B45F9BC8-9D5F-4036-B77D-38D6A2EDA6E3"><gtr:id>B45F9BC8-9D5F-4036-B77D-38D6A2EDA6E3</gtr:id><gtr:name>St. Johns Center For Clinical Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36AA115C-193F-455C-BCC8-B2E30841825C"><gtr:id>36AA115C-193F-455C-BCC8-B2E30841825C</gtr:id><gtr:name>Vancouver General Hospital</gtr:name><gtr:address><gtr:line1>910 West 10th Avenue</gtr:line1><gtr:postCode>V5Z 4E3</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B8D0486A-BEA8-4028-B0B2-85367D9CB290"><gtr:id>B8D0486A-BEA8-4028-B0B2-85367D9CB290</gtr:id><gtr:name>Holb?k Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/129081D6-64EA-49BF-A8EE-69D1925F6B8B"><gtr:id>129081D6-64EA-49BF-A8EE-69D1925F6B8B</gtr:id><gtr:name>Blackpool Victoria Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5148A86D-1AD0-45A1-9690-B5193D1C994A"><gtr:id>5148A86D-1AD0-45A1-9690-B5193D1C994A</gtr:id><gtr:name>Nephrology Center Villingen-Schwenningen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1E1EABBB-9A65-47C4-9E46-CE516CC31E40"><gtr:id>1E1EABBB-9A65-47C4-9E46-CE516CC31E40</gtr:id><gtr:name>Medialpha Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A8D2EC9-94C4-4EF6-9FC0-196AD5AB0B94"><gtr:id>0A8D2EC9-94C4-4EF6-9FC0-196AD5AB0B94</gtr:id><gtr:name>Sandwell General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33D34CD1-B648-4521-B37B-8CF4DA94DC4D"><gtr:id>33D34CD1-B648-4521-B37B-8CF4DA94DC4D</gtr:id><gtr:name>Provincial Specialist Hospital No. 4</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3FEB516-8904-471A-988B-63F9FE3E419E"><gtr:id>D3FEB516-8904-471A-988B-63F9FE3E419E</gtr:id><gtr:name>Hospital of St Cross, Rugby</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/45FB8B32-D202-420F-8BF5-410762544260"><gtr:id>45FB8B32-D202-420F-8BF5-410762544260</gtr:id><gtr:name>Wycombe General Hospital</gtr:name><gtr:address><gtr:line1>Department of Cardiology</gtr:line1><gtr:postCode>HP11 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D138473C-B2AB-4C88-A54E-6F0159DD9F11"><gtr:id>D138473C-B2AB-4C88-A54E-6F0159DD9F11</gtr:id><gtr:name>The Polyclinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AD58C2C8-7678-4048-A276-B8888EBCE9FA"><gtr:id>AD58C2C8-7678-4048-A276-B8888EBCE9FA</gtr:id><gtr:name>Santa Maria della Misericordia Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/263639C4-C98F-4CC7-A05B-B268F1C1BC69"><gtr:id>263639C4-C98F-4CC7-A05B-B268F1C1BC69</gtr:id><gtr:name>Yeovil District Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/79B385D4-191F-4B76-A615-F0803A40167F"><gtr:id>79B385D4-191F-4B76-A615-F0803A40167F</gtr:id><gtr:name>Green and Seidner Family Practice Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAC6A24E-71C2-476D-80D2-7CF844CDBA16"><gtr:id>DAC6A24E-71C2-476D-80D2-7CF844CDBA16</gtr:id><gtr:name>Queen Elizabeth Hospital Birmingham</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FD8B609D-89F8-4B17-BD36-406DD213E2EB"><gtr:id>FD8B609D-89F8-4B17-BD36-406DD213E2EB</gtr:id><gtr:name>Deutsches Zentrum fur Herzinsuffizienz</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF96472C-C9CC-4D84-A2E5-C304A7501580"><gtr:id>EF96472C-C9CC-4D84-A2E5-C304A7501580</gtr:id><gtr:name>Robert Bosch Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6247E498-92C6-4C0B-8147-1A071AF15CAC"><gtr:id>6247E498-92C6-4C0B-8147-1A071AF15CAC</gtr:id><gtr:name>Dialysezentrum Jacobistra?e D?sseldorf</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C2E28AF8-1471-480C-BE2D-46803E77DAD6"><gtr:id>C2E28AF8-1471-480C-BE2D-46803E77DAD6</gtr:id><gtr:name>Martini Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F81D027-0815-4811-9521-7663CE283316"><gtr:id>7F81D027-0815-4811-9521-7663CE283316</gtr:id><gtr:name>Oklahoma City VA Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8EE049D3-3DAA-40DD-89F2-6C3E4E1CA64D"><gtr:id>8EE049D3-3DAA-40DD-89F2-6C3E4E1CA64D</gtr:id><gtr:name>Whipps Cross University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89EE1AB0-C210-4309-8DB3-266D71B262C6"><gtr:id>89EE1AB0-C210-4309-8DB3-266D71B262C6</gtr:id><gtr:name>Capital Cardiology Associates (Albany)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE"><gtr:id>70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE</gtr:id><gtr:name>North Middlesex University Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D6C7DAD0-6919-4A1D-BD5B-FE848ADE5E11"><gtr:id>D6C7DAD0-6919-4A1D-BD5B-FE848ADE5E11</gtr:id><gtr:name>Royal Thai Air Force</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8718A14F-93E2-4E56-8383-740ED8B97887"><gtr:id>8718A14F-93E2-4E56-8383-740ED8B97887</gtr:id><gtr:name>Pottstown Medical Specialists</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBD09011-CD14-4117-A8E1-80993DE17411"><gtr:id>DBD09011-CD14-4117-A8E1-80993DE17411</gtr:id><gtr:name>St. Paul's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/24ECB2D8-76A9-42D7-8521-EFDD6E726909"><gtr:id>24ECB2D8-76A9-42D7-8521-EFDD6E726909</gtr:id><gtr:name>Inner Mongolia Baotou City Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/24BA4B6C-A7D3-4C6E-8823-03BC38817B09"><gtr:id>24BA4B6C-A7D3-4C6E-8823-03BC38817B09</gtr:id><gtr:name>Ryhov Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CC0CE6A-7116-4DF5-BD06-DCBB441D299D"><gtr:id>2CC0CE6A-7116-4DF5-BD06-DCBB441D299D</gtr:id><gtr:name>LeBauer Cardiovascular Research Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/588EB53D-3C4A-47E1-8701-6650F39FB6A8"><gtr:id>588EB53D-3C4A-47E1-8701-6650F39FB6A8</gtr:id><gtr:name>HDS Eurocare, Teplice</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5CF98B10-17A4-4967-BD26-AFA870C6F10B"><gtr:id>5CF98B10-17A4-4967-BD26-AFA870C6F10B</gtr:id><gtr:name>Capital Cardiology Associates (Troy)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/41E94F16-CF2C-4A4E-9784-C45BBBB5772D"><gtr:id>41E94F16-CF2C-4A4E-9784-C45BBBB5772D</gtr:id><gtr:name>Marin Endocrine Care Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EFBACAD1-5E59-41E9-BA5B-45D424EDE604"><gtr:id>EFBACAD1-5E59-41E9-BA5B-45D424EDE604</gtr:id><gtr:name>Infermi Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95911D1A-93BC-4C4F-99D4-F42F6D2BE9E0"><gtr:id>95911D1A-93BC-4C4F-99D4-F42F6D2BE9E0</gtr:id><gtr:name>Innovative Research of West Florida, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6FC20194-862D-4740-8B03-267ED4452E50"><gtr:id>6FC20194-862D-4740-8B03-267ED4452E50</gtr:id><gtr:name>Dialysezentrum Karlstra?e D?sseldorf</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA37F95F-14BE-4EB2-8572-1492865850ED"><gtr:id>FA37F95F-14BE-4EB2-8572-1492865850ED</gtr:id><gtr:name>Alingsas lasarett</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B593CA15-69E5-4012-919D-F74E2C405412"><gtr:id>B593CA15-69E5-4012-919D-F74E2C405412</gtr:id><gtr:name>First People's Hospital Of Shenyang</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/575D825E-6BAE-4FA1-ACB6-9069D2633D70"><gtr:id>575D825E-6BAE-4FA1-ACB6-9069D2633D70</gtr:id><gtr:name>Thunder Bay Regional Health Sciences Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B4B6AA94-773C-4584-A0D9-778866B08BD5"><gtr:id>B4B6AA94-773C-4584-A0D9-778866B08BD5</gtr:id><gtr:name>Anshan Shuangshan Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BDCC8BB0-21CC-4E55-AB38-C785D85BE3B0"><gtr:id>BDCC8BB0-21CC-4E55-AB38-C785D85BE3B0</gtr:id><gtr:name>Maine Research Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91C308E2-1EBA-4CC1-8183-0371468DE15E"><gtr:id>91C308E2-1EBA-4CC1-8183-0371468DE15E</gtr:id><gtr:name>Wayne State University</gtr:name><gtr:address><gtr:line1>Detroit</gtr:line1><gtr:line2>Michigan</gtr:line2><gtr:line3>MI 48202</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/27274B26-7873-4CFC-BE5E-3A9A7097F6B9"><gtr:id>27274B26-7873-4CFC-BE5E-3A9A7097F6B9</gtr:id><gtr:name>St Helier's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0C87EE67-DC4E-4238-A08B-045D4D715BC9"><gtr:id>0C87EE67-DC4E-4238-A08B-045D4D715BC9</gtr:id><gtr:name>Wythenshawe Hospital</gtr:name><gtr:address><gtr:line1>Southmoor Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:postCode>M23 9LT</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BC1B572-9F0A-4572-B840-6400E9A4CF89"><gtr:id>8BC1B572-9F0A-4572-B840-6400E9A4CF89</gtr:id><gtr:name>Albany Associates in Cardiology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF449342-AF1A-4D3F-B833-8F6DB8687F7D"><gtr:id>CF449342-AF1A-4D3F-B833-8F6DB8687F7D</gtr:id><gtr:name>Uppsala University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4DB24FF-1BAB-4902-AA72-42D4EC2BE555"><gtr:id>C4DB24FF-1BAB-4902-AA72-42D4EC2BE555</gtr:id><gtr:name>Beverly Hills Heart Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/367FC75E-8399-475A-BFA2-B4991E0FD569"><gtr:id>367FC75E-8399-475A-BFA2-B4991E0FD569</gtr:id><gtr:name>Fremantle Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61B567B5-BA73-491F-831C-F3F1C7E784C6"><gtr:id>61B567B5-BA73-491F-831C-F3F1C7E784C6</gtr:id><gtr:name>Hospital Kuala Lumpur</gtr:name><gtr:address><gtr:line1>Jalan Pahang</gtr:line1><gtr:line2>50586 Kuala Lumpur</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/061EAD10-B0F0-42F8-B9C1-79819FC4563A"><gtr:id>061EAD10-B0F0-42F8-B9C1-79819FC4563A</gtr:id><gtr:name>Royal Melbourne Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/28F5B392-EA84-4DF5-A95F-0743C03F261A"><gtr:id>28F5B392-EA84-4DF5-A95F-0743C03F261A</gtr:id><gtr:name>Georgia Health Sciences University</gtr:name><gtr:address><gtr:line1>1120 15th Street</gtr:line1><gtr:postCode>GA 30912</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E5EEDB92-C621-4C6E-AF7F-2EE1ACFEA8E4"><gtr:id>E5EEDB92-C621-4C6E-AF7F-2EE1ACFEA8E4</gtr:id><gtr:name>Peking University People's Hospital</gtr:name><gtr:address><gtr:line1>#11, South Street of Xizhimen</gtr:line1><gtr:line2>Xicheng District</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D2B3BB08-BC47-454D-B1E2-AE1982A0F950"><gtr:id>D2B3BB08-BC47-454D-B1E2-AE1982A0F950</gtr:id><gtr:name>?rebro University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E65CC67-B3CB-4AC1-9A16-2C56554D3562"><gtr:id>5E65CC67-B3CB-4AC1-9A16-2C56554D3562</gtr:id><gtr:name>Scunthorpe General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DFD0DB4C-91B2-408E-A4BC-3B0E097B3EC0"><gtr:id>DFD0DB4C-91B2-408E-A4BC-3B0E097B3EC0</gtr:id><gtr:name>Aberdeen Royal Infirmary</gtr:name><gtr:address><gtr:line1>Aberdeen Royal Infirmary</gtr:line1><gtr:line2>Foresterhill</gtr:line2><gtr:postCode>AB9 2ZN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DFF53E79-B438-4850-A76E-520A5D69CD78"><gtr:id>DFF53E79-B438-4850-A76E-520A5D69CD78</gtr:id><gtr:name>Mediwest Seinajoki, Finland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/909EE311-80DB-4B16-8C49-C75D72C2A3EB"><gtr:id>909EE311-80DB-4B16-8C49-C75D72C2A3EB</gtr:id><gtr:name>Medi 3 ?lesund / MEDI3 Alesund</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AA5E6C89-D9A3-4956-815F-011D897DAA74"><gtr:id>AA5E6C89-D9A3-4956-815F-011D897DAA74</gtr:id><gtr:name>St Richard's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/986EE485-1D22-4BE4-A206-31B6CB818A1B"><gtr:id>986EE485-1D22-4BE4-A206-31B6CB818A1B</gtr:id><gtr:name>Silentzv?gens V?rdcentral</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/409477FD-8ACA-4CB4-90FE-0C1EBF305220"><gtr:id>409477FD-8ACA-4CB4-90FE-0C1EBF305220</gtr:id><gtr:name>KfH Nierenzentrum Donauw?rth</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF33015D-7E03-4E1D-84D4-EDD44BE65229"><gtr:id>CF33015D-7E03-4E1D-84D4-EDD44BE65229</gtr:id><gtr:name>The Hillingdon Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C5B516AF-6198-4F9F-BBC2-2AEFF97709E5"><gtr:id>C5B516AF-6198-4F9F-BBC2-2AEFF97709E5</gtr:id><gtr:name>Universit?tsklinikum?Bonn</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/795B7795-71B7-4221-9F7A-47C68EDD6C0D"><gtr:id>795B7795-71B7-4221-9F7A-47C68EDD6C0D</gtr:id><gtr:name>Dialysepraxis Alt?tting</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/132E9C51-402A-48A2-BAF6-FA3653EAB9E1"><gtr:id>132E9C51-402A-48A2-BAF6-FA3653EAB9E1</gtr:id><gtr:name>Meriter Medical Group, Inc. DBA: Meriter Wisconsin Heart</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/764EFFF8-38B3-472C-B6D3-DC567EAB324B"><gtr:id>764EFFF8-38B3-472C-B6D3-DC567EAB324B</gtr:id><gtr:name>South Florida Research Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522"><gtr:id>4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522</gtr:id><gtr:name>UNLISTED</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF696CE0-3016-49B7-8C93-A165F80B0FDC"><gtr:id>BF696CE0-3016-49B7-8C93-A165F80B0FDC</gtr:id><gtr:name>Klinikum Bielefeld</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D7CD90A4-326C-45B8-AFA9-894111F87B4E"><gtr:id>D7CD90A4-326C-45B8-AFA9-894111F87B4E</gtr:id><gtr:name>Northwest Heart Clinical Research, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/606F6395-00B9-4707-8B98-93DC7F40BE2E"><gtr:id>606F6395-00B9-4707-8B98-93DC7F40BE2E</gtr:id><gtr:name>Melbourne Renal Research Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAE9EB6C-D647-4063-AAEE-0A63D90CB430"><gtr:id>FAE9EB6C-D647-4063-AAEE-0A63D90CB430</gtr:id><gtr:name>Weifang People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CA9759D7-7592-4A80-9FFA-122E41646548"><gtr:id>CA9759D7-7592-4A80-9FFA-122E41646548</gtr:id><gtr:name>Obacka Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8F424A15-A4BF-4E3A-97DB-879055E9077D"><gtr:id>8F424A15-A4BF-4E3A-97DB-879055E9077D</gtr:id><gtr:name>Nebraska Heart Institute (Dionisopoulos)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1"><gtr:id>6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1</gtr:id><gtr:name>Trondheim University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/997071E2-24EB-4B5D-A182-00DF49D3EF63"><gtr:id>997071E2-24EB-4B5D-A182-00DF49D3EF63</gtr:id><gtr:name>Green Biologics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3958029-F035-4BBA-869F-893050BCE7F4"><gtr:id>C3958029-F035-4BBA-869F-893050BCE7F4</gtr:id><gtr:name>Bergslagen Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D4DD97D-4C06-4E39-9A35-E05B268BB2D7"><gtr:id>9D4DD97D-4C06-4E39-9A35-E05B268BB2D7</gtr:id><gtr:name>Cambridge Cardiac Care Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EE48EE7C-FC67-4452-8456-7C81DC21BCE5"><gtr:id>EE48EE7C-FC67-4452-8456-7C81DC21BCE5</gtr:id><gtr:name>Third Peoples Hospital of Xuzhou</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3E215BE-8D5E-40B7-B8FA-415E9E853137"><gtr:id>F3E215BE-8D5E-40B7-B8FA-415E9E853137</gtr:id><gtr:name>Shangdong Province Qingdao Municipal Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/50C2D853-5374-4909-AEB1-E2BE2DACAA30"><gtr:id>50C2D853-5374-4909-AEB1-E2BE2DACAA30</gtr:id><gtr:name>Tyrone County Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A748A4B-92D7-446B-86D3-71AC8AF5AA99"><gtr:id>9A748A4B-92D7-446B-86D3-71AC8AF5AA99</gtr:id><gtr:name>Research Physicians Network Alliance</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E1670D4B-EB39-45CD-BF1B-D2FAEEB92560"><gtr:id>E1670D4B-EB39-45CD-BF1B-D2FAEEB92560</gtr:id><gtr:name>Watson Clinic Cancer &amp; Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8FE5219D-DF62-43B8-8957-7E949A5128FE"><gtr:id>8FE5219D-DF62-43B8-8957-7E949A5128FE</gtr:id><gtr:name>Gemeinschaftspraxis Marktredwitz &amp; Selb</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257F3119-F25C-41EA-9D55-9B301432B412"><gtr:id>257F3119-F25C-41EA-9D55-9B301432B412</gtr:id><gtr:name>Universitetssjukhuset i Lund</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DA33A89C-94AA-4135-8AEE-58470D395C32"><gtr:id>DA33A89C-94AA-4135-8AEE-58470D395C32</gtr:id><gtr:name>Tiexi Hospital of Anshan</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/00866200-F62B-429B-BF02-A0A841684ED5"><gtr:id>00866200-F62B-429B-BF02-A0A841684ED5</gtr:id><gtr:name>University of Salamanca</gtr:name><gtr:address><gtr:line1>Universidad de Salamanca</gtr:line1><gtr:line2>Patio de Escuelas 1</gtr:line2><gtr:line4>Salamanca</gtr:line4><gtr:line5>37071</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/71EF7A5A-CD0D-42C1-B6DD-69A8BDCFEB07"><gtr:id>71EF7A5A-CD0D-42C1-B6DD-69A8BDCFEB07</gtr:id><gtr:name>Vestre Viken Health Authority</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/81BEDE7B-2A9E-4EFC-88D0-4B7B01F4D20C"><gtr:id>81BEDE7B-2A9E-4EFC-88D0-4B7B01F4D20C</gtr:id><gtr:name>The Second Affiliated Hospital of Baotou Medical College</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BFC805F-63E4-4B8D-AC1A-76C12DC45D5F"><gtr:id>8BFC805F-63E4-4B8D-AC1A-76C12DC45D5F</gtr:id><gtr:name>Northwick Park Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2070F714-C13B-417D-B059-44B511471FF2"><gtr:id>2070F714-C13B-417D-B059-44B511471FF2</gtr:id><gtr:name>Institute for Clinical and Experimental Medicine (IKEM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B11F840B-3E0B-4C05-8863-4FB27BD36486"><gtr:id>B11F840B-3E0B-4C05-8863-4FB27BD36486</gtr:id><gtr:name>Sykehuset Innlandet HF, Kongsvinger</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9831257E-9E86-4640-880A-C137612471A5"><gtr:id>9831257E-9E86-4640-880A-C137612471A5</gtr:id><gtr:name>Provincial Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6C51C95E-9111-49DC-9C4E-ABD992FAA2E0"><gtr:id>6C51C95E-9111-49DC-9C4E-ABD992FAA2E0</gtr:id><gtr:name>Zell am See Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FB8FA26D-607E-4B25-A1A3-55ECCFF7645C"><gtr:id>FB8FA26D-607E-4B25-A1A3-55ECCFF7645C</gtr:id><gtr:name>Associated Cardiovascular Consultants</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2942060C-DAFA-426B-A8BF-A8537F1CCFA0"><gtr:id>2942060C-DAFA-426B-A8BF-A8537F1CCFA0</gtr:id><gtr:name>Klinikum Fulda</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C8AD3DF1-C820-4C65-9E0C-B25204B3A052"><gtr:id>C8AD3DF1-C820-4C65-9E0C-B25204B3A052</gtr:id><gtr:name>HOPE Research Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/42033730-EAC2-4B0A-997F-ABE987F956F5"><gtr:id>42033730-EAC2-4B0A-997F-ABE987F956F5</gtr:id><gtr:name>Hudson Valley Cardiovascular Practice, P.C.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ACDFCDC7-8EC1-4ED6-A43D-4F18B9B6A783"><gtr:id>ACDFCDC7-8EC1-4ED6-A43D-4F18B9B6A783</gtr:id><gtr:name>East Texas Cardiology, PA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ED0EEDDC-CDEA-4B84-A90D-EE445FB100CA"><gtr:id>ED0EEDDC-CDEA-4B84-A90D-EE445FB100CA</gtr:id><gtr:name>Dialysezentrum Heiligenstadt</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/041AF371-DA1D-48C9-B280-29CB3799C4E9"><gtr:id>041AF371-DA1D-48C9-B280-29CB3799C4E9</gtr:id><gtr:name>Dewsbury District Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4A360D8-CF0A-407E-83C4-1FE395CC406D"><gtr:id>E4A360D8-CF0A-407E-83C4-1FE395CC406D</gtr:id><gtr:name>Worthing Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49A43251-E792-4E2E-BB66-315B5CF29D6F"><gtr:id>49A43251-E792-4E2E-BB66-315B5CF29D6F</gtr:id><gtr:name>Second Affiliated Hospital of Zhengzhou University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B21F0467-98F5-4957-8C88-4DFFE2E86752"><gtr:id>B21F0467-98F5-4957-8C88-4DFFE2E86752</gtr:id><gtr:name>Albuquerque Clinical Trials</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF2DA6A3-5D93-459C-9908-DF6A2024EC21"><gtr:id>FF2DA6A3-5D93-459C-9908-DF6A2024EC21</gtr:id><gtr:name>Central and North West London NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EAB14A86-80E5-4DCD-A8E1-BD4111F84AFC"><gtr:id>EAB14A86-80E5-4DCD-A8E1-BD4111F84AFC</gtr:id><gtr:name>Meharry Medical College</gtr:name><gtr:address><gtr:line1>1005 Dr. D. B. Todd, Jr Boulevard</gtr:line1><gtr:postCode>37208-3599</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B5B8C98-DC67-4273-A875-4A6AEAC0FDC6"><gtr:id>7B5B8C98-DC67-4273-A875-4A6AEAC0FDC6</gtr:id><gtr:name>KfH Nierenzentrum W?rzburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70E543EA-F95A-46A5-8B3F-8AF927B77F9B"><gtr:id>70E543EA-F95A-46A5-8B3F-8AF927B77F9B</gtr:id><gtr:name>Advanced Heart Care LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C1EC297-2A44-444B-B38B-B52AF99068AD"><gtr:id>2C1EC297-2A44-444B-B38B-B52AF99068AD</gtr:id><gtr:name>Cardiovascular Institute of the South</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5434604E-D9AC-4B94-A674-60D8F11B91A3"><gtr:id>5434604E-D9AC-4B94-A674-60D8F11B91A3</gtr:id><gtr:name>Bradford Royal Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5FFCBED-656B-4E07-B2AD-D4EC8CCD73B2"><gtr:id>B5FFCBED-656B-4E07-B2AD-D4EC8CCD73B2</gtr:id><gtr:name>Peterborough City Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE9AB991-9971-4B17-AA28-3160878DBE4E"><gtr:id>FE9AB991-9971-4B17-AA28-3160878DBE4E</gtr:id><gtr:name>Bay Area Cardiology Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DF68B82-E71A-40BD-BA3F-06DCE2663E9E"><gtr:id>9DF68B82-E71A-40BD-BA3F-06DCE2663E9E</gtr:id><gtr:name>Hospital Tengku Ampuan Afzan</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/573318B7-623C-4822-BB5F-A4D0E832417B"><gtr:id>573318B7-623C-4822-BB5F-A4D0E832417B</gtr:id><gtr:name>Versilia New Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95591E08-AB58-42FB-ADFC-1B0612E16851"><gtr:id>95591E08-AB58-42FB-ADFC-1B0612E16851</gtr:id><gtr:name>Mid-Valley Cardiology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/73CA53CC-F7E8-42A3-B48E-91A83D279923"><gtr:id>73CA53CC-F7E8-42A3-B48E-91A83D279923</gtr:id><gtr:name>Nephrologisches Zentrum Wei?ensee Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DA4F97EE-6FB6-4B96-8750-D2CBFBF26150"><gtr:id>DA4F97EE-6FB6-4B96-8750-D2CBFBF26150</gtr:id><gtr:name>DKD HELIOS Klinik Wiesbaden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AA4CEA52-92C1-480A-B751-3EC42B26F78E"><gtr:id>AA4CEA52-92C1-480A-B751-3EC42B26F78E</gtr:id><gtr:name>Dialysezentrum Saarlouis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2A80153D-B99E-4A7F-9634-C194ACD38834"><gtr:id>2A80153D-B99E-4A7F-9634-C194ACD38834</gtr:id><gtr:name>Sykehuset Innlandet HF Lillehammer</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DFE187A-934E-4272-BFAD-E9098AEA8CA9"><gtr:id>3DFE187A-934E-4272-BFAD-E9098AEA8CA9</gtr:id><gtr:name>Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2100F7CE-AA0B-4CB0-98D0-8038DFFB477D"><gtr:id>2100F7CE-AA0B-4CB0-98D0-8038DFFB477D</gtr:id><gtr:name>Second Hospital of Shanxi Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6E015378-92E6-42BD-B57E-3FD7BCDEA2AB"><gtr:id>6E015378-92E6-42BD-B57E-3FD7BCDEA2AB</gtr:id><gtr:name>Silkeborg Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/98F441C1-1820-4E8E-A738-89E88BDCF67D"><gtr:id>98F441C1-1820-4E8E-A738-89E88BDCF67D</gtr:id><gtr:name>University Hospital Munich</gtr:name><gtr:address><gtr:line1>University Hospital Munich</gtr:line1><gtr:line2>Ziemssenstrasse 1</gtr:line2><gtr:postCode>D-80336</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAC2A9A1-65E9-4360-BA6E-76DA1876565F"><gtr:id>FAC2A9A1-65E9-4360-BA6E-76DA1876565F</gtr:id><gtr:name>Universit?tsklinikum Charite, Campus Virchow-Klinikum</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C13907A3-4872-4E56-8A5D-CC68FDF291E7"><gtr:id>C13907A3-4872-4E56-8A5D-CC68FDF291E7</gtr:id><gtr:name>Nephrologische Praxis Dr. Meyer Bad Nauheim</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/97863044-3296-4CA1-B587-8E29FD6C1C28"><gtr:id>97863044-3296-4CA1-B587-8E29FD6C1C28</gtr:id><gtr:name>KfH Nierenzentrum K?ln-Merheim</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5CF9155D-3F9C-4D7A-9018-14E8901E2FC6"><gtr:id>5CF9155D-3F9C-4D7A-9018-14E8901E2FC6</gtr:id><gtr:name>Belfast City Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9485D2FE-FC0B-474F-8F21-6F625F641A91"><gtr:id>9485D2FE-FC0B-474F-8F21-6F625F641A91</gtr:id><gtr:name>Szpital Kliniczny Dzieciatka Jezus, Centrum Leczenia Obrazen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83529BB1-DE12-4A82-A7CB-322B5FC0F63C"><gtr:id>83529BB1-DE12-4A82-A7CB-322B5FC0F63C</gtr:id><gtr:name>Fenyang Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E63069FE-C064-4B5E-A16B-480E9441E9C4"><gtr:id>E63069FE-C064-4B5E-A16B-480E9441E9C4</gtr:id><gtr:name>NJ Heart</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DA2C2925-8877-4228-B956-6D105D55917F"><gtr:id>DA2C2925-8877-4228-B956-6D105D55917F</gtr:id><gtr:name>Colwyn Bay Community Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/41E0CE10-4668-41AB-9AA1-6E4785EEE513"><gtr:id>41E0CE10-4668-41AB-9AA1-6E4785EEE513</gtr:id><gtr:name>First Affiliated Hospital of China Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D62FEB7F-785B-4649-844E-B425DAF64D4A"><gtr:id>D62FEB7F-785B-4649-844E-B425DAF64D4A</gtr:id><gtr:name>Queensland Government</gtr:name><gtr:address><gtr:line1>PO Box 156, Archerfield BC</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E76DFBA-6F03-4D84-9AEC-58CC86BA6F2F"><gtr:id>5E76DFBA-6F03-4D84-9AEC-58CC86BA6F2F</gtr:id><gtr:name>Wuxi People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/596371CD-A49A-4A6C-8C8E-19CA5AED24E7"><gtr:id>596371CD-A49A-4A6C-8C8E-19CA5AED24E7</gtr:id><gtr:name>Queen's Hospital</gtr:name><gtr:address><gtr:line1>Belvedere Rd.</gtr:line1><gtr:postCode>DE13 0RB</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7D5ADAB2-4253-41CC-A87D-ED627752A297"><gtr:id>7D5ADAB2-4253-41CC-A87D-ED627752A297</gtr:id><gtr:name>Eastbourne District General Hospital</gtr:name><gtr:address><gtr:line1>Kings Drive</gtr:line1><gtr:postCode>BN21 2UD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D85B1313-6DDA-4655-BCA9-DF25A3979453"><gtr:id>D85B1313-6DDA-4655-BCA9-DF25A3979453</gtr:id><gtr:name>Steno Diabetes Center Copenhagen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E950C03D-126E-4B3A-8B92-0D771110FFA8"><gtr:id>E950C03D-126E-4B3A-8B92-0D771110FFA8</gtr:id><gtr:name>University of Alabama Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E292008-39ED-4C67-B8A4-D89C936AEE05"><gtr:id>2E292008-39ED-4C67-B8A4-D89C936AEE05</gtr:id><gtr:name>Bundaberg Base Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76AFFC55-A859-4DC8-BF62-B74BFD8AEF08"><gtr:id>76AFFC55-A859-4DC8-BF62-B74BFD8AEF08</gtr:id><gtr:name>Norfolk and Norwich University Hospital</gtr:name><gtr:address><gtr:line1>Colney Lane</gtr:line1><gtr:postCode>NR4 7UY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/129AB3E1-3DC7-401C-B4BC-24985A00C8AF"><gtr:id>129AB3E1-3DC7-401C-B4BC-24985A00C8AF</gtr:id><gtr:name>Stockport NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Stepping Hill Hospital</gtr:line1><gtr:line2>Poplar Grove</gtr:line2><gtr:postCode>SK2 7JE</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57CE900C-282B-4473-9E51-6037071B8948"><gtr:id>57CE900C-282B-4473-9E51-6037071B8948</gtr:id><gtr:name>Sykehuset Levanger</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4F359B80-F722-4D8E-BB33-D669606D16D9"><gtr:id>4F359B80-F722-4D8E-BB33-D669606D16D9</gtr:id><gtr:name>Fraser Health Authority</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/08C52B07-D973-4565-8E88-5511BAFFF3D9"><gtr:id>08C52B07-D973-4565-8E88-5511BAFFF3D9</gtr:id><gtr:name>Peking Union Medical College</gtr:name><gtr:address><gtr:line1>Dongdan Santiao</gtr:line1><gtr:postCode>100005</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/87AC76A7-3A15-4AB0-9E9A-E41C186BF103"><gtr:id>87AC76A7-3A15-4AB0-9E9A-E41C186BF103</gtr:id><gtr:name>Klinikum Leverkusen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D878FB57-FB53-44E3-A356-AE364FC540EE"><gtr:id>D878FB57-FB53-44E3-A356-AE364FC540EE</gtr:id><gtr:name>University Hospital of North Staffordshire NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/146112CF-E930-4E77-9536-FD73E8F3B5E9"><gtr:id>146112CF-E930-4E77-9536-FD73E8F3B5E9</gtr:id><gtr:name>Hospital Raja Perempuan Zainab II, Kota Bharu</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/81190C17-8B18-4DE2-989D-09633B77FF0B"><gtr:id>81190C17-8B18-4DE2-989D-09633B77FF0B</gtr:id><gtr:name>Dumfries and Galloway Royal Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68BDBDB0-74B3-49EC-9C85-3F8540BC6860"><gtr:id>68BDBDB0-74B3-49EC-9C85-3F8540BC6860</gtr:id><gtr:name>Cardiovascular Associates of the Southeast LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20C5852A-7D0C-4B4D-9D5A-21B73023DCD7"><gtr:id>20C5852A-7D0C-4B4D-9D5A-21B73023DCD7</gtr:id><gtr:name>Hilleroed Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48DD62AA-9550-425C-B752-9F2C336C0A86"><gtr:id>48DD62AA-9550-425C-B752-9F2C336C0A86</gtr:id><gtr:name>Viacar Recherche Clinique Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9713190C-DF10-4B7A-86C0-1FA4DC960B12"><gtr:id>9713190C-DF10-4B7A-86C0-1FA4DC960B12</gtr:id><gtr:name>Rush University Medical Center</gtr:name><gtr:address><gtr:line1>Dept of Molecular Biophysics &amp; Physiol</gtr:line1><gtr:line2>Rush University Medical Center</gtr:line2><gtr:line3>1653 West Congress Parkway</gtr:line3><gtr:line4>Chicago</gtr:line4><gtr:line5>IL 60612</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8129ED41-8B69-4B4C-8115-E769FECCDFCC"><gtr:id>8129ED41-8B69-4B4C-8115-E769FECCDFCC</gtr:id><gtr:name>Aventura Heart Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B445E90C-9510-4724-9163-DC277653B965"><gtr:id>B445E90C-9510-4724-9163-DC277653B965</gtr:id><gtr:name>Royal Devon and Exeter Hospital</gtr:name><gtr:address><gtr:line1>Barrack Road</gtr:line1><gtr:line4>Exeter</gtr:line4><gtr:line5>Devon</gtr:line5><gtr:postCode>EX2 5DW</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CD9804F2-50A4-406E-AC16-DA4D12D481EA"><gtr:id>CD9804F2-50A4-406E-AC16-DA4D12D481EA</gtr:id><gtr:name>Singleton Hospital</gtr:name><gtr:address><gtr:line1>Singleton Hospital</gtr:line1><gtr:postCode>SA2 8QA</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC2247CE-9FDF-48A3-89FB-AAE126086D0B"><gtr:id>EC2247CE-9FDF-48A3-89FB-AAE126086D0B</gtr:id><gtr:name>University Hospital of M?nster</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B03C821-3274-45DE-9789-E3D2FBE5F6FE"><gtr:id>8B03C821-3274-45DE-9789-E3D2FBE5F6FE</gtr:id><gtr:name>Michigan Cardiovascular Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE52CF89-E0DA-4A6E-98D6-A7B7EB407AFB"><gtr:id>AE52CF89-E0DA-4A6E-98D6-A7B7EB407AFB</gtr:id><gtr:name>Royal Hobart Hospital</gtr:name><gtr:address><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7725941D-A4FA-45DC-A943-D0B29C42E369"><gtr:id>7725941D-A4FA-45DC-A943-D0B29C42E369</gtr:id><gtr:name>University Malaya Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47F1543E-FF00-444E-9767-7727EFD90FDC"><gtr:id>47F1543E-FF00-444E-9767-7727EFD90FDC</gtr:id><gtr:name>Trondheim Hjertesenter AS, Norway</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A6772282-59BF-404C-8FED-97C444A6F1A9"><gtr:id>A6772282-59BF-404C-8FED-97C444A6F1A9</gtr:id><gtr:name>Dorset County Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/983D5513-5CAD-450A-B298-09D08FF46D5E"><gtr:id>983D5513-5CAD-450A-B298-09D08FF46D5E</gtr:id><gtr:name>Stockholm Heart Center, Sweden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46FE9087-C02F-43E3-AB5E-96849656C36D"><gtr:id>46FE9087-C02F-43E3-AB5E-96849656C36D</gtr:id><gtr:name>Austin Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D90A6775-4A8B-4291-AF27-B6DA519CA8C2"><gtr:id>D90A6775-4A8B-4291-AF27-B6DA519CA8C2</gtr:id><gtr:name>Gemini Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A2216F59-63B4-4A3F-8FE4-BCB959DE918F"><gtr:id>A2216F59-63B4-4A3F-8FE4-BCB959DE918F</gtr:id><gtr:name>Tianjin Union Medicine Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7170192-17A0-405E-A30F-D271C263529F"><gtr:id>F7170192-17A0-405E-A30F-D271C263529F</gtr:id><gtr:name>Parkview Research Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B9C2D48-4CEC-46B1-89E7-DE5DCD1FA320"><gtr:id>7B9C2D48-4CEC-46B1-89E7-DE5DCD1FA320</gtr:id><gtr:name>Borstel Research Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7ADA7D81-CBD2-4BD5-A4BA-8DFEE7D751B7"><gtr:id>7ADA7D81-CBD2-4BD5-A4BA-8DFEE7D751B7</gtr:id><gtr:name>Vizel Cardiac Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AC2090F8-B473-4479-9B3D-694BBBA8B2CD"><gtr:id>AC2090F8-B473-4479-9B3D-694BBBA8B2CD</gtr:id><gtr:name>Slagelse Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2B1C1B39-0260-448F-B4A8-8DA96FC8C83E"><gtr:id>2B1C1B39-0260-448F-B4A8-8DA96FC8C83E</gtr:id><gtr:name>Taranaki Base Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EC955A9-7A7E-434C-BBD8-CE3B521C2821"><gtr:id>9EC955A9-7A7E-434C-BBD8-CE3B521C2821</gtr:id><gtr:name>University of Alberta</gtr:name><gtr:address><gtr:line1>University of Alberta</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/09D111C8-6EB5-422C-88AA-1C6DF485ED0A"><gtr:id>09D111C8-6EB5-422C-88AA-1C6DF485ED0A</gtr:id><gtr:name>University Hospital Tuebingen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/81B377D6-DF09-4AC0-B371-FDA08E3EB8AF"><gtr:id>81B377D6-DF09-4AC0-B371-FDA08E3EB8AF</gtr:id><gtr:name>Tianjin Third Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/51A751AB-38DA-40F0-9408-10E24875FEBA"><gtr:id>51A751AB-38DA-40F0-9408-10E24875FEBA</gtr:id><gtr:name>Christchurch Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3F8679E5-B5AE-4F87-AC9E-BA45604F1C54"><gtr:id>3F8679E5-B5AE-4F87-AC9E-BA45604F1C54</gtr:id><gtr:name>Worcestershire Royal Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E4B6187-6584-4FB7-AF1D-044BD915AD4A"><gtr:id>9E4B6187-6584-4FB7-AF1D-044BD915AD4A</gtr:id><gtr:name>Nambour General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B"><gtr:id>2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B</gtr:id><gtr:name>Aarhus University Hospital</gtr:name><gtr:address><gtr:line1>Aarhus University Hospital</gtr:line1><gtr:line2>Aarhus University Hospital</gtr:line2><gtr:line3>Norrebrogade 44</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/18B2C5D0-334F-4D9B-9CF6-9EB22647E3A0"><gtr:id>18B2C5D0-334F-4D9B-9CF6-9EB22647E3A0</gtr:id><gtr:name>Shandong Weifang People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F830486-F534-4F27-965E-B93A76D95A3C"><gtr:id>1F830486-F534-4F27-965E-B93A76D95A3C</gtr:id><gtr:name>KfH Nierenzentrum Wei?enburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C93867FA-27A5-4A79-8E93-38DBA4D880F9"><gtr:id>C93867FA-27A5-4A79-8E93-38DBA4D880F9</gtr:id><gtr:name>Praxis f?r Nierenkrankheiten und Dialyse</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3D8A940-2BB9-4960-A5F6-1F54554C34FA"><gtr:id>D3D8A940-2BB9-4960-A5F6-1F54554C34FA</gtr:id><gtr:name>Portsmouth Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2793DE81-083B-4962-B5C7-2B8FEFBF1F05"><gtr:id>2793DE81-083B-4962-B5C7-2B8FEFBF1F05</gtr:id><gtr:name>Hospital Tuanku Jafa'ar</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC3C093C-F9CE-4465-95FD-3A43C57E7F1A"><gtr:id>FC3C093C-F9CE-4465-95FD-3A43C57E7F1A</gtr:id><gtr:name>Rigshospitalet</gtr:name><gtr:address><gtr:line1>Blegdamsvej 9</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F5FE4B5-FDF3-43E9-85EE-52367E1CF46B"><gtr:id>6F5FE4B5-FDF3-43E9-85EE-52367E1CF46B</gtr:id><gtr:name>Charles River Medical Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F5D7507-4E0B-4726-98CD-1EA57897014F"><gtr:id>5F5D7507-4E0B-4726-98CD-1EA57897014F</gtr:id><gtr:name>FAW General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8"><gtr:id>C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8</gtr:id><gtr:name>Glenfield Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/788B4530-D2FD-42F0-9652-F642B852B425"><gtr:id>788B4530-D2FD-42F0-9652-F642B852B425</gtr:id><gtr:name>Kansas City VA Medical Center - 2</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/74299423-0E5D-4739-A3AA-B17137135C9B"><gtr:id>74299423-0E5D-4739-A3AA-B17137135C9B</gtr:id><gtr:name>Linkoping  University</gtr:name><gtr:address><gtr:line1>Linkoping</gtr:line1><gtr:postCode>SE-581 83</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A7ECFF0-F37C-4DA6-94D0-7AAB2A023275"><gtr:id>3A7ECFF0-F37C-4DA6-94D0-7AAB2A023275</gtr:id><gtr:name>VA Ann Arbor Healthcare System</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B132A9E7-5D4A-4270-B617-ED9D2F0613DB"><gtr:id>B132A9E7-5D4A-4270-B617-ED9D2F0613DB</gtr:id><gtr:name>Turku University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAE5BBE4-88D2-4A1B-A838-6A3E4A212964"><gtr:id>DAE5BBE4-88D2-4A1B-A838-6A3E4A212964</gtr:id><gtr:name>Boice Willis Clinic Nashville</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E0188E13-F6B4-4612-9F9C-E3158A500C8D"><gtr:id>E0188E13-F6B4-4612-9F9C-E3158A500C8D</gtr:id><gtr:name>Nordland Hjertesenter AS</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC29D444-CD61-45AC-A36A-5863E40A5BFB"><gtr:id>FC29D444-CD61-45AC-A36A-5863E40A5BFB</gtr:id><gtr:name>Brampton Research Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89E93EBE-6563-4E33-A4F2-9AC7482A5AD0"><gtr:id>89E93EBE-6563-4E33-A4F2-9AC7482A5AD0</gtr:id><gtr:name>Ipswich Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F640E0E-4E90-4549-87E5-38C52854748E"><gtr:id>1F640E0E-4E90-4549-87E5-38C52854748E</gtr:id><gtr:name>Hoglandssjukhuset Eksjo, Sweden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3489274E-7BA0-499D-AAB5-041F08BE5A96"><gtr:id>3489274E-7BA0-499D-AAB5-041F08BE5A96</gtr:id><gtr:name>St. Johannes Hospital Dortmund</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3E11056A-45C3-458F-9947-68F0D0BE2FE6"><gtr:id>3E11056A-45C3-458F-9947-68F0D0BE2FE6</gtr:id><gtr:name>Medisch Centrum Leeuwarden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAEF05D4-E453-4150-8259-D1C9474163FA"><gtr:id>FAEF05D4-E453-4150-8259-D1C9474163FA</gtr:id><gtr:name>CentraCare Heart &amp; Vascular Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/953FE5C5-5E16-478A-894A-0133F406540E"><gtr:id>953FE5C5-5E16-478A-894A-0133F406540E</gtr:id><gtr:name>University Hospital, Frankfurt</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6B5D961-98A4-40A7-8CC5-9B46AA3F1AF7"><gtr:id>B6B5D961-98A4-40A7-8CC5-9B46AA3F1AF7</gtr:id><gtr:name>Overlea Personal Physicians</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FDB68547-FA9D-47FF-B9C3-B347A7472FFF"><gtr:id>FDB68547-FA9D-47FF-B9C3-B347A7472FFF</gtr:id><gtr:name>Sondrio Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/65CA0C72-DDE4-4E06-8BD1-26C17F49FFF7"><gtr:id>65CA0C72-DDE4-4E06-8BD1-26C17F49FFF7</gtr:id><gtr:name>Liaoning Angang Lishan Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/236B9977-95DB-4E36-B395-8CAB40A5442F"><gtr:id>236B9977-95DB-4E36-B395-8CAB40A5442F</gtr:id><gtr:name>Orbassano - Ospedale San Luigi Gonzaga</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70527AB1-ED42-4DEC-9921-A1FE180562CD"><gtr:id>70527AB1-ED42-4DEC-9921-A1FE180562CD</gtr:id><gtr:name>Primary Care Cardiology Research, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/121A90D0-B47C-4314-B89E-4E09017E4384"><gtr:id>121A90D0-B47C-4314-B89E-4E09017E4384</gtr:id><gtr:name>Dialysezentrum Dormagen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8ED0AABF-E872-4827-A548-90CC0AC53D97"><gtr:id>8ED0AABF-E872-4827-A548-90CC0AC53D97</gtr:id><gtr:name>Dialysezentrum / Gemeinschaftspraxis Heilbronn</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5DDA9A11-36B8-4EE5-86CE-DEE9A9720843"><gtr:id>5DDA9A11-36B8-4EE5-86CE-DEE9A9720843</gtr:id><gtr:name>Gemeinschaftspraxis Schlo? Holte - Stukenbrock</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6CADD105-0E2C-4C73-A12A-F32153158C24"><gtr:id>6CADD105-0E2C-4C73-A12A-F32153158C24</gtr:id><gtr:name>Pentucket Medical Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F736259-FACF-47BC-99F4-B0E1A7617784"><gtr:id>6F736259-FACF-47BC-99F4-B0E1A7617784</gtr:id><gtr:name>Sygehus Fyn Svendborg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E51038EF-C40E-4668-ADBD-041FF6FE2205"><gtr:id>E51038EF-C40E-4668-ADBD-041FF6FE2205</gtr:id><gtr:name>Dialysezentrum Bad Godesberg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72E812C7-4492-4C83-A92B-BD1E09EE9D83"><gtr:id>72E812C7-4492-4C83-A92B-BD1E09EE9D83</gtr:id><gtr:name>Trinity Medical Center (Rock Island)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A28252F6-AD97-4A7D-82EF-6489C2EB868E"><gtr:id>A28252F6-AD97-4A7D-82EF-6489C2EB868E</gtr:id><gtr:name>Royal Prince Alfred Hospital (RPAH) Sydney</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1E8D5BD-639D-47C8-805A-F38DB10DC13F"><gtr:id>C1E8D5BD-639D-47C8-805A-F38DB10DC13F</gtr:id><gtr:name>St. Mary's Duluth Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83DB8510-2CEF-4407-A1DA-B3F1A53B2D1C"><gtr:id>83DB8510-2CEF-4407-A1DA-B3F1A53B2D1C</gtr:id><gtr:name>Northern General Hospital</gtr:name><gtr:address><gtr:line1>Herries Road</gtr:line1><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S5 7AY</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1FC3A77-AF6B-4D37-A41E-72AF4ACBF467"><gtr:id>C1FC3A77-AF6B-4D37-A41E-72AF4ACBF467</gtr:id><gtr:name>Glostrup Hospital</gtr:name><gtr:address><gtr:line1>Glostrup University Hospital</gtr:line1><gtr:line2>57 Ndr. Ringvej, DK-2600</gtr:line2><gtr:line3>Glostrup</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/899E24E0-CABA-47C7-9618-D27426F5DB95"><gtr:id>899E24E0-CABA-47C7-9618-D27426F5DB95</gtr:id><gtr:name>Istituti ospitalieri di Cremona</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4EA7F599-ACD2-430E-B5AE-3FFB07882626"><gtr:id>4EA7F599-ACD2-430E-B5AE-3FFB07882626</gtr:id><gtr:name>Centre de Cardologie et de Recherche Clinique Pierre-Le Gardeur</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C9DA1DA3-D9BD-4897-B554-5181400F24E0"><gtr:id>C9DA1DA3-D9BD-4897-B554-5181400F24E0</gtr:id><gtr:name>University Hospital of Besancon</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E5EE8164-F5A7-4E82-A362-D3D64BF53CA0"><gtr:id>E5EE8164-F5A7-4E82-A362-D3D64BF53CA0</gtr:id><gtr:name>Eastern Regional Health Authority</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D1F22D1-B5C4-4A4F-A88C-3DE36A6E3155"><gtr:id>9D1F22D1-B5C4-4A4F-A88C-3DE36A6E3155</gtr:id><gtr:name>Princess Royal Hospital</gtr:name><gtr:address><gtr:line1>Lewes Road</gtr:line1><gtr:postCode>RH16 4EX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A2C525FE-77BB-4CA7-9C48-D76FD97A876E"><gtr:id>A2C525FE-77BB-4CA7-9C48-D76FD97A876E</gtr:id><gtr:name>Russells Hall Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4BBE5221-98D9-4644-9209-15B40D17A39D"><gtr:id>4BBE5221-98D9-4644-9209-15B40D17A39D</gtr:id><gtr:name>Penticton Regional Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5CBB8107-6A9E-454C-B8C8-35F980076924"><gtr:id>5CBB8107-6A9E-454C-B8C8-35F980076924</gtr:id><gtr:name>Tenet Florida Physician Services</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DFD96BE4-B699-411E-B6E9-056CA4A26A49"><gtr:id>DFD96BE4-B699-411E-B6E9-056CA4A26A49</gtr:id><gtr:name>St. Joseph's Healthcare Hamilton</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4F9E1FB-3A0C-4123-9869-499B04BB0033"><gtr:id>C4F9E1FB-3A0C-4123-9869-499B04BB0033</gtr:id><gtr:name>Sykehuset Innlandet HF Hamar</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C6DA7F09-D7A6-4E5D-BB81-B7FF665572DC"><gtr:id>C6DA7F09-D7A6-4E5D-BB81-B7FF665572DC</gtr:id><gtr:name>Chesapeake Cardiovascular Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0A8E1D8-B74B-46BA-A42D-B575E2E15804"><gtr:id>C0A8E1D8-B74B-46BA-A42D-B575E2E15804</gtr:id><gtr:name>Royal Inland Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4ED9EDBF-AB80-4A92-8219-868950B96236"><gtr:id>4ED9EDBF-AB80-4A92-8219-868950B96236</gtr:id><gtr:name>First Hospital of Shanxi Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F48CE370-2E64-4C64-A61F-62294907C777"><gtr:id>F48CE370-2E64-4C64-A61F-62294907C777</gtr:id><gtr:name>Clinical Trials of America, Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEDC0BB2-81F5-4B93-B339-88B340DBCF38"><gtr:id>FEDC0BB2-81F5-4B93-B339-88B340DBCF38</gtr:id><gtr:name>Royal Bolton Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43970E8C-C2C1-4CC6-BE4A-4E48BB09BBD2"><gtr:id>43970E8C-C2C1-4CC6-BE4A-4E48BB09BBD2</gtr:id><gtr:name>Advanced Neurology Specialists</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49FBAC03-85EC-43B3-A9E5-930DC90D5FB3"><gtr:id>49FBAC03-85EC-43B3-A9E5-930DC90D5FB3</gtr:id><gtr:name>North Tyneside General Hospital</gtr:name><gtr:address><gtr:line1>Rake Lane</gtr:line1><gtr:line2>North Shields</gtr:line2><gtr:postCode>NE29 8NH</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F712308-0606-4CE0-A887-7867A0C0A137"><gtr:id>7F712308-0606-4CE0-A887-7867A0C0A137</gtr:id><gtr:name>St. Boniface General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82FDD508-2079-4BE0-AF84-FB2CBB56CC7C"><gtr:id>82FDD508-2079-4BE0-AF84-FB2CBB56CC7C</gtr:id><gtr:name>Morriston Hospital</gtr:name><gtr:address><gtr:line1>Heol Maes Eglwys</gtr:line1><gtr:line2>Morriston</gtr:line2><gtr:line3>Swansea</gtr:line3><gtr:line4>Abertawe</gtr:line4><gtr:postCode>SA6 6NL</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31ABE3DA-72D2-42DD-9625-40DE633EDB3E"><gtr:id>31ABE3DA-72D2-42DD-9625-40DE633EDB3E</gtr:id><gtr:name>Royal Perth Hospital</gtr:name><gtr:address><gtr:line1>Medical Research Foundation</gtr:line1><gtr:line2>Murray Street</gtr:line2><gtr:postCode>WA 6000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4BDA9D7-B6E8-44DF-B9A4-D56C879CE736"><gtr:id>F4BDA9D7-B6E8-44DF-B9A4-D56C879CE736</gtr:id><gtr:name>Provincial Specialist Hospital in Wroclaw</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/342F51D6-C5CB-4E4E-A705-842A96C1C07B"><gtr:id>342F51D6-C5CB-4E4E-A705-842A96C1C07B</gtr:id><gtr:name>Fondazione Salvatore Maugeri</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A44C419F-1C95-40F3-AFF2-CF24128B5643"><gtr:id>A44C419F-1C95-40F3-AFF2-CF24128B5643</gtr:id><gtr:name>Lanzhou University</gtr:name><gtr:address><gtr:line1>222 Tianshui S Rd</gtr:line1><gtr:line2>Chengguan</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D7EB639-B621-4CD7-A0B2-3B4364F7FD7B"><gtr:id>2D7EB639-B621-4CD7-A0B2-3B4364F7FD7B</gtr:id><gtr:name>Universitetssjukhuset Linkoping, Sweden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DC562560-B567-483E-9141-5F4DF6739687"><gtr:id>DC562560-B567-483E-9141-5F4DF6739687</gtr:id><gtr:name>Skaraborgs Hospital Sk?vde</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6B146064-3AEC-4843-B87D-C3F93F1817ED"><gtr:id>6B146064-3AEC-4843-B87D-C3F93F1817ED</gtr:id><gtr:name>Nordlandssykehuset HF</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43EEA31B-BB6D-4470-8200-019443D47F23"><gtr:id>43EEA31B-BB6D-4470-8200-019443D47F23</gtr:id><gtr:name>Kore Cv Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9A643A7-828D-414B-A34B-679DB472B37A"><gtr:id>B9A643A7-828D-414B-A34B-679DB472B37A</gtr:id><gtr:name>Wels-Grieskirchen Clinic (Klinikum Wels-Grieskirchen)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/410725D8-5F99-40B3-AA63-8FAA89613913"><gtr:id>410725D8-5F99-40B3-AA63-8FAA89613913</gtr:id><gtr:name>Roskilde Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43BFE210-8181-4478-A843-EDF217FAD892"><gtr:id>43BFE210-8181-4478-A843-EDF217FAD892</gtr:id><gtr:name>Kardiologie Universitaet Magdeburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46CE8BEC-8929-4C0A-9088-42BC4636CB23"><gtr:id>46CE8BEC-8929-4C0A-9088-42BC4636CB23</gtr:id><gtr:name>Dialysezentrum Halberstadt</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0E80DBC1-A928-4E7B-8553-F59869930C27"><gtr:id>0E80DBC1-A928-4E7B-8553-F59869930C27</gtr:id><gtr:name>Virginia Polytechnic Institute &amp; State U</gtr:name><gtr:address><gtr:line1>Virginia Polytechnic Inst &amp; State  Univ</gtr:line1><gtr:line4>Blacksburg</gtr:line4><gtr:line5>Virginia</gtr:line5><gtr:postCode>VA 24061</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B17DFAAE-D0B4-4F46-80A5-5BA02113F000"><gtr:id>B17DFAAE-D0B4-4F46-80A5-5BA02113F000</gtr:id><gtr:name>Overlake Medical Clinics Cardiology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2162C73C-CCEC-4405-8D44-94BB2D306505"><gtr:id>2162C73C-CCEC-4405-8D44-94BB2D306505</gtr:id><gtr:name>Universit?tsklinikum Schleswig-Holstein-L?beck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8399881F-B597-4491-B33D-CC7AA60C7516"><gtr:id>8399881F-B597-4491-B33D-CC7AA60C7516</gtr:id><gtr:name>Credit Valley Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E0DE6B2A-572B-41F6-923C-72A6330111B3"><gtr:id>E0DE6B2A-572B-41F6-923C-72A6330111B3</gtr:id><gtr:name>Palmetto Research Center, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80392F0C-23A4-449D-BC8D-4D77C0F53303"><gtr:id>80392F0C-23A4-449D-BC8D-4D77C0F53303</gtr:id><gtr:name>Mahidol University</gtr:name><gtr:address><gtr:line1>Mahidol University</gtr:line1><gtr:line2>Office of the President  Mahidol Univers</gtr:line2><gtr:line3>25/25 Moo 3, Phuttamonthon 4 Road</gtr:line3><gtr:postCode>73170</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DA65CF26-56B9-4170-9923-6FE32A33FA91"><gtr:id>DA65CF26-56B9-4170-9923-6FE32A33FA91</gtr:id><gtr:name>Hospital Sultanah Aminah, Johor Bahru</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82E66BDB-BFA0-46E2-ABB3-C8EBDA419217"><gtr:id>82E66BDB-BFA0-46E2-ABB3-C8EBDA419217</gtr:id><gtr:name>Central Hospital in Karlstad</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/58B8363B-07EB-40D9-917A-5DECE5979268"><gtr:id>58B8363B-07EB-40D9-917A-5DECE5979268</gtr:id><gtr:name>U.S. Department of Veteran Affairs</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4822D555-BD0C-4560-9E9B-4FA59A8ECD57"><gtr:id>4822D555-BD0C-4560-9E9B-4FA59A8ECD57</gtr:id><gtr:name>St Antonius Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/555E8F41-4811-4255-B742-986F6FF57F39"><gtr:id>555E8F41-4811-4255-B742-986F6FF57F39</gtr:id><gtr:name>North Karelia Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/42EB2762-A46A-469B-A74A-4BAA8E902411"><gtr:id>42EB2762-A46A-469B-A74A-4BAA8E902411</gtr:id><gtr:name>The First Affiliated Hospital of Harbin Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1C653F8-0E4E-4FE7-9AB2-4CC6CEE375FC"><gtr:id>C1C653F8-0E4E-4FE7-9AB2-4CC6CEE375FC</gtr:id><gtr:name>The Christ Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0F9EAEAD-5674-4E30-8A06-589629F2C422"><gtr:id>0F9EAEAD-5674-4E30-8A06-589629F2C422</gtr:id><gtr:name>Haukeland University Hospital</gtr:name><gtr:address><gtr:line1>Haukeland University Hospital</gtr:line1><gtr:line2>Jonas Liesvei 65</gtr:line2><gtr:postCode>N-5021</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57877830-679D-4C06-B9DB-5280139D33D8"><gtr:id>57877830-679D-4C06-B9DB-5280139D33D8</gtr:id><gtr:name>Kerckhoff Klinik GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78EC1292-873A-480D-8A0E-E4A2947A1F8A"><gtr:id>78EC1292-873A-480D-8A0E-E4A2947A1F8A</gtr:id><gtr:name>CAMC Clinical Trials Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/368B57E1-D587-4B9A-9889-9439BFE044E8"><gtr:id>368B57E1-D587-4B9A-9889-9439BFE044E8</gtr:id><gtr:name>Sykehuset??stfold</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/450B90BB-D91E-4019-B6DA-21B2EB423C39"><gtr:id>450B90BB-D91E-4019-B6DA-21B2EB423C39</gtr:id><gtr:name>Townsville Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E7C3165-D40E-4C74-93D1-FF28CDF429BA"><gtr:id>2E7C3165-D40E-4C74-93D1-FF28CDF429BA</gtr:id><gtr:name>Queen Elizabeth Hospital (Malaysia)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C873BE22-11BB-462E-8A08-66402DF71A5A"><gtr:id>C873BE22-11BB-462E-8A08-66402DF71A5A</gtr:id><gtr:name>Shanxi Cardiovascular Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E2B2F857-09D3-47F5-A71A-A6D314C652CD"><gtr:id>E2B2F857-09D3-47F5-A71A-A6D314C652CD</gtr:id><gtr:name>Molndal hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F58B2DF7-41FD-424F-BC6D-F259ADF07632"><gtr:id>F58B2DF7-41FD-424F-BC6D-F259ADF07632</gtr:id><gtr:name>Gemeinschaftspraxis am Sophienhof Kiel</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BFA56DFC-5905-4B77-BBB0-212A1151DBD2"><gtr:id>BFA56DFC-5905-4B77-BBB0-212A1151DBD2</gtr:id><gtr:name>Kolding Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/92A065DD-9E51-4F4E-8E24-45E1DB681062"><gtr:id>92A065DD-9E51-4F4E-8E24-45E1DB681062</gtr:id><gtr:name>Salem VA Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/422EAB5B-BF7C-461D-BB57-B7E3E727A3F0"><gtr:id>422EAB5B-BF7C-461D-BB57-B7E3E727A3F0</gtr:id><gtr:name>KfH Nierenzentrum Oberhausen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/73B0ADF6-14B7-42A6-9A64-8E8D9828BF68"><gtr:id>73B0ADF6-14B7-42A6-9A64-8E8D9828BF68</gtr:id><gtr:name>South Oklahoma Heart Research, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DE52904-C852-41F4-8170-6DE7257C145C"><gtr:id>3DE52904-C852-41F4-8170-6DE7257C145C</gtr:id><gtr:name>Cardiovascular Research of Knoxville</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4571FBC9-D38E-40A1-BE84-563400983ACF"><gtr:id>4571FBC9-D38E-40A1-BE84-563400983ACF</gtr:id><gtr:name>Affiliated Hospital of Medical College Qingdao University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4ACFDB4B-D413-45EC-8DE8-2B9FBB670994"><gtr:id>4ACFDB4B-D413-45EC-8DE8-2B9FBB670994</gtr:id><gtr:name>Macclesfield District General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C44C4B56-A32E-4355-817E-A8F6B4E1D224"><gtr:id>C44C4B56-A32E-4355-817E-A8F6B4E1D224</gtr:id><gtr:name>Ysbyty Gwynedd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CDB5C46C-3657-4E1A-A590-82CAF586546A"><gtr:id>CDB5C46C-3657-4E1A-A590-82CAF586546A</gtr:id><gtr:name>Clinique du Landy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/45319442-4D29-44ED-AAC1-631E1DFBF03A"><gtr:id>45319442-4D29-44ED-AAC1-631E1DFBF03A</gtr:id><gtr:name>Clinique Sante Cardio MC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6BCB8F32-042E-47EF-8275-627ED296F4B2"><gtr:id>6BCB8F32-042E-47EF-8275-627ED296F4B2</gtr:id><gtr:name>Central Hospital in Kristianstad</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E93D6C07-0652-4449-95E9-DF69D546E74A"><gtr:id>E93D6C07-0652-4449-95E9-DF69D546E74A</gtr:id><gtr:name>Heimdal Helsehus Legesenter AS, Norway</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43773B2C-AB3E-43EF-B4EE-37AE39D9B28E"><gtr:id>43773B2C-AB3E-43EF-B4EE-37AE39D9B28E</gtr:id><gtr:name>Xinxiang Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/979A02A7-EDD9-43D3-9B0F-6B0ACBFB4469"><gtr:id>979A02A7-EDD9-43D3-9B0F-6B0ACBFB4469</gtr:id><gtr:name>Investigators Research Group, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F1CC1F28-7C65-4DB8-B05D-86F313EED523"><gtr:id>F1CC1F28-7C65-4DB8-B05D-86F313EED523</gtr:id><gtr:name>Kootenai Heart Clinics, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/328A70ED-7A67-4E12-A777-2562355B66CD"><gtr:id>328A70ED-7A67-4E12-A777-2562355B66CD</gtr:id><gtr:name>Finmatica Mercia</gtr:name><gtr:address><gtr:line1>Mercia Software</gtr:line1><gtr:line2>Mercia House</gtr:line2><gtr:line3>Ashted Lock, Aston Science Park</gtr:line3><gtr:postCode>B7 4AZ</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8C480BF7-63FF-45A7-A556-FFFD91DDA905"><gtr:id>8C480BF7-63FF-45A7-A556-FFFD91DDA905</gtr:id><gtr:name>General Hospital of Shenyang Military Command</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF9C6405-2F3D-4FF2-9FD1-8F4D9A398F24"><gtr:id>CF9C6405-2F3D-4FF2-9FD1-8F4D9A398F24</gtr:id><gtr:name>KfH Nierenzentrum Frankfurt/Oder</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82B9CAEA-1CB7-49EC-AFDD-88DC5A4B26C0"><gtr:id>82B9CAEA-1CB7-49EC-AFDD-88DC5A4B26C0</gtr:id><gtr:name>Internistische Gemeinschaftspraxis Alzey</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49D610C2-5CFE-4F35-AB5B-F42CCFD2057A"><gtr:id>49D610C2-5CFE-4F35-AB5B-F42CCFD2057A</gtr:id><gtr:name>Palmerston North Hospital Area</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6080E18C-0F85-4F48-BBF6-070A8C2B4BE5"><gtr:id>6080E18C-0F85-4F48-BBF6-070A8C2B4BE5</gtr:id><gtr:name>Beijing Chao-Yang Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/87C3D54D-A192-4C58-920D-8E230F0FE10F"><gtr:id>87C3D54D-A192-4C58-920D-8E230F0FE10F</gtr:id><gtr:name>Ambulantes Herzzentrum Kassel</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/551210F5-4D38-4FE7-8FB9-5998A68A4D4A"><gtr:id>551210F5-4D38-4FE7-8FB9-5998A68A4D4A</gtr:id><gtr:name>Klinikum der Universit?t Regensburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EB12F8C8-FB6A-49D8-9A17-F50435FD9E20"><gtr:id>EB12F8C8-FB6A-49D8-9A17-F50435FD9E20</gtr:id><gtr:name>Etel?-karjalan Keskussairaala / Etela-Karjalan keskussairaala</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/742D7BC0-1823-40FB-8C73-9106F4565EBE"><gtr:id>742D7BC0-1823-40FB-8C73-9106F4565EBE</gtr:id><gtr:name>KfH Nierenzentrum Kulmbach</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1C9E096D-AC85-4EBE-A303-D76F04EDAE16"><gtr:id>1C9E096D-AC85-4EBE-A303-D76F04EDAE16</gtr:id><gtr:name>Cardio Centrum</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90BD4526-22E5-4DD3-B338-FE94D41A4AD0"><gtr:id>90BD4526-22E5-4DD3-B338-FE94D41A4AD0</gtr:id><gtr:name>KfH Nierenzentrum Bayreuth</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E9810A0B-AF27-43AA-9942-631EDA0B5F64"><gtr:id>E9810A0B-AF27-43AA-9942-631EDA0B5F64</gtr:id><gtr:name>Kansas City VA Medical Center - 1</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A67AB8CC-C3E2-475F-B86F-92FEB393A01E"><gtr:id>A67AB8CC-C3E2-475F-B86F-92FEB393A01E</gtr:id><gtr:name>Liverpool Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B426979-D09E-49AE-873E-704D74782E4A"><gtr:id>7B426979-D09E-49AE-873E-704D74782E4A</gtr:id><gtr:name>Gemeinschaftspraxis N?rnberg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4ABFD36B-C0A5-4AD0-AE78-8436C66A2969"><gtr:id>4ABFD36B-C0A5-4AD0-AE78-8436C66A2969</gtr:id><gtr:name>Halsobolaget i Jarfalla AB</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67E21C60-B8DD-4699-AC20-1A92454AB2DA"><gtr:id>67E21C60-B8DD-4699-AC20-1A92454AB2DA</gtr:id><gtr:name>Tianjin Medical University General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19400D8C-1FA7-4477-9DE6-0199FB7144CC"><gtr:id>19400D8C-1FA7-4477-9DE6-0199FB7144CC</gtr:id><gtr:name>Cohen Medical Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48911A3F-4ADE-4761-8F30-FC7D6BF9E09E"><gtr:id>48911A3F-4ADE-4761-8F30-FC7D6BF9E09E</gtr:id><gtr:name>Ljungby Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0EA925CB-3B74-43B5-AA46-74EBAFF31F96"><gtr:id>0EA925CB-3B74-43B5-AA46-74EBAFF31F96</gtr:id><gtr:name>University of Limoges</gtr:name><gtr:address><gtr:line1>16 rue d'Atlantis</gtr:line1><gtr:line2>Parc Ester Technopole</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/66977CFE-81F8-41E3-B203-24A6D752F07E"><gtr:id>66977CFE-81F8-41E3-B203-24A6D752F07E</gtr:id><gtr:name>Vienna General Hospital</gtr:name><gtr:address><gtr:line1>Universit?tskliniken</gtr:line1><gtr:line2>W?hringer G?rtel 18-20</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33762991-1280-47A2-935E-A369E0DAF18F"><gtr:id>33762991-1280-47A2-935E-A369E0DAF18F</gtr:id><gtr:name>Skedsmo Medical Center AS</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/319CD245-3BE5-493C-8EFF-182777A2446A"><gtr:id>319CD245-3BE5-493C-8EFF-182777A2446A</gtr:id><gtr:name>Aalborg University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4B61530-E555-421C-B44E-D4BFC4077167"><gtr:id>E4B61530-E555-421C-B44E-D4BFC4077167</gtr:id><gtr:name>Sydjysk Sygehus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/09A5B0A0-CBFE-4E08-8506-F24B81A2FF22"><gtr:id>09A5B0A0-CBFE-4E08-8506-F24B81A2FF22</gtr:id><gtr:name>Freeman Health System</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A9FC408-ACE9-4F71-AB93-245BF1F4A518"><gtr:id>0A9FC408-ACE9-4F71-AB93-245BF1F4A518</gtr:id><gtr:name>London Health Sciences Centre</gtr:name><gtr:address><gtr:line1>339 Windermere Road</gtr:line1><gtr:postCode>N6A 5A5</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EFC89042-CBB0-46F0-BAF2-3D23C9F74BD9"><gtr:id>EFC89042-CBB0-46F0-BAF2-3D23C9F74BD9</gtr:id><gtr:name>Rajavithi hospital</gtr:name><gtr:address><gtr:line1>2, Rajavithi road, Phyathai</gtr:line1><gtr:postCode>10400</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6274ADFB-8596-4E44-B786-53DB106EE630"><gtr:id>6274ADFB-8596-4E44-B786-53DB106EE630</gtr:id><gtr:name>Austin Heart, PLLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4DDAFB1E-C2DA-412D-A30F-393770AD3AD7"><gtr:id>4DDAFB1E-C2DA-412D-A30F-393770AD3AD7</gtr:id><gtr:name>Universit?tsklinikum Leipzig</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CC1CE9BC-D2C9-49A8-877E-522D7B59C147"><gtr:id>CC1CE9BC-D2C9-49A8-877E-522D7B59C147</gtr:id><gtr:name>Providence Saint Joseph Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/40261DBD-C79D-4CE4-A273-392E4D4B9C3E"><gtr:id>40261DBD-C79D-4CE4-A273-392E4D4B9C3E</gtr:id><gtr:name>Internistische Gemeinschaftspraxis und Dialyse Friedrichshafen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3CF64D0E-54D2-42CF-AF7D-E2176AB6CCAD"><gtr:id>3CF64D0E-54D2-42CF-AF7D-E2176AB6CCAD</gtr:id><gtr:name>Hull Royal Infirmary</gtr:name><gtr:address><gtr:line1>Anlaby Road</gtr:line1><gtr:line4>Hull</gtr:line4><gtr:line5>North Humberside</gtr:line5><gtr:postCode>HU3 2JZ</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/212329C1-E4C9-4CA2-BD4A-72FFBD010A4B"><gtr:id>212329C1-E4C9-4CA2-BD4A-72FFBD010A4B</gtr:id><gtr:name>Wuhan Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5C3D1AA-F273-458D-B776-CE02F592BECA"><gtr:id>D5C3D1AA-F273-458D-B776-CE02F592BECA</gtr:id><gtr:name>Nottingham Uni Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>City Hospital campus</gtr:line1><gtr:line2>Hucknall Road</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG5 1PB</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A18268E3-6796-43EB-A587-6E57828CB012"><gtr:id>A18268E3-6796-43EB-A587-6E57828CB012</gtr:id><gtr:name>Vrinnevisjukhuset in Norrkoping</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5B3EE014-8C69-4641-9BB6-C0A930B83BBF"><gtr:id>5B3EE014-8C69-4641-9BB6-C0A930B83BBF</gtr:id><gtr:name>The Royal Surrey County Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95CE67A3-2F94-4288-B4D9-A7EA0489F2F0"><gtr:id>95CE67A3-2F94-4288-B4D9-A7EA0489F2F0</gtr:id><gtr:name>Odense University Hospital</gtr:name><gtr:address><gtr:line1>5000 Odense C</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D545C73D-780E-4D1A-B5CD-1D6630A8CCCA"><gtr:id>D545C73D-780E-4D1A-B5CD-1D6630A8CCCA</gtr:id><gtr:name>Royal London Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ABAF22F6-C312-41E2-9D66-E4B3FF6E3D2D"><gtr:id>ABAF22F6-C312-41E2-9D66-E4B3FF6E3D2D</gtr:id><gtr:name>Nephrologische Gemeinschaftspraxis, Rostock</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A1BA128-2522-4D3E-B99A-BAA76B78782B"><gtr:id>0A1BA128-2522-4D3E-B99A-BAA76B78782B</gtr:id><gtr:name>Esbjerg Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3BDD0C7-54DD-4D15-9A0E-4495A7325C7F"><gtr:id>C3BDD0C7-54DD-4D15-9A0E-4495A7325C7F</gtr:id><gtr:name>Connecticut Heart &amp; Vascular Center PC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8F2566DF-4C39-4848-9426-F9C59147CE0A"><gtr:id>8F2566DF-4C39-4848-9426-F9C59147CE0A</gtr:id><gtr:name>University Heart Center Freiburg - Bad Krozingen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/801E5521-FA71-45F5-9BA7-77D765DCE06F"><gtr:id>801E5521-FA71-45F5-9BA7-77D765DCE06F</gtr:id><gtr:name>Juedisches Krankenhaus Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0E0D740E-3610-47C4-8941-29737E009E67"><gtr:id>0E0D740E-3610-47C4-8941-29737E009E67</gtr:id><gtr:name>Local Health Umbria 2</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D9453D9B-1E97-490C-A328-64016CEAC877"><gtr:id>D9453D9B-1E97-490C-A328-64016CEAC877</gtr:id><gtr:name>HeartCare Midwest</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BBCF719-BF61-45B0-BADF-41A6B4AA88EA"><gtr:id>8BBCF719-BF61-45B0-BADF-41A6B4AA88EA</gtr:id><gtr:name>F?rde Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CA4E0D3D-047E-4B03-AD66-A8542B474501"><gtr:id>CA4E0D3D-047E-4B03-AD66-A8542B474501</gtr:id><gtr:name>Centrallasarettet</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/454A8145-64B9-4738-81F1-6A6B0582A717"><gtr:id>454A8145-64B9-4738-81F1-6A6B0582A717</gtr:id><gtr:name>Denver Nephrologists, PC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF7B78B7-B451-451A-AC3F-8FE9A399E11D"><gtr:id>FF7B78B7-B451-451A-AC3F-8FE9A399E11D</gtr:id><gtr:name>Klinik am See</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3F86FCCF-A8E9-4257-92D6-CB15378E93F5"><gtr:id>3F86FCCF-A8E9-4257-92D6-CB15378E93F5</gtr:id><gtr:name>Medical University of Wurzburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CBFD096E-08FF-4EDB-8C79-5DC96B2162C6"><gtr:id>CBFD096E-08FF-4EDB-8C79-5DC96B2162C6</gtr:id><gtr:name>Dialysezentrum R?sselsheim</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C35D919C-B3D6-4EEB-9821-FF4701E7943E"><gtr:id>C35D919C-B3D6-4EEB-9821-FF4701E7943E</gtr:id><gtr:name>Iowa Diabetes and Endocrinology Research Center (IDERC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF0F5FA5-D345-41FF-A3C7-7FA5D560D645"><gtr:id>FF0F5FA5-D345-41FF-A3C7-7FA5D560D645</gtr:id><gtr:name>Gemeinschaftspraxis Kiel</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CD411D6F-284B-4E3F-B26B-55AD3AA94851"><gtr:id>CD411D6F-284B-4E3F-B26B-55AD3AA94851</gtr:id><gtr:name>Core Research Group Pty Ltd.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/064A41A2-AC2E-4ACC-A55B-D38D3434BD6A"><gtr:id>064A41A2-AC2E-4ACC-A55B-D38D3434BD6A</gtr:id><gtr:name>Queen's Medical Centre</gtr:name><gtr:address><gtr:line1>Queen's Medical Centre</gtr:line1><gtr:line2>Derby Rd</gtr:line2><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2A44C4EB-3210-49B2-BD66-4FF81F06D133"><gtr:id>2A44C4EB-3210-49B2-BD66-4FF81F06D133</gtr:id><gtr:name>Helsinki University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BEB8A09A-1D45-42C6-A270-F4E24852FC25"><gtr:id>BEB8A09A-1D45-42C6-A270-F4E24852FC25</gtr:id><gtr:name>Shenyang Fifth People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BD80BA0D-9194-4FBE-9658-43A41CFD4ACC"><gtr:id>BD80BA0D-9194-4FBE-9658-43A41CFD4ACC</gtr:id><gtr:name>Sunderland Royal Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3E018BA3-4B93-4B94-974E-8299919ABF8C"><gtr:id>3E018BA3-4B93-4B94-974E-8299919ABF8C</gtr:id><gtr:name>Westlake Medical Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DF1372D2-543A-41AF-8868-479423257B3B"><gtr:id>DF1372D2-543A-41AF-8868-479423257B3B</gtr:id><gtr:name>Asheville Cardiology Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4858FC05-0DBD-4608-9964-756D24EEC2EA"><gtr:id>4858FC05-0DBD-4608-9964-756D24EEC2EA</gtr:id><gtr:name>The Canberra Hospital</gtr:name><gtr:address><gtr:line1>The Canberra Hospital</gtr:line1><gtr:line2>Yamba Drive</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B424AD7D-B7FF-4DC1-9AF4-E74B96DFBFD5"><gtr:id>B424AD7D-B7FF-4DC1-9AF4-E74B96DFBFD5</gtr:id><gtr:name>The Second Affiliated Hospital of Harbin Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A3574BF1-069D-4E2A-905C-527179B4C447"><gtr:id>A3574BF1-069D-4E2A-905C-527179B4C447</gtr:id><gtr:name>The Center for Pharmaceutical Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/591A3A9A-B9DC-4D31-8660-2E747AAEDFAE"><gtr:id>591A3A9A-B9DC-4D31-8660-2E747AAEDFAE</gtr:id><gtr:name>Royal Sussex County Hospital</gtr:name><gtr:address><gtr:line1>Royal Sussex County Hospital</gtr:line1><gtr:line2>Eastern Road</gtr:line2><gtr:postCode>BN2  5BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DF63D71D-49D4-4161-AB34-81BBCE1E6C42"><gtr:id>DF63D71D-49D4-4161-AB34-81BBCE1E6C42</gtr:id><gtr:name>Nyk?pings lasarett</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1125BA61-FDB7-4E3A-B215-F3033C72C9DA"><gtr:id>1125BA61-FDB7-4E3A-B215-F3033C72C9DA</gtr:id><gtr:name>Aleris H?lsocentral Bolln?s</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F44FC935-8229-45D0-832A-AF35C6A449BF"><gtr:id>F44FC935-8229-45D0-832A-AF35C6A449BF</gtr:id><gtr:name>Churchill Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D70EC5C-F7A6-4289-8A66-9B5ECDAA06A5"><gtr:id>9D70EC5C-F7A6-4289-8A66-9B5ECDAA06A5</gtr:id><gtr:name>Northampton General Hospital, Northampton</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4051BFFD-1763-4071-82C2-32589D76267C"><gtr:id>4051BFFD-1763-4071-82C2-32589D76267C</gtr:id><gtr:name>Herlev Hospital</gtr:name><gtr:address><gtr:line1>Herlev Ringvej 75</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6"><gtr:id>0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6</gtr:id><gtr:name>Southampton General Hospital</gtr:name><gtr:address><gtr:line1>Southampton General Hospital</gtr:line1><gtr:line2>Tremona Road</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AC9D6A9E-DC44-4233-BF3A-14F1ED262B94"><gtr:id>AC9D6A9E-DC44-4233-BF3A-14F1ED262B94</gtr:id><gtr:name>Gemeinschaftspraxis Langenhagen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0AD29405-86CD-4E0D-893A-1B701BDDA723"><gtr:id>0AD29405-86CD-4E0D-893A-1B701BDDA723</gtr:id><gtr:name>Gdansk University Clinical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/031EF3F3-1DFC-40FC-B592-92E5FAB19781"><gtr:id>031EF3F3-1DFC-40FC-B592-92E5FAB19781</gtr:id><gtr:name>Fakultn? nemocnice?Kr?lovsk??Vinohrady?(FNKV)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/15BEA556-61BA-4A6D-96E2-68D203200E94"><gtr:id>15BEA556-61BA-4A6D-96E2-68D203200E94</gtr:id><gtr:name>Hospital Pulau Penang</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6965AB72-D958-4511-B6BC-C752F111E489"><gtr:id>6965AB72-D958-4511-B6BC-C752F111E489</gtr:id><gtr:name>Firenze - Ospedale San Giovanni di Dio</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B5A16882-91C9-46B8-AE20-1C37595B4BFC"><gtr:id>B5A16882-91C9-46B8-AE20-1C37595B4BFC</gtr:id><gtr:name>N?stved Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1FDA00D-83E7-4D74-8C35-821C0B3EABE0"><gtr:id>C1FDA00D-83E7-4D74-8C35-821C0B3EABE0</gtr:id><gtr:name>State Hospital Feldkirch</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/56116990-2173-4978-8D81-800676D3064A"><gtr:id>56116990-2173-4978-8D81-800676D3064A</gtr:id><gtr:name>Royal Jubilee Hospital (RJH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FB4D3938-DD53-4FE7-882A-5A0465C4C4D0"><gtr:id>FB4D3938-DD53-4FE7-882A-5A0465C4C4D0</gtr:id><gtr:name>Mobile Heart Specialists, PC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/445C872D-07E4-4AE6-9352-78A87D3D96FC"><gtr:id>445C872D-07E4-4AE6-9352-78A87D3D96FC</gtr:id><gtr:name>Upstate Cardiology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F2E28E8D-D750-45C1-8213-CFF8FE06C3F2"><gtr:id>F2E28E8D-D750-45C1-8213-CFF8FE06C3F2</gtr:id><gtr:name>Westside Center for Clinical Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88900EC3-E116-4610-B097-94BF4D657F87"><gtr:id>88900EC3-E116-4610-B097-94BF4D657F87</gtr:id><gtr:name>Prince of Wales Hospital</gtr:name><gtr:address><gtr:line1>High Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/492EAA54-6204-4CA7-A3F9-D68780986B33"><gtr:id>492EAA54-6204-4CA7-A3F9-D68780986B33</gtr:id><gtr:name>Hope Housing</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75FB476F-E4DE-487A-BF8E-62C211EAB0F4"><gtr:id>75FB476F-E4DE-487A-BF8E-62C211EAB0F4</gtr:id><gtr:name>Haderslev Sygehus, Denmark</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7576999C-67BA-4056-8896-3EBC0C076D27"><gtr:id>7576999C-67BA-4056-8896-3EBC0C076D27</gtr:id><gtr:name>Dialysezentrum W?rzburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C03225F3-03C3-43C0-BE65-A8A629530193"><gtr:id>C03225F3-03C3-43C0-BE65-A8A629530193</gtr:id><gtr:name>University Medical Ctr Hamburg-Eppendorf</gtr:name><gtr:address><gtr:line1>Martinistrasse 52</gtr:line1><gtr:postCode>D-20246</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A4C12BD-FDA4-4686-BF6C-8C2EC7CBFF2E"><gtr:id>0A4C12BD-FDA4-4686-BF6C-8C2EC7CBFF2E</gtr:id><gtr:name>Medicor Cardiology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FDF86AB3-DA29-42B0-8370-29D53879BD27"><gtr:id>FDF86AB3-DA29-42B0-8370-29D53879BD27</gtr:id><gtr:name>Wellington Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/09119199-D96A-4649-8EAF-958FD4BC899C"><gtr:id>09119199-D96A-4649-8EAF-958FD4BC899C</gtr:id><gtr:name>Lappi Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AEA8FC48-D733-4DB5-9359-02718FC482A3"><gtr:id>AEA8FC48-D733-4DB5-9359-02718FC482A3</gtr:id><gtr:name>Crosshouse Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE7B8401-F5DC-4B0D-AA2B-EFED1E664DC9"><gtr:id>FE7B8401-F5DC-4B0D-AA2B-EFED1E664DC9</gtr:id><gtr:name>Berman Center for Outcomes and Clinical Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/204D76BD-F4A1-4CD9-9962-88C505F80203"><gtr:id>204D76BD-F4A1-4CD9-9962-88C505F80203</gtr:id><gtr:name>Dialysepraxis Leipzig</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9D66421-09ED-4C76-8AF3-D38C6DDDC841"><gtr:id>B9D66421-09ED-4C76-8AF3-D38C6DDDC841</gtr:id><gtr:name>Royal Victoria Hospital, Belfast</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A1EFCEC-3C6C-4608-A8F5-4A8DB969E225"><gtr:id>0A1EFCEC-3C6C-4608-A8F5-4A8DB969E225</gtr:id><gtr:name>Luton and Dunstable University Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/967A0B4E-1393-43F3-BEFD-9C9867A735C6"><gtr:id>967A0B4E-1393-43F3-BEFD-9C9867A735C6</gtr:id><gtr:name>Community Clinical Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/663390AF-FE4A-42E9-8102-19EC13B453DC"><gtr:id>663390AF-FE4A-42E9-8102-19EC13B453DC</gtr:id><gtr:name>UNN Hjerte/Kar Poliklinikk</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1340E837-B8AC-4F9C-87CE-2FAD7E8F3FF8"><gtr:id>1340E837-B8AC-4F9C-87CE-2FAD7E8F3FF8</gtr:id><gtr:name>Ladulaas Clinical Studies</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/98290490-A636-4A33-9A01-A66F1B4B5E3B"><gtr:id>98290490-A636-4A33-9A01-A66F1B4B5E3B</gtr:id><gtr:name>Northern Michigan Regional Hospital (Nisus Research), Heart Center Research LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43794DA3-3A60-4319-9E12-915BDFACB691"><gtr:id>43794DA3-3A60-4319-9E12-915BDFACB691</gtr:id><gtr:name>The Affiliated Hospital of Inner Mongolia Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8DA7AD2E-B7F8-458C-8D14-CAA39CFD524C"><gtr:id>8DA7AD2E-B7F8-458C-8D14-CAA39CFD524C</gtr:id><gtr:name>Dayton Heart Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/25FEC6C2-48A2-46F7-851E-9C974EF85164"><gtr:id>25FEC6C2-48A2-46F7-851E-9C974EF85164</gtr:id><gtr:name>Fresenius Medical Care</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3F9CC77E-E3DE-4E5C-9CB5-E8A1DDC5138B"><gtr:id>3F9CC77E-E3DE-4E5C-9CB5-E8A1DDC5138B</gtr:id><gtr:name>FinnDiane</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D574CE3-6057-45B5-B41E-2041041E9991"><gtr:id>9D574CE3-6057-45B5-B41E-2041041E9991</gtr:id><gtr:name>Charing Cross Hospital</gtr:name><gtr:address><gtr:line1>Charing Cross Hospital</gtr:line1><gtr:line2>Fulham Palace Road</gtr:line2><gtr:postCode>W6 8RF</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55F0C099-77BD-4DF0-8919-5B996B2448CC"><gtr:id>55F0C099-77BD-4DF0-8919-5B996B2448CC</gtr:id><gtr:name>Jihlava Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D016E07C-85CE-4F24-8232-EC6631338580"><gtr:id>D016E07C-85CE-4F24-8232-EC6631338580</gtr:id><gtr:name>Dialysezentrum Bad Malente</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/746D157B-8C9A-4EF5-8F7F-7263B8D8120C"><gtr:id>746D157B-8C9A-4EF5-8F7F-7263B8D8120C</gtr:id><gtr:name>Dialysezentrum Darmstadt</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D98527E8-9205-4225-AFA0-5DE7000103C4"><gtr:id>D98527E8-9205-4225-AFA0-5DE7000103C4</gtr:id><gtr:name>Brothers of Charity Hospital in Trier</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/41892435-41D0-41C6-9C16-7AECA03C4C8D"><gtr:id>41892435-41D0-41C6-9C16-7AECA03C4C8D</gtr:id><gtr:name>Songklanagarind Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BBF43C8A-DF03-4122-A004-3AE2CE6ABFE5"><gtr:id>BBF43C8A-DF03-4122-A004-3AE2CE6ABFE5</gtr:id><gtr:name>Ziekenhuis ZGT Hengelo</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/082A46A6-EC47-4E85-890A-F3A052326F1B"><gtr:id>082A46A6-EC47-4E85-890A-F3A052326F1B</gtr:id><gtr:name>SP Health Care University Clinical Hospital No. 1 of the Medical University of Lodz</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A34B09B-7066-4F23-8602-8215DE25848B"><gtr:id>9A34B09B-7066-4F23-8602-8215DE25848B</gtr:id><gtr:name>Second Hospital Of Tianjin Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1C35FAE-6BFE-447C-837E-A6CDED283744"><gtr:id>A1C35FAE-6BFE-447C-837E-A6CDED283744</gtr:id><gtr:name>H?ssleholms Sjukhus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C8418798-A956-4BF4-A124-EB56B056D806"><gtr:id>C8418798-A956-4BF4-A124-EB56B056D806</gtr:id><gtr:name>Lutherville Personal Physicians</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4AAE76DE-5807-40EF-B3FE-824A330ECEF3"><gtr:id>4AAE76DE-5807-40EF-B3FE-824A330ECEF3</gtr:id><gtr:name>South Tees Hospitals NHS Foundtn Trust</gtr:name><gtr:address><gtr:line1>James Cook Hospital</gtr:line1><gtr:line2>Marton Road</gtr:line2><gtr:postCode>TS4 3BW</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF47A80C-C441-4380-84BD-0C6B80A00ED9"><gtr:id>FF47A80C-C441-4380-84BD-0C6B80A00ED9</gtr:id><gtr:name>Antrim Area Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4"><gtr:id>61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4</gtr:id><gtr:name>Basildon and Thurrock University Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3C8AF34-BF10-454B-A600-7E3CC9F96D11"><gtr:id>D3C8AF34-BF10-454B-A600-7E3CC9F96D11</gtr:id><gtr:name>M?larsjukhuset, Eskilstuna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAE5EB06-D833-4B36-9415-D617C213E27F"><gtr:id>DAE5EB06-D833-4B36-9415-D617C213E27F</gtr:id><gtr:name>Cleveland Cardiovascular Research Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EB43CBC1-0824-493C-A9FC-7597DBB0EBB8"><gtr:id>EB43CBC1-0824-493C-A9FC-7597DBB0EBB8</gtr:id><gtr:name>North Cumbria University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8C486C9D-2E29-4849-858B-18F5B19A1E18"><gtr:id>8C486C9D-2E29-4849-858B-18F5B19A1E18</gtr:id><gtr:name>Klinikum Am Urban (KAU)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D3E670F-EDE4-4E49-9AB6-57B1330ECAFE"><gtr:id>2D3E670F-EDE4-4E49-9AB6-57B1330ECAFE</gtr:id><gtr:name>Inner Mongolia Baogang Staff Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F371C741-9F2B-4C24-B47A-7DB1720126C8"><gtr:id>F371C741-9F2B-4C24-B47A-7DB1720126C8</gtr:id><gtr:name>University Hospital Aachen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/485F4A4C-6FF2-4683-9C18-6394C33128A7"><gtr:id>485F4A4C-6FF2-4683-9C18-6394C33128A7</gtr:id><gtr:name>Inner Mongolia Autonomous Region People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E5B5F7A3-A781-466F-B797-F6F65D7C4B92"><gtr:id>E5B5F7A3-A781-466F-B797-F6F65D7C4B92</gtr:id><gtr:name>Dialysezentrum Bovenden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/840FFA8C-E039-441F-BA4E-7FB201E6D480"><gtr:id>840FFA8C-E039-441F-BA4E-7FB201E6D480</gtr:id><gtr:name>Birmingham City Hospital</gtr:name><gtr:address><gtr:line1>Dudley Road</gtr:line1><gtr:postCode>B18  7QH</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/197E0A76-57CB-44A5-B7FF-42282BC64F3F"><gtr:id>197E0A76-57CB-44A5-B7FF-42282BC64F3F</gtr:id><gtr:name>Dialysezentrum Bad Laasphe</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D867F24-6FAF-4B71-8669-C23926264442"><gtr:id>2D867F24-6FAF-4B71-8669-C23926264442</gtr:id><gtr:name>Gold Coast Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A31B1E91-6F14-4754-8312-B033152F0E21"><gtr:id>A31B1E91-6F14-4754-8312-B033152F0E21</gtr:id><gtr:name>Pinderfieldss Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7881CF6C-5788-414B-954C-CA40CC925716"><gtr:id>7881CF6C-5788-414B-954C-CA40CC925716</gtr:id><gtr:name>Stavanger University Hospital</gtr:name><gtr:address><gtr:line1>Armauer Hansensvei 20</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE5BB6E9-F40A-479A-9A5D-1A4D2B717D02"><gtr:id>AE5BB6E9-F40A-479A-9A5D-1A4D2B717D02</gtr:id><gtr:name>Hospital Provincial de Rosario</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/199A6DA2-71B1-479D-AFD2-9173541DEA53"><gtr:id>199A6DA2-71B1-479D-AFD2-9173541DEA53</gtr:id><gtr:name>Universit?tsklinikum Schleswig-Holstein - Kiel</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C50B9F66-025F-47E7-9D13-121E7DF24A30"><gtr:id>C50B9F66-025F-47E7-9D13-121E7DF24A30</gtr:id><gtr:name>Hospital Santa Margherita</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4C7F04DC-65E6-4482-BCE6-D62C53494B4E"><gtr:id>4C7F04DC-65E6-4482-BCE6-D62C53494B4E</gtr:id><gtr:name>Harrisonburg Medical Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4E1DAA0-8180-41F1-9351-540577DB2B5F"><gtr:id>E4E1DAA0-8180-41F1-9351-540577DB2B5F</gtr:id><gtr:name>Saarland University</gtr:name><gtr:address><gtr:line1>Main Campus</gtr:line1><gtr:line2>Stuhlsatzenhausweg</gtr:line2><gtr:postCode>D-66123</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D7918F8A-0C53-4511-A333-B15D122956E9"><gtr:id>D7918F8A-0C53-4511-A333-B15D122956E9</gtr:id><gtr:name>Glan Clwyd District General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70C6D893-1F2A-48E8-9007-61D710DED337"><gtr:id>70C6D893-1F2A-48E8-9007-61D710DED337</gtr:id><gtr:name>Heritage Valley Medical Group, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4304D61E-AC4E-4F23-BA60-AAB848E52F91"><gtr:id>4304D61E-AC4E-4F23-BA60-AAB848E52F91</gtr:id><gtr:name>San Juan VA Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E93A8558-613B-451F-88F8-964379B61001"><gtr:id>E93A8558-613B-451F-88F8-964379B61001</gtr:id><gtr:name>Auckland City Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/02354C47-5EE3-4C1D-8AC0-35381ABFA7B6"><gtr:id>02354C47-5EE3-4C1D-8AC0-35381ABFA7B6</gtr:id><gtr:name>Mid-Ohio Heart Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8FF77491-6D8F-46B3-A501-502C02F1142F"><gtr:id>8FF77491-6D8F-46B3-A501-502C02F1142F</gtr:id><gtr:name>Bristol Royal Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A563CF9E-D910-4F6E-A378-DFA52E0D7C73"><gtr:id>A563CF9E-D910-4F6E-A378-DFA52E0D7C73</gtr:id><gtr:name>Grand View-Lehigh Valley Health Services, Buxmont Cardiology Division</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CDC99D45-9884-442F-BE35-819D60346A3E"><gtr:id>CDC99D45-9884-442F-BE35-819D60346A3E</gtr:id><gtr:name>Tongji University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D2595A40-02F9-40B1-B573-33B3549E4387"><gtr:id>D2595A40-02F9-40B1-B573-33B3549E4387</gtr:id><gtr:name>Royal Stoke University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3329A0A0-44CD-4A56-A967-27A9AA6B7E03"><gtr:id>3329A0A0-44CD-4A56-A967-27A9AA6B7E03</gtr:id><gtr:name>St. Paul's Hospital Saskatoon</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93F766A7-C3D5-4887-A6C3-A8EE13BEADC8"><gtr:id>93F766A7-C3D5-4887-A6C3-A8EE13BEADC8</gtr:id><gtr:name>Poznan Hospital Clinic 2</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DB5079E4-EF83-4AAE-B753-7E4C2283F0B0"><gtr:id>DB5079E4-EF83-4AAE-B753-7E4C2283F0B0</gtr:id><gtr:name>Royal Brisbane &amp; Women's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA2917FF-4A13-4973-ABDD-C1AFB2ABEA26"><gtr:id>FA2917FF-4A13-4973-ABDD-C1AFB2ABEA26</gtr:id><gtr:name>Wrexham Maelor Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/679189AF-44F0-429C-A7EF-08E0AD412A69"><gtr:id>679189AF-44F0-429C-A7EF-08E0AD412A69</gtr:id><gtr:name>King Chulalongkorn Memorial Hospital</gtr:name><gtr:address><gtr:line1>Sor Kor Building</gtr:line1><gtr:line2>1873 Rama IV Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C9F0518-B1C5-4A2F-9FF3-CA0424156A71"><gtr:id>9C9F0518-B1C5-4A2F-9FF3-CA0424156A71</gtr:id><gtr:name>Norrlands Universitetssjukhus</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EE12B2F4-8E8D-4C28-918A-8D2307D5E986"><gtr:id>EE12B2F4-8E8D-4C28-918A-8D2307D5E986</gtr:id><gtr:name>John Hunter Hospital</gtr:name><gtr:address><gtr:line1>John Hunter Hospital</gtr:line1><gtr:line2>Lookout Road</gtr:line2><gtr:postCode>NSW 2305</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61FCB95D-578A-4035-AB8D-4EF88551FC44"><gtr:id>61FCB95D-578A-4035-AB8D-4EF88551FC44</gtr:id><gtr:name>Florida Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/44732692-8608-469D-AD74-31CE8F0DAB19"><gtr:id>44732692-8608-469D-AD74-31CE8F0DAB19</gtr:id><gtr:name>Bendigo Health Care Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AA16163E-32C8-4098-B282-479F0F303DB3"><gtr:id>AA16163E-32C8-4098-B282-479F0F303DB3</gtr:id><gtr:name>Musgrove Park Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F518383F-A8B7-4D52-9974-2DA39525E7BC"><gtr:id>F518383F-A8B7-4D52-9974-2DA39525E7BC</gtr:id><gtr:name>Rameses Associates Ltd</gtr:name><gtr:address><gtr:line1>11 Margaret Street</gtr:line1><gtr:postCode>ST15 8EL</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/05D69417-BE9F-4C72-B26A-053781697575"><gtr:id>05D69417-BE9F-4C72-B26A-053781697575</gtr:id><gtr:name>Sunnybrook Health Sciences Centre</gtr:name><gtr:address><gtr:line1>Sunnybrook Health Sciences Centre</gtr:line1><gtr:line2>5112-2075 Bayview Ave</gtr:line2><gtr:postCode>M4N 3M5</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DB2AC066-46B3-4360-8F7A-25877A5257EB"><gtr:id>DB2AC066-46B3-4360-8F7A-25877A5257EB</gtr:id><gtr:name>St Mary's Hospital Portsmouth</gtr:name><gtr:address><gtr:line1>St Mary's Hospital Portsmouth</gtr:line1><gtr:line2>Milton Road</gtr:line2><gtr:postCode>PO3 6AD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D58A407-6680-474B-9287-9F0BF5202EB9"><gtr:id>2D58A407-6680-474B-9287-9F0BF5202EB9</gtr:id><gtr:name>School of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D6786532-77A9-4CDD-862E-D515B1F8ECAE"><gtr:id>D6786532-77A9-4CDD-862E-D515B1F8ECAE</gtr:id><gtr:name>Suzhou Kowloon Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/15ECCAA6-3377-470F-81DA-B3FB82899592"><gtr:id>15ECCAA6-3377-470F-81DA-B3FB82899592</gtr:id><gtr:name>Barnsley District General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F6A35A64-B938-432B-BF21-F0A436AE64C6"><gtr:id>F6A35A64-B938-432B-BF21-F0A436AE64C6</gtr:id><gtr:name>Central Denmark Region</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB786A43-F1A4-4783-BC0B-5F4CF7701992"><gtr:id>AB786A43-F1A4-4783-BC0B-5F4CF7701992</gtr:id><gtr:name>New Cross Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/302AA15A-7204-4286-8CE4-994DC46F09C2"><gtr:id>302AA15A-7204-4286-8CE4-994DC46F09C2</gtr:id><gtr:name>Norton Cardiovascular Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D62CCDB-B33F-4D29-BD59-BE7D305D233B"><gtr:id>5D62CCDB-B33F-4D29-BD59-BE7D305D233B</gtr:id><gtr:name>Shenyang Sujiatun Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5B0982CD-EDF6-4B1C-92CE-6DE5768C0241"><gtr:id>5B0982CD-EDF6-4B1C-92CE-6DE5768C0241</gtr:id><gtr:name>Jilin City Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6B0E70-1EDE-47A7-B3C4-27EF207152C7"><gtr:id>2F6B0E70-1EDE-47A7-B3C4-27EF207152C7</gtr:id><gtr:name>Julich Research Centre</gtr:name><gtr:address><gtr:line1>Forschungzentrum Julich GmbH</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80FA87D2-A534-45AC-A08F-7B257D59FE61"><gtr:id>80FA87D2-A534-45AC-A08F-7B257D59FE61</gtr:id><gtr:name>Waikato Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BD4E456F-AC31-4992-90AA-CACDC2DD4989"><gtr:id>BD4E456F-AC31-4992-90AA-CACDC2DD4989</gtr:id><gtr:name>Torbay Hospital</gtr:name><gtr:address><gtr:line1>Lawes Bridge</gtr:line1><gtr:postCode>TQ2 7AA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/978364D7-4073-4009-850C-0CF01A8FF936"><gtr:id>978364D7-4073-4009-850C-0CF01A8FF936</gtr:id><gtr:name>Glasgow Victoria Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5635674-848F-408A-B915-A59654BEE353"><gtr:id>F5635674-848F-408A-B915-A59654BEE353</gtr:id><gtr:name>University of Eastern Finland</gtr:name><gtr:address><gtr:line1>Yliopistokatu 7</gtr:line1><gtr:line2>Box 111</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0451156C-F2A3-4579-8F5E-BD3AED5E1B9A"><gtr:id>0451156C-F2A3-4579-8F5E-BD3AED5E1B9A</gtr:id><gtr:name>Sykehuset Telemark, Skien</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/74B72971-8647-485A-9D6C-7E30968F0135"><gtr:id>74B72971-8647-485A-9D6C-7E30968F0135</gtr:id><gtr:name>Escondido Cardiology Associates Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31D1B531-4A47-4855-B8D7-49AE02F6F66B"><gtr:id>31D1B531-4A47-4855-B8D7-49AE02F6F66B</gtr:id><gtr:name>Haugesund Hjertepraksis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/65849DDB-E500-4072-8E9D-E44749F838EE"><gtr:id>65849DDB-E500-4072-8E9D-E44749F838EE</gtr:id><gtr:name>St Vincent's Hospital</gtr:name><gtr:address><gtr:line1>St Vincent's Hospital</gtr:line1><gtr:line2>384 Victoria Street</gtr:line2><gtr:line3>Darlinghurst</gtr:line3><gtr:postCode>NSW 2010</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A0E5270-72DC-4C05-B948-ECDEB2AE1E58"><gtr:id>5A0E5270-72DC-4C05-B948-ECDEB2AE1E58</gtr:id><gtr:name>York Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F0362A7-0A4F-4B33-B00E-9C6AA3C14B32"><gtr:id>2F0362A7-0A4F-4B33-B00E-9C6AA3C14B32</gtr:id><gtr:name>SLK-Kliniken Heilbronn GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CCE44306-72AB-4B25-AF26-99F6332A69DE"><gtr:id>CCE44306-72AB-4B25-AF26-99F6332A69DE</gtr:id><gtr:name>Dialysezentrum Sch?neberg-Tempelhof Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CFE5B017-A9E3-4F81-AA65-F0D0AEB4B26A"><gtr:id>CFE5B017-A9E3-4F81-AA65-F0D0AEB4B26A</gtr:id><gtr:name>Health First Incorporation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/54622D05-A2D5-4BA5-8D00-10EDC9B430A1"><gtr:id>54622D05-A2D5-4BA5-8D00-10EDC9B430A1</gtr:id><gtr:name>Provincial Specialist Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B1CD680-6631-4C7B-A153-DD2C31509C3F"><gtr:id>7B1CD680-6631-4C7B-A153-DD2C31509C3F</gtr:id><gtr:name>Marseille Biological Cancer Laboratory</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1C44EED-5B42-4121-A76C-36754178E240"><gtr:id>A1C44EED-5B42-4121-A76C-36754178E240</gtr:id><gtr:name>KfH Nierenzentrum Eberswalde</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1342AD4A-EB68-4885-AA8C-083191883379"><gtr:id>1342AD4A-EB68-4885-AA8C-083191883379</gtr:id><gtr:name>Future Care Solution, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3DC1831-6AAD-4F98-9678-E15F5A7D5344"><gtr:id>F3DC1831-6AAD-4F98-9678-E15F5A7D5344</gtr:id><gtr:name>Universitetssykehuset Nord-Norge HF</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A915DFE8-FE38-452A-82AC-B2D05AAA3647"><gtr:id>A915DFE8-FE38-452A-82AC-B2D05AAA3647</gtr:id><gtr:name>Hopital Saint Jean - Perpignan</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D35EACB-6285-4F82-88E5-7A9EBBB78FDC"><gtr:id>5D35EACB-6285-4F82-88E5-7A9EBBB78FDC</gtr:id><gtr:name>Bedford Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Bedford Hospital 
Kempston Road</gtr:line1><gtr:city>Bedford</gtr:city><gtr:postCode>MK42 9DJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>UNITED KINGDOM</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/24716F75-ADF6-487F-BAE1-041AC6F8F49A"><gtr:id>24716F75-ADF6-487F-BAE1-041AC6F8F49A</gtr:id><gtr:name>The General Hospital Of Xuzhou Mining Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/884A93C8-8C7A-401A-9C78-C2DF85A6CE30"><gtr:id>884A93C8-8C7A-401A-9C78-C2DF85A6CE30</gtr:id><gtr:name>Verde Valley Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9526B2CC-53A2-4DC0-B1C7-B43AC1582583"><gtr:id>9526B2CC-53A2-4DC0-B1C7-B43AC1582583</gtr:id><gtr:name>Medical City</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FD7EBB98-CBC4-4658-9753-36E6BDE7D09C"><gtr:id>FD7EBB98-CBC4-4658-9753-36E6BDE7D09C</gtr:id><gtr:name>Wuhan Asia Heart Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BD266A87-3DA6-4DFA-82F0-B8DF5B091022"><gtr:id>BD266A87-3DA6-4DFA-82F0-B8DF5B091022</gtr:id><gtr:name>Middlemore Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/14DDA6BF-857D-49EA-A270-40F5DE6F4CAA"><gtr:id>14DDA6BF-857D-49EA-A270-40F5DE6F4CAA</gtr:id><gtr:name>Houma People's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/84411F68-FB80-47C5-9945-112A711ACD44"><gtr:id>84411F68-FB80-47C5-9945-112A711ACD44</gtr:id><gtr:name>Connect Clinical Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19AA400-C038-4D60-B9F6-D66C13D73703"><gtr:id>A19AA400-C038-4D60-B9F6-D66C13D73703</gtr:id><gtr:name>Falu Lasarett</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E1494FB1-6729-4473-ACC1-2186B405030B"><gtr:id>E1494FB1-6729-4473-ACC1-2186B405030B</gtr:id><gtr:name>Nephrology Center Emsland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C9DD8834-BF8B-44A9-9B79-4E1FA258C2BF"><gtr:id>C9DD8834-BF8B-44A9-9B79-4E1FA258C2BF</gtr:id><gtr:name>Nephrology Center Pforzheim</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ED5C93C8-4CAF-48C3-8392-B91D9851160F"><gtr:id>ED5C93C8-4CAF-48C3-8392-B91D9851160F</gtr:id><gtr:name>Daqing Oil Field General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E58B69F0-0D53-427E-8F78-CC0513DF733D"><gtr:id>E58B69F0-0D53-427E-8F78-CC0513DF733D</gtr:id><gtr:name>Legnano Public Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8E982CFE-5C39-4941-89F3-940E9DD2A8E0"><gtr:id>8E982CFE-5C39-4941-89F3-940E9DD2A8E0</gtr:id><gtr:name>Princess of Wales Hospital, Bridgend</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/27DE24AA-7A2D-4BD8-B074-D3E585B329FF"><gtr:id>27DE24AA-7A2D-4BD8-B074-D3E585B329FF</gtr:id><gtr:name>Royal Derby Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67F4DDE5-94CF-44CB-BBC0-24C3C582FD16"><gtr:id>67F4DDE5-94CF-44CB-BBC0-24C3C582FD16</gtr:id><gtr:name>Clearwater Cardiovascular</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ABD9F36C-3F20-4076-AE76-453AED593EA0"><gtr:id>ABD9F36C-3F20-4076-AE76-453AED593EA0</gtr:id><gtr:name>Geri-Med Oy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/905342C4-78ED-4A9F-BAE7-5160B9FDEF4E"><gtr:id>905342C4-78ED-4A9F-BAE7-5160B9FDEF4E</gtr:id><gtr:name>Ospedale F. Veneziale Pronto Soccorso</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75272066-6E82-4F65-B3F4-9BBC2C93921D"><gtr:id>75272066-6E82-4F65-B3F4-9BBC2C93921D</gtr:id><gtr:name>Lindesberg Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2892DB69-C6C1-457B-9B5E-41C8C24FBE26"><gtr:id>2892DB69-C6C1-457B-9B5E-41C8C24FBE26</gtr:id><gtr:name>Ospedale Ignazio Veris delli Ponti</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9697FD17-978E-4411-80C6-79F1837227EC"><gtr:id>9697FD17-978E-4411-80C6-79F1837227EC</gtr:id><gtr:name>The General Hospital Of AISCO</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D0BCCC88-A48A-41D9-BDE3-3F441F46D489"><gtr:id>D0BCCC88-A48A-41D9-BDE3-3F441F46D489</gtr:id><gtr:name>Southwest Florida Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/290C4F5D-FC73-40AC-821D-1A333358CFF7"><gtr:id>290C4F5D-FC73-40AC-821D-1A333358CFF7</gtr:id><gtr:name>Awasty Research Network, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1EF7934E-6F3B-4A28-BD9B-9A9538718340"><gtr:id>1EF7934E-6F3B-4A28-BD9B-9A9538718340</gtr:id><gtr:name>Peking University Third Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6DC63B6D-2F4A-4034-851A-ABB54D75E1F6"><gtr:id>6DC63B6D-2F4A-4034-851A-ABB54D75E1F6</gtr:id><gtr:name>Hospital of San Paolo</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43F2E53C-DC36-4B86-90C1-8083E914E84D"><gtr:id>43F2E53C-DC36-4B86-90C1-8083E914E84D</gtr:id><gtr:name>Community Practice Outpatient Dialysis in Augsburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E1ABB1DF-634E-4E6C-8C01-C98E5FD2851F"><gtr:id>E1ABB1DF-634E-4E6C-8C01-C98E5FD2851F</gtr:id><gtr:name>First Affiliated Hospital of Zhengzhou University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0B32E5D3-9B3C-4450-8C90-1750FB9C10EC"><gtr:id>0B32E5D3-9B3C-4450-8C90-1750FB9C10EC</gtr:id><gtr:name>Spesialistsenteret pa</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BA8DE40E-3418-4DEF-880F-B1C30C3F3E56"><gtr:id>BA8DE40E-3418-4DEF-880F-B1C30C3F3E56</gtr:id><gtr:name>Universitetssjukhuset MAS, Sweden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D0D74D75-52C4-4217-B30C-17D58BE868E5"><gtr:id>D0D74D75-52C4-4217-B30C-17D58BE868E5</gtr:id><gtr:name>Stavanger Health Research Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE35DC91-88BC-44C2-A5AD-12B6468BD7CA"><gtr:id>AE35DC91-88BC-44C2-A5AD-12B6468BD7CA</gtr:id><gtr:name>Albury Wodonga Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/64BDC344-D31D-4A63-BFDC-4ED692599F8B"><gtr:id>64BDC344-D31D-4A63-BFDC-4ED692599F8B</gtr:id><gtr:name>Skelleftea Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/171DFB17-BFDB-4090-8991-E3A1227E52A0"><gtr:id>171DFB17-BFDB-4090-8991-E3A1227E52A0</gtr:id><gtr:name>Sein?joen L??k?ritalo / Seinajoen Laakaritalo</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5382568-3EB8-401D-9279-BBE34BB27CA6"><gtr:id>D5382568-3EB8-401D-9279-BBE34BB27CA6</gtr:id><gtr:name>Barnsley Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>NHS Trust</gtr:line1><gtr:line2>Gawber Road</gtr:line2><gtr:line4>Barnsley</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S75 2EP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/98851699-8738-4111-B494-F623682216B9"><gtr:id>98851699-8738-4111-B494-F623682216B9</gtr:id><gtr:name>Harfleur - Clinic du Petit Colmoulins</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A138BDBB-F268-4730-9AB9-E560AE4A32F4"><gtr:id>A138BDBB-F268-4730-9AB9-E560AE4A32F4</gtr:id><gtr:name>Corusfit Oy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/24320172-946F-49F5-8356-40F1F4E6CB81"><gtr:id>24320172-946F-49F5-8356-40F1F4E6CB81</gtr:id><gtr:name>Watford General Hospital</gtr:name><gtr:address><gtr:line1>Watford General Hospital</gtr:line1><gtr:line2>Vicarage Road</gtr:line2><gtr:postCode>WD1 8HB</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EB2A92EB-5056-46DE-BB6E-846C4C45AD14"><gtr:id>EB2A92EB-5056-46DE-BB6E-846C4C45AD14</gtr:id><gtr:name>Nanocem Consortium</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1BB66625-E529-4E8D-B1F6-0D500FA18BF5"><gtr:id>1BB66625-E529-4E8D-B1F6-0D500FA18BF5</gtr:id><gtr:name>Epilepsy Research UK</gtr:name><gtr:address><gtr:line1>PO Box 3004</gtr:line1><gtr:postCode>W4 4XT</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C"><gtr:id>EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C</gtr:id><gtr:name>St Bartholomew's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E45EEE3E-AA10-4E7E-A143-DB1D2851810D"><gtr:id>E45EEE3E-AA10-4E7E-A143-DB1D2851810D</gtr:id><gtr:name>Heart Institute of Spokane</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D6E365B-1CB9-4312-B7D2-BE57216BF53F"><gtr:id>9D6E365B-1CB9-4312-B7D2-BE57216BF53F</gtr:id><gtr:name>Manor Hospital Walsall</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE1321FA-3A5C-482B-9B32-A9ACD5B04438"><gtr:id>BE1321FA-3A5C-482B-9B32-A9ACD5B04438</gtr:id><gtr:name>Dalian Municipal Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D4F213-AC1B-4E51-B57E-2684C82BF7D3"><gtr:id>03D4F213-AC1B-4E51-B57E-2684C82BF7D3</gtr:id><gtr:name>Health Sciences Centre - Winnipeg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19F0BEA3-1A0C-4E69-9B1B-0BB2B44C551E"><gtr:id>19F0BEA3-1A0C-4E69-9B1B-0BB2B44C551E</gtr:id><gtr:name>KfH Nierenzentrum F?rth</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90F1F733-5008-4E39-A50E-1CEF5F95B4AD"><gtr:id>90F1F733-5008-4E39-A50E-1CEF5F95B4AD</gtr:id><gtr:name>Third People's Hospital of Dalian</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F089B62D-EC0E-41A9-8126-76A9E3E1A261"><gtr:id>F089B62D-EC0E-41A9-8126-76A9E3E1A261</gtr:id><gtr:name>Peninsula Clinical Research Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/50411855-FCE3-4D0E-8916-ED312E4FB5CF"><gtr:id>50411855-FCE3-4D0E-8916-ED312E4FB5CF</gtr:id><gtr:name>Comprehensive Cardiovascular Medical Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ACF3A7B9-5DC0-4010-809A-57C74F32A308"><gtr:id>ACF3A7B9-5DC0-4010-809A-57C74F32A308</gtr:id><gtr:name>Conquest Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39EE08CC-477A-429D-BC48-2AED7098FC5A"><gtr:id>39EE08CC-477A-429D-BC48-2AED7098FC5A</gtr:id><gtr:name>Gentofte Hospital</gtr:name><gtr:address><gtr:postCode>DK-2900</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82702D12-D770-4B47-86DD-5120E4613C99"><gtr:id>82702D12-D770-4B47-86DD-5120E4613C99</gtr:id><gtr:name>Helse Sunnmmore HF</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EA4CA180-FA36-407D-AE6C-A75524ED7702"><gtr:id>EA4CA180-FA36-407D-AE6C-A75524ED7702</gtr:id><gtr:name>Jyvaskyla CorusFit Oy, Finland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75C61583-B98C-40A9-B245-9FE1FAEBFDF0"><gtr:id>75C61583-B98C-40A9-B245-9FE1FAEBFDF0</gtr:id><gtr:name>Poole Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CA10F5D0-8E26-4790-BF21-025009DDA322"><gtr:id>CA10F5D0-8E26-4790-BF21-025009DDA322</gtr:id><gtr:name>Medical University of Graz</gtr:name><gtr:address><gtr:line1>Harrachgasse 21</gtr:line1><gtr:line4>Graz</gtr:line4><gtr:line5>A-8010</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Austria</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B1E524F4-3A87-4E39-B472-75C907B5C807"><gtr:id>B1E524F4-3A87-4E39-B472-75C907B5C807</gtr:id><gtr:name>Universitetssjukhuset MAS Malm?</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4C5CA8B8-E117-4DCB-B209-BB28EE915DD7"><gtr:id>4C5CA8B8-E117-4DCB-B209-BB28EE915DD7</gtr:id><gtr:name>Ospedali Riuniti Albano - Genzano</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0860AB67-5A2F-4D97-B53D-A5FF78232595"><gtr:id>0860AB67-5A2F-4D97-B53D-A5FF78232595</gtr:id><gtr:name>KfH Nierenzentrum Trier</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55EC27AF-48C7-493C-AB4C-2B3E81114AEB"><gtr:id>55EC27AF-48C7-493C-AB4C-2B3E81114AEB</gtr:id><gtr:name>Ostersund Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/09BEB700-79CE-451D-907F-2E28054DA026"><gtr:id>09BEB700-79CE-451D-907F-2E28054DA026</gtr:id><gtr:name>St Michael's Hospital</gtr:name><gtr:address><gtr:line1>St Michael's Hospital</gtr:line1><gtr:line2>University of Bristol</gtr:line2><gtr:line3>Southwell Street</gtr:line3><gtr:postCode>BS2  8EG</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F550C119-5DE6-4E9C-8D07-97FE0315BAE1"><gtr:id>F550C119-5DE6-4E9C-8D07-97FE0315BAE1</gtr:id><gtr:name>The Rotherham NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/01C0798C-A4C2-429C-BB20-98F84676534E"><gtr:id>01C0798C-A4C2-429C-BB20-98F84676534E</gtr:id><gtr:name>Cardiovascular Associates of the Delaware Valley (CADV)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3887927A-B1C8-46AA-9422-28D266232423"><gtr:id>3887927A-B1C8-46AA-9422-28D266232423</gtr:id><gtr:name>Szpital Specjalistyczny, Dabrowa G?rnicza</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46328BEE-3030-4FB6-8468-23DC39114236"><gtr:id>46328BEE-3030-4FB6-8468-23DC39114236</gtr:id><gtr:name>Black Hills Cardiovascular</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86E7901F-BD5A-486E-BC7E-FBB7498B764E"><gtr:id>86E7901F-BD5A-486E-BC7E-FBB7498B764E</gtr:id><gtr:name>Glan Clwyd Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5C001875-4111-47E8-BCB1-1DA0ED382F9D"><gtr:id>5C001875-4111-47E8-BCB1-1DA0ED382F9D</gtr:id><gtr:name>University of Missouri Health Care</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A3DDF697-B161-42E9-A932-D49F6A3143D1"><gtr:id>A3DDF697-B161-42E9-A932-D49F6A3143D1</gtr:id><gtr:name>Regina Qu'Appelle Health Region</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/059C6045-48D4-4FFB-8C5B-14D65C740706"><gtr:id>059C6045-48D4-4FFB-8C5B-14D65C740706</gtr:id><gtr:name>Atlanta Heart Specialists, LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E34B9513-BEC0-4D97-AEFA-F3BC99F34804"><gtr:id>E34B9513-BEC0-4D97-AEFA-F3BC99F34804</gtr:id><gtr:name>Tianjin Fourth Central Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60028FD1-67AC-4B70-A3D6-94452C3C160B"><gtr:id>60028FD1-67AC-4B70-A3D6-94452C3C160B</gtr:id><gtr:name>Health Partners</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1514EF90-E0B5-468C-B560-BF831AB6BEF7"><gtr:id>1514EF90-E0B5-468C-B560-BF831AB6BEF7</gtr:id><gtr:name>Acadia Clinical Research LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4AE6001-1347-4246-84A7-81408473BD3B"><gtr:id>C4AE6001-1347-4246-84A7-81408473BD3B</gtr:id><gtr:name>Royal Cornwall Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Royal Cornwall Hospital</gtr:line1><gtr:line2>Treliske</gtr:line2><gtr:postCode>TR1 3LJ</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F409973E-3DAD-4B08-BD29-34B629FBC8DC"><gtr:id>F409973E-3DAD-4B08-BD29-34B629FBC8DC</gtr:id><gtr:name>Western New England Renal &amp; Transplant Associates (WNERTA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82810B84-873C-4E5D-B509-2919C144B2EC"><gtr:id>82810B84-873C-4E5D-B509-2919C144B2EC</gtr:id><gtr:name>First Affiliated Hospital of Xinxiang Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0822CD6A-9B78-43D7-A0F1-31617D27220E"><gtr:id>0822CD6A-9B78-43D7-A0F1-31617D27220E</gtr:id><gtr:name>Broomfield Hospital</gtr:name><gtr:address><gtr:line1>Broomfield Hospital</gtr:line1><gtr:postCode>CM1 7ET</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E913F6AA-9FFC-4300-83DB-799EC8F3A4E7"><gtr:id>E913F6AA-9FFC-4300-83DB-799EC8F3A4E7</gtr:id><gtr:name>University of Maryland</gtr:name><gtr:address><gtr:line1>University of Maryland</gtr:line1><gtr:postCode>20742</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3975F33B-4CCB-449E-8AA0-67417A3FC0AA"><gtr:id>3975F33B-4CCB-449E-8AA0-67417A3FC0AA</gtr:id><gtr:name>The 306th Hospital of PLA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AD5534A9-2E11-4569-B6B4-827643AE1A1D"><gtr:id>AD5534A9-2E11-4569-B6B4-827643AE1A1D</gtr:id><gtr:name>Westpfalz-Klinikum GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F254FBD-40D1-4FA4-B3A6-116756FAE87F"><gtr:id>7F254FBD-40D1-4FA4-B3A6-116756FAE87F</gtr:id><gtr:name>General Hospital Of Shanyang Army</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70190FBA-17F4-410B-99F0-8883DA732818"><gtr:id>70190FBA-17F4-410B-99F0-8883DA732818</gtr:id><gtr:name>Royal Victoria Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A7043EC-8B05-4B56-B68F-3E395C09AB9E"><gtr:id>4A7043EC-8B05-4B56-B68F-3E395C09AB9E</gtr:id><gtr:name>Wuhan Puai Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72E623C2-15F5-4E2A-81DD-F50F0E32358A"><gtr:id>72E623C2-15F5-4E2A-81DD-F50F0E32358A</gtr:id><gtr:name>Hospital Tengku Ampuan Rahimah</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2CDDAF38-8C8B-416D-A3E1-BA3F7E3484AD"><gtr:id>2CDDAF38-8C8B-416D-A3E1-BA3F7E3484AD</gtr:id><gtr:name>Universitaet Magdeburg Lipidambulanz</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EEC37B4-0488-487A-A125-BE8DBA45E27A"><gtr:id>9EEC37B4-0488-487A-A125-BE8DBA45E27A</gtr:id><gtr:name>Saratoga Cardiology Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8FBE4306-C04C-442E-8A40-C381F08FB50B"><gtr:id>8FBE4306-C04C-442E-8A40-C381F08FB50B</gtr:id><gtr:name>Dialysezentrum Pirmasens &amp; Kusel</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D048B75-2EBE-4220-8A00-C42953F9D76D"><gtr:id>4D048B75-2EBE-4220-8A00-C42953F9D76D</gtr:id><gtr:name>Texas Cardiology Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5C8C228-8BD6-4222-A3E3-B842AC68A36C"><gtr:id>D5C8C228-8BD6-4222-A3E3-B842AC68A36C</gtr:id><gtr:name>Launceston General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2294A225-2437-4CA3-94DA-50340C98A54E"><gtr:id>2294A225-2437-4CA3-94DA-50340C98A54E</gtr:id><gtr:name>Duke University Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE3A51FC-C401-4584-A22C-4D0619BE9801"><gtr:id>CE3A51FC-C401-4584-A22C-4D0619BE9801</gtr:id><gtr:name>Darlington Memorial Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/473F778F-73B3-4C69-BDD1-E819F5417AC9"><gtr:id>473F778F-73B3-4C69-BDD1-E819F5417AC9</gtr:id><gtr:name>Monash Children's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3178B45D-5F74-4CAB-BA6A-10796E718808"><gtr:id>3178B45D-5F74-4CAB-BA6A-10796E718808</gtr:id><gtr:name>VA Boston Healthcare System</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8CC2E3CE-75FA-461F-A3B0-860D294D060B"><gtr:id>8CC2E3CE-75FA-461F-A3B0-860D294D060B</gtr:id><gtr:name>West Cumberland Hospital</gtr:name><gtr:address><gtr:line1>Hensingham</gtr:line1><gtr:line2>Whitehaven</gtr:line2><gtr:postCode>CA28 AJG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6E097116-9BC5-4E19-9004-84DF25CC4D33"><gtr:id>6E097116-9BC5-4E19-9004-84DF25CC4D33</gtr:id><gtr:name>Shengjing Hospital of China Medical University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/29DFAD05-9F55-4706-A778-BC519B6D9B3D"><gtr:id>29DFAD05-9F55-4706-A778-BC519B6D9B3D</gtr:id><gtr:name>Gefaess Zentrum Universitaetsklinik Dresden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1C3A673-9335-402C-84FC-777BB3230197"><gtr:id>A1C3A673-9335-402C-84FC-777BB3230197</gtr:id><gtr:name>North Alabama Research Center, LLC</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C341426C-6B7F-40C3-BA31-A7169D241484"><gtr:id>C341426C-6B7F-40C3-BA31-A7169D241484</gtr:id><gtr:name>Cardiovascular Research Foundation of Southern California</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/15E25A93-2757-436A-AEDC-23749AFD09FA"><gtr:id>15E25A93-2757-436A-AEDC-23749AFD09FA</gtr:id><gtr:name>Oshawa Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/184FBFFE-8C68-4375-90C9-752F090AFE82"><gtr:id>184FBFFE-8C68-4375-90C9-752F090AFE82</gtr:id><gtr:name>Academic Clinical Hospital, Wroclaw</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1B2084F-4E44-45FB-8C5B-9A2A14B28E3D"><gtr:id>A1B2084F-4E44-45FB-8C5B-9A2A14B28E3D</gtr:id><gtr:name>Nordsj?llands Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/428B1B7D-9F67-498E-9162-8D72AE08A98A"><gtr:id>428B1B7D-9F67-498E-9162-8D72AE08A98A</gtr:id><gtr:name>Eastern Suffolk Cardiology (ESC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/429724C1-8CD5-48CE-9539-C80FEBC262A0"><gtr:id>429724C1-8CD5-48CE-9539-C80FEBC262A0</gtr:id><gtr:name>Hospital Umum Sarawak</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A601437-2EFC-42F2-9E23-3B4D475CF80D"><gtr:id>7A601437-2EFC-42F2-9E23-3B4D475CF80D</gtr:id><gtr:name>Gloucestershire Royal Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B428F6C-54DE-4BB6-B163-6FA0BD5B2368"><gtr:id>0B428F6C-54DE-4BB6-B163-6FA0BD5B2368</gtr:id><gtr:name>Hospital Kuala Terengganu</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19AE95AA-578C-40C4-907B-A3274DFFDAEB"><gtr:id>19AE95AA-578C-40C4-907B-A3274DFFDAEB</gtr:id><gtr:name>St Mark's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36E11EE6-DAC1-4D73-BCDE-158C1EF0B6C5"><gtr:id>36E11EE6-DAC1-4D73-BCDE-158C1EF0B6C5</gtr:id><gtr:name>Xuzhou Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/234BEB95-6825-49BA-ACB4-7871147654FA"><gtr:id>234BEB95-6825-49BA-ACB4-7871147654FA</gtr:id><gtr:name>UNLISTED</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/493210C7-4207-4BEA-B889-6BB88179AA95"><gtr:id>493210C7-4207-4BEA-B889-6BB88179AA95</gtr:id><gtr:name>KfH Nierenzentrum Coburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A941DC9-348C-4F6B-A556-8144215A3517"><gtr:id>0A941DC9-348C-4F6B-A556-8144215A3517</gtr:id><gtr:name>Tallahassee Research Institute Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7780E7DB-CA07-4C70-9022-F6ACAD15B202"><gtr:id>7780E7DB-CA07-4C70-9022-F6ACAD15B202</gtr:id><gtr:name>Sahlgrenska University Hospital</gtr:name><gtr:address><gtr:line1>Sahlgrenska Universitetssjukhuset</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F5629D4-145B-4F79-8D78-D7195EE2194A"><gtr:id>4F5629D4-145B-4F79-8D78-D7195EE2194A</gtr:id><gtr:name>Sydney Adventist Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3F38B91-A101-4885-AEF9-6BF7AE89A119"><gtr:id>C3F38B91-A101-4885-AEF9-6BF7AE89A119</gtr:id><gtr:name>Newmarket Cardiology Research Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/861ACCDE-0C5F-4548-A744-3332BC51C690"><gtr:id>861ACCDE-0C5F-4548-A744-3332BC51C690</gtr:id><gtr:name>PHV-Dialysezentrum Hildesheim</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78CA1442-F154-40E7-964B-12FE667ADBE0"><gtr:id>78CA1442-F154-40E7-964B-12FE667ADBE0</gtr:id><gtr:name>Hvidovre Hospital</gtr:name><gtr:address><gtr:line1>Hvidovre Hospital</gtr:line1><gtr:line2>Kettegard Alle 30</gtr:line2><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3BDF7A0F-6392-4C06-B9E2-DB17082FFDFB"><gtr:id>3BDF7A0F-6392-4C06-B9E2-DB17082FFDFB</gtr:id><gtr:name>Charite Campus Virchow-Klinikum</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51DBAC33-45DC-4304-9ACF-DDA2EB4B8482"><gtr:id>51DBAC33-45DC-4304-9ACF-DDA2EB4B8482</gtr:id><gtr:name>Cardiology Associates of Bellin Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/81897883-DBCF-400F-9BD9-6F1431971F60"><gtr:id>81897883-DBCF-400F-9BD9-6F1431971F60</gtr:id><gtr:name>Xuzhou No.1 People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FD8C7CE-7881-4D70-82C8-51E52071441B"><gtr:id>9FD8C7CE-7881-4D70-82C8-51E52071441B</gtr:id><gtr:name>Queen Margaret Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/73466115-4CD0-4CBE-B90D-28B8273E9FCC"><gtr:id>73466115-4CD0-4CBE-B90D-28B8273E9FCC</gtr:id><gtr:name>Strakonice Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D7A1300-F3AB-4A93-92E3-8EAD59F57EBF"><gtr:id>8D7A1300-F3AB-4A93-92E3-8EAD59F57EBF</gtr:id><gtr:name>Queen's University Canada</gtr:name><gtr:address><gtr:line1>99 University Avenue</gtr:line1><gtr:postCode>K7L 3N6</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9F3F5F5-C649-4720-933F-A3B567DEC3C1"><gtr:id>B9F3F5F5-C649-4720-933F-A3B567DEC3C1</gtr:id><gtr:name>Inner Mongolia Electrical Power Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BBA4B6D4-2D92-486A-9BC4-F93F0C462C0F"><gtr:id>BBA4B6D4-2D92-486A-9BC4-F93F0C462C0F</gtr:id><gtr:name>Qingdao Municipal Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E2587143-F6DB-4C96-981F-254B4BEED2C9"><gtr:id>E2587143-F6DB-4C96-981F-254B4BEED2C9</gtr:id><gtr:name>Oskarshamns Sjukhus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E62586E-7DE8-46E6-B59A-07EFD834F600"><gtr:id>4E62586E-7DE8-46E6-B59A-07EFD834F600</gtr:id><gtr:name>Saint Martin Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B769156F-CDD4-47AE-9115-AEA20000B692"><gtr:id>B769156F-CDD4-47AE-9115-AEA20000B692</gtr:id><gtr:name>Huddersfield Royal Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23CDF2CB-26A6-4301-9CD7-083C046041DA"><gtr:id>23CDF2CB-26A6-4301-9CD7-083C046041DA</gtr:id><gtr:name>Grosshadern Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8CA6AF58-E9E2-4F5A-81B8-D97AC4638AD8"><gtr:id>8CA6AF58-E9E2-4F5A-81B8-D97AC4638AD8</gtr:id><gtr:name>Carient Heart and Vascular</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62FDAC6F-3C5B-4F15-91A8-8BA72D02E149"><gtr:id>62FDAC6F-3C5B-4F15-91A8-8BA72D02E149</gtr:id><gtr:name>County Hospital, Stafford</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A8E1777-C962-47BC-8187-36ECBD3BB367"><gtr:id>4A8E1777-C962-47BC-8187-36ECBD3BB367</gtr:id><gtr:name>Francesco Ferrari Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/08631715-C842-4B84-834E-9FB33307A34D"><gtr:id>08631715-C842-4B84-834E-9FB33307A34D</gtr:id><gtr:name>Norra ?lvsborgs L?nssjukhus, Trollh?ttan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/69A8FD70-D16D-44F5-A887-6FCB239928C9"><gtr:id>69A8FD70-D16D-44F5-A887-6FCB239928C9</gtr:id><gtr:name>Rhode Island Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5FEA3988-CC47-43A0-82AB-48EBD2208B97"><gtr:id>5FEA3988-CC47-43A0-82AB-48EBD2208B97</gtr:id><gtr:name>Gotham Cardiovascular Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BEB6090A-3F57-441D-8D5A-794933DDC910"><gtr:id>BEB6090A-3F57-441D-8D5A-794933DDC910</gtr:id><gtr:name>Gentofte Sygehus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F1B962EA-3976-46C4-B486-A2AA3F1D4D8D"><gtr:id>F1B962EA-3976-46C4-B486-A2AA3F1D4D8D</gtr:id><gtr:name>Internistische Praxisklinik Kempten</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1DFD7952-2BAA-414D-AA15-F46D43D4EB55"><gtr:id>1DFD7952-2BAA-414D-AA15-F46D43D4EB55</gtr:id><gtr:name>Martin Luther University</gtr:name><gtr:address><gtr:line1>Universit?tsplatz 11</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E7F92D8-7E39-4756-AF1F-9D507C1F0098"><gtr:id>4E7F92D8-7E39-4756-AF1F-9D507C1F0098</gtr:id><gtr:name>Herning Regional Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9AB04997-6718-42F7-BA19-0AE17BBA50F1"><gtr:id>9AB04997-6718-42F7-BA19-0AE17BBA50F1</gtr:id><gtr:name>Blekinge Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80ABD8F4-FC22-47D8-BAFE-6F8D1114D2CC"><gtr:id>80ABD8F4-FC22-47D8-BAFE-6F8D1114D2CC</gtr:id><gtr:name>West Middlesex University Hospital</gtr:name><gtr:address><gtr:line1>University of Middlesex</gtr:line1><gtr:line2>Twickenham Road</gtr:line2><gtr:postCode>TW7 6AF</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C63F917E-007D-4CCB-995C-29711A966551"><gtr:id>C63F917E-007D-4CCB-995C-29711A966551</gtr:id><gtr:name>Second Affiliated Hospital of Dalian Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0EB1D5E7-E11B-4097-8AE4-7B2A41174360"><gtr:id>0EB1D5E7-E11B-4097-8AE4-7B2A41174360</gtr:id><gtr:name>Dialysepraxis Seehausen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E210CF35-6FAB-4850-90AE-9F74E7AA02AC"><gtr:id>E210CF35-6FAB-4850-90AE-9F74E7AA02AC</gtr:id><gtr:name>Royal Berkshire Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6DDF29AE-71F3-4D4B-9397-2D5E925CF93D"><gtr:id>6DDF29AE-71F3-4D4B-9397-2D5E925CF93D</gtr:id><gtr:name>Baogang Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F8EFCD07-7E2C-4F75-9E17-02C1D6A05DF4"><gtr:id>F8EFCD07-7E2C-4F75-9E17-02C1D6A05DF4</gtr:id><gtr:name>Gubbio - Ospedale Gubbio Gualdo Tadino</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8EE0E790-5A03-483D-9513-C7A090219006"><gtr:id>8EE0E790-5A03-483D-9513-C7A090219006</gtr:id><gtr:name>Vestfold Hjertesenter AS</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2593B548-FB87-4E1D-854E-2723C93D7921"><gtr:id>2593B548-FB87-4E1D-854E-2723C93D7921</gtr:id><gtr:name>Buffalo Cardiology and Pulmonary Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90586AE8-B1B4-4D85-B7CC-B9130F248E5C"><gtr:id>90586AE8-B1B4-4D85-B7CC-B9130F248E5C</gtr:id><gtr:name>University of Nebraska-Lincoln</gtr:name><gtr:address><gtr:line1>University of Nebraska-Lincoln</gtr:line1><gtr:line4>Lincoln</gtr:line4><gtr:line5>Nebraska</gtr:line5><gtr:postCode>68588-0340</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61346E56-180E-481C-B5F9-E022D99A6627"><gtr:id>61346E56-180E-481C-B5F9-E022D99A6627</gtr:id><gtr:name>Gemeinschaftspraxis Dr. Haggenmiller und Dr. Jeserich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/924D623F-7DCE-49AA-AF73-DB079B2FDE0E"><gtr:id>924D623F-7DCE-49AA-AF73-DB079B2FDE0E</gtr:id><gtr:name>Ocala Research Institute Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/701E3F4D-96E2-4A83-81E6-9605FDE69B25"><gtr:id>701E3F4D-96E2-4A83-81E6-9605FDE69B25</gtr:id><gtr:name>University Hospital of Erlangen</gtr:name><gtr:address><gtr:line1>Schwabachanlage 6</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BA04C796-8B9C-4FB5-BFE8-8B441176AC70"><gtr:id>BA04C796-8B9C-4FB5-BFE8-8B441176AC70</gtr:id><gtr:name>Oulu University Hospital</gtr:name><gtr:address><gtr:line1>Oulu University Hospital and University</gtr:line1><gtr:line2>PO Box 23</gtr:line2><gtr:postCode>90029 OYS</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECFCCC8C-325C-450F-82A7-F7B615FA1FAA"><gtr:id>ECFCCC8C-325C-450F-82A7-F7B615FA1FAA</gtr:id><gtr:name>Charlotte Heart Group Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/356FD650-5A2E-4C7B-A687-1BDEFF85C2FD"><gtr:id>356FD650-5A2E-4C7B-A687-1BDEFF85C2FD</gtr:id><gtr:name>National Clinical Research, Richmond</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A335403-97CB-467D-8557-1D6574E7270D"><gtr:id>3A335403-97CB-467D-8557-1D6574E7270D</gtr:id><gtr:name>Fu Wai Hospital</gtr:name><gtr:address><gtr:line1>167 Beilishi Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63D5DC2E-86DA-494B-AAE3-CA630ED82427"><gtr:id>63D5DC2E-86DA-494B-AAE3-CA630ED82427</gtr:id><gtr:name>MultiCare Health System</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECD366A1-8F9A-43CA-B58D-E5CDB32B1725"><gtr:id>ECD366A1-8F9A-43CA-B58D-E5CDB32B1725</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Hope Hospital</gtr:line1><gtr:line2>Stott Lane</gtr:line2><gtr:line4>Salford</gtr:line4><gtr:postCode>M6 8HD</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11BA1C71-9597-40ED-A8A0-615CE5C4E243"><gtr:id>11BA1C71-9597-40ED-A8A0-615CE5C4E243</gtr:id><gtr:name>Westmead Hospital</gtr:name><gtr:address><gtr:line1>Westmead Hospital</gtr:line1><gtr:line2>Cnr Hawkesbury and Darcy Roads</gtr:line2><gtr:postCode>NSW 2145</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F0DE12EC-900B-4C67-BB76-67A5C13B8ADC"><gtr:id>F0DE12EC-900B-4C67-BB76-67A5C13B8ADC</gtr:id><gtr:name>Frenchay Hospital</gtr:name><gtr:address><gtr:line1>Frenchay Hospital</gtr:line1><gtr:line2>Frenchay Park Road</gtr:line2><gtr:line3>Frenchay</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:postCode>BS16 1LE</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CC9E0DD3-10E2-4892-9974-F5952DB8AF8B"><gtr:id>CC9E0DD3-10E2-4892-9974-F5952DB8AF8B</gtr:id><gtr:name>Third Xiangya Hospital of Central South University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99883644-5867-461D-9568-962C7596135D"><gtr:id>99883644-5867-461D-9568-962C7596135D</gtr:id><gtr:name>KfH Nierenzentrum Bamberg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F213414-B66E-454F-9F35-596138E443BD"><gtr:id>5F213414-B66E-454F-9F35-596138E443BD</gtr:id><gtr:name>The People's Hospital Of Liaoning Province</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FE6FBD6-F011-47BA-90EE-39494C496CB3"><gtr:id>8FE6FBD6-F011-47BA-90EE-39494C496CB3</gtr:id><gtr:name>Southwest University</gtr:name><gtr:address><gtr:line1>2 Road Tiansheng</gtr:line1><gtr:postCode>400715</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/132225E8-29CD-4330-8185-C1A2A3699111"><gtr:id>132225E8-29CD-4330-8185-C1A2A3699111</gtr:id><gtr:name>Raigmore Hospital</gtr:name><gtr:address><gtr:line1>Old Perth Road</gtr:line1><gtr:postCode>IV2 3UJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/14BF88C8-470C-4093-B258-6BDF91FA5614"><gtr:id>14BF88C8-470C-4093-B258-6BDF91FA5614</gtr:id><gtr:name>Viborg Regional Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A3632DE8-BAC1-432B-B6AE-6D0AC367C94B"><gtr:id>A3632DE8-BAC1-432B-B6AE-6D0AC367C94B</gtr:id><gtr:name>Halmstads Sjukhus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/098DBCCE-4144-4026-9B7E-6A5EE41CF563"><gtr:id>098DBCCE-4144-4026-9B7E-6A5EE41CF563</gtr:id><gtr:name>Northampton General Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Cliftonville</gtr:line1><gtr:postCode>NN1 5BD</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62C09B8D-45DC-4EE0-93D7-03764D8D098B"><gtr:id>62C09B8D-45DC-4EE0-93D7-03764D8D098B</gtr:id><gtr:name>Gentofte Hospital 2</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8DFF6A88-08FC-405F-9C16-08057322BD26"><gtr:id>8DFF6A88-08FC-405F-9C16-08057322BD26</gtr:id><gtr:name>Zhengzhou Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30A555B-E689-4D06-8E68-3358E55788BE"><gtr:id>E30A555B-E689-4D06-8E68-3358E55788BE</gtr:id><gtr:name>Maharaj Nakorn Chiang Mai Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37099067-27C9-43AA-8AFD-84FF45326287"><gtr:id>37099067-27C9-43AA-8AFD-84FF45326287</gtr:id><gtr:name>Hjerteklinikken i Harstad AS, Norway</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3350DC58-5D48-4A46-86F2-4D31450BA798"><gtr:id>3350DC58-5D48-4A46-86F2-4D31450BA798</gtr:id><gtr:name>Harlem Hospital Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/92F81743-12CA-4C06-9CDF-5AB4B09B6F38"><gtr:id>92F81743-12CA-4C06-9CDF-5AB4B09B6F38</gtr:id><gtr:name>Sir Charles Gairdner Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/69D8A011-CBF3-4EB5-8ECE-63B5E70F6416"><gtr:id>69D8A011-CBF3-4EB5-8ECE-63B5E70F6416</gtr:id><gtr:name>Hopital Maisonneuve-Rosemont</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7C2010AB-D714-4749-BBF3-59C9C137056E"><gtr:id>7C2010AB-D714-4749-BBF3-59C9C137056E</gtr:id><gtr:name>Avera Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9CC28215-42C0-4D9B-A6AB-3E26FCAF5951"><gtr:id>9CC28215-42C0-4D9B-A6AB-3E26FCAF5951</gtr:id><gtr:name>Hjarthuset AB, Varberg, Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD6EF798-1631-4DB7-AD11-DD9BD00568B1"><gtr:id>DD6EF798-1631-4DB7-AD11-DD9BD00568B1</gtr:id><gtr:name>Hospital del Mar</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/662BF024-62D0-4EA2-B0EA-9A6EB07C704B"><gtr:id>662BF024-62D0-4EA2-B0EA-9A6EB07C704B</gtr:id><gtr:name>Memorial Hospital, Darlington</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1474FDAB-9358-4F6C-BA8F-A1D1F01B4617"><gtr:id>1474FDAB-9358-4F6C-BA8F-A1D1F01B4617</gtr:id><gtr:name>Klinikum Coburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E26C4939-F3A1-4655-A5E0-550A46380128"><gtr:id>E26C4939-F3A1-4655-A5E0-550A46380128</gtr:id><gtr:name>Klinikum Frankfurt H?chst</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D0580610-2CED-4B40-98FA-EC2311C94F96"><gtr:id>D0580610-2CED-4B40-98FA-EC2311C94F96</gtr:id><gtr:name>Shenyang Fourth People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1388E354-AFFA-4C1C-BC1F-2B09B644BA28"><gtr:id>1388E354-AFFA-4C1C-BC1F-2B09B644BA28</gtr:id><gtr:name>Ospedali Riuniti</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B81D5AE-90EB-42E6-855F-A0F582DA5820"><gtr:id>1B81D5AE-90EB-42E6-855F-A0F582DA5820</gtr:id><gtr:name>Royal North Shore Hospital</gtr:name><gtr:address><gtr:line1>St Lenards</gtr:line1><gtr:postCode>2065</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A6F1C95E-7B55-4CE1-8FA3-35E3267C5473"><gtr:id>A6F1C95E-7B55-4CE1-8FA3-35E3267C5473</gtr:id><gtr:name>InterMed</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30EB6540-762D-4FCA-8243-E7BE23908390"><gtr:id>30EB6540-762D-4FCA-8243-E7BE23908390</gtr:id><gtr:name>Nepean Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29"><gtr:id>7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29</gtr:id><gtr:name>Royal Preston Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BCD054BE-CBB2-4E2A-BF44-28547B2E9891"><gtr:id>BCD054BE-CBB2-4E2A-BF44-28547B2E9891</gtr:id><gtr:name>Novant Health Heart and Vascular Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/303E2392-4064-48A4-99F4-4ADB9D75C377"><gtr:id>303E2392-4064-48A4-99F4-4ADB9D75C377</gtr:id><gtr:name>St George's Hospital</gtr:name><gtr:address><gtr:line1>Blackshaw Road</gtr:line1><gtr:line2>Tooting</gtr:line2><gtr:postCode>SW17 0QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F835191-AA04-4F96-8432-277EFB3D9475"><gtr:id>1F835191-AA04-4F96-8432-277EFB3D9475</gtr:id><gtr:name>NYU Hudson Valley Cardiology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/468B44E5-2D7A-46BE-907F-426A83CDCB9C"><gtr:id>468B44E5-2D7A-46BE-907F-426A83CDCB9C</gtr:id><gtr:name>Ninewells Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CC884DBE-E63D-416D-8328-48CB16276834"><gtr:id>CC884DBE-E63D-416D-8328-48CB16276834</gtr:id><gtr:name>Manchester Royal Infirmary</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A040EC9D-77F3-4B52-8379-7621F3632C7E"><gtr:id>A040EC9D-77F3-4B52-8379-7621F3632C7E</gtr:id><gtr:name>G&amp;G Research Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F8E5752-68D3-477B-9E86-D7C9968C5560"><gtr:id>6F8E5752-68D3-477B-9E86-D7C9968C5560</gtr:id><gtr:name>North Ohio Research Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EF372E2-3083-4984-A0FA-AF78EB0C7E64"><gtr:id>9EF372E2-3083-4984-A0FA-AF78EB0C7E64</gtr:id><gtr:name>St. Josefs Hospital Cloppenburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CBBBC327-11B9-4689-A4F7-762CCB65DA26"><gtr:id>CBBBC327-11B9-4689-A4F7-762CCB65DA26</gtr:id><gtr:name>Discovery Clinical Services Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2B4890EC-5704-4F99-AE13-CC1371378CBB"><gtr:id>2B4890EC-5704-4F99-AE13-CC1371378CBB</gtr:id><gtr:name>Copenhagen University Hospital</gtr:name><gtr:address><gtr:line1>Kettegaard Alle 30</gtr:line1><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A643A122-531B-44C9-BE5F-7408FD89C354"><gtr:id>A643A122-531B-44C9-BE5F-7408FD89C354</gtr:id><gtr:name>North Karelia Project Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/79D90120-8141-469E-83F6-46828ABB0C89"><gtr:id>79D90120-8141-469E-83F6-46828ABB0C89</gtr:id><gtr:name>Zhuzhou No.1 Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77B70E31-12F7-45F4-B979-2F9951F0A344"><gtr:id>77B70E31-12F7-45F4-B979-2F9951F0A344</gtr:id><gtr:name>Affiliated Hospital of Xuzhou Medical College</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A6A4BD71-2EF8-4D38-80D0-0E5F9378688A"><gtr:id>A6A4BD71-2EF8-4D38-80D0-0E5F9378688A</gtr:id><gtr:name>Ministry of Justice (Brazil)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DA279075-4AF6-4948-8034-C98867EE3B27"><gtr:id>DA279075-4AF6-4948-8034-C98867EE3B27</gtr:id><gtr:name>H?pital du Sacr?-Coeur de Montr?al</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F94A5B13-041B-41FC-A2C4-F8ECF0A2F373"><gtr:id>F94A5B13-041B-41FC-A2C4-F8ECF0A2F373</gtr:id><gtr:name>Royal United Hospital NHS</gtr:name><gtr:address><gtr:line1>Royal United Hospital</gtr:line1><gtr:line2>Combe Park</gtr:line2><gtr:postCode>BA1 3NG</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/500AD7E2-35EF-4C02-AF6F-719636D6ADFD"><gtr:id>500AD7E2-35EF-4C02-AF6F-719636D6ADFD</gtr:id><gtr:name>Fourth Affiliated Hospital Of China Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6D82075A-731A-4ACD-994A-7C070DBD5FD0"><gtr:id>6D82075A-731A-4ACD-994A-7C070DBD5FD0</gtr:id><gtr:name>Hillingdon Hospital, Uxbridge</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4688C4BE-4DA7-44F6-B33C-8B701BCFEE33"><gtr:id>4688C4BE-4DA7-44F6-B33C-8B701BCFEE33</gtr:id><gtr:name>Heritage Medical Research Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1179BA2-D96B-48F9-8DEA-35D0E9F7427B"><gtr:id>A1179BA2-D96B-48F9-8DEA-35D0E9F7427B</gtr:id><gtr:name>Satakunta Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AF29214D-A1C5-45E9-81A8-831E2A50ECA0"><gtr:id>AF29214D-A1C5-45E9-81A8-831E2A50ECA0</gtr:id><gtr:name>Jacksonville Centre for Clinical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4489F2C4-061B-49A9-9E72-9ACC7ECCA2AF"><gtr:id>4489F2C4-061B-49A9-9E72-9ACC7ECCA2AF</gtr:id><gtr:name>Derriford Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE2E996-FB8F-4404-B8AD-8380898F8850"><gtr:id>5EE2E996-FB8F-4404-B8AD-8380898F8850</gtr:id><gtr:name>Sint Lucas Andreas Ziekenhuis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8AC941F7-8CF0-43F9-88AA-278632E6A962"><gtr:id>8AC941F7-8CF0-43F9-88AA-278632E6A962</gtr:id><gtr:name>First Hospital of Jilin University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC47A4DF-0946-4222-BDE6-982898A32DD1"><gtr:id>FC47A4DF-0946-4222-BDE6-982898A32DD1</gtr:id><gtr:name>Marshfield Clinic Research Foundation</gtr:name><gtr:address><gtr:line1>Center for Human Genetics, MLR</gtr:line1><gtr:line2>Marshfield Clinic</gtr:line2><gtr:line3>1000 North Oak Ave</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CDE11331-8129-4BDC-9AA9-09B828DC99EB"><gtr:id>CDE11331-8129-4BDC-9AA9-09B828DC99EB</gtr:id><gtr:name>Leighton Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDA71A8B-3A0A-45A6-884C-C267316CEDF6"><gtr:id>BDA71A8B-3A0A-45A6-884C-C267316CEDF6</gtr:id><gtr:name>Charles LeMoyne Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7A72D78-3889-48F8-BD20-1C70ED5D6A3E"><gtr:id>C7A72D78-3889-48F8-BD20-1C70ED5D6A3E</gtr:id><gtr:name>Q &amp; T Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF788313-87E6-4237-B2DD-B1E70FB4DD58"><gtr:id>FF788313-87E6-4237-B2DD-B1E70FB4DD58</gtr:id><gtr:name>University Medical Center G?ttingen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7E12A8CD-0F83-4A1D-BE8B-BE9189E0A54F"><gtr:id>7E12A8CD-0F83-4A1D-BE8B-BE9189E0A54F</gtr:id><gtr:name>Cairns Base Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/65CBBD28-0111-4C62-A98F-8CE7C8084C67"><gtr:id>65CBBD28-0111-4C62-A98F-8CE7C8084C67</gtr:id><gtr:name>Laurentius Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/07150914-4974-462F-8854-095C7E7D8655"><gtr:id>07150914-4974-462F-8854-095C7E7D8655</gtr:id><gtr:name>Premier Healthcare, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3344C704-70F4-4171-A461-83CC376CC533"><gtr:id>3344C704-70F4-4171-A461-83CC376CC533</gtr:id><gtr:name>Danderyd Hospital (Danderyds sjukhus)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE8B9EF4-AA3E-40BF-9C34-9203544CE129"><gtr:id>FE8B9EF4-AA3E-40BF-9C34-9203544CE129</gtr:id><gtr:name>China-Japan Union Hospital of Jilin University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3FABD0D8-DAEC-44D8-9072-2FD22B5BF2C6"><gtr:id>3FABD0D8-DAEC-44D8-9072-2FD22B5BF2C6</gtr:id><gtr:name>The First Affiliated Hospital of Baotou Medical College</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D7054AD-21D8-4F59-A4B0-824DB85B8741"><gtr:id>8D7054AD-21D8-4F59-A4B0-824DB85B8741</gtr:id><gtr:name>Liaoning Provincial People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C0EB6B5-6CC4-4FCE-A7B3-686186B00CDD"><gtr:id>2C0EB6B5-6CC4-4FCE-A7B3-686186B00CDD</gtr:id><gtr:name>Renal Research Institute RRI</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5418652-2386-4D9F-A0CC-463787258ABD"><gtr:id>F5418652-2386-4D9F-A0CC-463787258ABD</gtr:id><gtr:name>Alfred Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47AB0710-E78B-4799-8346-770708E44A0A"><gtr:id>47AB0710-E78B-4799-8346-770708E44A0A</gtr:id><gtr:name>Helse Forde HF</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D4B99A3F-3131-4DB7-94FA-25856BDD1B20"><gtr:id>D4B99A3F-3131-4DB7-94FA-25856BDD1B20</gtr:id><gtr:name>Ospedale Maggiore</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB478ACF-F8F9-40E4-BB10-E1DC69A6A75E"><gtr:id>BB478ACF-F8F9-40E4-BB10-E1DC69A6A75E</gtr:id><gtr:name>Heart Research UK</gtr:name><gtr:address><gtr:line1>Suite 12D</gtr:line1><gtr:line2>Josephs Well</gtr:line2><gtr:postCode>LS3 1AB</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8516D1B6-37AA-4051-A58C-59EB501A16E9"><gtr:id>8516D1B6-37AA-4051-A58C-59EB501A16E9</gtr:id><gtr:name>Taiyuan City Centre Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5157264D-6981-4EBC-97E0-9DACD40D3DEC"><gtr:id>5157264D-6981-4EBC-97E0-9DACD40D3DEC</gtr:id><gtr:name>Fana Hjertesenter AS</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/18189AC3-F58B-4875-B612-3E6DFECC63CA"><gtr:id>18189AC3-F58B-4875-B612-3E6DFECC63CA</gtr:id><gtr:name>Kidney Associates, PLLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1A4EA0D0-69DB-4E7F-A621-CC2BAA3550E2"><gtr:id>1A4EA0D0-69DB-4E7F-A621-CC2BAA3550E2</gtr:id><gtr:name>Associated Research Partners LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/166BBB5A-BE49-4AD7-9F54-6256F059C802"><gtr:id>166BBB5A-BE49-4AD7-9F54-6256F059C802</gtr:id><gtr:name>The Wallace-Kelsey Research Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80E0171B-8C2E-4229-A9F3-041CCB348217"><gtr:id>80E0171B-8C2E-4229-A9F3-041CCB348217</gtr:id><gtr:name>St Luke's Hospital, Dublin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4EBF298-A6F7-4512-8612-770C8233F31A"><gtr:id>F4EBF298-A6F7-4512-8612-770C8233F31A</gtr:id><gtr:name>Wollongong Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75E7FC4F-8F59-4D32-9008-5976FFFFF12D"><gtr:id>75E7FC4F-8F59-4D32-9008-5976FFFFF12D</gtr:id><gtr:name>Tenon Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8ACE27BB-E375-48BA-9F43-EB264C0BCF04"><gtr:id>8ACE27BB-E375-48BA-9F43-EB264C0BCF04</gtr:id><gtr:name>Dalecarlia Clinical Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AF8E13-A8FB-4FB6-8E64-CDD23B65A006"><gtr:id>75AF8E13-A8FB-4FB6-8E64-CDD23B65A006</gtr:id><gtr:name>Permian Research Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0CEB4460-F06F-4F94-A663-33125D59655F"><gtr:id>0CEB4460-F06F-4F94-A663-33125D59655F</gtr:id><gtr:name>Provincial Specialist Hospital No 5. St. Barbara</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B7F99893-CCBE-456F-B252-698F8A130EF9"><gtr:id>B7F99893-CCBE-456F-B252-698F8A130EF9</gtr:id><gtr:name>PHV-Dialysezentrum Wilhelmshaven</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F4D3582-0B23-4B99-A6F9-921D48A3935A"><gtr:id>6F4D3582-0B23-4B99-A6F9-921D48A3935A</gtr:id><gtr:name>Milano - Ospedale Niguarda</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95FB2B17-31DC-4679-9388-DA58B9CC7917"><gtr:id>95FB2B17-31DC-4679-9388-DA58B9CC7917</gtr:id><gtr:name>David M. Kates Medical Services Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4847D437-2655-4B81-8F64-C8426072D914"><gtr:id>4847D437-2655-4B81-8F64-C8426072D914</gtr:id><gtr:name>KfH Nierenzentrum Marl</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8DFDF247-A072-43F9-BEC8-F171E33182BB"><gtr:id>8DFDF247-A072-43F9-BEC8-F171E33182BB</gtr:id><gtr:name>Universit?tsklinik f?r Innere Medizin Innsbruck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C0E103C-B16F-4556-8152-5BAAD1BAC79C"><gtr:id>4C0E103C-B16F-4556-8152-5BAAD1BAC79C</gtr:id><gtr:name>Santa Rosa Cardiology Medical Group, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2AAEC2E2-EAC7-4AAE-8496-5231A5D18AEB"><gtr:id>2AAEC2E2-EAC7-4AAE-8496-5231A5D18AEB</gtr:id><gtr:name>DRK Kliniken Berlin Westend</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/21DC7FA1-CCE0-4E14-9708-B2AC7026E58A"><gtr:id>21DC7FA1-CCE0-4E14-9708-B2AC7026E58A</gtr:id><gtr:name>S?nderborg Sygehus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/00FF9FA9-F966-4D0D-80A6-A11BE7C2CFE6"><gtr:id>00FF9FA9-F966-4D0D-80A6-A11BE7C2CFE6</gtr:id><gtr:name>Louisville Metabolic and Atherosclerosis Research Centre (L-MARC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8E5E2AD5-89D3-4388-A262-CFB545B5ABDD"><gtr:id>8E5E2AD5-89D3-4388-A262-CFB545B5ABDD</gtr:id><gtr:name>Tianjin Chest Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F294D2A2-D662-4307-9966-020275C7F6F7"><gtr:id>F294D2A2-D662-4307-9966-020275C7F6F7</gtr:id><gtr:name>The Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFE4BBFC-F5BB-4312-8DD8-B8741BE3B856"><gtr:id>AFE4BBFC-F5BB-4312-8DD8-B8741BE3B856</gtr:id><gtr:name>Whiston Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B5E4682-9906-4E2B-9B5A-FE53A302974E"><gtr:id>4B5E4682-9906-4E2B-9B5A-FE53A302974E</gtr:id><gtr:name>Ospedale di Jalmicco di Palmanova</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E8E15A6C-B983-40C3-9EA5-64ABDD6EB216"><gtr:id>E8E15A6C-B983-40C3-9EA5-64ABDD6EB216</gtr:id><gtr:name>King's Mill Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B15331A-48F1-49FC-9B5D-B2578070359B"><gtr:id>3B15331A-48F1-49FC-9B5D-B2578070359B</gtr:id><gtr:name>East and North Hertfordshire NHS Trust</gtr:name><gtr:address><gtr:line1>R &amp; D, LC357D</gtr:line1><gtr:line2>Clinical Governance</gtr:line2><gtr:line3>Anritsu House</gtr:line3><gtr:postCode>SG1 4AB</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44FD3240-3F57-4563-8656-1BE32246E2A6"><gtr:id>44FD3240-3F57-4563-8656-1BE32246E2A6</gtr:id><gtr:name>Nephrology Practice and Dialysis Oldenburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B0511743-88C0-483B-A46D-AFE931364B77"><gtr:id>B0511743-88C0-483B-A46D-AFE931364B77</gtr:id><gtr:name>Royal Adelaide Hospital</gtr:name><gtr:address><gtr:line1>Royal Adelaide Hospital</gtr:line1><gtr:line2>North Terrace</gtr:line2><gtr:postCode>SA 5000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E6ADDEA8-D0AE-4CA2-8C9F-42AAE8E6ECCC"><gtr:id>E6ADDEA8-D0AE-4CA2-8C9F-42AAE8E6ECCC</gtr:id><gtr:name>East Lancashire Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Midtherm Estate</gtr:line1><gtr:line2>New Road</gtr:line2><gtr:line3>Netherton</gtr:line3><gtr:postCode>DY2 8SY</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/21E92A8C-1B13-4E25-97C2-F0248458657B"><gtr:id>21E92A8C-1B13-4E25-97C2-F0248458657B</gtr:id><gtr:name>San Giuseppe E Melorio Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE63160B-D70B-48E2-B58D-A1EEA035E9A5"><gtr:id>EE63160B-D70B-48E2-B58D-A1EEA035E9A5</gtr:id><gtr:name>Victoria Hospital</gtr:name><gtr:address><gtr:line1>Victoria Hospital</gtr:line1><gtr:line2>Avon &amp; Wilts Mental Health Partnership</gtr:line2><gtr:line3>Okus Road</gtr:line3><gtr:postCode>SN1 4HZ</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B45F9BC8-9D5F-4036-B77D-38D6A2EDA6E3"><gtr:id>B45F9BC8-9D5F-4036-B77D-38D6A2EDA6E3</gtr:id><gtr:name>St. Johns Center For Clinical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36AA115C-193F-455C-BCC8-B2E30841825C"><gtr:id>36AA115C-193F-455C-BCC8-B2E30841825C</gtr:id><gtr:name>Vancouver General Hospital</gtr:name><gtr:address><gtr:line1>910 West 10th Avenue</gtr:line1><gtr:postCode>V5Z 4E3</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8D0486A-BEA8-4028-B0B2-85367D9CB290"><gtr:id>B8D0486A-BEA8-4028-B0B2-85367D9CB290</gtr:id><gtr:name>Holb?k Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/129081D6-64EA-49BF-A8EE-69D1925F6B8B"><gtr:id>129081D6-64EA-49BF-A8EE-69D1925F6B8B</gtr:id><gtr:name>Blackpool Victoria Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5148A86D-1AD0-45A1-9690-B5193D1C994A"><gtr:id>5148A86D-1AD0-45A1-9690-B5193D1C994A</gtr:id><gtr:name>Nephrology Center Villingen-Schwenningen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E1EABBB-9A65-47C4-9E46-CE516CC31E40"><gtr:id>1E1EABBB-9A65-47C4-9E46-CE516CC31E40</gtr:id><gtr:name>Medialpha Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A8D2EC9-94C4-4EF6-9FC0-196AD5AB0B94"><gtr:id>0A8D2EC9-94C4-4EF6-9FC0-196AD5AB0B94</gtr:id><gtr:name>Sandwell General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33D34CD1-B648-4521-B37B-8CF4DA94DC4D"><gtr:id>33D34CD1-B648-4521-B37B-8CF4DA94DC4D</gtr:id><gtr:name>Provincial Specialist Hospital No. 4</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3FEB516-8904-471A-988B-63F9FE3E419E"><gtr:id>D3FEB516-8904-471A-988B-63F9FE3E419E</gtr:id><gtr:name>Hospital of St Cross, Rugby</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/45FB8B32-D202-420F-8BF5-410762544260"><gtr:id>45FB8B32-D202-420F-8BF5-410762544260</gtr:id><gtr:name>Wycombe General Hospital</gtr:name><gtr:address><gtr:line1>Department of Cardiology</gtr:line1><gtr:postCode>HP11 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D138473C-B2AB-4C88-A54E-6F0159DD9F11"><gtr:id>D138473C-B2AB-4C88-A54E-6F0159DD9F11</gtr:id><gtr:name>The Polyclinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AD58C2C8-7678-4048-A276-B8888EBCE9FA"><gtr:id>AD58C2C8-7678-4048-A276-B8888EBCE9FA</gtr:id><gtr:name>Santa Maria della Misericordia Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/263639C4-C98F-4CC7-A05B-B268F1C1BC69"><gtr:id>263639C4-C98F-4CC7-A05B-B268F1C1BC69</gtr:id><gtr:name>Yeovil District Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/79B385D4-191F-4B76-A615-F0803A40167F"><gtr:id>79B385D4-191F-4B76-A615-F0803A40167F</gtr:id><gtr:name>Green and Seidner Family Practice Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAC6A24E-71C2-476D-80D2-7CF844CDBA16"><gtr:id>DAC6A24E-71C2-476D-80D2-7CF844CDBA16</gtr:id><gtr:name>Queen Elizabeth Hospital Birmingham</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FD8B609D-89F8-4B17-BD36-406DD213E2EB"><gtr:id>FD8B609D-89F8-4B17-BD36-406DD213E2EB</gtr:id><gtr:name>Deutsches Zentrum fur Herzinsuffizienz</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF96472C-C9CC-4D84-A2E5-C304A7501580"><gtr:id>EF96472C-C9CC-4D84-A2E5-C304A7501580</gtr:id><gtr:name>Robert Bosch Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6247E498-92C6-4C0B-8147-1A071AF15CAC"><gtr:id>6247E498-92C6-4C0B-8147-1A071AF15CAC</gtr:id><gtr:name>Dialysezentrum Jacobistra?e D?sseldorf</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C2E28AF8-1471-480C-BE2D-46803E77DAD6"><gtr:id>C2E28AF8-1471-480C-BE2D-46803E77DAD6</gtr:id><gtr:name>Martini Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F81D027-0815-4811-9521-7663CE283316"><gtr:id>7F81D027-0815-4811-9521-7663CE283316</gtr:id><gtr:name>Oklahoma City VA Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8EE049D3-3DAA-40DD-89F2-6C3E4E1CA64D"><gtr:id>8EE049D3-3DAA-40DD-89F2-6C3E4E1CA64D</gtr:id><gtr:name>Whipps Cross University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89EE1AB0-C210-4309-8DB3-266D71B262C6"><gtr:id>89EE1AB0-C210-4309-8DB3-266D71B262C6</gtr:id><gtr:name>Capital Cardiology Associates (Albany)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE"><gtr:id>70E126BA-0BE9-4210-9FDB-18ECEE1A3FEE</gtr:id><gtr:name>North Middlesex University Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D6C7DAD0-6919-4A1D-BD5B-FE848ADE5E11"><gtr:id>D6C7DAD0-6919-4A1D-BD5B-FE848ADE5E11</gtr:id><gtr:name>Royal Thai Air Force</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8718A14F-93E2-4E56-8383-740ED8B97887"><gtr:id>8718A14F-93E2-4E56-8383-740ED8B97887</gtr:id><gtr:name>Pottstown Medical Specialists</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBD09011-CD14-4117-A8E1-80993DE17411"><gtr:id>DBD09011-CD14-4117-A8E1-80993DE17411</gtr:id><gtr:name>St. Paul's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/24ECB2D8-76A9-42D7-8521-EFDD6E726909"><gtr:id>24ECB2D8-76A9-42D7-8521-EFDD6E726909</gtr:id><gtr:name>Inner Mongolia Baotou City Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/24BA4B6C-A7D3-4C6E-8823-03BC38817B09"><gtr:id>24BA4B6C-A7D3-4C6E-8823-03BC38817B09</gtr:id><gtr:name>Ryhov Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CC0CE6A-7116-4DF5-BD06-DCBB441D299D"><gtr:id>2CC0CE6A-7116-4DF5-BD06-DCBB441D299D</gtr:id><gtr:name>LeBauer Cardiovascular Research Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/588EB53D-3C4A-47E1-8701-6650F39FB6A8"><gtr:id>588EB53D-3C4A-47E1-8701-6650F39FB6A8</gtr:id><gtr:name>HDS Eurocare, Teplice</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5CF98B10-17A4-4967-BD26-AFA870C6F10B"><gtr:id>5CF98B10-17A4-4967-BD26-AFA870C6F10B</gtr:id><gtr:name>Capital Cardiology Associates (Troy)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41E94F16-CF2C-4A4E-9784-C45BBBB5772D"><gtr:id>41E94F16-CF2C-4A4E-9784-C45BBBB5772D</gtr:id><gtr:name>Marin Endocrine Care Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EFBACAD1-5E59-41E9-BA5B-45D424EDE604"><gtr:id>EFBACAD1-5E59-41E9-BA5B-45D424EDE604</gtr:id><gtr:name>Infermi Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95911D1A-93BC-4C4F-99D4-F42F6D2BE9E0"><gtr:id>95911D1A-93BC-4C4F-99D4-F42F6D2BE9E0</gtr:id><gtr:name>Innovative Research of West Florida, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6FC20194-862D-4740-8B03-267ED4452E50"><gtr:id>6FC20194-862D-4740-8B03-267ED4452E50</gtr:id><gtr:name>Dialysezentrum Karlstra?e D?sseldorf</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA37F95F-14BE-4EB2-8572-1492865850ED"><gtr:id>FA37F95F-14BE-4EB2-8572-1492865850ED</gtr:id><gtr:name>Alingsas lasarett</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B593CA15-69E5-4012-919D-F74E2C405412"><gtr:id>B593CA15-69E5-4012-919D-F74E2C405412</gtr:id><gtr:name>First People's Hospital Of Shenyang</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/575D825E-6BAE-4FA1-ACB6-9069D2633D70"><gtr:id>575D825E-6BAE-4FA1-ACB6-9069D2633D70</gtr:id><gtr:name>Thunder Bay Regional Health Sciences Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B4B6AA94-773C-4584-A0D9-778866B08BD5"><gtr:id>B4B6AA94-773C-4584-A0D9-778866B08BD5</gtr:id><gtr:name>Anshan Shuangshan Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDCC8BB0-21CC-4E55-AB38-C785D85BE3B0"><gtr:id>BDCC8BB0-21CC-4E55-AB38-C785D85BE3B0</gtr:id><gtr:name>Maine Research Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91C308E2-1EBA-4CC1-8183-0371468DE15E"><gtr:id>91C308E2-1EBA-4CC1-8183-0371468DE15E</gtr:id><gtr:name>Wayne State University</gtr:name><gtr:address><gtr:line1>Detroit</gtr:line1><gtr:line2>Michigan</gtr:line2><gtr:line3>MI 48202</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/27274B26-7873-4CFC-BE5E-3A9A7097F6B9"><gtr:id>27274B26-7873-4CFC-BE5E-3A9A7097F6B9</gtr:id><gtr:name>St Helier's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0C87EE67-DC4E-4238-A08B-045D4D715BC9"><gtr:id>0C87EE67-DC4E-4238-A08B-045D4D715BC9</gtr:id><gtr:name>Wythenshawe Hospital</gtr:name><gtr:address><gtr:line1>Southmoor Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:postCode>M23 9LT</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BC1B572-9F0A-4572-B840-6400E9A4CF89"><gtr:id>8BC1B572-9F0A-4572-B840-6400E9A4CF89</gtr:id><gtr:name>Albany Associates in Cardiology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF449342-AF1A-4D3F-B833-8F6DB8687F7D"><gtr:id>CF449342-AF1A-4D3F-B833-8F6DB8687F7D</gtr:id><gtr:name>Uppsala University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4DB24FF-1BAB-4902-AA72-42D4EC2BE555"><gtr:id>C4DB24FF-1BAB-4902-AA72-42D4EC2BE555</gtr:id><gtr:name>Beverly Hills Heart Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/367FC75E-8399-475A-BFA2-B4991E0FD569"><gtr:id>367FC75E-8399-475A-BFA2-B4991E0FD569</gtr:id><gtr:name>Fremantle Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61B567B5-BA73-491F-831C-F3F1C7E784C6"><gtr:id>61B567B5-BA73-491F-831C-F3F1C7E784C6</gtr:id><gtr:name>Hospital Kuala Lumpur</gtr:name><gtr:address><gtr:line1>Jalan Pahang</gtr:line1><gtr:line2>50586 Kuala Lumpur</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/061EAD10-B0F0-42F8-B9C1-79819FC4563A"><gtr:id>061EAD10-B0F0-42F8-B9C1-79819FC4563A</gtr:id><gtr:name>Royal Melbourne Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/28F5B392-EA84-4DF5-A95F-0743C03F261A"><gtr:id>28F5B392-EA84-4DF5-A95F-0743C03F261A</gtr:id><gtr:name>Georgia Health Sciences University</gtr:name><gtr:address><gtr:line1>1120 15th Street</gtr:line1><gtr:postCode>GA 30912</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E5EEDB92-C621-4C6E-AF7F-2EE1ACFEA8E4"><gtr:id>E5EEDB92-C621-4C6E-AF7F-2EE1ACFEA8E4</gtr:id><gtr:name>Peking University People's Hospital</gtr:name><gtr:address><gtr:line1>#11, South Street of Xizhimen</gtr:line1><gtr:line2>Xicheng District</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D2B3BB08-BC47-454D-B1E2-AE1982A0F950"><gtr:id>D2B3BB08-BC47-454D-B1E2-AE1982A0F950</gtr:id><gtr:name>?rebro University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E65CC67-B3CB-4AC1-9A16-2C56554D3562"><gtr:id>5E65CC67-B3CB-4AC1-9A16-2C56554D3562</gtr:id><gtr:name>Scunthorpe General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DFD0DB4C-91B2-408E-A4BC-3B0E097B3EC0"><gtr:id>DFD0DB4C-91B2-408E-A4BC-3B0E097B3EC0</gtr:id><gtr:name>Aberdeen Royal Infirmary</gtr:name><gtr:address><gtr:line1>Aberdeen Royal Infirmary</gtr:line1><gtr:line2>Foresterhill</gtr:line2><gtr:postCode>AB9 2ZN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DFF53E79-B438-4850-A76E-520A5D69CD78"><gtr:id>DFF53E79-B438-4850-A76E-520A5D69CD78</gtr:id><gtr:name>Mediwest Seinajoki, Finland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/909EE311-80DB-4B16-8C49-C75D72C2A3EB"><gtr:id>909EE311-80DB-4B16-8C49-C75D72C2A3EB</gtr:id><gtr:name>Medi 3 ?lesund / MEDI3 Alesund</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AA5E6C89-D9A3-4956-815F-011D897DAA74"><gtr:id>AA5E6C89-D9A3-4956-815F-011D897DAA74</gtr:id><gtr:name>St Richard's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/986EE485-1D22-4BE4-A206-31B6CB818A1B"><gtr:id>986EE485-1D22-4BE4-A206-31B6CB818A1B</gtr:id><gtr:name>Silentzv?gens V?rdcentral</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/409477FD-8ACA-4CB4-90FE-0C1EBF305220"><gtr:id>409477FD-8ACA-4CB4-90FE-0C1EBF305220</gtr:id><gtr:name>KfH Nierenzentrum Donauw?rth</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF33015D-7E03-4E1D-84D4-EDD44BE65229"><gtr:id>CF33015D-7E03-4E1D-84D4-EDD44BE65229</gtr:id><gtr:name>The Hillingdon Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C5B516AF-6198-4F9F-BBC2-2AEFF97709E5"><gtr:id>C5B516AF-6198-4F9F-BBC2-2AEFF97709E5</gtr:id><gtr:name>Universit?tsklinikum?Bonn</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/795B7795-71B7-4221-9F7A-47C68EDD6C0D"><gtr:id>795B7795-71B7-4221-9F7A-47C68EDD6C0D</gtr:id><gtr:name>Dialysepraxis Alt?tting</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/132E9C51-402A-48A2-BAF6-FA3653EAB9E1"><gtr:id>132E9C51-402A-48A2-BAF6-FA3653EAB9E1</gtr:id><gtr:name>Meriter Medical Group, Inc. DBA: Meriter Wisconsin Heart</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/764EFFF8-38B3-472C-B6D3-DC567EAB324B"><gtr:id>764EFFF8-38B3-472C-B6D3-DC567EAB324B</gtr:id><gtr:name>South Florida Research Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522"><gtr:id>4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522</gtr:id><gtr:name>UNLISTED</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF696CE0-3016-49B7-8C93-A165F80B0FDC"><gtr:id>BF696CE0-3016-49B7-8C93-A165F80B0FDC</gtr:id><gtr:name>Klinikum Bielefeld</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D7CD90A4-326C-45B8-AFA9-894111F87B4E"><gtr:id>D7CD90A4-326C-45B8-AFA9-894111F87B4E</gtr:id><gtr:name>Northwest Heart Clinical Research, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/606F6395-00B9-4707-8B98-93DC7F40BE2E"><gtr:id>606F6395-00B9-4707-8B98-93DC7F40BE2E</gtr:id><gtr:name>Melbourne Renal Research Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAE9EB6C-D647-4063-AAEE-0A63D90CB430"><gtr:id>FAE9EB6C-D647-4063-AAEE-0A63D90CB430</gtr:id><gtr:name>Weifang People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CA9759D7-7592-4A80-9FFA-122E41646548"><gtr:id>CA9759D7-7592-4A80-9FFA-122E41646548</gtr:id><gtr:name>Obacka Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F424A15-A4BF-4E3A-97DB-879055E9077D"><gtr:id>8F424A15-A4BF-4E3A-97DB-879055E9077D</gtr:id><gtr:name>Nebraska Heart Institute (Dionisopoulos)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1"><gtr:id>6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1</gtr:id><gtr:name>Trondheim University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/997071E2-24EB-4B5D-A182-00DF49D3EF63"><gtr:id>997071E2-24EB-4B5D-A182-00DF49D3EF63</gtr:id><gtr:name>Green Biologics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3958029-F035-4BBA-869F-893050BCE7F4"><gtr:id>C3958029-F035-4BBA-869F-893050BCE7F4</gtr:id><gtr:name>Bergslagen Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D4DD97D-4C06-4E39-9A35-E05B268BB2D7"><gtr:id>9D4DD97D-4C06-4E39-9A35-E05B268BB2D7</gtr:id><gtr:name>Cambridge Cardiac Care Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE48EE7C-FC67-4452-8456-7C81DC21BCE5"><gtr:id>EE48EE7C-FC67-4452-8456-7C81DC21BCE5</gtr:id><gtr:name>Third Peoples Hospital of Xuzhou</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3E215BE-8D5E-40B7-B8FA-415E9E853137"><gtr:id>F3E215BE-8D5E-40B7-B8FA-415E9E853137</gtr:id><gtr:name>Shangdong Province Qingdao Municipal Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/50C2D853-5374-4909-AEB1-E2BE2DACAA30"><gtr:id>50C2D853-5374-4909-AEB1-E2BE2DACAA30</gtr:id><gtr:name>Tyrone County Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A748A4B-92D7-446B-86D3-71AC8AF5AA99"><gtr:id>9A748A4B-92D7-446B-86D3-71AC8AF5AA99</gtr:id><gtr:name>Research Physicians Network Alliance</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1670D4B-EB39-45CD-BF1B-D2FAEEB92560"><gtr:id>E1670D4B-EB39-45CD-BF1B-D2FAEEB92560</gtr:id><gtr:name>Watson Clinic Cancer &amp; Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FE5219D-DF62-43B8-8957-7E949A5128FE"><gtr:id>8FE5219D-DF62-43B8-8957-7E949A5128FE</gtr:id><gtr:name>Gemeinschaftspraxis Marktredwitz &amp; Selb</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257F3119-F25C-41EA-9D55-9B301432B412"><gtr:id>257F3119-F25C-41EA-9D55-9B301432B412</gtr:id><gtr:name>Universitetssjukhuset i Lund</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DA33A89C-94AA-4135-8AEE-58470D395C32"><gtr:id>DA33A89C-94AA-4135-8AEE-58470D395C32</gtr:id><gtr:name>Tiexi Hospital of Anshan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/00866200-F62B-429B-BF02-A0A841684ED5"><gtr:id>00866200-F62B-429B-BF02-A0A841684ED5</gtr:id><gtr:name>University of Salamanca</gtr:name><gtr:address><gtr:line1>Universidad de Salamanca</gtr:line1><gtr:line2>Patio de Escuelas 1</gtr:line2><gtr:line4>Salamanca</gtr:line4><gtr:line5>37071</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/71EF7A5A-CD0D-42C1-B6DD-69A8BDCFEB07"><gtr:id>71EF7A5A-CD0D-42C1-B6DD-69A8BDCFEB07</gtr:id><gtr:name>Vestre Viken Health Authority</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/81BEDE7B-2A9E-4EFC-88D0-4B7B01F4D20C"><gtr:id>81BEDE7B-2A9E-4EFC-88D0-4B7B01F4D20C</gtr:id><gtr:name>The Second Affiliated Hospital of Baotou Medical College</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BFC805F-63E4-4B8D-AC1A-76C12DC45D5F"><gtr:id>8BFC805F-63E4-4B8D-AC1A-76C12DC45D5F</gtr:id><gtr:name>Northwick Park Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2070F714-C13B-417D-B059-44B511471FF2"><gtr:id>2070F714-C13B-417D-B059-44B511471FF2</gtr:id><gtr:name>Institute for Clinical and Experimental Medicine (IKEM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B11F840B-3E0B-4C05-8863-4FB27BD36486"><gtr:id>B11F840B-3E0B-4C05-8863-4FB27BD36486</gtr:id><gtr:name>Sykehuset Innlandet HF, Kongsvinger</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9831257E-9E86-4640-880A-C137612471A5"><gtr:id>9831257E-9E86-4640-880A-C137612471A5</gtr:id><gtr:name>Provincial Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6C51C95E-9111-49DC-9C4E-ABD992FAA2E0"><gtr:id>6C51C95E-9111-49DC-9C4E-ABD992FAA2E0</gtr:id><gtr:name>Zell am See Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FB8FA26D-607E-4B25-A1A3-55ECCFF7645C"><gtr:id>FB8FA26D-607E-4B25-A1A3-55ECCFF7645C</gtr:id><gtr:name>Associated Cardiovascular Consultants</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2942060C-DAFA-426B-A8BF-A8537F1CCFA0"><gtr:id>2942060C-DAFA-426B-A8BF-A8537F1CCFA0</gtr:id><gtr:name>Klinikum Fulda</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C8AD3DF1-C820-4C65-9E0C-B25204B3A052"><gtr:id>C8AD3DF1-C820-4C65-9E0C-B25204B3A052</gtr:id><gtr:name>HOPE Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/42033730-EAC2-4B0A-997F-ABE987F956F5"><gtr:id>42033730-EAC2-4B0A-997F-ABE987F956F5</gtr:id><gtr:name>Hudson Valley Cardiovascular Practice, P.C.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACDFCDC7-8EC1-4ED6-A43D-4F18B9B6A783"><gtr:id>ACDFCDC7-8EC1-4ED6-A43D-4F18B9B6A783</gtr:id><gtr:name>East Texas Cardiology, PA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ED0EEDDC-CDEA-4B84-A90D-EE445FB100CA"><gtr:id>ED0EEDDC-CDEA-4B84-A90D-EE445FB100CA</gtr:id><gtr:name>Dialysezentrum Heiligenstadt</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/041AF371-DA1D-48C9-B280-29CB3799C4E9"><gtr:id>041AF371-DA1D-48C9-B280-29CB3799C4E9</gtr:id><gtr:name>Dewsbury District Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4A360D8-CF0A-407E-83C4-1FE395CC406D"><gtr:id>E4A360D8-CF0A-407E-83C4-1FE395CC406D</gtr:id><gtr:name>Worthing Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49A43251-E792-4E2E-BB66-315B5CF29D6F"><gtr:id>49A43251-E792-4E2E-BB66-315B5CF29D6F</gtr:id><gtr:name>Second Affiliated Hospital of Zhengzhou University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B21F0467-98F5-4957-8C88-4DFFE2E86752"><gtr:id>B21F0467-98F5-4957-8C88-4DFFE2E86752</gtr:id><gtr:name>Albuquerque Clinical Trials</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF2DA6A3-5D93-459C-9908-DF6A2024EC21"><gtr:id>FF2DA6A3-5D93-459C-9908-DF6A2024EC21</gtr:id><gtr:name>Central and North West London NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EAB14A86-80E5-4DCD-A8E1-BD4111F84AFC"><gtr:id>EAB14A86-80E5-4DCD-A8E1-BD4111F84AFC</gtr:id><gtr:name>Meharry Medical College</gtr:name><gtr:address><gtr:line1>1005 Dr. D. B. Todd, Jr Boulevard</gtr:line1><gtr:postCode>37208-3599</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B5B8C98-DC67-4273-A875-4A6AEAC0FDC6"><gtr:id>7B5B8C98-DC67-4273-A875-4A6AEAC0FDC6</gtr:id><gtr:name>KfH Nierenzentrum W?rzburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70E543EA-F95A-46A5-8B3F-8AF927B77F9B"><gtr:id>70E543EA-F95A-46A5-8B3F-8AF927B77F9B</gtr:id><gtr:name>Advanced Heart Care LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C1EC297-2A44-444B-B38B-B52AF99068AD"><gtr:id>2C1EC297-2A44-444B-B38B-B52AF99068AD</gtr:id><gtr:name>Cardiovascular Institute of the South</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5434604E-D9AC-4B94-A674-60D8F11B91A3"><gtr:id>5434604E-D9AC-4B94-A674-60D8F11B91A3</gtr:id><gtr:name>Bradford Royal Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5FFCBED-656B-4E07-B2AD-D4EC8CCD73B2"><gtr:id>B5FFCBED-656B-4E07-B2AD-D4EC8CCD73B2</gtr:id><gtr:name>Peterborough City Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE9AB991-9971-4B17-AA28-3160878DBE4E"><gtr:id>FE9AB991-9971-4B17-AA28-3160878DBE4E</gtr:id><gtr:name>Bay Area Cardiology Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DF68B82-E71A-40BD-BA3F-06DCE2663E9E"><gtr:id>9DF68B82-E71A-40BD-BA3F-06DCE2663E9E</gtr:id><gtr:name>Hospital Tengku Ampuan Afzan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/573318B7-623C-4822-BB5F-A4D0E832417B"><gtr:id>573318B7-623C-4822-BB5F-A4D0E832417B</gtr:id><gtr:name>Versilia New Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516"><gtr:id>0719BE0D-CCE5-4FEA-BD59-08BFA7F0E516</gtr:id><gtr:name>University Hospital Southampton NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Trust Management Offices Mailpoint 18, Tremona Road</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95591E08-AB58-42FB-ADFC-1B0612E16851"><gtr:id>95591E08-AB58-42FB-ADFC-1B0612E16851</gtr:id><gtr:name>Mid-Valley Cardiology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/73CA53CC-F7E8-42A3-B48E-91A83D279923"><gtr:id>73CA53CC-F7E8-42A3-B48E-91A83D279923</gtr:id><gtr:name>Nephrologisches Zentrum Wei?ensee Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DA4F97EE-6FB6-4B96-8750-D2CBFBF26150"><gtr:id>DA4F97EE-6FB6-4B96-8750-D2CBFBF26150</gtr:id><gtr:name>DKD HELIOS Klinik Wiesbaden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AA4CEA52-92C1-480A-B751-3EC42B26F78E"><gtr:id>AA4CEA52-92C1-480A-B751-3EC42B26F78E</gtr:id><gtr:name>Dialysezentrum Saarlouis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2A80153D-B99E-4A7F-9634-C194ACD38834"><gtr:id>2A80153D-B99E-4A7F-9634-C194ACD38834</gtr:id><gtr:name>Sykehuset Innlandet HF Lillehammer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DFE187A-934E-4272-BFAD-E9098AEA8CA9"><gtr:id>3DFE187A-934E-4272-BFAD-E9098AEA8CA9</gtr:id><gtr:name>Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2100F7CE-AA0B-4CB0-98D0-8038DFFB477D"><gtr:id>2100F7CE-AA0B-4CB0-98D0-8038DFFB477D</gtr:id><gtr:name>Second Hospital of Shanxi Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6E015378-92E6-42BD-B57E-3FD7BCDEA2AB"><gtr:id>6E015378-92E6-42BD-B57E-3FD7BCDEA2AB</gtr:id><gtr:name>Silkeborg Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/98F441C1-1820-4E8E-A738-89E88BDCF67D"><gtr:id>98F441C1-1820-4E8E-A738-89E88BDCF67D</gtr:id><gtr:name>University Hospital Munich</gtr:name><gtr:address><gtr:line1>University Hospital Munich</gtr:line1><gtr:line2>Ziemssenstrasse 1</gtr:line2><gtr:postCode>D-80336</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAC2A9A1-65E9-4360-BA6E-76DA1876565F"><gtr:id>FAC2A9A1-65E9-4360-BA6E-76DA1876565F</gtr:id><gtr:name>Universit?tsklinikum Charite, Campus Virchow-Klinikum</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C13907A3-4872-4E56-8A5D-CC68FDF291E7"><gtr:id>C13907A3-4872-4E56-8A5D-CC68FDF291E7</gtr:id><gtr:name>Nephrologische Praxis Dr. Meyer Bad Nauheim</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/97863044-3296-4CA1-B587-8E29FD6C1C28"><gtr:id>97863044-3296-4CA1-B587-8E29FD6C1C28</gtr:id><gtr:name>KfH Nierenzentrum K?ln-Merheim</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5CF9155D-3F9C-4D7A-9018-14E8901E2FC6"><gtr:id>5CF9155D-3F9C-4D7A-9018-14E8901E2FC6</gtr:id><gtr:name>Belfast City Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9485D2FE-FC0B-474F-8F21-6F625F641A91"><gtr:id>9485D2FE-FC0B-474F-8F21-6F625F641A91</gtr:id><gtr:name>Szpital Kliniczny Dzieciatka Jezus, Centrum Leczenia Obrazen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83529BB1-DE12-4A82-A7CB-322B5FC0F63C"><gtr:id>83529BB1-DE12-4A82-A7CB-322B5FC0F63C</gtr:id><gtr:name>Fenyang Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E63069FE-C064-4B5E-A16B-480E9441E9C4"><gtr:id>E63069FE-C064-4B5E-A16B-480E9441E9C4</gtr:id><gtr:name>NJ Heart</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DA2C2925-8877-4228-B956-6D105D55917F"><gtr:id>DA2C2925-8877-4228-B956-6D105D55917F</gtr:id><gtr:name>Colwyn Bay Community Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41E0CE10-4668-41AB-9AA1-6E4785EEE513"><gtr:id>41E0CE10-4668-41AB-9AA1-6E4785EEE513</gtr:id><gtr:name>First Affiliated Hospital of China Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D62FEB7F-785B-4649-844E-B425DAF64D4A"><gtr:id>D62FEB7F-785B-4649-844E-B425DAF64D4A</gtr:id><gtr:name>Queensland Government</gtr:name><gtr:address><gtr:line1>PO Box 156, Archerfield BC</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E76DFBA-6F03-4D84-9AEC-58CC86BA6F2F"><gtr:id>5E76DFBA-6F03-4D84-9AEC-58CC86BA6F2F</gtr:id><gtr:name>Wuxi People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/596371CD-A49A-4A6C-8C8E-19CA5AED24E7"><gtr:id>596371CD-A49A-4A6C-8C8E-19CA5AED24E7</gtr:id><gtr:name>Queen's Hospital</gtr:name><gtr:address><gtr:line1>Belvedere Rd.</gtr:line1><gtr:postCode>DE13 0RB</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7D5ADAB2-4253-41CC-A87D-ED627752A297"><gtr:id>7D5ADAB2-4253-41CC-A87D-ED627752A297</gtr:id><gtr:name>Eastbourne District General Hospital</gtr:name><gtr:address><gtr:line1>Kings Drive</gtr:line1><gtr:postCode>BN21 2UD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D85B1313-6DDA-4655-BCA9-DF25A3979453"><gtr:id>D85B1313-6DDA-4655-BCA9-DF25A3979453</gtr:id><gtr:name>Steno Diabetes Center Copenhagen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E950C03D-126E-4B3A-8B92-0D771110FFA8"><gtr:id>E950C03D-126E-4B3A-8B92-0D771110FFA8</gtr:id><gtr:name>University of Alabama Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E292008-39ED-4C67-B8A4-D89C936AEE05"><gtr:id>2E292008-39ED-4C67-B8A4-D89C936AEE05</gtr:id><gtr:name>Bundaberg Base Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76AFFC55-A859-4DC8-BF62-B74BFD8AEF08"><gtr:id>76AFFC55-A859-4DC8-BF62-B74BFD8AEF08</gtr:id><gtr:name>Norfolk and Norwich University Hospital</gtr:name><gtr:address><gtr:line1>Colney Lane</gtr:line1><gtr:postCode>NR4 7UY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/129AB3E1-3DC7-401C-B4BC-24985A00C8AF"><gtr:id>129AB3E1-3DC7-401C-B4BC-24985A00C8AF</gtr:id><gtr:name>Stockport NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Stepping Hill Hospital</gtr:line1><gtr:line2>Poplar Grove</gtr:line2><gtr:postCode>SK2 7JE</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57CE900C-282B-4473-9E51-6037071B8948"><gtr:id>57CE900C-282B-4473-9E51-6037071B8948</gtr:id><gtr:name>Sykehuset Levanger</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F359B80-F722-4D8E-BB33-D669606D16D9"><gtr:id>4F359B80-F722-4D8E-BB33-D669606D16D9</gtr:id><gtr:name>Fraser Health Authority</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/08C52B07-D973-4565-8E88-5511BAFFF3D9"><gtr:id>08C52B07-D973-4565-8E88-5511BAFFF3D9</gtr:id><gtr:name>Peking Union Medical College</gtr:name><gtr:address><gtr:line1>Dongdan Santiao</gtr:line1><gtr:postCode>100005</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/87AC76A7-3A15-4AB0-9E9A-E41C186BF103"><gtr:id>87AC76A7-3A15-4AB0-9E9A-E41C186BF103</gtr:id><gtr:name>Klinikum Leverkusen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D878FB57-FB53-44E3-A356-AE364FC540EE"><gtr:id>D878FB57-FB53-44E3-A356-AE364FC540EE</gtr:id><gtr:name>University Hospital of North Staffordshire NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/146112CF-E930-4E77-9536-FD73E8F3B5E9"><gtr:id>146112CF-E930-4E77-9536-FD73E8F3B5E9</gtr:id><gtr:name>Hospital Raja Perempuan Zainab II, Kota Bharu</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/81190C17-8B18-4DE2-989D-09633B77FF0B"><gtr:id>81190C17-8B18-4DE2-989D-09633B77FF0B</gtr:id><gtr:name>Dumfries and Galloway Royal Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68BDBDB0-74B3-49EC-9C85-3F8540BC6860"><gtr:id>68BDBDB0-74B3-49EC-9C85-3F8540BC6860</gtr:id><gtr:name>Cardiovascular Associates of the Southeast LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20C5852A-7D0C-4B4D-9D5A-21B73023DCD7"><gtr:id>20C5852A-7D0C-4B4D-9D5A-21B73023DCD7</gtr:id><gtr:name>Hilleroed Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48DD62AA-9550-425C-B752-9F2C336C0A86"><gtr:id>48DD62AA-9550-425C-B752-9F2C336C0A86</gtr:id><gtr:name>Viacar Recherche Clinique Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9713190C-DF10-4B7A-86C0-1FA4DC960B12"><gtr:id>9713190C-DF10-4B7A-86C0-1FA4DC960B12</gtr:id><gtr:name>Rush University Medical Center</gtr:name><gtr:address><gtr:line1>Dept of Molecular Biophysics &amp; Physiol</gtr:line1><gtr:line2>Rush University Medical Center</gtr:line2><gtr:line3>1653 West Congress Parkway</gtr:line3><gtr:line4>Chicago</gtr:line4><gtr:line5>IL 60612</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8129ED41-8B69-4B4C-8115-E769FECCDFCC"><gtr:id>8129ED41-8B69-4B4C-8115-E769FECCDFCC</gtr:id><gtr:name>Aventura Heart Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B445E90C-9510-4724-9163-DC277653B965"><gtr:id>B445E90C-9510-4724-9163-DC277653B965</gtr:id><gtr:name>Royal Devon and Exeter Hospital</gtr:name><gtr:address><gtr:line1>Barrack Road</gtr:line1><gtr:line4>Exeter</gtr:line4><gtr:line5>Devon</gtr:line5><gtr:postCode>EX2 5DW</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD9804F2-50A4-406E-AC16-DA4D12D481EA"><gtr:id>CD9804F2-50A4-406E-AC16-DA4D12D481EA</gtr:id><gtr:name>Singleton Hospital</gtr:name><gtr:address><gtr:line1>Singleton Hospital</gtr:line1><gtr:postCode>SA2 8QA</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC2247CE-9FDF-48A3-89FB-AAE126086D0B"><gtr:id>EC2247CE-9FDF-48A3-89FB-AAE126086D0B</gtr:id><gtr:name>University Hospital of M?nster</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B03C821-3274-45DE-9789-E3D2FBE5F6FE"><gtr:id>8B03C821-3274-45DE-9789-E3D2FBE5F6FE</gtr:id><gtr:name>Michigan Cardiovascular Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE52CF89-E0DA-4A6E-98D6-A7B7EB407AFB"><gtr:id>AE52CF89-E0DA-4A6E-98D6-A7B7EB407AFB</gtr:id><gtr:name>Royal Hobart Hospital</gtr:name><gtr:address><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7725941D-A4FA-45DC-A943-D0B29C42E369"><gtr:id>7725941D-A4FA-45DC-A943-D0B29C42E369</gtr:id><gtr:name>University Malaya Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47F1543E-FF00-444E-9767-7727EFD90FDC"><gtr:id>47F1543E-FF00-444E-9767-7727EFD90FDC</gtr:id><gtr:name>Trondheim Hjertesenter AS, Norway</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A6772282-59BF-404C-8FED-97C444A6F1A9"><gtr:id>A6772282-59BF-404C-8FED-97C444A6F1A9</gtr:id><gtr:name>Dorset County Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/983D5513-5CAD-450A-B298-09D08FF46D5E"><gtr:id>983D5513-5CAD-450A-B298-09D08FF46D5E</gtr:id><gtr:name>Stockholm Heart Center, Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46FE9087-C02F-43E3-AB5E-96849656C36D"><gtr:id>46FE9087-C02F-43E3-AB5E-96849656C36D</gtr:id><gtr:name>Austin Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D90A6775-4A8B-4291-AF27-B6DA519CA8C2"><gtr:id>D90A6775-4A8B-4291-AF27-B6DA519CA8C2</gtr:id><gtr:name>Gemini Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A2216F59-63B4-4A3F-8FE4-BCB959DE918F"><gtr:id>A2216F59-63B4-4A3F-8FE4-BCB959DE918F</gtr:id><gtr:name>Tianjin Union Medicine Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7170192-17A0-405E-A30F-D271C263529F"><gtr:id>F7170192-17A0-405E-A30F-D271C263529F</gtr:id><gtr:name>Parkview Research Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B9C2D48-4CEC-46B1-89E7-DE5DCD1FA320"><gtr:id>7B9C2D48-4CEC-46B1-89E7-DE5DCD1FA320</gtr:id><gtr:name>Borstel Research Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7ADA7D81-CBD2-4BD5-A4BA-8DFEE7D751B7"><gtr:id>7ADA7D81-CBD2-4BD5-A4BA-8DFEE7D751B7</gtr:id><gtr:name>Vizel Cardiac Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC2090F8-B473-4479-9B3D-694BBBA8B2CD"><gtr:id>AC2090F8-B473-4479-9B3D-694BBBA8B2CD</gtr:id><gtr:name>Slagelse Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2B1C1B39-0260-448F-B4A8-8DA96FC8C83E"><gtr:id>2B1C1B39-0260-448F-B4A8-8DA96FC8C83E</gtr:id><gtr:name>Taranaki Base Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EC955A9-7A7E-434C-BBD8-CE3B521C2821"><gtr:id>9EC955A9-7A7E-434C-BBD8-CE3B521C2821</gtr:id><gtr:name>University of Alberta</gtr:name><gtr:address><gtr:line1>University of Alberta</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/09D111C8-6EB5-422C-88AA-1C6DF485ED0A"><gtr:id>09D111C8-6EB5-422C-88AA-1C6DF485ED0A</gtr:id><gtr:name>University Hospital Tuebingen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/81B377D6-DF09-4AC0-B371-FDA08E3EB8AF"><gtr:id>81B377D6-DF09-4AC0-B371-FDA08E3EB8AF</gtr:id><gtr:name>Tianjin Third Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51A751AB-38DA-40F0-9408-10E24875FEBA"><gtr:id>51A751AB-38DA-40F0-9408-10E24875FEBA</gtr:id><gtr:name>Christchurch Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3F8679E5-B5AE-4F87-AC9E-BA45604F1C54"><gtr:id>3F8679E5-B5AE-4F87-AC9E-BA45604F1C54</gtr:id><gtr:name>Worcestershire Royal Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E4B6187-6584-4FB7-AF1D-044BD915AD4A"><gtr:id>9E4B6187-6584-4FB7-AF1D-044BD915AD4A</gtr:id><gtr:name>Nambour General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B"><gtr:id>2CCB5A47-ADB6-4D56-A419-6E4F3D3BAF2B</gtr:id><gtr:name>Aarhus University Hospital</gtr:name><gtr:address><gtr:line1>Aarhus University Hospital</gtr:line1><gtr:line2>Aarhus University Hospital</gtr:line2><gtr:line3>Norrebrogade 44</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/18B2C5D0-334F-4D9B-9CF6-9EB22647E3A0"><gtr:id>18B2C5D0-334F-4D9B-9CF6-9EB22647E3A0</gtr:id><gtr:name>Shandong Weifang People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F830486-F534-4F27-965E-B93A76D95A3C"><gtr:id>1F830486-F534-4F27-965E-B93A76D95A3C</gtr:id><gtr:name>KfH Nierenzentrum Wei?enburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C93867FA-27A5-4A79-8E93-38DBA4D880F9"><gtr:id>C93867FA-27A5-4A79-8E93-38DBA4D880F9</gtr:id><gtr:name>Praxis f?r Nierenkrankheiten und Dialyse</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3D8A940-2BB9-4960-A5F6-1F54554C34FA"><gtr:id>D3D8A940-2BB9-4960-A5F6-1F54554C34FA</gtr:id><gtr:name>Portsmouth Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2793DE81-083B-4962-B5C7-2B8FEFBF1F05"><gtr:id>2793DE81-083B-4962-B5C7-2B8FEFBF1F05</gtr:id><gtr:name>Hospital Tuanku Jafa'ar</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC3C093C-F9CE-4465-95FD-3A43C57E7F1A"><gtr:id>FC3C093C-F9CE-4465-95FD-3A43C57E7F1A</gtr:id><gtr:name>Rigshospitalet</gtr:name><gtr:address><gtr:line1>Blegdamsvej 9</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F5FE4B5-FDF3-43E9-85EE-52367E1CF46B"><gtr:id>6F5FE4B5-FDF3-43E9-85EE-52367E1CF46B</gtr:id><gtr:name>Charles River Medical Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F5D7507-4E0B-4726-98CD-1EA57897014F"><gtr:id>5F5D7507-4E0B-4726-98CD-1EA57897014F</gtr:id><gtr:name>FAW General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8"><gtr:id>C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8</gtr:id><gtr:name>Glenfield Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/788B4530-D2FD-42F0-9652-F642B852B425"><gtr:id>788B4530-D2FD-42F0-9652-F642B852B425</gtr:id><gtr:name>Kansas City VA Medical Center - 2</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/74299423-0E5D-4739-A3AA-B17137135C9B"><gtr:id>74299423-0E5D-4739-A3AA-B17137135C9B</gtr:id><gtr:name>Linkoping  University</gtr:name><gtr:address><gtr:line1>Linkoping</gtr:line1><gtr:postCode>SE-581 83</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A7ECFF0-F37C-4DA6-94D0-7AAB2A023275"><gtr:id>3A7ECFF0-F37C-4DA6-94D0-7AAB2A023275</gtr:id><gtr:name>VA Ann Arbor Healthcare System</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B132A9E7-5D4A-4270-B617-ED9D2F0613DB"><gtr:id>B132A9E7-5D4A-4270-B617-ED9D2F0613DB</gtr:id><gtr:name>Turku University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAE5BBE4-88D2-4A1B-A838-6A3E4A212964"><gtr:id>DAE5BBE4-88D2-4A1B-A838-6A3E4A212964</gtr:id><gtr:name>Boice Willis Clinic Nashville</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E0188E13-F6B4-4612-9F9C-E3158A500C8D"><gtr:id>E0188E13-F6B4-4612-9F9C-E3158A500C8D</gtr:id><gtr:name>Nordland Hjertesenter AS</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC29D444-CD61-45AC-A36A-5863E40A5BFB"><gtr:id>FC29D444-CD61-45AC-A36A-5863E40A5BFB</gtr:id><gtr:name>Brampton Research Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89E93EBE-6563-4E33-A4F2-9AC7482A5AD0"><gtr:id>89E93EBE-6563-4E33-A4F2-9AC7482A5AD0</gtr:id><gtr:name>Ipswich Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F640E0E-4E90-4549-87E5-38C52854748E"><gtr:id>1F640E0E-4E90-4549-87E5-38C52854748E</gtr:id><gtr:name>Hoglandssjukhuset Eksjo, Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3489274E-7BA0-499D-AAB5-041F08BE5A96"><gtr:id>3489274E-7BA0-499D-AAB5-041F08BE5A96</gtr:id><gtr:name>St. Johannes Hospital Dortmund</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3E11056A-45C3-458F-9947-68F0D0BE2FE6"><gtr:id>3E11056A-45C3-458F-9947-68F0D0BE2FE6</gtr:id><gtr:name>Medisch Centrum Leeuwarden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAEF05D4-E453-4150-8259-D1C9474163FA"><gtr:id>FAEF05D4-E453-4150-8259-D1C9474163FA</gtr:id><gtr:name>CentraCare Heart &amp; Vascular Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/953FE5C5-5E16-478A-894A-0133F406540E"><gtr:id>953FE5C5-5E16-478A-894A-0133F406540E</gtr:id><gtr:name>University Hospital, Frankfurt</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6B5D961-98A4-40A7-8CC5-9B46AA3F1AF7"><gtr:id>B6B5D961-98A4-40A7-8CC5-9B46AA3F1AF7</gtr:id><gtr:name>Overlea Personal Physicians</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FDB68547-FA9D-47FF-B9C3-B347A7472FFF"><gtr:id>FDB68547-FA9D-47FF-B9C3-B347A7472FFF</gtr:id><gtr:name>Sondrio Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/65CA0C72-DDE4-4E06-8BD1-26C17F49FFF7"><gtr:id>65CA0C72-DDE4-4E06-8BD1-26C17F49FFF7</gtr:id><gtr:name>Liaoning Angang Lishan Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/236B9977-95DB-4E36-B395-8CAB40A5442F"><gtr:id>236B9977-95DB-4E36-B395-8CAB40A5442F</gtr:id><gtr:name>Orbassano - Ospedale San Luigi Gonzaga</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70527AB1-ED42-4DEC-9921-A1FE180562CD"><gtr:id>70527AB1-ED42-4DEC-9921-A1FE180562CD</gtr:id><gtr:name>Primary Care Cardiology Research, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/121A90D0-B47C-4314-B89E-4E09017E4384"><gtr:id>121A90D0-B47C-4314-B89E-4E09017E4384</gtr:id><gtr:name>Dialysezentrum Dormagen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8ED0AABF-E872-4827-A548-90CC0AC53D97"><gtr:id>8ED0AABF-E872-4827-A548-90CC0AC53D97</gtr:id><gtr:name>Dialysezentrum / Gemeinschaftspraxis Heilbronn</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5DDA9A11-36B8-4EE5-86CE-DEE9A9720843"><gtr:id>5DDA9A11-36B8-4EE5-86CE-DEE9A9720843</gtr:id><gtr:name>Gemeinschaftspraxis Schlo? Holte - Stukenbrock</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6CADD105-0E2C-4C73-A12A-F32153158C24"><gtr:id>6CADD105-0E2C-4C73-A12A-F32153158C24</gtr:id><gtr:name>Pentucket Medical Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F736259-FACF-47BC-99F4-B0E1A7617784"><gtr:id>6F736259-FACF-47BC-99F4-B0E1A7617784</gtr:id><gtr:name>Sygehus Fyn Svendborg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E51038EF-C40E-4668-ADBD-041FF6FE2205"><gtr:id>E51038EF-C40E-4668-ADBD-041FF6FE2205</gtr:id><gtr:name>Dialysezentrum Bad Godesberg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72E812C7-4492-4C83-A92B-BD1E09EE9D83"><gtr:id>72E812C7-4492-4C83-A92B-BD1E09EE9D83</gtr:id><gtr:name>Trinity Medical Center (Rock Island)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A28252F6-AD97-4A7D-82EF-6489C2EB868E"><gtr:id>A28252F6-AD97-4A7D-82EF-6489C2EB868E</gtr:id><gtr:name>Royal Prince Alfred Hospital (RPAH) Sydney</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E8D5BD-639D-47C8-805A-F38DB10DC13F"><gtr:id>C1E8D5BD-639D-47C8-805A-F38DB10DC13F</gtr:id><gtr:name>St. Mary's Duluth Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83DB8510-2CEF-4407-A1DA-B3F1A53B2D1C"><gtr:id>83DB8510-2CEF-4407-A1DA-B3F1A53B2D1C</gtr:id><gtr:name>Northern General Hospital</gtr:name><gtr:address><gtr:line1>Herries Road</gtr:line1><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S5 7AY</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1FC3A77-AF6B-4D37-A41E-72AF4ACBF467"><gtr:id>C1FC3A77-AF6B-4D37-A41E-72AF4ACBF467</gtr:id><gtr:name>Glostrup Hospital</gtr:name><gtr:address><gtr:line1>Glostrup University Hospital</gtr:line1><gtr:line2>57 Ndr. Ringvej, DK-2600</gtr:line2><gtr:line3>Glostrup</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/899E24E0-CABA-47C7-9618-D27426F5DB95"><gtr:id>899E24E0-CABA-47C7-9618-D27426F5DB95</gtr:id><gtr:name>Istituti ospitalieri di Cremona</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4EA7F599-ACD2-430E-B5AE-3FFB07882626"><gtr:id>4EA7F599-ACD2-430E-B5AE-3FFB07882626</gtr:id><gtr:name>Centre de Cardologie et de Recherche Clinique Pierre-Le Gardeur</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C9DA1DA3-D9BD-4897-B554-5181400F24E0"><gtr:id>C9DA1DA3-D9BD-4897-B554-5181400F24E0</gtr:id><gtr:name>University Hospital of Besancon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E5EE8164-F5A7-4E82-A362-D3D64BF53CA0"><gtr:id>E5EE8164-F5A7-4E82-A362-D3D64BF53CA0</gtr:id><gtr:name>Eastern Regional Health Authority</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D1F22D1-B5C4-4A4F-A88C-3DE36A6E3155"><gtr:id>9D1F22D1-B5C4-4A4F-A88C-3DE36A6E3155</gtr:id><gtr:name>Princess Royal Hospital</gtr:name><gtr:address><gtr:line1>Lewes Road</gtr:line1><gtr:postCode>RH16 4EX</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A2C525FE-77BB-4CA7-9C48-D76FD97A876E"><gtr:id>A2C525FE-77BB-4CA7-9C48-D76FD97A876E</gtr:id><gtr:name>Russells Hall Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4BBE5221-98D9-4644-9209-15B40D17A39D"><gtr:id>4BBE5221-98D9-4644-9209-15B40D17A39D</gtr:id><gtr:name>Penticton Regional Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5CBB8107-6A9E-454C-B8C8-35F980076924"><gtr:id>5CBB8107-6A9E-454C-B8C8-35F980076924</gtr:id><gtr:name>Tenet Florida Physician Services</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DFD96BE4-B699-411E-B6E9-056CA4A26A49"><gtr:id>DFD96BE4-B699-411E-B6E9-056CA4A26A49</gtr:id><gtr:name>St. Joseph's Healthcare Hamilton</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4F9E1FB-3A0C-4123-9869-499B04BB0033"><gtr:id>C4F9E1FB-3A0C-4123-9869-499B04BB0033</gtr:id><gtr:name>Sykehuset Innlandet HF Hamar</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6DA7F09-D7A6-4E5D-BB81-B7FF665572DC"><gtr:id>C6DA7F09-D7A6-4E5D-BB81-B7FF665572DC</gtr:id><gtr:name>Chesapeake Cardiovascular Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0A8E1D8-B74B-46BA-A42D-B575E2E15804"><gtr:id>C0A8E1D8-B74B-46BA-A42D-B575E2E15804</gtr:id><gtr:name>Royal Inland Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4ED9EDBF-AB80-4A92-8219-868950B96236"><gtr:id>4ED9EDBF-AB80-4A92-8219-868950B96236</gtr:id><gtr:name>First Hospital of Shanxi Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F48CE370-2E64-4C64-A61F-62294907C777"><gtr:id>F48CE370-2E64-4C64-A61F-62294907C777</gtr:id><gtr:name>Clinical Trials of America, Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEDC0BB2-81F5-4B93-B339-88B340DBCF38"><gtr:id>FEDC0BB2-81F5-4B93-B339-88B340DBCF38</gtr:id><gtr:name>Royal Bolton Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43970E8C-C2C1-4CC6-BE4A-4E48BB09BBD2"><gtr:id>43970E8C-C2C1-4CC6-BE4A-4E48BB09BBD2</gtr:id><gtr:name>Advanced Neurology Specialists</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49FBAC03-85EC-43B3-A9E5-930DC90D5FB3"><gtr:id>49FBAC03-85EC-43B3-A9E5-930DC90D5FB3</gtr:id><gtr:name>North Tyneside General Hospital</gtr:name><gtr:address><gtr:line1>Rake Lane</gtr:line1><gtr:line2>North Shields</gtr:line2><gtr:postCode>NE29 8NH</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F712308-0606-4CE0-A887-7867A0C0A137"><gtr:id>7F712308-0606-4CE0-A887-7867A0C0A137</gtr:id><gtr:name>St. Boniface General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82FDD508-2079-4BE0-AF84-FB2CBB56CC7C"><gtr:id>82FDD508-2079-4BE0-AF84-FB2CBB56CC7C</gtr:id><gtr:name>Morriston Hospital</gtr:name><gtr:address><gtr:line1>Heol Maes Eglwys</gtr:line1><gtr:line2>Morriston</gtr:line2><gtr:line3>Swansea</gtr:line3><gtr:line4>Abertawe</gtr:line4><gtr:postCode>SA6 6NL</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31ABE3DA-72D2-42DD-9625-40DE633EDB3E"><gtr:id>31ABE3DA-72D2-42DD-9625-40DE633EDB3E</gtr:id><gtr:name>Royal Perth Hospital</gtr:name><gtr:address><gtr:line1>Medical Research Foundation</gtr:line1><gtr:line2>Murray Street</gtr:line2><gtr:postCode>WA 6000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4BDA9D7-B6E8-44DF-B9A4-D56C879CE736"><gtr:id>F4BDA9D7-B6E8-44DF-B9A4-D56C879CE736</gtr:id><gtr:name>Provincial Specialist Hospital in Wroclaw</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/342F51D6-C5CB-4E4E-A705-842A96C1C07B"><gtr:id>342F51D6-C5CB-4E4E-A705-842A96C1C07B</gtr:id><gtr:name>Fondazione Salvatore Maugeri</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A44C419F-1C95-40F3-AFF2-CF24128B5643"><gtr:id>A44C419F-1C95-40F3-AFF2-CF24128B5643</gtr:id><gtr:name>Lanzhou University</gtr:name><gtr:address><gtr:line1>222 Tianshui S Rd</gtr:line1><gtr:line2>Chengguan</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D7EB639-B621-4CD7-A0B2-3B4364F7FD7B"><gtr:id>2D7EB639-B621-4CD7-A0B2-3B4364F7FD7B</gtr:id><gtr:name>Universitetssjukhuset Linkoping, Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DC562560-B567-483E-9141-5F4DF6739687"><gtr:id>DC562560-B567-483E-9141-5F4DF6739687</gtr:id><gtr:name>Skaraborgs Hospital Sk?vde</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6B146064-3AEC-4843-B87D-C3F93F1817ED"><gtr:id>6B146064-3AEC-4843-B87D-C3F93F1817ED</gtr:id><gtr:name>Nordlandssykehuset HF</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43EEA31B-BB6D-4470-8200-019443D47F23"><gtr:id>43EEA31B-BB6D-4470-8200-019443D47F23</gtr:id><gtr:name>Kore Cv Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9A643A7-828D-414B-A34B-679DB472B37A"><gtr:id>B9A643A7-828D-414B-A34B-679DB472B37A</gtr:id><gtr:name>Wels-Grieskirchen Clinic (Klinikum Wels-Grieskirchen)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/410725D8-5F99-40B3-AA63-8FAA89613913"><gtr:id>410725D8-5F99-40B3-AA63-8FAA89613913</gtr:id><gtr:name>Roskilde Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43BFE210-8181-4478-A843-EDF217FAD892"><gtr:id>43BFE210-8181-4478-A843-EDF217FAD892</gtr:id><gtr:name>Kardiologie Universitaet Magdeburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46CE8BEC-8929-4C0A-9088-42BC4636CB23"><gtr:id>46CE8BEC-8929-4C0A-9088-42BC4636CB23</gtr:id><gtr:name>Dialysezentrum Halberstadt</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0E80DBC1-A928-4E7B-8553-F59869930C27"><gtr:id>0E80DBC1-A928-4E7B-8553-F59869930C27</gtr:id><gtr:name>Virginia Polytechnic Institute &amp; State U</gtr:name><gtr:address><gtr:line1>Virginia Polytechnic Inst &amp; State  Univ</gtr:line1><gtr:line4>Blacksburg</gtr:line4><gtr:line5>Virginia</gtr:line5><gtr:postCode>VA 24061</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B17DFAAE-D0B4-4F46-80A5-5BA02113F000"><gtr:id>B17DFAAE-D0B4-4F46-80A5-5BA02113F000</gtr:id><gtr:name>Overlake Medical Clinics Cardiology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2162C73C-CCEC-4405-8D44-94BB2D306505"><gtr:id>2162C73C-CCEC-4405-8D44-94BB2D306505</gtr:id><gtr:name>Universit?tsklinikum Schleswig-Holstein-L?beck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8399881F-B597-4491-B33D-CC7AA60C7516"><gtr:id>8399881F-B597-4491-B33D-CC7AA60C7516</gtr:id><gtr:name>Credit Valley Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E0DE6B2A-572B-41F6-923C-72A6330111B3"><gtr:id>E0DE6B2A-572B-41F6-923C-72A6330111B3</gtr:id><gtr:name>Palmetto Research Center, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80392F0C-23A4-449D-BC8D-4D77C0F53303"><gtr:id>80392F0C-23A4-449D-BC8D-4D77C0F53303</gtr:id><gtr:name>Mahidol University</gtr:name><gtr:address><gtr:line1>Mahidol University</gtr:line1><gtr:line2>Office of the President  Mahidol Univers</gtr:line2><gtr:line3>25/25 Moo 3, Phuttamonthon 4 Road</gtr:line3><gtr:postCode>73170</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DA65CF26-56B9-4170-9923-6FE32A33FA91"><gtr:id>DA65CF26-56B9-4170-9923-6FE32A33FA91</gtr:id><gtr:name>Hospital Sultanah Aminah, Johor Bahru</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82E66BDB-BFA0-46E2-ABB3-C8EBDA419217"><gtr:id>82E66BDB-BFA0-46E2-ABB3-C8EBDA419217</gtr:id><gtr:name>Central Hospital in Karlstad</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/58B8363B-07EB-40D9-917A-5DECE5979268"><gtr:id>58B8363B-07EB-40D9-917A-5DECE5979268</gtr:id><gtr:name>U.S. Department of Veteran Affairs</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4822D555-BD0C-4560-9E9B-4FA59A8ECD57"><gtr:id>4822D555-BD0C-4560-9E9B-4FA59A8ECD57</gtr:id><gtr:name>St Antonius Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/555E8F41-4811-4255-B742-986F6FF57F39"><gtr:id>555E8F41-4811-4255-B742-986F6FF57F39</gtr:id><gtr:name>North Karelia Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/42EB2762-A46A-469B-A74A-4BAA8E902411"><gtr:id>42EB2762-A46A-469B-A74A-4BAA8E902411</gtr:id><gtr:name>The First Affiliated Hospital of Harbin Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1C653F8-0E4E-4FE7-9AB2-4CC6CEE375FC"><gtr:id>C1C653F8-0E4E-4FE7-9AB2-4CC6CEE375FC</gtr:id><gtr:name>The Christ Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0F9EAEAD-5674-4E30-8A06-589629F2C422"><gtr:id>0F9EAEAD-5674-4E30-8A06-589629F2C422</gtr:id><gtr:name>Haukeland University Hospital</gtr:name><gtr:address><gtr:line1>Haukeland University Hospital</gtr:line1><gtr:line2>Jonas Liesvei 65</gtr:line2><gtr:postCode>N-5021</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57877830-679D-4C06-B9DB-5280139D33D8"><gtr:id>57877830-679D-4C06-B9DB-5280139D33D8</gtr:id><gtr:name>Kerckhoff Klinik GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78EC1292-873A-480D-8A0E-E4A2947A1F8A"><gtr:id>78EC1292-873A-480D-8A0E-E4A2947A1F8A</gtr:id><gtr:name>CAMC Clinical Trials Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/368B57E1-D587-4B9A-9889-9439BFE044E8"><gtr:id>368B57E1-D587-4B9A-9889-9439BFE044E8</gtr:id><gtr:name>Sykehuset??stfold</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/450B90BB-D91E-4019-B6DA-21B2EB423C39"><gtr:id>450B90BB-D91E-4019-B6DA-21B2EB423C39</gtr:id><gtr:name>Townsville Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E7C3165-D40E-4C74-93D1-FF28CDF429BA"><gtr:id>2E7C3165-D40E-4C74-93D1-FF28CDF429BA</gtr:id><gtr:name>Queen Elizabeth Hospital (Malaysia)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C873BE22-11BB-462E-8A08-66402DF71A5A"><gtr:id>C873BE22-11BB-462E-8A08-66402DF71A5A</gtr:id><gtr:name>Shanxi Cardiovascular Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E2B2F857-09D3-47F5-A71A-A6D314C652CD"><gtr:id>E2B2F857-09D3-47F5-A71A-A6D314C652CD</gtr:id><gtr:name>Molndal hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F58B2DF7-41FD-424F-BC6D-F259ADF07632"><gtr:id>F58B2DF7-41FD-424F-BC6D-F259ADF07632</gtr:id><gtr:name>Gemeinschaftspraxis am Sophienhof Kiel</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BFA56DFC-5905-4B77-BBB0-212A1151DBD2"><gtr:id>BFA56DFC-5905-4B77-BBB0-212A1151DBD2</gtr:id><gtr:name>Kolding Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/92A065DD-9E51-4F4E-8E24-45E1DB681062"><gtr:id>92A065DD-9E51-4F4E-8E24-45E1DB681062</gtr:id><gtr:name>Salem VA Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/422EAB5B-BF7C-461D-BB57-B7E3E727A3F0"><gtr:id>422EAB5B-BF7C-461D-BB57-B7E3E727A3F0</gtr:id><gtr:name>KfH Nierenzentrum Oberhausen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F"><gtr:id>FEF0A749-B120-4F09-B8E8-01CFCDFC0A2F</gtr:id><gtr:name>Baylor College of Medicine</gtr:name><gtr:address><gtr:line1>Baylor College of Medicine</gtr:line1><gtr:line2>Texas Medical Center</gtr:line2><gtr:line4>Houston</gtr:line4><gtr:line5>Texas</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/73B0ADF6-14B7-42A6-9A64-8E8D9828BF68"><gtr:id>73B0ADF6-14B7-42A6-9A64-8E8D9828BF68</gtr:id><gtr:name>South Oklahoma Heart Research, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DE52904-C852-41F4-8170-6DE7257C145C"><gtr:id>3DE52904-C852-41F4-8170-6DE7257C145C</gtr:id><gtr:name>Cardiovascular Research of Knoxville</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4571FBC9-D38E-40A1-BE84-563400983ACF"><gtr:id>4571FBC9-D38E-40A1-BE84-563400983ACF</gtr:id><gtr:name>Affiliated Hospital of Medical College Qingdao University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4ACFDB4B-D413-45EC-8DE8-2B9FBB670994"><gtr:id>4ACFDB4B-D413-45EC-8DE8-2B9FBB670994</gtr:id><gtr:name>Macclesfield District General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C44C4B56-A32E-4355-817E-A8F6B4E1D224"><gtr:id>C44C4B56-A32E-4355-817E-A8F6B4E1D224</gtr:id><gtr:name>Ysbyty Gwynedd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CDB5C46C-3657-4E1A-A590-82CAF586546A"><gtr:id>CDB5C46C-3657-4E1A-A590-82CAF586546A</gtr:id><gtr:name>Clinique du Landy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/45319442-4D29-44ED-AAC1-631E1DFBF03A"><gtr:id>45319442-4D29-44ED-AAC1-631E1DFBF03A</gtr:id><gtr:name>Clinique Sante Cardio MC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6BCB8F32-042E-47EF-8275-627ED296F4B2"><gtr:id>6BCB8F32-042E-47EF-8275-627ED296F4B2</gtr:id><gtr:name>Central Hospital in Kristianstad</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E93D6C07-0652-4449-95E9-DF69D546E74A"><gtr:id>E93D6C07-0652-4449-95E9-DF69D546E74A</gtr:id><gtr:name>Heimdal Helsehus Legesenter AS, Norway</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43773B2C-AB3E-43EF-B4EE-37AE39D9B28E"><gtr:id>43773B2C-AB3E-43EF-B4EE-37AE39D9B28E</gtr:id><gtr:name>Xinxiang Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/979A02A7-EDD9-43D3-9B0F-6B0ACBFB4469"><gtr:id>979A02A7-EDD9-43D3-9B0F-6B0ACBFB4469</gtr:id><gtr:name>Investigators Research Group, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F1CC1F28-7C65-4DB8-B05D-86F313EED523"><gtr:id>F1CC1F28-7C65-4DB8-B05D-86F313EED523</gtr:id><gtr:name>Kootenai Heart Clinics, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/328A70ED-7A67-4E12-A777-2562355B66CD"><gtr:id>328A70ED-7A67-4E12-A777-2562355B66CD</gtr:id><gtr:name>Finmatica Mercia</gtr:name><gtr:address><gtr:line1>Mercia Software</gtr:line1><gtr:line2>Mercia House</gtr:line2><gtr:line3>Ashted Lock, Aston Science Park</gtr:line3><gtr:postCode>B7 4AZ</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8C480BF7-63FF-45A7-A556-FFFD91DDA905"><gtr:id>8C480BF7-63FF-45A7-A556-FFFD91DDA905</gtr:id><gtr:name>General Hospital of Shenyang Military Command</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF9C6405-2F3D-4FF2-9FD1-8F4D9A398F24"><gtr:id>CF9C6405-2F3D-4FF2-9FD1-8F4D9A398F24</gtr:id><gtr:name>KfH Nierenzentrum Frankfurt/Oder</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82B9CAEA-1CB7-49EC-AFDD-88DC5A4B26C0"><gtr:id>82B9CAEA-1CB7-49EC-AFDD-88DC5A4B26C0</gtr:id><gtr:name>Internistische Gemeinschaftspraxis Alzey</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49D610C2-5CFE-4F35-AB5B-F42CCFD2057A"><gtr:id>49D610C2-5CFE-4F35-AB5B-F42CCFD2057A</gtr:id><gtr:name>Palmerston North Hospital Area</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6080E18C-0F85-4F48-BBF6-070A8C2B4BE5"><gtr:id>6080E18C-0F85-4F48-BBF6-070A8C2B4BE5</gtr:id><gtr:name>Beijing Chao-Yang Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/87C3D54D-A192-4C58-920D-8E230F0FE10F"><gtr:id>87C3D54D-A192-4C58-920D-8E230F0FE10F</gtr:id><gtr:name>Ambulantes Herzzentrum Kassel</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/551210F5-4D38-4FE7-8FB9-5998A68A4D4A"><gtr:id>551210F5-4D38-4FE7-8FB9-5998A68A4D4A</gtr:id><gtr:name>Klinikum der Universit?t Regensburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB12F8C8-FB6A-49D8-9A17-F50435FD9E20"><gtr:id>EB12F8C8-FB6A-49D8-9A17-F50435FD9E20</gtr:id><gtr:name>Etel?-karjalan Keskussairaala / Etela-Karjalan keskussairaala</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/742D7BC0-1823-40FB-8C73-9106F4565EBE"><gtr:id>742D7BC0-1823-40FB-8C73-9106F4565EBE</gtr:id><gtr:name>KfH Nierenzentrum Kulmbach</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1C9E096D-AC85-4EBE-A303-D76F04EDAE16"><gtr:id>1C9E096D-AC85-4EBE-A303-D76F04EDAE16</gtr:id><gtr:name>Cardio Centrum</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90BD4526-22E5-4DD3-B338-FE94D41A4AD0"><gtr:id>90BD4526-22E5-4DD3-B338-FE94D41A4AD0</gtr:id><gtr:name>KfH Nierenzentrum Bayreuth</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E9810A0B-AF27-43AA-9942-631EDA0B5F64"><gtr:id>E9810A0B-AF27-43AA-9942-631EDA0B5F64</gtr:id><gtr:name>Kansas City VA Medical Center - 1</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A67AB8CC-C3E2-475F-B86F-92FEB393A01E"><gtr:id>A67AB8CC-C3E2-475F-B86F-92FEB393A01E</gtr:id><gtr:name>Liverpool Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B426979-D09E-49AE-873E-704D74782E4A"><gtr:id>7B426979-D09E-49AE-873E-704D74782E4A</gtr:id><gtr:name>Gemeinschaftspraxis N?rnberg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4ABFD36B-C0A5-4AD0-AE78-8436C66A2969"><gtr:id>4ABFD36B-C0A5-4AD0-AE78-8436C66A2969</gtr:id><gtr:name>Halsobolaget i Jarfalla AB</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67E21C60-B8DD-4699-AC20-1A92454AB2DA"><gtr:id>67E21C60-B8DD-4699-AC20-1A92454AB2DA</gtr:id><gtr:name>Tianjin Medical University General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19400D8C-1FA7-4477-9DE6-0199FB7144CC"><gtr:id>19400D8C-1FA7-4477-9DE6-0199FB7144CC</gtr:id><gtr:name>Cohen Medical Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48911A3F-4ADE-4761-8F30-FC7D6BF9E09E"><gtr:id>48911A3F-4ADE-4761-8F30-FC7D6BF9E09E</gtr:id><gtr:name>Ljungby Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0EA925CB-3B74-43B5-AA46-74EBAFF31F96"><gtr:id>0EA925CB-3B74-43B5-AA46-74EBAFF31F96</gtr:id><gtr:name>University of Limoges</gtr:name><gtr:address><gtr:line1>16 rue d'Atlantis</gtr:line1><gtr:line2>Parc Ester Technopole</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/66977CFE-81F8-41E3-B203-24A6D752F07E"><gtr:id>66977CFE-81F8-41E3-B203-24A6D752F07E</gtr:id><gtr:name>Vienna General Hospital</gtr:name><gtr:address><gtr:line1>Universit?tskliniken</gtr:line1><gtr:line2>W?hringer G?rtel 18-20</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33762991-1280-47A2-935E-A369E0DAF18F"><gtr:id>33762991-1280-47A2-935E-A369E0DAF18F</gtr:id><gtr:name>Skedsmo Medical Center AS</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/319CD245-3BE5-493C-8EFF-182777A2446A"><gtr:id>319CD245-3BE5-493C-8EFF-182777A2446A</gtr:id><gtr:name>Aalborg University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4B61530-E555-421C-B44E-D4BFC4077167"><gtr:id>E4B61530-E555-421C-B44E-D4BFC4077167</gtr:id><gtr:name>Sydjysk Sygehus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/09A5B0A0-CBFE-4E08-8506-F24B81A2FF22"><gtr:id>09A5B0A0-CBFE-4E08-8506-F24B81A2FF22</gtr:id><gtr:name>Freeman Health System</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A9FC408-ACE9-4F71-AB93-245BF1F4A518"><gtr:id>0A9FC408-ACE9-4F71-AB93-245BF1F4A518</gtr:id><gtr:name>London Health Sciences Centre</gtr:name><gtr:address><gtr:line1>339 Windermere Road</gtr:line1><gtr:postCode>N6A 5A5</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EFC89042-CBB0-46F0-BAF2-3D23C9F74BD9"><gtr:id>EFC89042-CBB0-46F0-BAF2-3D23C9F74BD9</gtr:id><gtr:name>Rajavithi hospital</gtr:name><gtr:address><gtr:line1>2, Rajavithi road, Phyathai</gtr:line1><gtr:postCode>10400</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6274ADFB-8596-4E44-B786-53DB106EE630"><gtr:id>6274ADFB-8596-4E44-B786-53DB106EE630</gtr:id><gtr:name>Austin Heart, PLLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4DDAFB1E-C2DA-412D-A30F-393770AD3AD7"><gtr:id>4DDAFB1E-C2DA-412D-A30F-393770AD3AD7</gtr:id><gtr:name>Universit?tsklinikum Leipzig</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CC1CE9BC-D2C9-49A8-877E-522D7B59C147"><gtr:id>CC1CE9BC-D2C9-49A8-877E-522D7B59C147</gtr:id><gtr:name>Providence Saint Joseph Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/40261DBD-C79D-4CE4-A273-392E4D4B9C3E"><gtr:id>40261DBD-C79D-4CE4-A273-392E4D4B9C3E</gtr:id><gtr:name>Internistische Gemeinschaftspraxis und Dialyse Friedrichshafen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CF64D0E-54D2-42CF-AF7D-E2176AB6CCAD"><gtr:id>3CF64D0E-54D2-42CF-AF7D-E2176AB6CCAD</gtr:id><gtr:name>Hull Royal Infirmary</gtr:name><gtr:address><gtr:line1>Anlaby Road</gtr:line1><gtr:line4>Hull</gtr:line4><gtr:line5>North Humberside</gtr:line5><gtr:postCode>HU3 2JZ</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/212329C1-E4C9-4CA2-BD4A-72FFBD010A4B"><gtr:id>212329C1-E4C9-4CA2-BD4A-72FFBD010A4B</gtr:id><gtr:name>Wuhan Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5C3D1AA-F273-458D-B776-CE02F592BECA"><gtr:id>D5C3D1AA-F273-458D-B776-CE02F592BECA</gtr:id><gtr:name>Nottingham Uni Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>City Hospital campus</gtr:line1><gtr:line2>Hucknall Road</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG5 1PB</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A18268E3-6796-43EB-A587-6E57828CB012"><gtr:id>A18268E3-6796-43EB-A587-6E57828CB012</gtr:id><gtr:name>Vrinnevisjukhuset in Norrkoping</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B3EE014-8C69-4641-9BB6-C0A930B83BBF"><gtr:id>5B3EE014-8C69-4641-9BB6-C0A930B83BBF</gtr:id><gtr:name>The Royal Surrey County Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95CE67A3-2F94-4288-B4D9-A7EA0489F2F0"><gtr:id>95CE67A3-2F94-4288-B4D9-A7EA0489F2F0</gtr:id><gtr:name>Odense University Hospital</gtr:name><gtr:address><gtr:line1>5000 Odense C</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D545C73D-780E-4D1A-B5CD-1D6630A8CCCA"><gtr:id>D545C73D-780E-4D1A-B5CD-1D6630A8CCCA</gtr:id><gtr:name>Royal London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ABAF22F6-C312-41E2-9D66-E4B3FF6E3D2D"><gtr:id>ABAF22F6-C312-41E2-9D66-E4B3FF6E3D2D</gtr:id><gtr:name>Nephrologische Gemeinschaftspraxis, Rostock</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A1BA128-2522-4D3E-B99A-BAA76B78782B"><gtr:id>0A1BA128-2522-4D3E-B99A-BAA76B78782B</gtr:id><gtr:name>Esbjerg Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3BDD0C7-54DD-4D15-9A0E-4495A7325C7F"><gtr:id>C3BDD0C7-54DD-4D15-9A0E-4495A7325C7F</gtr:id><gtr:name>Connecticut Heart &amp; Vascular Center PC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F2566DF-4C39-4848-9426-F9C59147CE0A"><gtr:id>8F2566DF-4C39-4848-9426-F9C59147CE0A</gtr:id><gtr:name>University Heart Center Freiburg - Bad Krozingen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/801E5521-FA71-45F5-9BA7-77D765DCE06F"><gtr:id>801E5521-FA71-45F5-9BA7-77D765DCE06F</gtr:id><gtr:name>Juedisches Krankenhaus Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0E0D740E-3610-47C4-8941-29737E009E67"><gtr:id>0E0D740E-3610-47C4-8941-29737E009E67</gtr:id><gtr:name>Local Health Umbria 2</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D9453D9B-1E97-490C-A328-64016CEAC877"><gtr:id>D9453D9B-1E97-490C-A328-64016CEAC877</gtr:id><gtr:name>HeartCare Midwest</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BBCF719-BF61-45B0-BADF-41A6B4AA88EA"><gtr:id>8BBCF719-BF61-45B0-BADF-41A6B4AA88EA</gtr:id><gtr:name>F?rde Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CA4E0D3D-047E-4B03-AD66-A8542B474501"><gtr:id>CA4E0D3D-047E-4B03-AD66-A8542B474501</gtr:id><gtr:name>Centrallasarettet</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/454A8145-64B9-4738-81F1-6A6B0582A717"><gtr:id>454A8145-64B9-4738-81F1-6A6B0582A717</gtr:id><gtr:name>Denver Nephrologists, PC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF7B78B7-B451-451A-AC3F-8FE9A399E11D"><gtr:id>FF7B78B7-B451-451A-AC3F-8FE9A399E11D</gtr:id><gtr:name>Klinik am See</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3F86FCCF-A8E9-4257-92D6-CB15378E93F5"><gtr:id>3F86FCCF-A8E9-4257-92D6-CB15378E93F5</gtr:id><gtr:name>Medical University of Wurzburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CBFD096E-08FF-4EDB-8C79-5DC96B2162C6"><gtr:id>CBFD096E-08FF-4EDB-8C79-5DC96B2162C6</gtr:id><gtr:name>Dialysezentrum R?sselsheim</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C35D919C-B3D6-4EEB-9821-FF4701E7943E"><gtr:id>C35D919C-B3D6-4EEB-9821-FF4701E7943E</gtr:id><gtr:name>Iowa Diabetes and Endocrinology Research Center (IDERC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF0F5FA5-D345-41FF-A3C7-7FA5D560D645"><gtr:id>FF0F5FA5-D345-41FF-A3C7-7FA5D560D645</gtr:id><gtr:name>Gemeinschaftspraxis Kiel</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD411D6F-284B-4E3F-B26B-55AD3AA94851"><gtr:id>CD411D6F-284B-4E3F-B26B-55AD3AA94851</gtr:id><gtr:name>Core Research Group Pty Ltd.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/064A41A2-AC2E-4ACC-A55B-D38D3434BD6A"><gtr:id>064A41A2-AC2E-4ACC-A55B-D38D3434BD6A</gtr:id><gtr:name>Queen's Medical Centre</gtr:name><gtr:address><gtr:line1>Queen's Medical Centre</gtr:line1><gtr:line2>Derby Rd</gtr:line2><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2A44C4EB-3210-49B2-BD66-4FF81F06D133"><gtr:id>2A44C4EB-3210-49B2-BD66-4FF81F06D133</gtr:id><gtr:name>Helsinki University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BEB8A09A-1D45-42C6-A270-F4E24852FC25"><gtr:id>BEB8A09A-1D45-42C6-A270-F4E24852FC25</gtr:id><gtr:name>Shenyang Fifth People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BD80BA0D-9194-4FBE-9658-43A41CFD4ACC"><gtr:id>BD80BA0D-9194-4FBE-9658-43A41CFD4ACC</gtr:id><gtr:name>Sunderland Royal Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3E018BA3-4B93-4B94-974E-8299919ABF8C"><gtr:id>3E018BA3-4B93-4B94-974E-8299919ABF8C</gtr:id><gtr:name>Westlake Medical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF1372D2-543A-41AF-8868-479423257B3B"><gtr:id>DF1372D2-543A-41AF-8868-479423257B3B</gtr:id><gtr:name>Asheville Cardiology Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4858FC05-0DBD-4608-9964-756D24EEC2EA"><gtr:id>4858FC05-0DBD-4608-9964-756D24EEC2EA</gtr:id><gtr:name>The Canberra Hospital</gtr:name><gtr:address><gtr:line1>The Canberra Hospital</gtr:line1><gtr:line2>Yamba Drive</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B424AD7D-B7FF-4DC1-9AF4-E74B96DFBFD5"><gtr:id>B424AD7D-B7FF-4DC1-9AF4-E74B96DFBFD5</gtr:id><gtr:name>The Second Affiliated Hospital of Harbin Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A3574BF1-069D-4E2A-905C-527179B4C447"><gtr:id>A3574BF1-069D-4E2A-905C-527179B4C447</gtr:id><gtr:name>The Center for Pharmaceutical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/591A3A9A-B9DC-4D31-8660-2E747AAEDFAE"><gtr:id>591A3A9A-B9DC-4D31-8660-2E747AAEDFAE</gtr:id><gtr:name>Royal Sussex County Hospital</gtr:name><gtr:address><gtr:line1>Royal Sussex County Hospital</gtr:line1><gtr:line2>Eastern Road</gtr:line2><gtr:postCode>BN2  5BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF63D71D-49D4-4161-AB34-81BBCE1E6C42"><gtr:id>DF63D71D-49D4-4161-AB34-81BBCE1E6C42</gtr:id><gtr:name>Nyk?pings lasarett</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1125BA61-FDB7-4E3A-B215-F3033C72C9DA"><gtr:id>1125BA61-FDB7-4E3A-B215-F3033C72C9DA</gtr:id><gtr:name>Aleris H?lsocentral Bolln?s</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F44FC935-8229-45D0-832A-AF35C6A449BF"><gtr:id>F44FC935-8229-45D0-832A-AF35C6A449BF</gtr:id><gtr:name>Churchill Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D70EC5C-F7A6-4289-8A66-9B5ECDAA06A5"><gtr:id>9D70EC5C-F7A6-4289-8A66-9B5ECDAA06A5</gtr:id><gtr:name>Northampton General Hospital, Northampton</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4051BFFD-1763-4071-82C2-32589D76267C"><gtr:id>4051BFFD-1763-4071-82C2-32589D76267C</gtr:id><gtr:name>Herlev Hospital</gtr:name><gtr:address><gtr:line1>Herlev Ringvej 75</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6"><gtr:id>0FD01CC2-BEC0-446C-B6B3-492C7AEEBAD6</gtr:id><gtr:name>Southampton General Hospital</gtr:name><gtr:address><gtr:line1>Southampton General Hospital</gtr:line1><gtr:line2>Tremona Road</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO16 6YD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC9D6A9E-DC44-4233-BF3A-14F1ED262B94"><gtr:id>AC9D6A9E-DC44-4233-BF3A-14F1ED262B94</gtr:id><gtr:name>Gemeinschaftspraxis Langenhagen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0AD29405-86CD-4E0D-893A-1B701BDDA723"><gtr:id>0AD29405-86CD-4E0D-893A-1B701BDDA723</gtr:id><gtr:name>Gdansk University Clinical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/031EF3F3-1DFC-40FC-B592-92E5FAB19781"><gtr:id>031EF3F3-1DFC-40FC-B592-92E5FAB19781</gtr:id><gtr:name>Fakultn? nemocnice?Kr?lovsk??Vinohrady?(FNKV)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/15BEA556-61BA-4A6D-96E2-68D203200E94"><gtr:id>15BEA556-61BA-4A6D-96E2-68D203200E94</gtr:id><gtr:name>Hospital Pulau Penang</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6965AB72-D958-4511-B6BC-C752F111E489"><gtr:id>6965AB72-D958-4511-B6BC-C752F111E489</gtr:id><gtr:name>Firenze - Ospedale San Giovanni di Dio</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5A16882-91C9-46B8-AE20-1C37595B4BFC"><gtr:id>B5A16882-91C9-46B8-AE20-1C37595B4BFC</gtr:id><gtr:name>N?stved Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1FDA00D-83E7-4D74-8C35-821C0B3EABE0"><gtr:id>C1FDA00D-83E7-4D74-8C35-821C0B3EABE0</gtr:id><gtr:name>State Hospital Feldkirch</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/56116990-2173-4978-8D81-800676D3064A"><gtr:id>56116990-2173-4978-8D81-800676D3064A</gtr:id><gtr:name>Royal Jubilee Hospital (RJH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FB4D3938-DD53-4FE7-882A-5A0465C4C4D0"><gtr:id>FB4D3938-DD53-4FE7-882A-5A0465C4C4D0</gtr:id><gtr:name>Mobile Heart Specialists, PC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/445C872D-07E4-4AE6-9352-78A87D3D96FC"><gtr:id>445C872D-07E4-4AE6-9352-78A87D3D96FC</gtr:id><gtr:name>Upstate Cardiology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F2E28E8D-D750-45C1-8213-CFF8FE06C3F2"><gtr:id>F2E28E8D-D750-45C1-8213-CFF8FE06C3F2</gtr:id><gtr:name>Westside Center for Clinical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88900EC3-E116-4610-B097-94BF4D657F87"><gtr:id>88900EC3-E116-4610-B097-94BF4D657F87</gtr:id><gtr:name>Prince of Wales Hospital</gtr:name><gtr:address><gtr:line1>High Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/492EAA54-6204-4CA7-A3F9-D68780986B33"><gtr:id>492EAA54-6204-4CA7-A3F9-D68780986B33</gtr:id><gtr:name>Hope Housing</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75FB476F-E4DE-487A-BF8E-62C211EAB0F4"><gtr:id>75FB476F-E4DE-487A-BF8E-62C211EAB0F4</gtr:id><gtr:name>Haderslev Sygehus, Denmark</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7576999C-67BA-4056-8896-3EBC0C076D27"><gtr:id>7576999C-67BA-4056-8896-3EBC0C076D27</gtr:id><gtr:name>Dialysezentrum W?rzburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C03225F3-03C3-43C0-BE65-A8A629530193"><gtr:id>C03225F3-03C3-43C0-BE65-A8A629530193</gtr:id><gtr:name>University Medical Ctr Hamburg-Eppendorf</gtr:name><gtr:address><gtr:line1>Martinistrasse 52</gtr:line1><gtr:postCode>D-20246</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A4C12BD-FDA4-4686-BF6C-8C2EC7CBFF2E"><gtr:id>0A4C12BD-FDA4-4686-BF6C-8C2EC7CBFF2E</gtr:id><gtr:name>Medicor Cardiology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FDF86AB3-DA29-42B0-8370-29D53879BD27"><gtr:id>FDF86AB3-DA29-42B0-8370-29D53879BD27</gtr:id><gtr:name>Wellington Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/09119199-D96A-4649-8EAF-958FD4BC899C"><gtr:id>09119199-D96A-4649-8EAF-958FD4BC899C</gtr:id><gtr:name>Lappi Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AEA8FC48-D733-4DB5-9359-02718FC482A3"><gtr:id>AEA8FC48-D733-4DB5-9359-02718FC482A3</gtr:id><gtr:name>Crosshouse Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE7B8401-F5DC-4B0D-AA2B-EFED1E664DC9"><gtr:id>FE7B8401-F5DC-4B0D-AA2B-EFED1E664DC9</gtr:id><gtr:name>Berman Center for Outcomes and Clinical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/204D76BD-F4A1-4CD9-9962-88C505F80203"><gtr:id>204D76BD-F4A1-4CD9-9962-88C505F80203</gtr:id><gtr:name>Dialysepraxis Leipzig</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9D66421-09ED-4C76-8AF3-D38C6DDDC841"><gtr:id>B9D66421-09ED-4C76-8AF3-D38C6DDDC841</gtr:id><gtr:name>Royal Victoria Hospital, Belfast</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A1EFCEC-3C6C-4608-A8F5-4A8DB969E225"><gtr:id>0A1EFCEC-3C6C-4608-A8F5-4A8DB969E225</gtr:id><gtr:name>Luton and Dunstable University Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/967A0B4E-1393-43F3-BEFD-9C9867A735C6"><gtr:id>967A0B4E-1393-43F3-BEFD-9C9867A735C6</gtr:id><gtr:name>Community Clinical Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/663390AF-FE4A-42E9-8102-19EC13B453DC"><gtr:id>663390AF-FE4A-42E9-8102-19EC13B453DC</gtr:id><gtr:name>UNN Hjerte/Kar Poliklinikk</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1340E837-B8AC-4F9C-87CE-2FAD7E8F3FF8"><gtr:id>1340E837-B8AC-4F9C-87CE-2FAD7E8F3FF8</gtr:id><gtr:name>Ladulaas Clinical Studies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/98290490-A636-4A33-9A01-A66F1B4B5E3B"><gtr:id>98290490-A636-4A33-9A01-A66F1B4B5E3B</gtr:id><gtr:name>Northern Michigan Regional Hospital (Nisus Research), Heart Center Research LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43794DA3-3A60-4319-9E12-915BDFACB691"><gtr:id>43794DA3-3A60-4319-9E12-915BDFACB691</gtr:id><gtr:name>The Affiliated Hospital of Inner Mongolia Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8DA7AD2E-B7F8-458C-8D14-CAA39CFD524C"><gtr:id>8DA7AD2E-B7F8-458C-8D14-CAA39CFD524C</gtr:id><gtr:name>Dayton Heart Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/25FEC6C2-48A2-46F7-851E-9C974EF85164"><gtr:id>25FEC6C2-48A2-46F7-851E-9C974EF85164</gtr:id><gtr:name>Fresenius Medical Care</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3F9CC77E-E3DE-4E5C-9CB5-E8A1DDC5138B"><gtr:id>3F9CC77E-E3DE-4E5C-9CB5-E8A1DDC5138B</gtr:id><gtr:name>FinnDiane</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D574CE3-6057-45B5-B41E-2041041E9991"><gtr:id>9D574CE3-6057-45B5-B41E-2041041E9991</gtr:id><gtr:name>Charing Cross Hospital</gtr:name><gtr:address><gtr:line1>Charing Cross Hospital</gtr:line1><gtr:line2>Fulham Palace Road</gtr:line2><gtr:postCode>W6 8RF</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55F0C099-77BD-4DF0-8919-5B996B2448CC"><gtr:id>55F0C099-77BD-4DF0-8919-5B996B2448CC</gtr:id><gtr:name>Jihlava Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D016E07C-85CE-4F24-8232-EC6631338580"><gtr:id>D016E07C-85CE-4F24-8232-EC6631338580</gtr:id><gtr:name>Dialysezentrum Bad Malente</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/746D157B-8C9A-4EF5-8F7F-7263B8D8120C"><gtr:id>746D157B-8C9A-4EF5-8F7F-7263B8D8120C</gtr:id><gtr:name>Dialysezentrum Darmstadt</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D98527E8-9205-4225-AFA0-5DE7000103C4"><gtr:id>D98527E8-9205-4225-AFA0-5DE7000103C4</gtr:id><gtr:name>Brothers of Charity Hospital in Trier</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41892435-41D0-41C6-9C16-7AECA03C4C8D"><gtr:id>41892435-41D0-41C6-9C16-7AECA03C4C8D</gtr:id><gtr:name>Songklanagarind Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BBF43C8A-DF03-4122-A004-3AE2CE6ABFE5"><gtr:id>BBF43C8A-DF03-4122-A004-3AE2CE6ABFE5</gtr:id><gtr:name>Ziekenhuis ZGT Hengelo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/082A46A6-EC47-4E85-890A-F3A052326F1B"><gtr:id>082A46A6-EC47-4E85-890A-F3A052326F1B</gtr:id><gtr:name>SP Health Care University Clinical Hospital No. 1 of the Medical University of Lodz</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A34B09B-7066-4F23-8602-8215DE25848B"><gtr:id>9A34B09B-7066-4F23-8602-8215DE25848B</gtr:id><gtr:name>Second Hospital Of Tianjin Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1C35FAE-6BFE-447C-837E-A6CDED283744"><gtr:id>A1C35FAE-6BFE-447C-837E-A6CDED283744</gtr:id><gtr:name>H?ssleholms Sjukhus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD1F1403-9928-4563-8E48-326ACF87C706"><gtr:id>DD1F1403-9928-4563-8E48-326ACF87C706</gtr:id><gtr:name>University Hospital of Wales</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C8418798-A956-4BF4-A124-EB56B056D806"><gtr:id>C8418798-A956-4BF4-A124-EB56B056D806</gtr:id><gtr:name>Lutherville Personal Physicians</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4AAE76DE-5807-40EF-B3FE-824A330ECEF3"><gtr:id>4AAE76DE-5807-40EF-B3FE-824A330ECEF3</gtr:id><gtr:name>South Tees Hospitals NHS Foundtn Trust</gtr:name><gtr:address><gtr:line1>James Cook Hospital</gtr:line1><gtr:line2>Marton Road</gtr:line2><gtr:postCode>TS4 3BW</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF47A80C-C441-4380-84BD-0C6B80A00ED9"><gtr:id>FF47A80C-C441-4380-84BD-0C6B80A00ED9</gtr:id><gtr:name>Antrim Area Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4"><gtr:id>61EA6E05-55C5-4A83-8A3B-FFF2B3B8D1E4</gtr:id><gtr:name>Basildon and Thurrock University Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3C8AF34-BF10-454B-A600-7E3CC9F96D11"><gtr:id>D3C8AF34-BF10-454B-A600-7E3CC9F96D11</gtr:id><gtr:name>M?larsjukhuset, Eskilstuna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAE5EB06-D833-4B36-9415-D617C213E27F"><gtr:id>DAE5EB06-D833-4B36-9415-D617C213E27F</gtr:id><gtr:name>Cleveland Cardiovascular Research Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB43CBC1-0824-493C-A9FC-7597DBB0EBB8"><gtr:id>EB43CBC1-0824-493C-A9FC-7597DBB0EBB8</gtr:id><gtr:name>North Cumbria University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8C486C9D-2E29-4849-858B-18F5B19A1E18"><gtr:id>8C486C9D-2E29-4849-858B-18F5B19A1E18</gtr:id><gtr:name>Klinikum Am Urban (KAU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D3E670F-EDE4-4E49-9AB6-57B1330ECAFE"><gtr:id>2D3E670F-EDE4-4E49-9AB6-57B1330ECAFE</gtr:id><gtr:name>Inner Mongolia Baogang Staff Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F371C741-9F2B-4C24-B47A-7DB1720126C8"><gtr:id>F371C741-9F2B-4C24-B47A-7DB1720126C8</gtr:id><gtr:name>University Hospital Aachen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/485F4A4C-6FF2-4683-9C18-6394C33128A7"><gtr:id>485F4A4C-6FF2-4683-9C18-6394C33128A7</gtr:id><gtr:name>Inner Mongolia Autonomous Region People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E5B5F7A3-A781-466F-B797-F6F65D7C4B92"><gtr:id>E5B5F7A3-A781-466F-B797-F6F65D7C4B92</gtr:id><gtr:name>Dialysezentrum Bovenden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/840FFA8C-E039-441F-BA4E-7FB201E6D480"><gtr:id>840FFA8C-E039-441F-BA4E-7FB201E6D480</gtr:id><gtr:name>Birmingham City Hospital</gtr:name><gtr:address><gtr:line1>Dudley Road</gtr:line1><gtr:postCode>B18  7QH</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/197E0A76-57CB-44A5-B7FF-42282BC64F3F"><gtr:id>197E0A76-57CB-44A5-B7FF-42282BC64F3F</gtr:id><gtr:name>Dialysezentrum Bad Laasphe</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D867F24-6FAF-4B71-8669-C23926264442"><gtr:id>2D867F24-6FAF-4B71-8669-C23926264442</gtr:id><gtr:name>Gold Coast Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A31B1E91-6F14-4754-8312-B033152F0E21"><gtr:id>A31B1E91-6F14-4754-8312-B033152F0E21</gtr:id><gtr:name>Pinderfieldss Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7881CF6C-5788-414B-954C-CA40CC925716"><gtr:id>7881CF6C-5788-414B-954C-CA40CC925716</gtr:id><gtr:name>Stavanger University Hospital</gtr:name><gtr:address><gtr:line1>Armauer Hansensvei 20</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE5BB6E9-F40A-479A-9A5D-1A4D2B717D02"><gtr:id>AE5BB6E9-F40A-479A-9A5D-1A4D2B717D02</gtr:id><gtr:name>Hospital Provincial de Rosario</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/199A6DA2-71B1-479D-AFD2-9173541DEA53"><gtr:id>199A6DA2-71B1-479D-AFD2-9173541DEA53</gtr:id><gtr:name>Universit?tsklinikum Schleswig-Holstein - Kiel</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C50B9F66-025F-47E7-9D13-121E7DF24A30"><gtr:id>C50B9F66-025F-47E7-9D13-121E7DF24A30</gtr:id><gtr:name>Hospital Santa Margherita</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C7F04DC-65E6-4482-BCE6-D62C53494B4E"><gtr:id>4C7F04DC-65E6-4482-BCE6-D62C53494B4E</gtr:id><gtr:name>Harrisonburg Medical Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4E1DAA0-8180-41F1-9351-540577DB2B5F"><gtr:id>E4E1DAA0-8180-41F1-9351-540577DB2B5F</gtr:id><gtr:name>Saarland University</gtr:name><gtr:address><gtr:line1>Main Campus</gtr:line1><gtr:line2>Stuhlsatzenhausweg</gtr:line2><gtr:postCode>D-66123</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D7918F8A-0C53-4511-A333-B15D122956E9"><gtr:id>D7918F8A-0C53-4511-A333-B15D122956E9</gtr:id><gtr:name>Glan Clwyd District General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70C6D893-1F2A-48E8-9007-61D710DED337"><gtr:id>70C6D893-1F2A-48E8-9007-61D710DED337</gtr:id><gtr:name>Heritage Valley Medical Group, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4304D61E-AC4E-4F23-BA60-AAB848E52F91"><gtr:id>4304D61E-AC4E-4F23-BA60-AAB848E52F91</gtr:id><gtr:name>San Juan VA Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E93A8558-613B-451F-88F8-964379B61001"><gtr:id>E93A8558-613B-451F-88F8-964379B61001</gtr:id><gtr:name>Auckland City Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02354C47-5EE3-4C1D-8AC0-35381ABFA7B6"><gtr:id>02354C47-5EE3-4C1D-8AC0-35381ABFA7B6</gtr:id><gtr:name>Mid-Ohio Heart Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DBCEE86-6873-4669-9B35-B4EEEAE13F52"><gtr:id>3DBCEE86-6873-4669-9B35-B4EEEAE13F52</gtr:id><gtr:name>Royal Liverpool University NHS Hospitals</gtr:name><gtr:address><gtr:line1>Prescot Street</gtr:line1><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L7 8XP</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FF77491-6D8F-46B3-A501-502C02F1142F"><gtr:id>8FF77491-6D8F-46B3-A501-502C02F1142F</gtr:id><gtr:name>Bristol Royal Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A563CF9E-D910-4F6E-A378-DFA52E0D7C73"><gtr:id>A563CF9E-D910-4F6E-A378-DFA52E0D7C73</gtr:id><gtr:name>Grand View-Lehigh Valley Health Services, Buxmont Cardiology Division</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CDC99D45-9884-442F-BE35-819D60346A3E"><gtr:id>CDC99D45-9884-442F-BE35-819D60346A3E</gtr:id><gtr:name>Tongji University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D2595A40-02F9-40B1-B573-33B3549E4387"><gtr:id>D2595A40-02F9-40B1-B573-33B3549E4387</gtr:id><gtr:name>Royal Stoke University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3329A0A0-44CD-4A56-A967-27A9AA6B7E03"><gtr:id>3329A0A0-44CD-4A56-A967-27A9AA6B7E03</gtr:id><gtr:name>St. Paul's Hospital Saskatoon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93F766A7-C3D5-4887-A6C3-A8EE13BEADC8"><gtr:id>93F766A7-C3D5-4887-A6C3-A8EE13BEADC8</gtr:id><gtr:name>Poznan Hospital Clinic 2</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DB5079E4-EF83-4AAE-B753-7E4C2283F0B0"><gtr:id>DB5079E4-EF83-4AAE-B753-7E4C2283F0B0</gtr:id><gtr:name>Royal Brisbane &amp; Women's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA2917FF-4A13-4973-ABDD-C1AFB2ABEA26"><gtr:id>FA2917FF-4A13-4973-ABDD-C1AFB2ABEA26</gtr:id><gtr:name>Wrexham Maelor Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/679189AF-44F0-429C-A7EF-08E0AD412A69"><gtr:id>679189AF-44F0-429C-A7EF-08E0AD412A69</gtr:id><gtr:name>King Chulalongkorn Memorial Hospital</gtr:name><gtr:address><gtr:line1>Sor Kor Building</gtr:line1><gtr:line2>1873 Rama IV Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C9F0518-B1C5-4A2F-9FF3-CA0424156A71"><gtr:id>9C9F0518-B1C5-4A2F-9FF3-CA0424156A71</gtr:id><gtr:name>Norrlands Universitetssjukhus</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE12B2F4-8E8D-4C28-918A-8D2307D5E986"><gtr:id>EE12B2F4-8E8D-4C28-918A-8D2307D5E986</gtr:id><gtr:name>John Hunter Hospital</gtr:name><gtr:address><gtr:line1>John Hunter Hospital</gtr:line1><gtr:line2>Lookout Road</gtr:line2><gtr:postCode>NSW 2305</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61FCB95D-578A-4035-AB8D-4EF88551FC44"><gtr:id>61FCB95D-578A-4035-AB8D-4EF88551FC44</gtr:id><gtr:name>Florida Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44732692-8608-469D-AD74-31CE8F0DAB19"><gtr:id>44732692-8608-469D-AD74-31CE8F0DAB19</gtr:id><gtr:name>Bendigo Health Care Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AA16163E-32C8-4098-B282-479F0F303DB3"><gtr:id>AA16163E-32C8-4098-B282-479F0F303DB3</gtr:id><gtr:name>Musgrove Park Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F518383F-A8B7-4D52-9974-2DA39525E7BC"><gtr:id>F518383F-A8B7-4D52-9974-2DA39525E7BC</gtr:id><gtr:name>Rameses Associates Ltd</gtr:name><gtr:address><gtr:line1>11 Margaret Street</gtr:line1><gtr:postCode>ST15 8EL</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/05D69417-BE9F-4C72-B26A-053781697575"><gtr:id>05D69417-BE9F-4C72-B26A-053781697575</gtr:id><gtr:name>Sunnybrook Health Sciences Centre</gtr:name><gtr:address><gtr:line1>Sunnybrook Health Sciences Centre</gtr:line1><gtr:line2>5112-2075 Bayview Ave</gtr:line2><gtr:postCode>M4N 3M5</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DB2AC066-46B3-4360-8F7A-25877A5257EB"><gtr:id>DB2AC066-46B3-4360-8F7A-25877A5257EB</gtr:id><gtr:name>St Mary's Hospital Portsmouth</gtr:name><gtr:address><gtr:line1>St Mary's Hospital Portsmouth</gtr:line1><gtr:line2>Milton Road</gtr:line2><gtr:postCode>PO3 6AD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D58A407-6680-474B-9287-9F0BF5202EB9"><gtr:id>2D58A407-6680-474B-9287-9F0BF5202EB9</gtr:id><gtr:name>School of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D6786532-77A9-4CDD-862E-D515B1F8ECAE"><gtr:id>D6786532-77A9-4CDD-862E-D515B1F8ECAE</gtr:id><gtr:name>Suzhou Kowloon Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/15ECCAA6-3377-470F-81DA-B3FB82899592"><gtr:id>15ECCAA6-3377-470F-81DA-B3FB82899592</gtr:id><gtr:name>Barnsley District General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F6A35A64-B938-432B-BF21-F0A436AE64C6"><gtr:id>F6A35A64-B938-432B-BF21-F0A436AE64C6</gtr:id><gtr:name>Central Denmark Region</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB786A43-F1A4-4783-BC0B-5F4CF7701992"><gtr:id>AB786A43-F1A4-4783-BC0B-5F4CF7701992</gtr:id><gtr:name>New Cross Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/302AA15A-7204-4286-8CE4-994DC46F09C2"><gtr:id>302AA15A-7204-4286-8CE4-994DC46F09C2</gtr:id><gtr:name>Norton Cardiovascular Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D62CCDB-B33F-4D29-BD59-BE7D305D233B"><gtr:id>5D62CCDB-B33F-4D29-BD59-BE7D305D233B</gtr:id><gtr:name>Shenyang Sujiatun Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B0982CD-EDF6-4B1C-92CE-6DE5768C0241"><gtr:id>5B0982CD-EDF6-4B1C-92CE-6DE5768C0241</gtr:id><gtr:name>Jilin City Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6B0E70-1EDE-47A7-B3C4-27EF207152C7"><gtr:id>2F6B0E70-1EDE-47A7-B3C4-27EF207152C7</gtr:id><gtr:name>Julich Research Centre</gtr:name><gtr:address><gtr:line1>Forschungzentrum Julich GmbH</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80FA87D2-A534-45AC-A08F-7B257D59FE61"><gtr:id>80FA87D2-A534-45AC-A08F-7B257D59FE61</gtr:id><gtr:name>Waikato Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BD4E456F-AC31-4992-90AA-CACDC2DD4989"><gtr:id>BD4E456F-AC31-4992-90AA-CACDC2DD4989</gtr:id><gtr:name>Torbay Hospital</gtr:name><gtr:address><gtr:line1>Lawes Bridge</gtr:line1><gtr:postCode>TQ2 7AA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/978364D7-4073-4009-850C-0CF01A8FF936"><gtr:id>978364D7-4073-4009-850C-0CF01A8FF936</gtr:id><gtr:name>Glasgow Victoria Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5635674-848F-408A-B915-A59654BEE353"><gtr:id>F5635674-848F-408A-B915-A59654BEE353</gtr:id><gtr:name>University of Eastern Finland</gtr:name><gtr:address><gtr:line1>Yliopistokatu 7</gtr:line1><gtr:line2>Box 111</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0451156C-F2A3-4579-8F5E-BD3AED5E1B9A"><gtr:id>0451156C-F2A3-4579-8F5E-BD3AED5E1B9A</gtr:id><gtr:name>Sykehuset Telemark, Skien</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/74B72971-8647-485A-9D6C-7E30968F0135"><gtr:id>74B72971-8647-485A-9D6C-7E30968F0135</gtr:id><gtr:name>Escondido Cardiology Associates Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31D1B531-4A47-4855-B8D7-49AE02F6F66B"><gtr:id>31D1B531-4A47-4855-B8D7-49AE02F6F66B</gtr:id><gtr:name>Haugesund Hjertepraksis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/65849DDB-E500-4072-8E9D-E44749F838EE"><gtr:id>65849DDB-E500-4072-8E9D-E44749F838EE</gtr:id><gtr:name>St Vincent's Hospital</gtr:name><gtr:address><gtr:line1>St Vincent's Hospital</gtr:line1><gtr:line2>384 Victoria Street</gtr:line2><gtr:line3>Darlinghurst</gtr:line3><gtr:postCode>NSW 2010</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A0E5270-72DC-4C05-B948-ECDEB2AE1E58"><gtr:id>5A0E5270-72DC-4C05-B948-ECDEB2AE1E58</gtr:id><gtr:name>York Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F0362A7-0A4F-4B33-B00E-9C6AA3C14B32"><gtr:id>2F0362A7-0A4F-4B33-B00E-9C6AA3C14B32</gtr:id><gtr:name>SLK-Kliniken Heilbronn GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CCE44306-72AB-4B25-AF26-99F6332A69DE"><gtr:id>CCE44306-72AB-4B25-AF26-99F6332A69DE</gtr:id><gtr:name>Dialysezentrum Sch?neberg-Tempelhof Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CFE5B017-A9E3-4F81-AA65-F0D0AEB4B26A"><gtr:id>CFE5B017-A9E3-4F81-AA65-F0D0AEB4B26A</gtr:id><gtr:name>Health First Incorporation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54622D05-A2D5-4BA5-8D00-10EDC9B430A1"><gtr:id>54622D05-A2D5-4BA5-8D00-10EDC9B430A1</gtr:id><gtr:name>Provincial Specialist Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B1CD680-6631-4C7B-A153-DD2C31509C3F"><gtr:id>7B1CD680-6631-4C7B-A153-DD2C31509C3F</gtr:id><gtr:name>Marseille Biological Cancer Laboratory</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1C44EED-5B42-4121-A76C-36754178E240"><gtr:id>A1C44EED-5B42-4121-A76C-36754178E240</gtr:id><gtr:name>KfH Nierenzentrum Eberswalde</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1342AD4A-EB68-4885-AA8C-083191883379"><gtr:id>1342AD4A-EB68-4885-AA8C-083191883379</gtr:id><gtr:name>Future Care Solution, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3DC1831-6AAD-4F98-9678-E15F5A7D5344"><gtr:id>F3DC1831-6AAD-4F98-9678-E15F5A7D5344</gtr:id><gtr:name>Universitetssykehuset Nord-Norge HF</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A915DFE8-FE38-452A-82AC-B2D05AAA3647"><gtr:id>A915DFE8-FE38-452A-82AC-B2D05AAA3647</gtr:id><gtr:name>Hopital Saint Jean - Perpignan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D35EACB-6285-4F82-88E5-7A9EBBB78FDC"><gtr:id>5D35EACB-6285-4F82-88E5-7A9EBBB78FDC</gtr:id><gtr:name>Bedford Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Bedford Hospital 
Kempston Road</gtr:line1><gtr:city>Bedford</gtr:city><gtr:postCode>MK42 9DJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>UNITED KINGDOM</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/24716F75-ADF6-487F-BAE1-041AC6F8F49A"><gtr:id>24716F75-ADF6-487F-BAE1-041AC6F8F49A</gtr:id><gtr:name>The General Hospital Of Xuzhou Mining Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/884A93C8-8C7A-401A-9C78-C2DF85A6CE30"><gtr:id>884A93C8-8C7A-401A-9C78-C2DF85A6CE30</gtr:id><gtr:name>Verde Valley Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9526B2CC-53A2-4DC0-B1C7-B43AC1582583"><gtr:id>9526B2CC-53A2-4DC0-B1C7-B43AC1582583</gtr:id><gtr:name>Medical City</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FD7EBB98-CBC4-4658-9753-36E6BDE7D09C"><gtr:id>FD7EBB98-CBC4-4658-9753-36E6BDE7D09C</gtr:id><gtr:name>Wuhan Asia Heart Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BD266A87-3DA6-4DFA-82F0-B8DF5B091022"><gtr:id>BD266A87-3DA6-4DFA-82F0-B8DF5B091022</gtr:id><gtr:name>Middlemore Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/14DDA6BF-857D-49EA-A270-40F5DE6F4CAA"><gtr:id>14DDA6BF-857D-49EA-A270-40F5DE6F4CAA</gtr:id><gtr:name>Houma People's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84411F68-FB80-47C5-9945-112A711ACD44"><gtr:id>84411F68-FB80-47C5-9945-112A711ACD44</gtr:id><gtr:name>Connect Clinical Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19AA400-C038-4D60-B9F6-D66C13D73703"><gtr:id>A19AA400-C038-4D60-B9F6-D66C13D73703</gtr:id><gtr:name>Falu Lasarett</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1494FB1-6729-4473-ACC1-2186B405030B"><gtr:id>E1494FB1-6729-4473-ACC1-2186B405030B</gtr:id><gtr:name>Nephrology Center Emsland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C9DD8834-BF8B-44A9-9B79-4E1FA258C2BF"><gtr:id>C9DD8834-BF8B-44A9-9B79-4E1FA258C2BF</gtr:id><gtr:name>Nephrology Center Pforzheim</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ED5C93C8-4CAF-48C3-8392-B91D9851160F"><gtr:id>ED5C93C8-4CAF-48C3-8392-B91D9851160F</gtr:id><gtr:name>Daqing Oil Field General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E58B69F0-0D53-427E-8F78-CC0513DF733D"><gtr:id>E58B69F0-0D53-427E-8F78-CC0513DF733D</gtr:id><gtr:name>Legnano Public Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8E982CFE-5C39-4941-89F3-940E9DD2A8E0"><gtr:id>8E982CFE-5C39-4941-89F3-940E9DD2A8E0</gtr:id><gtr:name>Princess of Wales Hospital, Bridgend</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/27DE24AA-7A2D-4BD8-B074-D3E585B329FF"><gtr:id>27DE24AA-7A2D-4BD8-B074-D3E585B329FF</gtr:id><gtr:name>Royal Derby Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67F4DDE5-94CF-44CB-BBC0-24C3C582FD16"><gtr:id>67F4DDE5-94CF-44CB-BBC0-24C3C582FD16</gtr:id><gtr:name>Clearwater Cardiovascular</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ABD9F36C-3F20-4076-AE76-453AED593EA0"><gtr:id>ABD9F36C-3F20-4076-AE76-453AED593EA0</gtr:id><gtr:name>Geri-Med Oy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/905342C4-78ED-4A9F-BAE7-5160B9FDEF4E"><gtr:id>905342C4-78ED-4A9F-BAE7-5160B9FDEF4E</gtr:id><gtr:name>Ospedale F. Veneziale Pronto Soccorso</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75272066-6E82-4F65-B3F4-9BBC2C93921D"><gtr:id>75272066-6E82-4F65-B3F4-9BBC2C93921D</gtr:id><gtr:name>Lindesberg Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2892DB69-C6C1-457B-9B5E-41C8C24FBE26"><gtr:id>2892DB69-C6C1-457B-9B5E-41C8C24FBE26</gtr:id><gtr:name>Ospedale Ignazio Veris delli Ponti</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9697FD17-978E-4411-80C6-79F1837227EC"><gtr:id>9697FD17-978E-4411-80C6-79F1837227EC</gtr:id><gtr:name>The General Hospital Of AISCO</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D0BCCC88-A48A-41D9-BDE3-3F441F46D489"><gtr:id>D0BCCC88-A48A-41D9-BDE3-3F441F46D489</gtr:id><gtr:name>Southwest Florida Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/290C4F5D-FC73-40AC-821D-1A333358CFF7"><gtr:id>290C4F5D-FC73-40AC-821D-1A333358CFF7</gtr:id><gtr:name>Awasty Research Network, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1EF7934E-6F3B-4A28-BD9B-9A9538718340"><gtr:id>1EF7934E-6F3B-4A28-BD9B-9A9538718340</gtr:id><gtr:name>Peking University Third Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6DC63B6D-2F4A-4034-851A-ABB54D75E1F6"><gtr:id>6DC63B6D-2F4A-4034-851A-ABB54D75E1F6</gtr:id><gtr:name>Hospital of San Paolo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43F2E53C-DC36-4B86-90C1-8083E914E84D"><gtr:id>43F2E53C-DC36-4B86-90C1-8083E914E84D</gtr:id><gtr:name>Community Practice Outpatient Dialysis in Augsburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1ABB1DF-634E-4E6C-8C01-C98E5FD2851F"><gtr:id>E1ABB1DF-634E-4E6C-8C01-C98E5FD2851F</gtr:id><gtr:name>First Affiliated Hospital of Zhengzhou University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B32E5D3-9B3C-4450-8C90-1750FB9C10EC"><gtr:id>0B32E5D3-9B3C-4450-8C90-1750FB9C10EC</gtr:id><gtr:name>Spesialistsenteret pa</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BA8DE40E-3418-4DEF-880F-B1C30C3F3E56"><gtr:id>BA8DE40E-3418-4DEF-880F-B1C30C3F3E56</gtr:id><gtr:name>Universitetssjukhuset MAS, Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D0D74D75-52C4-4217-B30C-17D58BE868E5"><gtr:id>D0D74D75-52C4-4217-B30C-17D58BE868E5</gtr:id><gtr:name>Stavanger Health Research Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE35DC91-88BC-44C2-A5AD-12B6468BD7CA"><gtr:id>AE35DC91-88BC-44C2-A5AD-12B6468BD7CA</gtr:id><gtr:name>Albury Wodonga Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64BDC344-D31D-4A63-BFDC-4ED692599F8B"><gtr:id>64BDC344-D31D-4A63-BFDC-4ED692599F8B</gtr:id><gtr:name>Skelleftea Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/171DFB17-BFDB-4090-8991-E3A1227E52A0"><gtr:id>171DFB17-BFDB-4090-8991-E3A1227E52A0</gtr:id><gtr:name>Sein?joen L??k?ritalo / Seinajoen Laakaritalo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5382568-3EB8-401D-9279-BBE34BB27CA6"><gtr:id>D5382568-3EB8-401D-9279-BBE34BB27CA6</gtr:id><gtr:name>Barnsley Hospital NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>NHS Trust</gtr:line1><gtr:line2>Gawber Road</gtr:line2><gtr:line4>Barnsley</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S75 2EP</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/98851699-8738-4111-B494-F623682216B9"><gtr:id>98851699-8738-4111-B494-F623682216B9</gtr:id><gtr:name>Harfleur - Clinic du Petit Colmoulins</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A138BDBB-F268-4730-9AB9-E560AE4A32F4"><gtr:id>A138BDBB-F268-4730-9AB9-E560AE4A32F4</gtr:id><gtr:name>Corusfit Oy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/24320172-946F-49F5-8356-40F1F4E6CB81"><gtr:id>24320172-946F-49F5-8356-40F1F4E6CB81</gtr:id><gtr:name>Watford General Hospital</gtr:name><gtr:address><gtr:line1>Watford General Hospital</gtr:line1><gtr:line2>Vicarage Road</gtr:line2><gtr:postCode>WD1 8HB</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB2A92EB-5056-46DE-BB6E-846C4C45AD14"><gtr:id>EB2A92EB-5056-46DE-BB6E-846C4C45AD14</gtr:id><gtr:name>Nanocem Consortium</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1BB66625-E529-4E8D-B1F6-0D500FA18BF5"><gtr:id>1BB66625-E529-4E8D-B1F6-0D500FA18BF5</gtr:id><gtr:name>Epilepsy Research UK</gtr:name><gtr:address><gtr:line1>PO Box 3004</gtr:line1><gtr:postCode>W4 4XT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C"><gtr:id>EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C</gtr:id><gtr:name>St Bartholomew's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E45EEE3E-AA10-4E7E-A143-DB1D2851810D"><gtr:id>E45EEE3E-AA10-4E7E-A143-DB1D2851810D</gtr:id><gtr:name>Heart Institute of Spokane</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D6E365B-1CB9-4312-B7D2-BE57216BF53F"><gtr:id>9D6E365B-1CB9-4312-B7D2-BE57216BF53F</gtr:id><gtr:name>Manor Hospital Walsall</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE1321FA-3A5C-482B-9B32-A9ACD5B04438"><gtr:id>BE1321FA-3A5C-482B-9B32-A9ACD5B04438</gtr:id><gtr:name>Dalian Municipal Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D4F213-AC1B-4E51-B57E-2684C82BF7D3"><gtr:id>03D4F213-AC1B-4E51-B57E-2684C82BF7D3</gtr:id><gtr:name>Health Sciences Centre - Winnipeg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19F0BEA3-1A0C-4E69-9B1B-0BB2B44C551E"><gtr:id>19F0BEA3-1A0C-4E69-9B1B-0BB2B44C551E</gtr:id><gtr:name>KfH Nierenzentrum F?rth</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90F1F733-5008-4E39-A50E-1CEF5F95B4AD"><gtr:id>90F1F733-5008-4E39-A50E-1CEF5F95B4AD</gtr:id><gtr:name>Third People's Hospital of Dalian</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F089B62D-EC0E-41A9-8126-76A9E3E1A261"><gtr:id>F089B62D-EC0E-41A9-8126-76A9E3E1A261</gtr:id><gtr:name>Peninsula Clinical Research Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/50411855-FCE3-4D0E-8916-ED312E4FB5CF"><gtr:id>50411855-FCE3-4D0E-8916-ED312E4FB5CF</gtr:id><gtr:name>Comprehensive Cardiovascular Medical Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACF3A7B9-5DC0-4010-809A-57C74F32A308"><gtr:id>ACF3A7B9-5DC0-4010-809A-57C74F32A308</gtr:id><gtr:name>Conquest Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39EE08CC-477A-429D-BC48-2AED7098FC5A"><gtr:id>39EE08CC-477A-429D-BC48-2AED7098FC5A</gtr:id><gtr:name>Gentofte Hospital</gtr:name><gtr:address><gtr:postCode>DK-2900</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82702D12-D770-4B47-86DD-5120E4613C99"><gtr:id>82702D12-D770-4B47-86DD-5120E4613C99</gtr:id><gtr:name>Helse Sunnmmore HF</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EA4CA180-FA36-407D-AE6C-A75524ED7702"><gtr:id>EA4CA180-FA36-407D-AE6C-A75524ED7702</gtr:id><gtr:name>Jyvaskyla CorusFit Oy, Finland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75C61583-B98C-40A9-B245-9FE1FAEBFDF0"><gtr:id>75C61583-B98C-40A9-B245-9FE1FAEBFDF0</gtr:id><gtr:name>Poole Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CA10F5D0-8E26-4790-BF21-025009DDA322"><gtr:id>CA10F5D0-8E26-4790-BF21-025009DDA322</gtr:id><gtr:name>Medical University of Graz</gtr:name><gtr:address><gtr:line1>Harrachgasse 21</gtr:line1><gtr:line4>Graz</gtr:line4><gtr:line5>A-8010</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Austria</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B1E524F4-3A87-4E39-B472-75C907B5C807"><gtr:id>B1E524F4-3A87-4E39-B472-75C907B5C807</gtr:id><gtr:name>Universitetssjukhuset MAS Malm?</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C5CA8B8-E117-4DCB-B209-BB28EE915DD7"><gtr:id>4C5CA8B8-E117-4DCB-B209-BB28EE915DD7</gtr:id><gtr:name>Ospedali Riuniti Albano - Genzano</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0860AB67-5A2F-4D97-B53D-A5FF78232595"><gtr:id>0860AB67-5A2F-4D97-B53D-A5FF78232595</gtr:id><gtr:name>KfH Nierenzentrum Trier</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55EC27AF-48C7-493C-AB4C-2B3E81114AEB"><gtr:id>55EC27AF-48C7-493C-AB4C-2B3E81114AEB</gtr:id><gtr:name>Ostersund Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/09BEB700-79CE-451D-907F-2E28054DA026"><gtr:id>09BEB700-79CE-451D-907F-2E28054DA026</gtr:id><gtr:name>St Michael's Hospital</gtr:name><gtr:address><gtr:line1>St Michael's Hospital</gtr:line1><gtr:line2>University of Bristol</gtr:line2><gtr:line3>Southwell Street</gtr:line3><gtr:postCode>BS2  8EG</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F550C119-5DE6-4E9C-8D07-97FE0315BAE1"><gtr:id>F550C119-5DE6-4E9C-8D07-97FE0315BAE1</gtr:id><gtr:name>The Rotherham NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/01C0798C-A4C2-429C-BB20-98F84676534E"><gtr:id>01C0798C-A4C2-429C-BB20-98F84676534E</gtr:id><gtr:name>Cardiovascular Associates of the Delaware Valley (CADV)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3887927A-B1C8-46AA-9422-28D266232423"><gtr:id>3887927A-B1C8-46AA-9422-28D266232423</gtr:id><gtr:name>Szpital Specjalistyczny, Dabrowa G?rnicza</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46328BEE-3030-4FB6-8468-23DC39114236"><gtr:id>46328BEE-3030-4FB6-8468-23DC39114236</gtr:id><gtr:name>Black Hills Cardiovascular</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86E7901F-BD5A-486E-BC7E-FBB7498B764E"><gtr:id>86E7901F-BD5A-486E-BC7E-FBB7498B764E</gtr:id><gtr:name>Glan Clwyd Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5C001875-4111-47E8-BCB1-1DA0ED382F9D"><gtr:id>5C001875-4111-47E8-BCB1-1DA0ED382F9D</gtr:id><gtr:name>University of Missouri Health Care</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A3DDF697-B161-42E9-A932-D49F6A3143D1"><gtr:id>A3DDF697-B161-42E9-A932-D49F6A3143D1</gtr:id><gtr:name>Regina Qu'Appelle Health Region</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/059C6045-48D4-4FFB-8C5B-14D65C740706"><gtr:id>059C6045-48D4-4FFB-8C5B-14D65C740706</gtr:id><gtr:name>Atlanta Heart Specialists, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E34B9513-BEC0-4D97-AEFA-F3BC99F34804"><gtr:id>E34B9513-BEC0-4D97-AEFA-F3BC99F34804</gtr:id><gtr:name>Tianjin Fourth Central Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60028FD1-67AC-4B70-A3D6-94452C3C160B"><gtr:id>60028FD1-67AC-4B70-A3D6-94452C3C160B</gtr:id><gtr:name>Health Partners</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1514EF90-E0B5-468C-B560-BF831AB6BEF7"><gtr:id>1514EF90-E0B5-468C-B560-BF831AB6BEF7</gtr:id><gtr:name>Acadia Clinical Research LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4AE6001-1347-4246-84A7-81408473BD3B"><gtr:id>C4AE6001-1347-4246-84A7-81408473BD3B</gtr:id><gtr:name>Royal Cornwall Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Royal Cornwall Hospital</gtr:line1><gtr:line2>Treliske</gtr:line2><gtr:postCode>TR1 3LJ</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F409973E-3DAD-4B08-BD29-34B629FBC8DC"><gtr:id>F409973E-3DAD-4B08-BD29-34B629FBC8DC</gtr:id><gtr:name>Western New England Renal &amp; Transplant Associates (WNERTA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82810B84-873C-4E5D-B509-2919C144B2EC"><gtr:id>82810B84-873C-4E5D-B509-2919C144B2EC</gtr:id><gtr:name>First Affiliated Hospital of Xinxiang Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0822CD6A-9B78-43D7-A0F1-31617D27220E"><gtr:id>0822CD6A-9B78-43D7-A0F1-31617D27220E</gtr:id><gtr:name>Broomfield Hospital</gtr:name><gtr:address><gtr:line1>Broomfield Hospital</gtr:line1><gtr:postCode>CM1 7ET</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E913F6AA-9FFC-4300-83DB-799EC8F3A4E7"><gtr:id>E913F6AA-9FFC-4300-83DB-799EC8F3A4E7</gtr:id><gtr:name>University of Maryland</gtr:name><gtr:address><gtr:line1>University of Maryland</gtr:line1><gtr:postCode>20742</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3975F33B-4CCB-449E-8AA0-67417A3FC0AA"><gtr:id>3975F33B-4CCB-449E-8AA0-67417A3FC0AA</gtr:id><gtr:name>The 306th Hospital of PLA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AD5534A9-2E11-4569-B6B4-827643AE1A1D"><gtr:id>AD5534A9-2E11-4569-B6B4-827643AE1A1D</gtr:id><gtr:name>Westpfalz-Klinikum GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F254FBD-40D1-4FA4-B3A6-116756FAE87F"><gtr:id>7F254FBD-40D1-4FA4-B3A6-116756FAE87F</gtr:id><gtr:name>General Hospital Of Shanyang Army</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70190FBA-17F4-410B-99F0-8883DA732818"><gtr:id>70190FBA-17F4-410B-99F0-8883DA732818</gtr:id><gtr:name>Royal Victoria Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A7043EC-8B05-4B56-B68F-3E395C09AB9E"><gtr:id>4A7043EC-8B05-4B56-B68F-3E395C09AB9E</gtr:id><gtr:name>Wuhan Puai Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72E623C2-15F5-4E2A-81DD-F50F0E32358A"><gtr:id>72E623C2-15F5-4E2A-81DD-F50F0E32358A</gtr:id><gtr:name>Hospital Tengku Ampuan Rahimah</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2CDDAF38-8C8B-416D-A3E1-BA3F7E3484AD"><gtr:id>2CDDAF38-8C8B-416D-A3E1-BA3F7E3484AD</gtr:id><gtr:name>Universitaet Magdeburg Lipidambulanz</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EEC37B4-0488-487A-A125-BE8DBA45E27A"><gtr:id>9EEC37B4-0488-487A-A125-BE8DBA45E27A</gtr:id><gtr:name>Saratoga Cardiology Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FBE4306-C04C-442E-8A40-C381F08FB50B"><gtr:id>8FBE4306-C04C-442E-8A40-C381F08FB50B</gtr:id><gtr:name>Dialysezentrum Pirmasens &amp; Kusel</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D048B75-2EBE-4220-8A00-C42953F9D76D"><gtr:id>4D048B75-2EBE-4220-8A00-C42953F9D76D</gtr:id><gtr:name>Texas Cardiology Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5C8C228-8BD6-4222-A3E3-B842AC68A36C"><gtr:id>D5C8C228-8BD6-4222-A3E3-B842AC68A36C</gtr:id><gtr:name>Launceston General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2294A225-2437-4CA3-94DA-50340C98A54E"><gtr:id>2294A225-2437-4CA3-94DA-50340C98A54E</gtr:id><gtr:name>Duke University Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE3A51FC-C401-4584-A22C-4D0619BE9801"><gtr:id>CE3A51FC-C401-4584-A22C-4D0619BE9801</gtr:id><gtr:name>Darlington Memorial Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/473F778F-73B3-4C69-BDD1-E819F5417AC9"><gtr:id>473F778F-73B3-4C69-BDD1-E819F5417AC9</gtr:id><gtr:name>Monash Children's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3178B45D-5F74-4CAB-BA6A-10796E718808"><gtr:id>3178B45D-5F74-4CAB-BA6A-10796E718808</gtr:id><gtr:name>VA Boston Healthcare System</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8CC2E3CE-75FA-461F-A3B0-860D294D060B"><gtr:id>8CC2E3CE-75FA-461F-A3B0-860D294D060B</gtr:id><gtr:name>West Cumberland Hospital</gtr:name><gtr:address><gtr:line1>Hensingham</gtr:line1><gtr:line2>Whitehaven</gtr:line2><gtr:postCode>CA28 AJG</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6E097116-9BC5-4E19-9004-84DF25CC4D33"><gtr:id>6E097116-9BC5-4E19-9004-84DF25CC4D33</gtr:id><gtr:name>Shengjing Hospital of China Medical University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/29DFAD05-9F55-4706-A778-BC519B6D9B3D"><gtr:id>29DFAD05-9F55-4706-A778-BC519B6D9B3D</gtr:id><gtr:name>Gefaess Zentrum Universitaetsklinik Dresden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1C3A673-9335-402C-84FC-777BB3230197"><gtr:id>A1C3A673-9335-402C-84FC-777BB3230197</gtr:id><gtr:name>North Alabama Research Center, LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8F91D8A6-2743-4F23-9EEC-3D2EF168FBB5"><gtr:id>8F91D8A6-2743-4F23-9EEC-3D2EF168FBB5</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:surname>Bowman</gtr:surname><gtr:orcidId>0000-0003-1125-8616</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3843697-EACF-4836-9052-44E6043B606D"><gtr:id>C3843697-EACF-4836-9052-44E6043B606D</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Armitage</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/10D9EDDD-90BD-45A5-B620-831BC7AC90EC"><gtr:id>10D9EDDD-90BD-45A5-B620-831BC7AC90EC</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Emberson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A0EF6BCA-9925-46DE-BA83-96D25371ABDF"><gtr:id>A0EF6BCA-9925-46DE-BA83-96D25371ABDF</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Landray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90232D94-C2A5-4E0C-9214-D1F2E407E8B7"><gtr:id>90232D94-C2A5-4E0C-9214-D1F2E407E8B7</gtr:id><gtr:firstName>Christine</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Reith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F24D4F73-2C89-4052-9485-F6B0A44E71B8"><gtr:id>F24D4F73-2C89-4052-9485-F6B0A44E71B8</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Haynes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/42EA1F7C-61E8-4457-99C1-1437D6FEC7F6"><gtr:id>42EA1F7C-61E8-4457-99C1-1437D6FEC7F6</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Bulbulia</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC7211B0-C16B-4EFD-A60E-6DDCFC72ECC9"><gtr:id>DC7211B0-C16B-4EFD-A60E-6DDCFC72ECC9</gtr:id><gtr:firstName>Karl</gtr:firstName><gtr:surname>Wallendszuz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AA2AE571-69F8-46E6-AF9B-B27E8D0E2B93"><gtr:id>AA2AE571-69F8-46E6-AF9B-B27E8D0E2B93</gtr:id><gtr:firstName>MD</gtr:firstName><gtr:surname>Lay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F4479AD7-66C1-4474-8AB6-E8F33ACCEBC0"><gtr:id>F4479AD7-66C1-4474-8AB6-E8F33ACCEBC0</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Baigent</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0688D1E8-800A-4CC8-A843-F41340BAA8D7"><gtr:id>0688D1E8-800A-4CC8-A843-F41340BAA8D7</gtr:id><gtr:firstName>Jemma</gtr:firstName><gtr:otherNames>Caroline</gtr:otherNames><gtr:surname>Hopewell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BA3A40E5-534B-402B-AF40-5EC1FDF91ED1"><gtr:id>BA3A40E5-534B-402B-AF40-5EC1FDF91ED1</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Parish</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3A08924-3211-47F9-A709-DC28DAD85A96"><gtr:id>C3A08924-3211-47F9-A709-DC28DAD85A96</gtr:id><gtr:firstName>Rory</gtr:firstName><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B00E18C5-7C75-421E-A239-12D0184DFF26"><gtr:id>B00E18C5-7C75-421E-A239-12D0184DFF26</gtr:id><gtr:firstName>Jolyon</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Cox</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137686853"><gtr:id>2E9C42EF-5F40-469B-B17D-B28BE745DCB8</gtr:id><gtr:title>Large Randomised Lipid Modification Trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137686853</gtr:grantReference><gtr:abstractText>Heart disease and stroke are the leading causes of death and disability in the developed and developing world. Blood fats (cholesterol) along with smoking and blood pressure are major causes of these problems. CTSU has run a series of large trials of cholesterol lowering using statins which have provided clear evidence of the benefits of such treatment. Statins lower the blood cholesterol and have been shown to substantially reduce the risk of heart attacks and stroke in a wide variety of people at high-risk of these conditions. These studies have resulted in worldwide changes in clinical practice and very widespread use of statins. However, despite the benefits of statin treatment, some people remain at risk of heart disease and stroke. Further research is required on the long term benefits and risks of therapy in different groups and newer lipid modifying drugs are needed to provide additional benefits. The effects of these newer drugs on the background of statin treatment are likely to be modest so evidence is required from very large randomised studies in order to provide reliable answers about the benefits or otherwise.</gtr:abstractText><gtr:technicalSummary>Along with smoking and blood pressure, blood lipids are a major cause of cardiovascular disease, which remains the leading cause of morbidity and mortality in the developed and developing world. Higher levels of LDL cholesterol and lower levels of HDL cholesterol are associated with higher risks of coronary heart disease. This programme continues the long-running series of large scale trials of lipid modification (both LDL-lowering and HDL-raising) that have been coordinated by CTSU over the last two decades. These studies include the MRC/BHF Heart Protection Study (1993-2001) which assessed the effects of a statin versus placebo in 20,000 high risk patients, SEARCH (1998-2008) which compared more intensive versus standard dose statin, SHARP (2003-2010) which assessed statin plus ezetimibe versus placebo in 9000 patients with chronic kidney disease, HPS2-THRIVE (2006-2012) which assessed niacin and REVEAL (2011-ongoing) which is assessing anacetrapib. These studies and associated meta-analyses (including those conducted by CTSU) have resulted in widespread use of statins, which effectively lower LDL cholesterol, for the primary and secondary prevention of cardiovascular disease. However, there have been questions about their long-term safety and efficacy in different populations. Although statins are widely available and highly cost-effective, some patients remain at high risk despite statin use, thus additional safe treatments to modify risk are needed. Attention is now turning to newer drugs which modulate lipids by other mechanisms. The effects of such additional treatments on top of statins are likely to be modest, so large-scale randomised evidence is required to assess their effects reliably. The HPS2-THRIVE trial assessed the effects of niacin (a lipid-modifying drug used for 50 years) on a background of statin therapy in 25,000 high cardiovascular risk patients from the UK, Scandinavia and China. Niacin raises HDL and lowers LDL-cholesterol but the effects are small. HPS2-THRIVE showed no cardiovascular benefit with niacin and, furthermore, niacin caused substantial harms, including increased diabetes, infections and bleeding. The results led to the niacin preparation being withdrawn. The HPS3-TIMI-55-REVEAL study is currently testing the value of a new inhibitor of the cholesteryl ester transfer protein which raises HDL cholesterol and lowers LDL cholesterol substantially. Over 30,000 patients from Europe, North America and China who are at high cardiovascular risk and already on effective statin treatment have been randomised to receive anacetrapib or placebo and are currently being followed up. Studies of other promising lipid-modifying drugs are also being considered.</gtr:technicalSummary><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3154690</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Hobart Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3FDBD22B-5801-4EF9-A9B3-833178B8F533</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-24</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Holb?k Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8BC7D789-FAFE-470E-B749-F634FADD90EB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-104</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Derby Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A03EE974-83DC-4D42-A406-4A70795F8E86</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-5</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Besancon</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>75555189-2BFE-4BA5-8E26-DCC9ADAF39E4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-115</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Associated Cardiovascular Consultants</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>023EF49E-F4BB-4AF5-BEB1-1F31192A5C69</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-251</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>H?ssleholms Sjukhus</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>100A4E78-BDBD-4108-AB04-666DC7A15CC4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-124</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Obacka Clinic</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>42AFFED1-6822-428F-98E9-20DA704BA42B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-88</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Verde Valley Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CE39872B-78CE-4DBC-AFEC-1E7ED2B8A6A2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-135</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Memorial Hospital, Darlington</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C6AAEC74-4098-4CC5-ADAD-F92E36D58DC2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-3</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiovascular Research of Knoxville</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>89601BA2-9162-48FA-AB55-C39F13A533B3</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-181</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Richard's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3F24C3F0-95ED-423C-8D75-03C4EA70B75E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-53</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Odense University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2535C189-BB66-429A-ADDC-9EBFFEE25A04</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-123</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Derriford Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>EA6504BC-E51E-4BC9-8892-CCBA3FDC3005</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-1</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Affiliated Hospital of Medical College Qingdao University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Emergency</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FD53ADEF-DEE5-4F53-8099-5315A3B1CFBB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-225</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Second Affiliated Hospital of Dalian Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7BFFEE71-1134-4DB9-8CBE-F1EB5E36C39D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-402</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Melbourne Renal Research Group</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>ECC106EF-8258-4432-B03B-568D2B2CE79A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-13</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit?tsklinikum Leipzig</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>94FB48AA-F20D-45F8-88D7-07FA699608BC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-211</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jacksonville Centre for Clinical Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0D17A77B-7052-4A3C-B7DB-72EED739B62D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-261</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Florida Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>23EF6035-51B7-4852-B331-C0B0A0A0CC98</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-269</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Martin Luther University of Halle-Wittenberg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>ABDA8849-9F7F-4204-BB7D-8EA662BFF073</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-187</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BB027FFD-12EB-4FB6-9F15-9368DC31F5EF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-93</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemeinschaftspraxis Schlo? Holte - Stukenbrock</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9C3B1651-BE2A-4883-A81B-0351A9B7A13E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-163</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>New York University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>BEST-D Collaboration</gtr:description><gtr:id>BF2A8463-0CF2-4861-9BD0-50E8AC8BB4A9</gtr:id><gtr:impact>provided expertise on endocrinology of bone disease collaboration</gtr:impact><gtr:outcomeId>56d6cbbacae619.35738858-1</gtr:outcomeId><gtr:partnerContribution>provided expertise on endocrinology of bone disease collaboration</gtr:partnerContribution><gtr:piContribution>joint academic collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First People's Hospital Of Shenyang</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E6555773-8191-49D8-82F3-2D24B659278C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-194</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peking Union Medical College Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0FE702D3-16D9-4322-8B80-9359F5718C30</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-171</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CentraCare Heart &amp; Vascular Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5CC76D3C-62B6-4374-A478-3F49875FD23E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-279</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ryhov Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FAE57512-7B07-49D8-BC8D-286634950D25</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-275</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D3F2F804-68C6-4AE9-ACF2-51D5BB8F12C4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-12</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Sultanah Aminah, Johor Bahru</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>16E7A8B7-37E0-44BB-9D95-3996FCF46029</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-223</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemini Hospital</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>19706A2D-51D5-43D6-BA72-56198B10F5D4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-235</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SP Health Care University Clinical Hospital No. 1 of the Medical University of Lodz</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E472E0C9-254B-465E-85BB-6E48FE7AD754</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-255</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gdansk University Clinical Centre</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1E6E6899-B59F-40B3-B556-22EC635B08FB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-253</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heritage Valley Medical Group, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>35AFB1B9-817A-4802-8FA3-328A9C6DE990</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-223</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Belfast City Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B47249D0-711E-4639-ADF8-78476157E673</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-299</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wythenshawe Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>68D50934-817A-4F71-A2CD-61A47ABEECE7</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-78</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tongji University Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9908BC92-71A4-44E3-B708-682EEBA118F0</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-391</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Cornwall Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Cornwall Hospital (Treliske)</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>5CC5E423-924F-4F9C-9E72-0AE0ECB89828</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-66</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brampton Research Associates</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7A0E6AC8-3B8C-4C66-BF4F-99AC7AFC9F81</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-292</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital del Mar</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>05CC70B9-48EA-4F38-9317-AFABF77CD5D1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-222</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alingsas lasarett</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E72A4432-0636-4EA1-A0D3-579C35A8412B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-106</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roskilde Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FA1A4957-12F9-4A6B-B816-4EAE182E30AF</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-144</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The General Hospital Of AISCO</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4197E93D-295A-4CF4-A38C-BFBEDBB260FB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-376</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fenyang Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C3FD8157-EA9B-4456-9476-EB5E49EEB2CD</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-417</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charing Cross Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7E778320-6083-4850-ACCD-4B7DFB17F423</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-303</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Spesialistsenteret pa</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6C4ADB1C-03B7-4E5B-9AD2-615CAFFB0BA4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-132</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Sussex County Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>168A872E-24C1-4BFD-BF55-A1DA48F34866</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-346</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Slagelse Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FDF916BD-F30B-415F-BAAB-6A295B11DB87</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-161</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peterborough City Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>16F66D83-859A-4767-8ED2-56C28602C98C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-62</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First People's Hospital Of Shenyang</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>762AD1F2-ED21-42BB-AAFF-C54431A3E05D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-381</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Carient Heart and Vascular</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8A861032-805C-4986-A3E3-577944FBF124</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-186</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Oberhausen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0781C113-74D4-4DDB-863F-E7A6DB02710A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-180</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stockport NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Stepping Hill Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>375CB94E-5DBE-4407-AA2C-EE154DF6C2E6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-45</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tongji University Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E7D68191-552B-41FC-A1CD-CF804D08FE0B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-205</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of North Staffordshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8E6099A4-229E-457B-9974-C72C68E9AE86</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-44</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Poole Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>80CF10BD-8181-48D6-B274-E9FE12063D6C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-9</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Bamberg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>07003204-693C-405F-B7AB-66BD5B039C4F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-169</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Freeman Health System</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8D9FCCF7-04ED-43FA-9AE6-26B59A4AAEB0</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-281</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Kulmbach</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A5BD3B74-9013-4CDC-8722-9A4D683BD69C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-177</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Comprehensive Cardiovascular Medical Group</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D22C3605-B606-4902-8091-42D7130AAA2B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-159</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Missouri Health Care</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5D17601C-31B9-452C-A2AC-8A60742CAFA4</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-200</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Provincial Specialist Hospital No 5. St. Barbara</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F18E655D-4FF2-405E-815D-C0C833E0F15F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-261</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center G?ttingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A7F9E3CD-FD6F-4260-8A2C-839435F2565C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-209</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>72F2C38D-44E2-4CFA-ACF9-09F3C84E7221</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-271</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heart Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8DB4DB46-B37E-483D-9DE4-FAA054B05EED</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-295</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christ Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>The Lindner Center for Research &amp; Education</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>94B5CBC4-BDCC-4E66-8B4E-F0354A8A4252</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-233</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centrallasarettet</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1015B706-3EE5-419A-B13F-DD0FEA38F302</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-76</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>York Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>84B4BB85-5778-435B-933F-CA98EA6DD49C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-239</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Robert Bosch Foundation</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Robert Bosch Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FDAB482A-E687-482A-A847-3D2E25F894F8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-350</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Royal Surrey County Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7B9BE3DA-B226-43A4-9D48-73FB325236F4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-83</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kolding Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>AE5E2502-D91B-4181-99AD-B82B307E1ABB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-158</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gentofte Hospital 2</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>4B2E5E58-7F88-4538-B89E-1A518ECFBEC5</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-153</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Denver Nephrologists, PC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>934E45A2-E2FB-4DB2-AA17-A94ED3570C11</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-364</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fakultn? nemocnice?Kr?lovsk??Vinohrady?(FNKV)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>Dialysis center Fresenius Medical Care</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>723140DF-FC32-491F-8923-3B0E96795490</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-90</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Fourth Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>72A9543A-9685-4708-84EB-1FE73363AFD6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-374</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Milano - Ospedale Niguarda</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7451B8FF-5DB6-4310-AA4B-1C491EA48A98</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-307</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cairns Base Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>595F7E7F-18E4-4638-A754-CD2509DF1C5D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-6</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medialpha Research Center</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7EFD5D85-1447-46EB-AB88-F8EF3B62168C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-290</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Jubilee Hospital (RJH)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3058354B-9877-460A-B54C-ECF48EB4BC6C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-57</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fraser Health Authority</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3CD15024-7344-4D31-B42B-B2D066FABB5E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-48</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Hospital in Kristianstad</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>712F83F6-708F-4C0C-AA43-08F8D7002EC0</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-103</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stavanger University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C1A97E0E-8420-4BDB-AE5B-B5855C9FBD74</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-243</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastern Suffolk Cardiology (ESC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E774E793-83E7-40D8-B5A2-B813D9A5C1AE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-144</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medisch Centrum Leeuwarden</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3F62B2EE-E2CD-4034-9263-C65CC8B5752A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-234</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>West Cumberland Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D5694348-36D4-4368-9EC6-8341D44602B4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-85</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fana Hjertesenter AS</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>3FB6CC76-5E65-45A5-A8AF-11E2F47953E6</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-131</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The 306th Hospital of PLA</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>856BDE90-B40A-4759-BCE9-8530A448D06E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-168</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinikum Am Urban (KAU)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2104E0BD-0CAB-426F-BE3E-B56D9882D689</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-327</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universitetssykehuset Nord-Norge HF</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>30D821ED-978A-486C-A6B2-D0D5C7957A45</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-249</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Heartlands Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7BC8B289-35B4-43BE-A3B4-4B7A5BC23DFC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-23</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>H?ssleholms Sjukhus</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DCB37810-4B8B-4D35-AD40-55F6CBC939EF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-84</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clinical Trials of America, Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DA0969DB-BE27-481B-B3DC-F9F64A864F6E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-276</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vancouver General Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9D4CCD17-F0F5-43E7-A322-D37509FD2D63</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-67</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Devon and Exeter Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9DB5B0A0-2FB7-4110-811A-E664E77F972D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-38</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Luton and Dunstable University Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>CDFC7B43-E3A2-4662-A46A-6DEABC771317</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-81</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mahidol University</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:department>Faculty of Medicine Ramathibodi Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6234A214-FEDE-479B-B47E-7CE785A9773C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-292</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sahlgrenska University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A19B9562-B2C2-4022-9684-EF3A9411E6E1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-280</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Health Sciences Centre - Winnipeg</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B74AD28C-8BBE-4C6D-B576-29EA697A82EB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-68</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tiexi Hospital of Anshan</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>43C7C3B0-1749-451B-A161-AB31A49EE181</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-187</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northern General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0448E424-0EA6-446A-8DE1-2622D822A50D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-48</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King Chulalongkorn Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F3B940A5-B344-416C-9DF5-E59B2F590A64</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-289</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portsmouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen Alexandra Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9E070F79-9EDF-4F09-93F7-28729895C1BE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-334</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fondazione Salvatore Maugeri</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F5D185D2-0976-415D-BB89-3EAF2C6E6FF1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-321</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemeinschaftspraxis Kiel</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>380D62D5-D30E-4636-A753-130BC12C97BD</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-159</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8C51DCC6-06E3-47A2-BD30-D58926D4A2CF</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-45</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Santa Margherita</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F27EB675-BB99-441E-A68E-64D53A03C272</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-313</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Orbassano - Ospedale San Luigi Gonzaga</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FC860CAE-C330-4285-B9CF-ED1128C40017</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-299</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of Zhengzhou University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FC9C18A7-9F21-4610-BBF9-1DD27C74D468</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-212</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8116C94B-CF4E-4E09-90BF-89B1B350A669</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-67</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Massachusetts (UMass)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Massachusetts Medical School</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>BDDE4495-2660-4D87-9FFB-FB872CA282C1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-386</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charite Campus Virchow-Klinikum</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5F06E78C-79A2-4558-8CB6-D7D2CC11D05F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-328</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysepraxis Seehausen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>227492BF-2B7C-44D5-AF16-6548EACF3B71</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-140</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dewsbury District Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>53EADBAE-40EA-42C8-B408-8820DB2748B4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-21</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum W?rzburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>72702BE6-9D95-4BBC-8F5F-F4B369A77E96</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-158</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Darlington Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>36385D2F-30CB-4ED4-B3FC-F29DF76ECF7B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-3</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nephrology Center Emsland</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>CA6C3F47-3888-45DB-AE21-0B614C07BF31</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-196</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kansas City VA Medical Center - 1</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>AFA85B5A-E826-4B49-8BAD-72E550AF0746</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-371</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nordsj?llands Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>986775A0-59D9-4C37-A8C4-1935F190EDFA</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-155</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicor Cardiology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CD9F383E-1333-4F62-A148-A2F0ACC54CD7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-267</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuhan Puai Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E63ECEA8-3974-49B0-8E97-2E879F94EEBB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-207</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical City</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Sinsen Clinic</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6A86F7ED-97BE-41ED-9F4B-ED1F2019511A</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-138</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Eastern Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Kuopio Technopolis</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>BBEF4762-B7AB-40CB-BC68-025D4A97358B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-90</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southmead Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7D0EF554-CB9C-4DED-8E21-92054103FC51</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-349</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Norfolk and Norwich University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7838CFC6-0AE4-4D4C-9E03-BA6A81625CE4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-74</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Borstel Research Centre</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>330EACBD-C097-47ED-BF99-C357C0B4E589</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-117</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Affiliated Hospital of Xuzhou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>3A14B53A-30B2-4174-BB85-66EFB0FDE7A2</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-217</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>David M. Kates Medical Services Inc</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>046900E7-4BA1-4345-A955-F94C3D82DFAB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-46</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Colwyn Bay Community Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>457FB636-3A7E-488E-9F0C-21C59AA30519</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-49</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Cornwall Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AD0C3748-4777-495C-8D1A-2460F66ECE49</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-50</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NJ Heart</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A202FAE0-AC04-4AC7-A122-5E4C9FD0D2ED</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-256</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Suzhou Kowloon Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FCBA26D5-CE6D-4491-ADF0-D4A79092DE35</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-167</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Infirmary of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6B459E35-76EE-4AD6-9FB3-E4AE3675B86C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-20</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Odense University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B35E8DD5-688E-4F2F-89D7-9A0864231754</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-105</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>DF681262-2BDF-4322-9DB1-C478241305E0</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-34</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Darmstadt</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>83EF1873-FC10-4A91-AC81-A4B4F5961FA7</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-146</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northwest Heart Clinical Research, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>64C84FC3-2E67-48C7-9AB1-0F3934E9B932</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-199</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charles River Medical Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C4FA638A-D4C3-4502-9D21-7C2FDB13D8C8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-147</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinikum Frankfurt H?chst</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>46C67A53-F494-4D63-9100-61E57A21A6C6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-335</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Broomfield Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8993721A-9755-4986-88D9-8DA371C4EF71</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-302</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ministry of Justice (Brazil)</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:department>Amnesty Commission</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3F1B3C79-0AD5-49B5-8D07-52C0B240681F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-114</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Danderyd Hospital (Danderyds sjukhus)</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>AA347FF2-06CC-4C14-A0B8-3C5757EB5F26</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-273</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heidelberg University</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Mannheim Faculty of Medicine</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>32C8628E-50C5-446B-B231-3C2F60C8D129</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-184</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Chest Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>5D5449C5-E4C2-481A-A987-D6881C0AE601</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-184</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cohen Medical Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>433BEA3F-11EE-4B59-AF52-CFD75FD93101</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-255</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aalborg University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Aalborg University Hospital, South</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FE3A8280-355C-46EA-ADEE-7C0234C0ED95</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-100</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peninsula Clinical Research Centre</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FC1C40F0-0174-4778-BAF0-698E11B80EBD</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-17</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scunthorpe General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FAD321F8-BA63-4F28-BA8F-0E4D78780069</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-51</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>DRK Kliniken Berlin Westend</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7BC9CCE5-8CE6-42BA-BDC9-7F13EE9B2A2D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-357</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gentofte Hospital 2</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Cholesterol Laboratory 2</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A86F295F-8C6F-4F8B-8595-F1CF3D75AE9A</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-159</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nephrology Center Villingen-Schwenningen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>824BA589-C099-4926-AD8A-3F70D63A04E9</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-198</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Pulau Penang</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2CBAF8D1-93C8-4C1B-8744-5E551872B773</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-220</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aalborg University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Aalborg University Hospital, South</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>B37E3926-1CF6-4175-9E2E-0A66A7AE6781</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-157</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Infirmary of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>DB4A0156-7A51-4997-98D1-8067DD7CC2E7</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-312</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Tuanku Jafa'ar</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3614919C-586D-485E-BE5C-A31FF970FDEF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-227</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ninewells Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5D871761-F139-496B-A2AF-125AF35DBCC0</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-328</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Prince of Wales Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5B4F6CF7-142A-4794-8AEB-27487CA02765</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-301</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tenon Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>728A60AD-9848-4E89-88E2-C8836345265C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-128</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ipswich Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FD7F204C-F2E0-4C92-BA8D-C9C34BEBD0CD</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-319</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Hospital in Karlstad</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>88B4B07D-80CC-478A-8618-7963454D960E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-272</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rhode Island Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>149D3D15-91E7-4565-B54B-F3765343A8EE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-379</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jilin City Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AC73FEBD-A36D-4E79-94AC-73A58498EA89</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-365</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Versilia New Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5E95B923-AA84-45AE-B519-D239FD78E51F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-303</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiovascular Institute of the South</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>19703406-8444-408E-9B69-2625E4173071</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-228</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queensland Government</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Princess Alexandra Hospital (Australia)</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>88B0C6D7-1EDF-4B61-AC81-AFB7665FB62C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-21</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stavanger Health Research Ltd</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>68F6DB7C-4300-468B-9FB8-6982993FEA84</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-97</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oshawa Clinic</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>36FD4E8D-B479-466A-AB1B-B62C92268139</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-287</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barnsley District General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2BFD1978-0CC5-429D-8D89-55EF94245596</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-32</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Internistische Praxisklinik Kempten</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E99808BF-C0A6-4C71-BAE5-B102E427DDAF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-167</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Umum Sarawak</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E2AEA892-4B3A-41A1-8922-0A0B1FB9C951</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-228</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ninewells Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>05EB5234-6305-4575-B5CA-266704FC8B36</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-46</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Steno Diabetes Center Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A23E6822-DAF2-4C5D-A31C-FBA29E9365DB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-124</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>West Cumberland Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>74EF8F68-468B-4765-96D2-C077914905F5</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-62</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Westside Center for Clinical Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2D46C064-171B-4876-BCA1-561C7DF0DE76</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-249</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Affiliated Hospital of Inner Mongolia Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>90CD784A-EA5B-4BA9-BAC9-D077FF99F17D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-203</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trondheim University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>St.Olavs Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0D95B275-6FAD-4574-95C3-E8F071E26FB3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-242</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Primary Care Cardiology Research, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4EAD1EA6-83DB-41D6-B98F-B0606395FA68</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-240</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0836B47F-3F7D-47F6-B093-DFB638EFB532</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-129</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northampton General Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>535FAA50-90D6-4587-AE12-3BA18CE0DEE5</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-24</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sint Lucas Andreas Ziekenhuis</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5648CBC7-688A-4059-952F-52A6D321FD5D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-236</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albany Associates in Cardiology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>27D863B0-A308-4E0D-BF4C-619EAE53D825</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-177</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Walsgrave General Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>570A40F1-CEB1-4272-8DD9-1035E1627D69</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-357</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Overlea Personal Physicians</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>70CB327D-9F96-4635-B57A-E1D5D6C64A68</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-214</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Halsobolaget i Jarfalla AB</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8EF2CFDE-B490-4C38-9B59-551619AF5B68</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-108</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Etel?-karjalan Keskussairaala / Etela-Karjalan keskussairaala</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>76910756-7BA4-4216-8755-11B8FAFE4158</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-68</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Bad Malente</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>39DF4956-4C6C-40DF-9C94-38E0C93029B2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-144</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinikum Leverkusen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>EA3B5A93-1211-4994-B539-7D0A1D8A7C51</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-339</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Antrim Area Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6C492335-7959-4D3E-8F73-C22BA64F88E8</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-297</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Mary's Duluth Clinic</gtr:collaboratingOrganisation><gtr:country>Georgia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>38B72E7C-CABE-4E62-AFC0-3BC8A63EACD5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-383</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's Medical Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D5FFB37F-9667-4778-AF7E-F6CAFDD1532E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-82</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>South Florida Research Group</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3F590A25-70B3-46C5-AD79-854D80B90156</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-270</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Derriford Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>138D8A54-91C6-498B-82D0-C35D5EEE6356</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-308</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Martini Hospital</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>19EB2502-B83B-48C9-8933-CFE3BFBBD88E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-233</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Luton and Dunstable University Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>14BAC327-975B-4F33-9EF4-42955E75F29B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-59</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Esbjerg Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2155AB68-F227-4A50-8C9C-0929CCDE559E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-111</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Second Affiliated Hospital of Harbin Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B6ED4751-1A4D-4DA3-B2E0-C51A353BDCF3</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-412</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universitetssjukhuset Linkoping, Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6301E601-C695-42FA-81D9-AAA3F87D775D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-282</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Grand View-Lehigh Valley Health Services, Buxmont Cardiology Division</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C27D508C-52A8-4025-B938-CA789443F74C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-188</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>09543E9A-36C1-44FE-BDFF-6813CB4D0AE6</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-128</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Michigan Cardiovascular Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>755D5856-DCD8-4155-84CC-250DDAC94515</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-204</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gefaess Zentrum Universitaetsklinik Dresden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D94DEE4A-39D2-4950-92D1-CFA2AFAAA5C6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-334</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Provincial Specialist Hospital</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A5764999-DB17-4FE6-9445-90631092C6BF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-258</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Asheville Cardiology Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E64BE273-5B28-44C1-A4D5-C1D76E3626E6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-146</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Brisbane &amp; Women's Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>48CB3F4A-746D-423B-98A7-3CCFB447176C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-23</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Third Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>204EDEDD-F7EF-4740-A867-815EE8499CE8</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-182</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of China Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>5AAE78F1-CAD2-470A-9DBF-99FB33375A37</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-191</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>?rebro University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>602139AA-BDC0-49E3-9223-17D116007D9A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-285</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuhan Puai Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>82473DF3-0750-4297-A75C-AA3231CD2464</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-208</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southwest Florida Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>949717A3-4137-4F68-94CD-D60F3F05E1F7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-262</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kootenai Heart Clinics, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D1A16899-36EB-4879-A0C2-DC6376F92138</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-165</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central and North West London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Mortimer Market Centre</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AF90C127-1D38-41FB-972C-8EF0124E47AB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-164</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Iowa</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>College of Public Health</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1B0930CC-B1AE-4672-98C3-913F3D481F75</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-245</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Innovative Research of West Florida, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>11B2DC3C-FE54-407A-8E8A-806A872DB382</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-369</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Skelleftea Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A84A099F-A60C-4CD9-BBFC-CE86E0581781</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-83</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Devon and Exeter Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6BBD3AC3-8ADE-4242-AD15-CFF2045BE5B1</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-50</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kolding Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>412E04C5-32FB-413E-BFE8-E4A320AFB574</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-113</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Launceston General Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9704D842-AFDE-4FCB-8ACC-041E85218D43</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-11</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clinique Sante Cardio MC</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>82B1D007-5B49-470E-A653-071F7B16C400</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-288</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Wurzburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9412F626-4B6D-41A2-BE77-98A7D39B08EC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-188</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xuzhou Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>196BE3DD-0905-4092-ACDB-5C42F9779898</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-399</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Tuebingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>706F3E02-AE8F-479D-BE29-D5936D8F5D9B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-214</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Worcestershire Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3FD44658-AF9E-4616-8198-ACCF65E643E3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-358</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit?tsklinikum Schleswig-Holstein-L?beck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>29501B5C-4195-4236-80B2-91ACA7346E28</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-340</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F?rde Central Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2F3903F5-9B0B-4218-A9A9-F242B80BBE9A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-101</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum / Gemeinschaftspraxis Heilbronn</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5F07A355-5B17-4C13-8D4F-D7F60918BC5A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-141</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nordlandssykehuset HF</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B940AEA3-28AB-4E80-AA2C-3D786E418473</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-241</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Cornwall Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Cornwall Hospital (Treliske)</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E31F53D3-2C02-4279-889B-BEDF7171F950</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-340</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Second Affiliated Hospital of Zhengzhou University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>2D00561C-C180-42B2-8315-04861DEE5C3A</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-213</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of M?nster</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Universitaetsklinikum Muenster Kardiologie</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5E64E600-E6A9-48D4-A173-AF5C4DF54E40</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-346</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Bartholomew's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0FDFFD45-FD14-47C7-9D00-06890462C94B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-301</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum W?rzburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>56D68862-CCF6-4F7A-9826-ADF44773371E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-183</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sandwell General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>96B6E6C5-7072-44D0-A8E0-D6D40E000C3C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-40</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's Mill Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>196159FB-5FCD-4B1F-9DAE-BA90BC72E77F</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-6</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Eastern Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Kuopio Technopolis</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>78EB1BE1-1480-4DFA-9247-135E26208BDE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-65</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sondrio Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A1D8F861-3D61-46AF-9712-9E2CAAE869D5</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-306</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Tyneside General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DDAAD763-2C05-42D0-850F-21955D03E6D0</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-29</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Aachen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6550E9DA-2A41-4694-B651-FC5AF8786D65</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-206</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vestre Viken Health Authority</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Kongsberg Sykehus</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>039F26CE-CB3D-4FF9-9353-54EAFC8F79FF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-250</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Affiliated Hospital of Inner Mongolia Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>941D41B2-8ED0-4AAE-8AB5-BB95039E13B7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-389</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Innlandet HF Lillehammer</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B53428B7-46D1-427B-8706-115E20CECA10</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-96</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clearwater Cardiovascular</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>EDF58F1E-3508-4320-8F6A-D01982C71B4F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-268</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bedford Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BEBEBB1C-2D86-4718-B6B6-82EAA4DEF3DB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-12</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rameses Associates Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C420880E-194A-4D4F-B9B2-A16FA3554714</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-127</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's Mill Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1F137AE9-FCA9-4857-A145-0E7EEB01A0FC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-5</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cambridge Cardiac Care Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CF0543A6-FD26-436E-A59C-045CC821AA92</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-285</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Marin Endocrine Care Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4C69DB7C-DA2C-4493-A3CC-2BFFE386F4EE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-141</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nephrology Practice and Dialysis Oldenburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>102568FA-7B14-447F-A2D5-43DE95D02D19</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-195</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NYU Hudson Valley Cardiology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FA8A492D-B604-4916-80A0-5B9A0D9026D2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-136</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Austin Heart, PLLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F12FEDC5-565B-496B-A1A5-699E2C604B9F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-222</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Silkeborg Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>99BA9AFB-36F4-46E2-8A81-90F921E7EA74</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-122</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vienna General Hospital</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D9BD433B-3DA9-4A23-921D-BBE17446DEC4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-38</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Third Peoples Hospital of Xuzhou</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>B380042D-AA4D-4889-95D2-E6E46AB59095</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-224</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sunnybrook Health Sciences Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FA2A70DF-CEE0-4679-B459-B17135472B4A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-64</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Linkoping University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5C805BB7-359B-4F7C-B018-D20972DE5DDE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-75</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wollongong Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>EC90CE8F-CD1D-4E4C-A32C-E8E64D96047F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-37</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Inner Mongolia Baotou City Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>71384E6E-6BC6-47C0-AB55-66CB26F906A1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-73</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dorset County Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9B50632E-4235-4EF2-8770-71F8BDBC063E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-63</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Elizabeth Hospital (Malaysia)</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>796A2AD2-4E2D-4C78-B1CE-438CB0548CF1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-335</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University, Kingston</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Kingston General Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E98B2848-1C55-4157-B387-6FC4C477FC6F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-51</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fourth Affiliated Hospital Of China Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>197ABAA7-5A5C-4BE3-9E06-32E24C56E7EE</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-195</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lanzhou University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Second Affiliated Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5DA8218D-BFC1-422C-86C1-25D86897F9BF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-78</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum F?rth</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>78E0C3EB-41C8-4308-AB2E-1650E177EFF2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-176</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Margaret Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>AB4081B8-0BB4-4A1D-B305-701FB2B613E9</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-336</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southern California</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:department>Keck School of Medicine</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>76C5755C-F59A-4DEC-A607-31EF61742EDD</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-384</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Karlstra?e D?sseldorf</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A6211515-8FC5-47D6-BB90-3861BA886A4A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-152</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinikum Bielefeld</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>50ED08CD-6114-4978-B073-3BD869277993</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-330</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manor Hospital Walsall</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>263183D8-AA34-4DD0-8FE9-9A6EC8AB66D0</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-28</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shandong Weifang People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>4541FA61-F6E9-4C5B-BB45-70D84BF38C51</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-83</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Auckland City Hospital</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C9EC63B3-AC94-405A-84A7-AC67A1E4AF39</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-263</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Heiligenstadt</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FE5FBA5A-4F55-4E03-91C1-6132F8C1E2BC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-149</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ljungby Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>9C853633-08DC-4E49-85D9-8018C497A8A5</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-102</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of China Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>31B99DAB-0248-4366-B778-15F0FBABBAA7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-378</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>VA Boston Healthcare System</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>VA Boston Healthcare System - Jamaica Plain Campus</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>10E2CFDD-6D05-4791-B18B-9FE87B7FCEDE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-392</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Viborg Regional Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>44C9EBD1-7D1F-425B-B612-2F65795ED7DE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-108</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hillingdon Hospital, Uxbridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>4A111823-990B-4F01-8143-78FFD1C63DE7</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-4</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dorset County Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FB33D162-1485-4DA2-B0B6-AECD86C9477C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-309</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baogang Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>06677551-3513-49D6-9144-66C373BC736B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-199</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Rotherham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rotherham Hospital</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>632B4D01-795C-4523-91F0-D85262C3C45E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-49</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham City Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>EE52C786-8899-4087-BB37-E8AE9FEDCDB3</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-25</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Marseille Biological Cancer Laboratory</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5DCEB3D9-7B8C-400F-9C07-46A384366657</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-121</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wythenshawe Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3327A9CB-82A3-4867-8359-30105B943AF3</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-57</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lutherville Personal Physicians</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CE026F60-9BF9-4964-97F6-2D453987FCBA</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-225</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universitetssjukhuset MAS, Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>5FA36E9D-3326-44A7-B7A9-985FE692EF91</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-112</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Haukeland University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DFDBC910-F924-4905-BF7E-93A5143FF9A8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-99</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northern General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>11EFE956-B8C9-4152-9857-A900B013E940</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-331</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1AA9E1E1-F07B-40CF-BABB-8179CD29795A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-389</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Medical University General Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BD04DB64-D0F6-460F-B840-318895F56FC9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-371</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Kuala Terengganu</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E3022326-B7A2-4CF7-BC79-02B71CC1BBD3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-218</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hull Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E955A3B5-772F-4F2E-90AD-C6C6554BD760</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-318</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HDS Eurocare, Teplice</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6239764A-FCDF-430B-9A4D-0CD2A956E707</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-99</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xuzhou Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>2FF6462E-8A6E-4A6E-875F-0FA5F80CF79C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-218</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Townsville Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>CEE86EDF-95A2-42A3-B234-F7A98201FEDF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-35</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sandwell General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B30F2C2F-37B7-4530-94D8-03C4E17DA9EC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-347</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newmarket Cardiology Research Group</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CBD8C5FC-B92C-434D-B199-8CC1040F0BEB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-283</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FinnDiane</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5B8C2118-6F6F-4669-BCF3-BD20DD7E3B32</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-130</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Upstate Cardiology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C30F36BC-0370-4537-B698-F2C6B45A127F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-178</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemeinschaftspraxis Marktredwitz &amp; Selb</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>21F41860-4728-4739-8830-6D6A00D77E5E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-161</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysepraxis Leipzig</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E3E58661-A5E2-4612-B900-B96D462D7425</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-138</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Avera Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A35DAAAB-FC53-4BD9-8FE0-EF8146306026</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-362</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MultiCare Health System</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Institute of Research &amp; Innovation</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>04D60153-5E8D-44DA-BD47-D06BE6789B0A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-172</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Levanger</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FF701B49-9716-49DE-8CEA-B19F558C1C9F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-245</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sein?joen L??k?ritalo / Seinajoen Laakaritalo</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>66C22D0E-F37A-4F35-862B-B61F20C4860C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-70</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Louisville Metabolic and Atherosclerosis Research Centre (L-MARC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C2DBB733-6E22-4AD0-A669-A9D32B0C9944</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-130</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Taranaki Base Hospital</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>CA8772AF-1452-442C-9C37-ACF1C913280E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-268</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital of San Paolo</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D94C3C66-2DE9-4E22-8E69-74ACDC459592</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-317</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Saint Martin Clinic</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7B2F2A7D-6546-4355-9F65-9453A74B7B58</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-126</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stockport NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Stepping Hill Hospital</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A6C36C2D-54A3-4B70-AFBE-F2428050D60E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-60</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HOPE Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>417600B3-50E3-451A-AF20-4563B84FDE00</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-229</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Mary's Hospital Portsmouth</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>22948BAA-B7FC-4686-9D57-85499E5C1365</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-40</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Chest Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1FDD936B-81A2-4A28-A086-AC334DB7BC41</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-375</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>H?pital du Sacr?-Coeur de Montr?al</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>30CE9EDC-012E-4E37-89D5-3E966098D6E9</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-50</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Third Xiangya Hospital of Central South University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>45E218E8-0FAC-4E4B-8AE3-A94CC8DA1392</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-85</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Atlanta Heart Specialists, LLC</gtr:collaboratingOrganisation><gtr:country>Georgia</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7D5C43BB-7E3F-4CF0-A109-A55582805F2F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-263</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aalborg University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2C7126DC-456E-47CD-8B3A-A7D9192FB4D7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-120</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shengjing Hospital of China Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A092043C-5D37-43C2-9927-6AC591566D2E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-192</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albuquerque Clinical Trials</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9B7B44C7-2340-4B71-A8EB-EFBD78A014F9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-190</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dalecarlia Clinical Research Center</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C2D2816C-9D74-4A14-8543-2FD13D21DBF0</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-101</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Third Xiangya Hospital of Central South University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology and Metabolism</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E82F11E3-CB39-43D1-8F06-E5E9F26AC57A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-408</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sydjysk Sygehus</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6D5FD5DE-5085-4150-BCFC-B9C36DE28FDD</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-143</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heimdal Helsehus Legesenter AS, Norway</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0A5FBE69-CF55-40C4-9781-A316FC0093EF</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-137</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jilin City Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>AB026C38-66F0-4C33-84A8-BB2A73F6B17B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-77</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fresenius Medical Care</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>FMC Dialysis Unit Sokolov</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B69965A2-B5AB-4640-902D-33548A20CD1C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-98</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gentofte Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Cholesterol Laboratory</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>171C0BCE-BB1D-4328-9223-C1DC8CAF78E0</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-126</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Julich Research Centre</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>969AD8B8-F29B-4FE8-9B5B-8AA016A18203</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-351</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre de Cardologie et de Recherche Clinique Pierre-Le Gardeur</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A2FE2B62-A52F-49C4-B67B-C2BC96B605C8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-294</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Conquest Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>08858B2A-28AB-424C-9AC9-526547F65752</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-19</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Satakunta Central Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>873C77B0-09ED-4E2A-A7CF-2043212AD787</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-112</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>42C9EF8B-0766-4533-9C04-10014CC48974</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-122</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Rotherham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rotherham Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CE33BB7B-56DC-40D0-B3A6-E79FD78C9846</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-37</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tongji University Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>828A3918-8AE4-443A-9D71-30F363331321</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-204</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Innlandet HF, Kongsvinger</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FF939C94-0802-4504-8E48-471CF9CF779D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-136</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Skelleftea Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>66571B34-58E3-4531-B3B1-FFB495034642</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-116</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hopital Saint Jean - Perpignan</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>08C0861D-C39E-4832-82B6-B145A5CCCA42</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-125</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nephrologische Gemeinschaftspraxis, Rostock</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>714373B5-6D7C-461D-BE9B-81CD1AB135E0</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-190</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wels-Grieskirchen Clinic (Klinikum Wels-Grieskirchen)</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>707E979A-8F66-4C69-BDD8-E569C28EEC1E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-39</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chesapeake Cardiovascular Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>16F32275-03C0-43B4-8F5B-A3C98534F448</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-213</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Victoria Hospital, Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>4A4177DB-81E8-4AFE-B293-66FAF8A3EDDA</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-71</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Heartlands Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2E86BE55-F256-4CB7-949C-8F7816420114</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-300</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Haugesund Hjertepraksis</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>ADEFA467-018C-47DC-8FC5-D7EEA9819F61</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-98</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leighton Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>865DBA2D-7FF6-458D-9EAE-0D358C89E2EF</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-29</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oklahoma City VA Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FC7DED6B-4B03-4342-9198-20A195B6C5CC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-378</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Poznan Hospital Clinic 2</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A52638BD-CC06-4162-8325-776B4F4F9F38</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-254</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Stoke University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6665548E-3DA6-4ED4-B6C3-4F9D6DA9FCE1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-356</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Karelia Central Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Department of Internal Medicine</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>80E094B5-286B-4EAF-AB82-504D84A53F88</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-111</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Torbay Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>385BDE23-7B13-4479-8645-7A84B48A943E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-57</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Macclesfield District General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>09AC298E-A37C-4E2F-AF50-8885005EA535</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-7</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FB657C67-7E0E-4946-B480-2416327C0639</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-296</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Worcestershire Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>211602EC-FBC6-4C89-9779-A27062EA3D0C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-13</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Princess of Wales Hospital, Bridgend</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C34D4712-826D-472B-B1E0-07C674261770</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-31</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Investigators Research Group, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>880E9BB7-F688-428C-9691-D6A10DD1044A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-151</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0660F8AC-D048-46CE-BAE4-4D6591D23C48</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-2</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bedford Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>3C9878B2-233B-4D9E-BBC4-DA3C6AC2C9FE</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-16</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The First Affiliated Hospital of Harbin Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5FEEA288-A7AD-4764-970E-0C3832726517</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-411</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The General Hospital Of AISCO</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>9D00DF40-4CB1-47DF-B587-299803CE8BC9</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-185</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Watford General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7B5C3416-DD03-4C04-BFC3-C02CC29456AA</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-36</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinikum Coburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7B048319-0686-4014-A162-4B3566F39185</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-332</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heritage Medical Research Clinic</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>850D1686-0B2A-4764-95EF-C0B74EA24DE9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-296</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6ABAEA36-60E1-4682-9F21-9081929068B3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-12</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Innlandet HF Lillehammer</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5AAC0567-F179-4E6A-9951-DBEF34AD3D3A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-244</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Bad Laasphe</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>CCE93654-15B5-42A6-9180-5D6CF554BC90</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-143</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Marl</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E1CAF2FE-846C-4413-9133-290E6F455A91</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-179</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Manchester General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F4394BDD-BCD0-4486-80F0-716673A999B0</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-25</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Qingdao Municipal Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1FC4AE2E-D0F2-4F9F-9DE1-86ED4F2E28C9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-406</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leicester General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>35CCC31B-970B-4458-823A-8A779F8AD9B3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-322</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinik am See</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7A8C36A4-2514-48DF-BC8C-623ACEC66805</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-349</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Geri-Med Oy</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E1EE1D85-E06D-493A-968E-1DC8ADBE4925</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-69</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemeinschaftspraxis Dr. Haggenmiller und Dr. Jeserich</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D8DE7F24-48A7-480D-A403-1C7C49DD9BCE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-347</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Tengku Ampuan Rahimah</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>38C8C28C-D0CA-4D35-A054-C94C5D565C5F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-226</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Berman Center for Outcomes and Clinical Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7280E282-72C4-452A-BF43-26B9D5CA00CA</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-277</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rush University Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>54615A80-2C34-438E-A35F-23E080DEA6A9</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-380</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Affiliated Hospital of Xuzhou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology and Metabolism</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>B179D087-6A04-4BDA-B2BF-5C80DC1BD719</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-216</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Provincial de Rosario</gtr:collaboratingOrganisation><gtr:country>Argentina, Argentine Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A0A24703-886F-4B43-9B69-A8C208DF6822</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-216</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glasgow Victoria Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>009A2621-BFD9-402D-BBA6-3460DDC3BD82</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-314</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Union Medicine Centre</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>1D781199-2FED-418E-BA68-387B2CBB8B2D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-180</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mobile Heart Specialists, PC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DC67F646-AE64-457D-8C13-AE83D20B26F2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-129</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hjerteklinikken i Harstad AS, Norway</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>B01027C4-F5DE-46DB-B1B8-042414CBD27F</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-134</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shenyang Fifth People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7CB7C8B0-A0AC-4B48-ABCF-CB8B7E68F6B8</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-197</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Alabama Research Center, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3CBE1954-C764-4C5E-AD9B-41944A3532BB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-206</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuhan Asia Heart Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>F07AB3F3-A88E-46DE-A094-982117BE9087</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-210</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wycombe General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>2B76E993-1FEF-43A7-9412-B1E47C9C61C8</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-15</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mediwest Seinajoki, Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E938A217-57F8-41D1-BDE0-1440CC12FEF3</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-92</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cardiology Unit</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AA327C7A-BA79-4529-A073-53B4C6546F25</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-274</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chesapeake Cardiovascular Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4F545944-9857-457E-9A4E-1073F1DF30E2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-193</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinikum Fulda</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>59EB13AD-B2E5-4B4A-A533-D5306E3A70AA</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-336</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oulu University Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8E966D8E-14B7-4204-8978-AAAB1094B3F2</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-87</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fremantle Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0B2858AC-5099-487B-BE11-E7727C0560AE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-8</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Viborg Regional Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C27610AD-3A76-4D6C-AB63-ABD08C6BF0D6</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-149</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Hospital of Jilin University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>36C02697-AC4D-4F72-AE9C-CF647F668CDC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-360</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Manchester General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E6B5C5F4-61E5-4814-B76C-CFA947094CCE</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-33</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Anshan Shuangshan Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>95F43B9B-04A0-4062-BCE4-35017E9A517D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-186</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Penticton Regional Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B1145C93-CE34-48D7-8B48-E32717E850FF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-54</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Eberswalde</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A4BAD672-DF27-429A-A08D-44F1EF5521F3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-174</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yeovil District Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>94F420FF-C9C8-44B6-B007-529EBF921E7F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-55</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The General Hospital Of Xuzhou Mining Group</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7306E260-329D-4275-92D1-5BF57AF2EFD4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-223</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>InterMed</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C584C15F-7EFB-44AB-A546-BE548CA49CFE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-179</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Inland Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6F593C21-AE7A-4EC6-8840-1E656A7712F5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-56</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Paul's Hospital Saskatoon</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E491CD0A-FACD-458D-A1A4-DB52002FCF8E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-63</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barnsley Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E51B1E0A-D0EB-415A-BA8A-E64DB7C421C8</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-42</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuhan Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>AF838780-D94C-450F-A929-53348BB5A403</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-87</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kootenai Heart Clinics, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>45255C4E-F484-4075-BBF1-970741472890</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-191</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Johns Center For Clinical Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>36FA256A-4C25-4C4D-8468-DF9D08B086A1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-257</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital of St Cross, Rugby</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>BB027A83-9EC7-4EDB-B3C6-7D1618F254A6</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-56</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Canberra Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B32A0340-38CD-4F46-B6E4-1459639724E5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-33</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nanocem Consortium</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>80586994-FF17-4D92-A63E-6D9E1FB2D8EF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-123</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9AF9A356-40DB-48CE-ABFE-CC8B07952473</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-2</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Morriston Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5BC6A339-5775-46CD-B96B-184DDF85C490</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-326</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tyrone County Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>76F43AD0-66C9-4427-BFD9-3D97052372B9</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-355</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bradford Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>18746690-E597-48A3-AEE3-0196D887B052</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-77</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysepraxis Alt?tting</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>83505ABC-E3C0-4634-A1DA-DD66714F3241</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-136</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fu Wai Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Cardiac Surgery Center</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C75AF2DE-AABF-412E-BAB6-9BF73B2332DF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-368</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Marshfield Clinic Research Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>92704088-FCF6-449A-BC6C-21F85A28E192</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-375</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bergslagen Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>My Heart</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C236993C-465E-43EB-B597-7BC203FA5496</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-113</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Sch?neberg-Tempelhof Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>761D1797-48BA-4FE6-A8FD-EE28D56B8EE5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-156</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Luke's Hospital, Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>535B30E6-FF48-4BD5-9F16-6D3AF60EFD2A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-353</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Center for Pharmaceutical Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>35913E31-0878-4AFC-B500-527FD5AC6030</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-153</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Melbourne</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2E2C4733-54F0-4768-8B4E-4E63F8E524E9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-221</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Hospital of Shanxi Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>353B2B05-9506-43E5-B796-478F66560984</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-414</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cheltenham General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ASCEND Collaboration</gtr:description><gtr:id>0F5EB7EF-7CEC-4F7C-8F8F-385A94D3FED0</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>56d6cc6f943912.69326369-1</gtr:outcomeId><gtr:partnerContribution>enhance eye outcomes from ASCEND trial</gtr:partnerContribution><gtr:piContribution>joint academic collaboration</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baogang Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>BB6CB04A-A0C3-4015-A990-6AA4C2BE70AF</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-198</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hilleroed Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>12EA551C-11EF-4168-A02A-8426F8419B29</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-103</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Advanced Heart Care LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A642EB51-1545-41FE-A3E2-8A8768C39D42</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-271</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Santa Maria della Misericordia Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>369626C4-1968-41D7-BAB2-46E0C09A4806</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-322</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedali Riuniti</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>EFD81A30-0416-47AE-8140-222DCCE9627C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-318</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Taiyuan City Centre Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AADEEF33-54E8-4D34-8CE5-E160E0CB8BBB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-416</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Heart Center Freiburg - Bad Krozingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9603D9F4-3DCD-48EF-B920-71B42DED335E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-354</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Eberswalde</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>45FE9077-CE7A-4564-BADD-E17F6E35BA2B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-173</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gotham Cardiovascular Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>88C393ED-4E39-40A2-AEAB-3281D6BFC434</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-137</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gloucestershire Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9BF09BD6-7EC3-403F-A5E6-21B177C8CAC7</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-315</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nephrology Center Pforzheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5B849AC8-2316-4C6A-B792-9084C5FA6DEF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-197</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Musgrove Park Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A5AC8969-3EE5-495A-A283-03752FDBC4BB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-54</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lister Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>78141163-EC0F-4789-B401-74DC95F96B64</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-58</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Waikato Hospital</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>68AC1C39-EB46-46F8-9757-EB31882358A3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-269</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Trier</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7986C40B-D015-4AED-94C1-B27EC612E42C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-181</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>214F1AC0-C317-4601-B5F8-2D3B37BC39A5</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-23</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HeartCare Midwest</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7A5ECCAE-73E6-48D9-BD92-B38BF9B965B6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-215</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FAW General Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>6D4F0BEF-D0C8-45DE-A589-372F1837AC7C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-363</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>China-Japan Union Hospital of Jilin University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>957C3104-F152-464E-A6F7-1C8B1C9DCFAA</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-362</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of Zhengzhou University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>719BA064-2E7C-4519-8768-84D4397B1A7C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-394</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Watson Clinic Cancer &amp; Research Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F4D76209-3DCC-46EE-B203-DD4604C5ED64</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-265</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PHV-Dialysezentrum Wilhelmshaven</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>45C6A937-A646-40C0-A66B-EF933A3A7085</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-157</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Anshan Shuangshan Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5C9A604B-825E-4037-962B-8F3678B135BD</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-377</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Danderyd Hospital (Danderyds sjukhus)</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6F2760B1-4B99-40AC-963F-843787412353</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-114</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gentofte Sygehus</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2F1479F9-6640-40A7-81FA-13BBFF77E59B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-117</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AE7B097F-642B-4D26-B855-F23AD0571984</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-61</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lister Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A833E6D4-96DD-4275-A669-567055BB54A2</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-79</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Michael's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>12023150-0BDA-4E45-AFA4-A0BD47DC4274</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-61</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fu Wai Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>09BD9CF6-56A7-403A-A391-0224727662C0</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-369</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Preston Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>24D2F832-9B39-4420-806B-D2CD7BA28BEE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-345</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Infermi Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E7D4A2EE-4976-44BE-A35A-6459A5CBBAA1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-311</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Deutsches Zentrum fur Herzinsuffizienz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CFD8CDDF-03CA-46A7-B020-3E56B20CA8B1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-324</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Firenze - Ospedale San Giovanni di Dio</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5B94493D-35A0-44CB-A4F9-0ED53192CFA9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-312</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Clinical Hospital, Wroclaw</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E3EDD840-CE8C-4F98-A447-064FE5351645</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-251</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aleris H?lsocentral Bolln?s</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>343DF065-7A1D-4448-99BF-9400565297A7</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-123</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trondheim Hjertesenter AS, Norway</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>CE9FBC07-54DB-4B52-B4AF-901DD3475F38</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-133</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Herning Regional Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8E95442D-818A-4316-8AA3-3D84E9EFD14B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-151</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jilin City Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FABCF614-D73F-4821-B1E7-6837C0C3AD2E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-76</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital, Frankfurt</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>75E6A208-DFEE-4C71-BAA4-CD5E302C328C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-185</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Princess Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>BFDE7347-3B5C-4398-A610-B611F1E3ECCE</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-24</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Cumbria University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cumberland Infirmary</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5CB69E9D-62A4-4F3C-B3B1-B5C68F6A37CF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-306</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dalecarlia Clinical Research Center</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E1A7F250-6EFA-47DE-BD9B-746D78E71BAC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-77</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clinical Trials of America, Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>909DEB36-57D0-4B77-99E2-AF7948C4977D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-212</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bundaberg Base Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>50B61897-0E68-4793-8FDD-368F95569261</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-5</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pentucket Medical Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4E14EDF3-7EA1-42B9-8967-B9513F86B494</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-187</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nordland Hjertesenter AS</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C813CCE2-4F3B-45E8-9102-68156724DFCE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-105</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Qingdao Municipal Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0C96378D-D9CC-4538-973A-2C1E9CC23826</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-228</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Whipps Cross University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>55C7A44A-6D03-40C1-BB8F-D66C9CC1532F</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-63</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Overlake Medical Clinics Cardiology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>6B24A6E3-EDD6-4F6D-A670-F590B9E02101</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-142</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Haukeland University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D9BD71EA-2574-4E36-A1F7-D0A766321090</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-130</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Community Clinical Research Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DFA76672-823B-4175-9E88-B0C4C824E84D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-140</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Halberstadt</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A3BD18EB-EC86-4DE6-B1DA-FABF5D54B052</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-148</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiovascular Associates of the Delaware Valley (CADV)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>6E06989F-A9FE-492D-A2DB-29BCA1DCB0AB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-253</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Affiliated Hospital of Xuzhou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>016EE75F-4FE6-427A-B31B-746941A068C5</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-398</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Istituti ospitalieri di Cremona</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B7B10213-B316-46F4-BBAA-E6DBB8FF70C2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-309</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kore Cv Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9FBA6F9F-B40B-4DC2-897A-F93ED319E286</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-155</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuhan Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>688EBD74-35E1-456B-9B61-BD1041002698</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-209</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Kuala Lumpur</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>673585C1-AAD0-4BC8-9A2A-1FBF2AE7363B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-217</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gentofte Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Cholesterol Laboratory</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>3703B8B2-D2C0-44B8-936A-5652B08FF4F6</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-160</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Internistische Gemeinschaftspraxis und Dialyse Friedrichshafen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0BF821C0-D1AB-4588-8510-48B654836E5A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-166</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ocala Research Institute Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8E4CF2E8-9E28-4AEA-AEEF-F072C57C5E61</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-273</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nebraska?Lincoln</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Nebraska Medical Centre</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>970E01A5-0790-4ACA-9228-4F8DAEE2CD01</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-387</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Raja Perempuan Zainab II, Kota Bharu</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>EEF9C07F-841B-4F6A-A6D7-5F1CA947550A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-221</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sygehus Fyn Svendborg</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C18408A7-1BA9-4FD8-99B1-A34C9421408D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-141</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Washington University School of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E251B2FE-B56B-4335-95E7-AD5EFF07437D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-394</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Second Affiliated Hospital of Baotou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4D42CDF6-4924-4CC7-BFF0-7E7DE1F3D47B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-387</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kidney Associates, PLLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5434B3D0-AC39-44BC-9008-9AB0733449D6</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-374</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>N?stved Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>66DF2F0C-CBF4-43EC-8DFC-79F5403DB4CA</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-128</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albury Wodonga Health</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>BA3A63A0-35AF-444C-AA82-D109999E6FFC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-1</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Victoria Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>F304E286-0EC8-47AE-8372-3F61B391F6ED</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-41</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Helier's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>226B7290-FBFA-4EF3-B6C8-7FB93D9A69EB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-17</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Fourth Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>38033DDC-C058-404A-BC15-3368A6EC0E39</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-183</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3F037B24-164F-4BA9-8F56-C5628903BD61</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-30</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Future Care Solution, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>790CC7D1-C66C-4F2A-8A3B-08294D434F91</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-252</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Herlev Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>73318130-D96F-40AA-BD6D-1655B9169DC7</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-102</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oregon Health and Science University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1CA12010-6CF0-4BA7-8DA4-DDD4D54B6981</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-224</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Holb?k Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C39BA24B-6C07-4483-A218-89C3337887C0</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-150</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hudson Valley Cardiovascular Practice, P.C.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>55A40DCB-C7EA-46BC-8C65-4CD8E78C942D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-132</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tenet Florida Physician Services</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>38E3B75A-A1CB-4C29-A105-0987B61EAB16</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-192</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Churchill Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B7A9DD18-E438-4CE7-A818-F0D1749FF941</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-304</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Green Biologics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>496829E9-452D-46E6-9621-9DAD62A68724</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-118</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Discovery Clinical Services Ltd</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FBC512CF-732C-490B-9233-1D2ABE3AD311</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-286</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nyk?pings lasarett</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>4A9BFA9A-1F07-4668-A1C4-C923D8F06E22</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-279</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D3B07F41-A41A-41FF-9769-54E99B846E4E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-84</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Denmark Region</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Randers Regional Hospital</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>EE263914-5324-4B0B-B656-C36F1384750F</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-142</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pinderfieldss Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>DFC38B46-EB4B-4F6F-9912-9547B4055C15</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-8</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glenfield Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>111318D3-2D3D-4897-8839-9CD691EA0971</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-58</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Salamanca</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Hospital Clinic</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6DA4117A-DADD-4C6B-BCB9-8565508D2941</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-224</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sunderland Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0935AADF-339C-46D1-B257-ABE1614A6BDE</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-59</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>DKD HELIOS Klinik Wiesbaden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D6323349-197E-44E5-A432-6AA45A5AD832</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-133</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stockholm Heart Center, Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>44BD7B1F-EEBE-43B2-8C3D-2E066B654D53</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-86</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bay Area Cardiology Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3B7A1727-CA97-48DF-8005-E06F792144B6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-264</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sandwell General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F3134142-BC67-4A3B-B0CE-ADFB15C18CCB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-30</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kolding Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E81A6BE8-62E3-46D4-AFAB-84481DE92722</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-148</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1B1329A7-0D90-404C-A888-FE610F024944</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-91</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Middlesex University Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9FF523BE-E052-4DBA-B053-EC61AEF1895B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-330</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Saratoga Cardiology Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4645AE8B-9C20-4164-8A46-7377FEC29F10</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-148</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Maharaj Nakorn Chiang Mai Hospital</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>66021AC8-7F1C-4704-B6F4-6F55420F8565</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-290</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universitetssjukhuset Linkoping, Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>DFE1A48D-DCE7-471C-827D-71350606A26B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-97</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universitaet Magdeburg Lipidambulanz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>39BD3DE2-0991-49C7-8485-B6BAE6DE9EBD</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-355</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellington Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>991730BC-DA66-42F0-8010-297AE96ACEE3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-270</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Molndal hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>EC3EA994-B159-4DA9-ADCB-8A2A24977365</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-89</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Christchurch Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9407F273-20A5-4080-ABED-1D9E43187FAA</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-264</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Bolton Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A33F6AFF-D4B7-40E2-A2D9-C1B99419B7E3</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-33</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Huddersfield Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FABE1275-14F0-4EC4-9729-B1913735E5CE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-20</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Prince Alfred Hospital (RPAH) Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>41A5D85B-300B-481F-9563-A45B1DFB1EC8</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-28</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novant Health Heart and Vascular Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D39CA076-4DFB-4552-B916-ADF83A8D9C0B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-227</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blekinge Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>17E2C0C0-7920-4A59-A0B6-8B079C457149</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-125</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Lancashire Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Blackburn Hospital</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>13478396-BCB8-4EC9-A2B5-79210B843421</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-70</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peking Union Medical College Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7465C92C-DDB1-490F-A346-A3E0DDD9F974</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-367</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit?tsklinikum Schleswig-Holstein-L?beck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>93CF6CC0-EFBE-4CF4-9BDE-4428CA75053A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-213</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>West Middlesex University Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>37933F6D-54C8-40FB-AD34-871876C413A2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-325</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Berkshire Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7DA13DDF-7C09-4689-A66F-097C8CED458A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-54</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>24F8C36A-F799-4FB8-BFBA-EB149AE508E4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-324</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heart Institute of Spokane</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1CAAA939-9FC8-40B0-A74B-E450E6FB4CE7</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-368</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kerckhoff Klinik GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F17A2020-8BED-4103-85EF-9BD6D5967F65</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-326</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glostrup Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>5F33EBA4-2F3E-44BC-B3C5-83EDE6FB90A9</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-146</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charlotte Heart Group Research Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>45AD742B-B3E1-41A7-85FE-AE0F0AD91F7A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-258</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Russells Hall Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>415C5449-AA6D-4518-AE9D-6B8B6DC445A3</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-35</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Laurentius Hospital</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>ACF81246-8245-463B-A166-F2B5F3EFB8A7</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-232</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit?tsklinikum Charite, Campus Virchow-Klinikum</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>466DAA47-00E5-467C-A82B-33DEA136D843</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-207</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blackpool Victoria Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0B9016B3-8EE4-4300-B13B-4F4DF05E5BE7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-46</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Parkview Research Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D4039C49-5799-47B2-8E75-C752830A29DF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-173</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Juedisches Krankenhaus Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>427FD838-C3F5-428A-B3E5-B4D46DB024D1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-329</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Community Practice Outpatient Dialysis in Augsburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>153A1FCA-E7B2-406E-96EE-263A3F5FB369</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-131</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fu Wai Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>BF16D8EF-DA58-4DAE-8227-C3977FE5152D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-173</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vizel Cardiac Research</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2AF8267A-1358-4F59-A8F1-2E2755A08B76</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-284</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Weifang People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Emergency</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C7E69736-B83E-4177-87A8-C89A22891826</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-175</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>James Cook University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>ACF8C996-F5CD-4B20-803E-263979B7A05D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-320</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dalecarlia Clinical Research Center</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0D114E8E-F71E-4516-82F6-C1102E633C9B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-118</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Innlandet HF Hamar</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5C148D41-CE78-4A7E-80D4-8EB072C4482A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-95</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Mary's Hospital Portsmouth</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>1A7C2EB6-91F3-485B-AA76-42A3453076B5</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-53</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epilepsy Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0868602B-FDEA-457A-8F70-D89E93C29423</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-242</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Buffalo Cardiology and Pulmonary Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>6DB8A1E2-2E86-4DAF-AFC8-A545F3C41D4F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-244</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Ohio Research Ltd</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8DFBF56A-B629-49BF-A356-6674A02B54C1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-232</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastern Regional Health Authority</gtr:collaboratingOrganisation><gtr:country>Trinidad and Tobago, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1A6A44AC-46E1-47E7-89DC-1C6FB048F9D5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-47</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xuzhou No.1 People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>082CE494-A554-4A51-BF56-710AF2ABFA22</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-221</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nephrologisches Zentrum Wei?ensee Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>DF5D0561-9C70-4F41-8345-9DAF8B1C26C0</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-199</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Falu Lasarett</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5119C02D-2411-4E9B-A834-133E78A5C056</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-274</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Union Medicine Centre</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>1F1C0122-A8B0-4FA3-A40D-DAEE7C75B234</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-179</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brigham and Women's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B6E790C6-7B89-44C4-9F1A-DC9327D0B42C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-150</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peking University Third Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>03E5133C-02BA-4C68-A200-D738C0DE66FE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-366</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sunderland Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>EE049848-E51A-4631-889A-CBE8DC93A328</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-354</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>42FA98D9-D328-48CF-AE61-6FAC780CF00C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-88</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dorset County Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FE21CB6C-0DE3-4310-9E62-2337E5DE27B6</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-86</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Richard's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>BCC41C1E-7EFE-426D-8E15-3AC180CC1517</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-72</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Maryland</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CC54CC61-D72A-475A-97F4-6AACD6270150</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-237</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>AF581CE0-4197-43CA-B9F2-3AC136338549</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-55</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemeinschaftspraxis am Sophienhof Kiel</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>68C5DEF9-EB19-4C1D-B4AA-FF99FB00225B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-164</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Bad Godesberg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0F7272C0-8349-453B-8FC7-96CFF7960806</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-142</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helse Sunnmmore HF</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>DC41B835-D030-48B5-BF31-AF6398E97F6B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-135</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nebraska Heart Institute (Dionisopoulos)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AC9FCAB6-F938-4F32-BD20-0C4D3D0ECC1C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-182</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Acadia Clinical Research LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>238273B3-CCD0-4710-93C4-5A9A70F72A7F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-158</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Copenhagen University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>156FA655-F5C1-40BF-8D6E-BB83B3CC9830</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-118</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Second Hospital of Shanxi Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A12A5CCE-5EED-454C-87E6-456D1D755FFC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-415</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of China Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AA20DBEF-555A-47A5-BAF2-AE24240C13A9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-380</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Dresden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>63FF2647-4FBE-4C45-98E7-4436E2F5836B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-358</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Limoges</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>205F337E-9C94-484B-BB3F-CF32CA7333D2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-120</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>4ACCE497-0752-48B1-9D69-4019361B21FB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-351</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>State Hospital Feldkirch</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9EA66240-A87C-444A-9A59-AEF33D446EF4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-41</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>U.S. Department of Veteran Affairs</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>VA Southern Nevada Healthcare System</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>874BCD77-01A4-4DA9-8F39-DDB9ED0BE4B6</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-393</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centrallasarettet</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>EE8F05DE-9F16-4FAC-8201-83B2831C1AA8</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-99</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The People's Hospital Of Liaoning Province</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>709F5A93-2F90-48F1-B4AA-91E956A8D882</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-188</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southmead Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D689254A-BA31-418B-8237-476330CFE4DC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-14</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sunderland Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CE76C812-2D89-4020-8791-F05687ABEF6F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-44</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shangdong Province Qingdao Municipal Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>4FE64867-759B-4380-9675-9275AD03E9E1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-82</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>57F312C9-BCFC-4F50-8072-6268DE9C5D73</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-35</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Watford General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9CFF930B-DFA9-4AA2-8354-3151250CE7A1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-27</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Palmerston North Hospital Area</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>78211704-B5A6-4DDF-A165-D13FB393A5C2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-267</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Frenchay Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>17AB4BBC-10A5-4285-A1F2-247E3627AF6B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-18</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Core Research Group Pty Ltd.</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9AA9CA00-2EFB-4CA3-81F9-41237B1F18CC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-7</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cheltenham General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CD754A4F-A93D-450E-AB96-DFF6069DC2E6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-48</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Jacobistra?e D?sseldorf</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7F3F8DA8-A855-4FF8-8F08-55963E70E4C2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-150</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Hospital of Jilin University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D1D99F16-74D1-43FC-8ED9-89A7B5247DFB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-163</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wayne State University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>92ADBC70-374D-490A-81A5-7D2A22C69E0E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-395</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Inner Mongolia Electrical Power Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>082F5403-0CDE-47B5-AFF9-F852297C0DC3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-74</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3070F7D0-90D6-42B5-A74A-135A94A29E6A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-321</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A274FADF-A1F4-4E08-9D83-2832B637BB11</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-343</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Saarland University Hospital</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F732AE5D-3E57-4DB3-A752-171939B13DA4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-210</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glan Clwyd Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C502610F-F5E8-4DE0-94AE-A16947C65D71</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-313</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Connecticut Heart &amp; Vascular Center PC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7071E472-0D63-4BA3-9FE2-1AF79E4B29AE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-208</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hopital Maisonneuve-Rosemont</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2B86DE59-E981-4D70-B66D-5BF7CA14C0A4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-49</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Polyclinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F143DA98-7534-47D6-B5E9-1884472F7F39</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-247</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Second Affiliated Hospital of Baotou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>755E88E6-E33F-4EA0-B7E0-5AE020712AD1</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-200</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jihlava Hospital</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C5617C89-39B0-4151-A1D9-11EEFCD09A9B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-94</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Gronigen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E0C026B1-27E9-4669-84AF-A5125F4DF803</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-239</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Norra ?lvsborgs L?nssjukhus, Trollh?ttan</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>38946DCD-125F-4C11-B6C2-C294A8169984</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-278</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Robert Bosch Foundation</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Robert Bosch Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8B5FC37B-13B9-453A-A2A2-B926C4F6A4E2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-203</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glostrup Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D98330EE-AEC6-4E11-A97F-F983D3622F30</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-125</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Hospital of Jilin University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology and Metabolism</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>9F6A10D5-5780-4CFB-9803-E11A78F468A4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-164</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Iowa Diabetes and Endocrinology Research Center (IDERC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B4A61DCF-AD3B-4294-92BB-7F7AB0B62663</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-201</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CDECBAA8-691A-4FD7-A778-CBB6F8C7390A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-18</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First People's Hospital Of Shenyang</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>43FA78CB-D5DF-4EBD-A7AB-A038E3939002</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-193</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Capital Cardiology Associates (Troy)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1B51B2F8-7497-4BCF-9429-90F02B89D58C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-143</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Pirmasens &amp; Kusel</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3E35EB4F-361F-4F91-B176-CE996FA73F86</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-153</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Tengku Ampuan Afzan</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8AC82FFE-B960-4B5B-A537-888EA7F83419</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-225</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sir Charles Gairdner Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>49CA8C7D-72EC-4E70-9B29-F42B931B2B52</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-29</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's Medical Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D39829B3-BBC2-4BA0-B434-54D24FEF9E17</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-60</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Sussex County Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D29CA3C7-DD0D-4388-9F00-46A97FAEF48B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-38</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ninewells Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B18BD502-E0E9-4E80-A07E-4FFCE02E9829</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-36</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ziekenhuis ZGT Hengelo</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9F17E6A7-8C1B-447F-9D51-1197083A4B86</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-238</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Etel?-karjalan Keskussairaala / Etela-Karjalan keskussairaala</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7DBB0FDF-5DE9-4265-A7B7-A388C8A182AB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-95</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Hamburg-Eppendorf</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F2F9922A-3494-4439-B127-F98320A88FD7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-337</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Second Hospital Of Tianjin Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6C91EAB0-323E-40D1-BCDC-CE710FE9AE18</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-178</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of Xinxiang Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>55D54504-994E-4604-960E-A2E5EA86EEFF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-396</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helsinki University Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>019832B8-10B6-4E9C-9A80-6F8D2CD553B4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-109</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Premier Healthcare, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A28BBB14-9669-479D-AC01-8574DD5DC273</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-134</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Karelia Project Foundation</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1BD613C2-826D-4470-8D98-AFECDEEB1CE1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-74</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Zhengzhou Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>67BDAD72-C9FF-45A5-A152-7EFF472652CE</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-215</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Berkshire Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8AEC8AB8-BC3F-4322-A607-C15F6BAADC3D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-339</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Helier's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FE62520C-8CD0-4FBD-9F87-BBE60A2343BD</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-13</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Juan VA Medical Centre</gtr:collaboratingOrganisation><gtr:country>Puerto Rico, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5865424B-193D-4B5C-811B-295D39967D10</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-382</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blackpool Victoria Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A22627B4-77E2-42E8-8891-CA0B5F885ECC</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-61</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Hospital of Jilin University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology and Metabolism</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5F5F8E1C-5219-4609-8ABF-2C7FAE039BF5</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-361</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Credit Valley Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>410CF4AA-E5C9-4521-985B-2C32EFA1B50A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-45</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Second Affiliated Hospital of Harbin Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>F48C6B32-2DD1-4320-A780-C550B42F2EE5</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-232</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gold Coast Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2CC21E38-F68C-4E30-BD5D-6C6F80D5FD77</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-9</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Westlake Medical Research</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>50F4A005-67A1-4879-A495-8F9AA822511D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-219</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>44AECAEC-337A-4857-ACEF-42C7DC9EBD20</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-370</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Georgia Health Sciences University (GHSU)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Medical College of Georgia</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>14DDEF49-4E9E-4A8A-B519-B3DFDEEDE2E5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-376</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harrisonburg Medical Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1C49FE19-1EAA-4E21-BB12-B85E3F94CBBB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-243</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wallace-Kelsey Research Foundation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>269A797B-1D76-45C6-9D5B-7C20EDC9C259</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-373</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trinity Medical Center (Rock Island)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2778FF3C-612F-4004-AC1F-8F6877FF6B9A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-231</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Medical Clinic Innenstadt</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DFBC89E3-4666-4D32-8082-9839DE7D6C08</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-344</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Derby Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>580C47B3-0CB0-4B7F-B217-F8F2DAD78468</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-307</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harlem Hospital Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>66915ECC-0897-44A4-A6FD-C2A596E314FB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-367</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The General Hospital Of Xuzhou Mining Group</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>527BECC6-B1A0-4270-9E3A-EED84609CD46</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-401</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yeovil District Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>3BC46EF5-4809-4939-BC89-1CC8BF345B49</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-75</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal North Shore Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>ED6892CF-2777-4496-A0DA-23843251CEE5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-26</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>3495C552-8B36-4C41-8BFE-A8D8C1596157</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-22</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Santa Rosa Cardiology Medical Group, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E9D4FF1C-7223-4AF0-8482-7A7323E02C14</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-133</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Green and Seidner Family Practice Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>81C74AB3-A42F-46FE-BD68-D6D0E4EDF8F4</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-217</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Bayreuth</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>248ABC34-BFDF-403C-8179-7EF176927EDE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-170</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salem VA Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0E11AF14-C148-49E1-934B-BA75E12FFF2A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-381</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Grosshadern Hospital</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>93F7A21E-2CA8-4A3E-92C3-4419BF608B23</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-343</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Second Affiliated Hospital of Baotou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>EEF2B60E-05FD-4502-A7B4-CAAEEB5227A3</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-385</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuxi People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5688819C-FE60-416E-8B9B-72CE721A1199</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-397</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiovascular Associates of the Southeast LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>93AFD34D-C39E-4268-BF40-09E65D4DBA90</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-185</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beijing Chao-Yang Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C2215DA8-A334-40DE-AFF8-E7009B19DE0C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-174</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Palmetto Research Center, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3A607255-1832-4D98-9343-64C695427393</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-197</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kardiologie Universitaet Magdeburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FD2BE404-ABC4-40E9-9D70-50CE2E491B98</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-341</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Turku University Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B01110D9-09A2-4838-99D4-430E7F7490D8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-71</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Viacar Recherche Clinique Inc</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>50F42A7E-665E-4926-AB66-F57382045092</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-297</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jyvaskyla CorusFit Oy, Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8454E32C-5519-4988-AF12-E8EE952ECB6C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-93</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D4EBEB60-D18C-410D-878B-F11FBEA29980</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-17</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Norfolk and Norwich University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D238EFC1-90BF-4C38-832D-BDFFEF3484E6</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-329</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aberdeen Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D143A0F1-663C-4799-8F01-881A81CE0693</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-22</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Second Hospital Of Tianjin Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>252D9057-C943-40F8-8CBB-512F455FE06E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-372</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Worcestershire Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>6CEE3F50-3DD2-47A0-B2A7-2BE2C1D03E39</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-9</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FAW General Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E89DDF6B-D3A0-40E1-93E4-C4AE707D9306</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-166</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Viborg Regional Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>387D1683-C8C2-4257-99E1-3E95971DC303</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-114</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal United Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E5422518-E93E-4F71-820D-EC6E80C0F4BF</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-11</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UNN Hjerte/Kar Poliklinikk</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F649C937-5C90-4716-8A92-ED18133BE9A7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-103</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peking University Third Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FD2F52FC-E83F-420A-B969-FE2A2D27B97F</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-170</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beverly Hills Heart Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B080D7F7-C605-4F4A-9E5E-3D39702E3E30</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-235</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Silentzv?gens V?rdcentral</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>8CED7F48-A805-481A-AE5C-46A581DBF8C3</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-120</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kansas City VA Medical Center - 2</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8BBECDF5-7C8A-42E0-A538-71D1C90FE8F7</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-372</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Medical University General Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0B77EB55-0ECA-4404-9B51-A60F4A668E3B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-176</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Odense University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Svendborg Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8A2CA7C1-B6B1-4132-BA31-3F23C6065D3A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-110</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xuzhou No.1 People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>31230DB5-E6DB-40C7-B1B8-CBE0C3116396</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-400</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hope Housing</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9AC08CF4-A291-416A-A638-4DFEAC6064F4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-317</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Karlstra?e D?sseldorf</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B64F25CB-BDAC-4A6C-81E4-358497773678</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-151</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Victoria Hospital, Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>71644147-E998-47D5-AC96-9AA9CBEE4B61</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-58</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Meharry Medical College</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>84702995-DEE8-4392-9D10-5D817914BC11</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-377</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pinderfieldss Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3B0BAEED-8732-4562-9088-48C560B5B9F9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-7</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aberdeen Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>EF725F3D-575A-4859-9776-2C4ACBAF3A8D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-30</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rigshospitalet</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9D8854F1-A034-4F62-A392-B660806167CA</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-101</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Meriter Medical Group, Inc. DBA: Meriter Wisconsin Heart</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C69CD92A-2E0C-4593-B7A7-068368EBB4F1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-280</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brothers of Charity Hospital in Trier</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Br?derkrankenhaus Trier</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0D87A94D-DA52-4345-BF4A-F86A7BE91144</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-132</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ljungby Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8CA1180A-1100-4A42-A968-AAB1C02256F0</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-78</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>General Hospital Of Shanyang Army</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D94DC572-59C2-4146-8EC1-7B5B139EAF71</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-71</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Victoria Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E7ACB6EE-7372-4E14-96B2-2BFE9BDF3A34</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-37</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shenyang Fifth People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C77A9E1D-5EBF-4422-84DC-7579ABDD58A1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-383</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of M?nster</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Universitaetsklinikum Muenster Lipidambulanz</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BDB89BA1-7156-499D-A556-A3692D99FD8D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-356</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clearwater Cardiovascular</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B879A31C-96AB-402E-971F-2C89B5BD45A4</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-275</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Emory University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FB5D86AC-8A04-4F83-9780-DA3B15F48764</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-366</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Huddersfield Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C2A72FA0-AE4E-4E25-8772-A1D0725089C3</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-26</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ysbyty Gwynedd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D6A7E3E4-C36A-4ADA-8028-617E0DD0196B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-361</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Western New England Renal &amp; Transplant Associates (WNERTA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>26262AA4-9F14-4E24-82AA-845A447ECB0E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-396</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boice Willis Clinic Nashville</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0449DFCA-1F6D-4389-9203-87AFDB76FDC8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-175</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Health Partners</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Regions Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F8976833-0CA9-43C3-B790-DA9238EB9D4F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-278</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>S?nderborg Sygehus</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B8ED1BC6-1758-402C-A709-DD23F81FBE37</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-107</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>New Cross Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B74CA76F-1C03-4D92-AAB4-997A950C4BA2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-327</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Wei?enburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0A08442B-F8B7-4433-8998-F0319A6AF549</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-182</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Texas Cardiology Research Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0BC95BCA-9446-4060-9F24-EABE19EA603A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-163</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The 306th Hospital of PLA</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D09A5BED-87DD-4D9C-9AB8-2DF40A9150D3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-81</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Q &amp; T Research</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9BA18A34-1385-48E0-BFAB-BBA0B0EC3410</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-282</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>South Oklahoma Heart Research, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>088DFEEB-0AB1-492A-9A0E-A56DF48352B2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-170</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>626D3039-CA12-49A1-8336-CD459E8AE216</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-344</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Zell am See Hospital</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B20F5962-8074-4F97-A6CE-C691554EFC1F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-40</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ambulantes Herzzentrum Kassel</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A632AE45-1E9E-4C02-9A4A-1108154231CB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-359</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>45E84239-C504-467C-B0AC-BADF44843CBF</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-316</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Research Physicians Network Alliance</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>376AB44C-2233-450B-AA3C-A8182EFC60A9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-254</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fondazione Salvatore Maugeri</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CE5FCF52-5015-498B-A09A-008681F4A423</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-300</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Adelaide Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5DB64EF4-FC54-40BB-9783-312A4382C527</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-22</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Giuseppe E Melorio Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>69FF5D6F-1E9A-4E16-AC7D-1D243E92C2E2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-315</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Lancashire Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Blackburn Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>08F7A3F9-0CEF-48CE-8937-FA025C599D32</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-52</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal United Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AA073B2E-D19B-4922-BC84-B2C627933F17</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-8</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital del Mar</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6E8F1AEC-4B51-4E6C-9B60-DE2B86374174</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-219</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Praxis f?r Nierenkrankheiten und Dialyse</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3A79B726-E9A9-4ECC-BC12-2311B496437D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-202</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Josefs Hospital Cloppenburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>82017003-5D21-49FE-82B2-89B68AC01323</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-205</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wycombe General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C422853A-A3CB-4824-86D1-EA8D49F72699</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-11</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Szpital Kliniczny Dzieciatka Jezus, Centrum Leczenia Obrazen</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>32FEF507-0C50-40BC-BB59-C79159773825</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-256</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Tyneside General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C9E1FF0B-D980-4803-AB0A-1F2ED4B0D70D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-39</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Bovenden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A8D8CA94-72A4-42ED-BCF5-C4F49478FEFB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-145</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiology Associates of Bellin Health</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0BA2FB69-FDDF-4EE5-8603-E3F82152BB83</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-152</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Daqing Oil Field General Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>BA4F6C3A-954F-47AC-9FF2-05064A7C0E99</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-70</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southwest University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B6C14F75-AFBC-49B3-B6AB-7A345E1837C4</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-149</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Westmead Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>419294D3-8330-4308-9E9B-B3A09FEEFD09</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-36</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>M?larsjukhuset, Eskilstuna</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9B468C3E-26E7-466B-BA38-E7DB4CA90AC3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-277</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nottingham City Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>EB71A7BA-8A8F-4D77-A7A1-68BB566A54CB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-332</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Renal Research Institute RRI</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F1995388-BD73-410C-935A-5FB56698939C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-20</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Singleton Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>4798294F-4299-41E0-A9C2-581311E6A1C4</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-34</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Inner Mongolia Autonomous Region People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>67FBF275-C061-40A3-AC02-76B36D4EA3E7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-386</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedale di Jalmicco di Palmanova</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>4F2E3F4D-D3C3-4DEC-AE9C-253418224866</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-310</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Health First Incorporation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D890C2A4-1ED2-4A04-996D-06C8040C6B3D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-250</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedale Ignazio Veris delli Ponti</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E2D5ABA6-DD5C-46B3-8F66-599CA012CEDE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-320</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Austin Health</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D1B185C7-63B9-4B18-BB4E-BD17E359CCE6</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-3</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sydney Adventist Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1AECEE47-E991-46AA-B748-8AFDF909B43F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-32</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastbourne District General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>5EAA4A0E-7C83-4997-B6C9-1615DF2B4DC8</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-80</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lappi Central Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>99110134-9FD5-44B7-825E-730D751652AE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-73</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Awasty Research Network, LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>312BEAFF-E225-4710-8F19-FEFDE8BDCBF9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-226</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xinxiang Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AFF9E5E3-0644-4112-8438-E810C543DE31</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-395</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>G&amp;G Research Inc.</gtr:collaboratingOrganisation><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>05629DC5-C2F8-4252-B4A5-DEDB3AFF6858</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-272</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gentofte Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>820EC44B-2A37-45BF-9FDB-928B55BD545E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-147</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fu Wai Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Cardiac Surgery Center</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>9D29647B-D0E0-4C4A-9000-6F40A749E251</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-172</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wrexham Maelor Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0DC6E0B6-0807-4471-A192-3A3A60543957</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-359</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>32986894-F2E8-4AAE-96E7-FB31E75C9B9A</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-96</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shenyang Sujiatun Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>F0BD241F-1D65-4F37-A9A2-94807B0177D8</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-196</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Mark's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Heart Center at St. Mark's Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>84E459DC-00A7-4F9A-A2B3-9923A0DCE113</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-168</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universitetssjukhuset i Lund</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C86095DB-33C8-467F-962B-5C34199B0293</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-284</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johannes Gutenberg University of Mainz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D35A7CB8-E19C-4F83-AFA3-86FBB29C1BE1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-168</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Local Health Umbria 2</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AD9E2970-7A6C-4FDB-B7E4-35D53EB0316F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-304</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuhan Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Endocrinology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8A9F83E3-E28D-4AD2-B675-5179BEBE1D77</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-392</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiovascular Research Foundation of Southern California</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C998BB15-6489-4C41-A34F-ECC62B5047B8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-218</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Middlemore Hospital</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C81780A6-9CF0-43C9-B9EC-FD9FBDC35C84</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-266</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Black Hills Cardiovascular</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>23DD4A7C-FB86-4512-BCE0-FE5BE37E8B8C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-209</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The First Affiliated Hospital of Baotou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2FFCD6F1-D30F-460C-B038-AFAA73572C6B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-69</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PHV-Dialysezentrum Hildesheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>667DC337-7D6D-4205-B749-0218FBDDB78B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-200</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stockholm Heart Center, Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>DF064A44-2875-4602-9F72-63391C6EC5B9</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-127</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dalian Municipal Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>96856DAF-8A23-445A-8FC9-7FCFD520CA2A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-404</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Inner Mongolia Autonomous Region People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AF94B6DE-5682-44DA-BEBA-34ABF77D4B07</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-388</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Torbay Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BFB20646-2B2B-4084-8472-7AB9E5F41FD2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-43</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Skedsmo Medical Center AS</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F58CCEE7-C001-417D-98A1-C2CFE4E2BA07</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-94</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Bolton Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>2309DB11-0A4F-4487-991C-4B884C6AE39B</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-43</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southmead Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B0B13245-C24E-4CC0-AF53-8B0BEAF594A2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-350</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fu Wai Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0A24AAD4-A541-4E18-8F9A-69B1BFB2E3EF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-407</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Cumbria University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cumberland Infirmary</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C088DF90-EE30-4E4E-AE05-8FCAC8664C2C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-69</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beijing Chao-Yang Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>6B40299C-48EF-4F59-A220-6D3979EAB797</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-370</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aventura Heart Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B4E7680B-4817-4AB9-90BB-BCDC38A5D317</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-248</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Second Affiliated Hospital of Harbin Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>2CFCCB37-2694-41B6-B613-F90CA961AC99</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-233</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedali Riuniti Albano - Genzano</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>34021052-09CE-409C-8E47-15365976A86F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-302</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bradford Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B0A70E6E-1DD7-4591-8B4B-90BC98C32208</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-56</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>China-Japan Union Hospital of Jilin University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>CD4278CC-6066-410D-8025-500880BD8A83</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-165</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rajavithi Hospital</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9B1C0B07-43EA-4A8F-9063-B2005B696FBB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-291</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Hillingdon Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CB586455-096C-4376-B4E6-C74E11848685</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-4</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Provincial Hospital</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6D6A0A28-8098-46D1-834B-26316F10C0C1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-262</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of Zhengzhou University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>FDCFC5CD-3D7E-4B77-82D5-3D0167A84382</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-211</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wuhan Asia Heart Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>974A59BF-9BC4-443A-B505-6772A94620BC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-393</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>General Hospital of Shenyang Military Command</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8705E5F5-B997-4476-A2B6-20DC5739150B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-384</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glan Clwyd District General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>55460BE7-B16B-45B2-A362-8781D5C97ABC</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-65</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aarhus University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>45577093-5BBA-493A-992E-F86049DE6478</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-121</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harfleur - Clinic du Petit Colmoulins</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8C2B1DF0-3D4B-425B-BFF4-27C1FF86D6BA</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-119</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Connect Clinical Research Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>41CB4A1C-E95E-473A-81C8-D6C6C1B47281</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-236</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Johannes Hospital Dortmund</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2DE0FCEB-1A1F-4779-9D79-0D95618D4A05</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-204</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Victoria Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BDBD6655-3C78-4EB7-AEFF-3237AB02C37F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-31</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Zhuzhou No.1 Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1E812912-A784-4F1A-ABAE-D5F38F89E13C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-410</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dewsbury District Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A2971BCD-CD54-4700-9096-E6C8DB030FB9</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-16</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Research Facilities</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>6EF903D9-BA9B-4CD1-BECA-CAFCF4698467</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-169</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roskilde Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8BBD9A5E-B666-4FBF-97F8-142F992E089C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-112</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>John Hunter Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>226E00E6-291A-4DB9-8DFC-1891DFB2A332</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-10</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Medical University General Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>F44F391C-C649-4B81-B00D-23194013A500</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-177</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chesapeake Cardiovascular Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D477AE18-1E28-45F8-BD59-A8C4C6A77311</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-241</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Skaraborgs Hospital Sk?vde</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>18B31709-7119-4325-A960-6FE5A2BC4DE2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-281</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Crosshouse Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F87D460A-400A-40A1-A02D-96C730B87322</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-305</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Coburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>52AD855F-A534-4538-9EB8-7151057609BB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-171</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baylor College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Center for Cardiovascular Disease Prevention</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>11692626-4603-4807-BBF5-31834537BF6C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-230</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mahidol University</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:department>Siriraj Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A2CBFF8C-1D1D-4E49-825B-0DE625F7F993</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-293</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rigshospitalet</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>BCE24330-1BDB-4D62-B6EF-CB807804CE87</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-154</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Capital Cardiology Associates (Albany)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>5868894C-C4E9-40EE-923C-E8129AF6A907</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-166</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Provincial Specialist Hospital in Wroclaw</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A2473F07-A2E2-4ED1-A1EC-0F37C926CAD2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-259</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Wales</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>791CE199-0B81-40C5-833D-F0ED709734FC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-41</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southampton General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>B81F2722-DEBA-4F3E-892A-20147CD5409D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-52</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The General Hospital Of Xuzhou Mining Group</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>02DBD9E9-D5B5-4ECF-BBE8-7C998A761DCA</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-222</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gubbio - Ospedale Gubbio Gualdo Tadino</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CE270EA9-F63E-40C5-B5C7-704107178DA1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-314</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Musgrove Park Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>35A9025C-C754-46E6-B3E1-19A6B34C7812</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-42</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Songklanagarind Hospital</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A664D62C-35C5-4A15-930B-096D1DB4CC49</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-294</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northern Michigan Regional Hospital (Nisus Research), Heart Center Research LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>00378C8B-48C2-415C-A8D4-0F4E591479C2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-183</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Donauw?rth</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C8415233-3BE1-467B-BC43-21B0E03E8E5E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-172</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CAMC Clinical Trials Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>964D18F7-C4A7-412B-B913-16FC2F239C36</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-203</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Norrlands Universitetssjukhus</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>267C5983-DFBB-4419-B0D3-28FA84EF9E7B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-87</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Russells Hall Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A0770F79-857F-47A3-984B-27CEBD931311</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-26</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Bournemouth Hospital</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>586E7212-6F48-47BC-9170-9854840C0EB6</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-10</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London Health Sciences Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F4F9A61F-60E8-4CB0-A262-1FB68DD3F526</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-52</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Francesco Ferrari Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CCDA5CC8-206C-444F-8559-36E1A7A25D70</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-319</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liaoning Angang Lishan Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0B6C6FFE-0F7A-4BEB-8468-7E9DC16F9541</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-79</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southampton General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>0B7E4461-30F2-4B03-9DE5-995ADB185EA5</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-39</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alfred Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>500C9D41-011A-4637-8785-D500E3B478B2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-2</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Legnano Public Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>56550878-0C4D-4AE5-BA77-9887FEB350CF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-308</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Infirmary of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7CE61DC6-9B1C-43FD-85F0-0B326B380E85</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-15</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Escondido Cardiology Associates Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3A113E95-8E5B-4A68-9A71-0443FD189978</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-176</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Providence Saint Joseph Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7C2F6185-3D2B-45BA-821E-306C9709CC5D</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-220</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Bordeaux</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1BF51DCC-9B06-46BC-9946-2EA8E44CBD8A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-116</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dumfries and Galloway Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>ABD0CADE-EF81-4255-99BF-ACD624A1B184</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-311</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit?tsklinik f?r Innere Medizin Innsbruck</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8F3C1D63-F495-4C5E-B62F-7EA17D859FC1</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-42</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Thai Air Force</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>828DA21A-0E7C-4542-B69B-CA233A850220</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-288</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Malaya Medical Centre</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D034786E-149E-4037-B74D-4B5D5C81A9B8</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-229</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Holb?k Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>31FA0991-A97D-475F-8C09-AF0C4901088F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-115</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universitetssjukhuset MAS Malm?</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F65289FB-33C0-4E8E-BC10-3DBF59CEB4E4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-283</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash Children's Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7ADE06A5-B2EC-4622-AB35-DE2A586E6F6B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-14</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit?tsklinikum?Bonn</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>584D8444-F65B-4434-885F-BDE90686D18E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-331</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Associated Research Partners LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D719E6B8-A9C5-47DB-AD67-79DA3BAD161B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-139</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hjarthuset AB, Varberg, Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>1A80A29C-9E26-41D5-B912-2F07AA7E16EA</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-107</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Dormagen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>0A0A287D-8A41-48A9-81DA-52D758BA6232</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-147</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Finmatica Mercia</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>97243CEB-DF7F-44DF-8076-6D97FDB23E83</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-72</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemeinschaftspraxis N?rnberg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D97133E1-82EB-4A24-B957-837A1B406116</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-162</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>ABFFF9A3-233E-4F0F-80D6-B1921A7AF082</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-342</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7945C7C0-6DE2-4ACC-93A0-164D8CD8BF34</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-248</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fourth Affiliated Hospital Of China Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3E70BEB3-61E7-4AE9-ACDD-4151DC76519E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-382</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Slagelse Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C6CB14D7-8449-44FB-9A76-3451F057B75C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-127</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Regina Qu'Appelle Health Region</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C5D3F044-9C31-4899-A44E-A397BEEFDA3C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-55</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Permian Research Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>75FDBD13-1F52-4826-8253-9A80596D5EDD</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-195</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The First Affiliated Hospital of Baotou Medical College</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>36732254-9C95-44D0-B740-BE83EA753DC3</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-201</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bendigo Health Care Group</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>151238F1-8193-47D0-942C-02D6EC4E31C8</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-4</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Second Affiliated Hospital of Zhengzhou University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>B29B30B8-44FD-4AA0-9657-909D647E776C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-214</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Innlandet HF, Kongsvinger</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B4EB55D9-039C-41C2-A194-E8A53BE8480F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-100</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Qingdao Municipal Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Emergency</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>A0DA6009-D02A-40AE-AB6A-20BBF864721A</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-227</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of North Staffordshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>954B0861-1693-4727-9DDC-5E21193BA7AE</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-34</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Maryland</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Nephrology</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C93E5657-B26C-48F9-8E48-D52D48777ED8</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-385</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Joseph's Healthcare Hamilton</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>467DE8A7-1744-4D32-B4AB-64846CA67A7C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-60</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Vincent's Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>70795808-B572-48AE-840F-DF13BA93EC45</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-31</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>County Hospital, Stafford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0715D468-56AE-4B54-BA46-27819DAC4770</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-76</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oskarshamns Sjukhus</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>C0C57F78-1242-423E-83D9-5A3358A3AD34</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-126</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Texas Cardiology, PA</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AEC7560E-C990-4D3D-9F7A-3CC214712928</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-194</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Antonius Hospital</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>BFEC93CB-9E8E-477F-B2C7-909BA4509E6F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-237</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lindesberg Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E3DB9B0E-C215-471A-9D4E-CE8C2AD2D51D</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-110</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Szpital Specjalistyczny, Dabrowa G?rnicza</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>585CBA6A-B208-49E0-B4C6-7BC6C3ADCB2D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-257</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Telemark, Skien</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FB4DCE05-07A4-4DCD-95C7-232E2C59076B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-102</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cheltenham General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>450A9EC4-FAD2-4699-9EFA-8D1C672593BA</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-64</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manor Hospital Walsall</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AD6E7780-BFB4-40B9-A9A1-39C78EBC2D51</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-21</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helsingin Yliopisto, Kansanterveystieteenlaitos, Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D2CEDA37-AAB0-4C52-AC81-57714091F0AC</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-91</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roskilde Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5D40A8CB-19CA-41E5-B3EF-00265B2FE4B5</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-106</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Victoria Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DEDFF0AF-F5AB-494A-90DC-4AA97F64E94B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-28</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Erlangen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>04F04039-D64D-4F0E-B77C-E3D53A44C6EB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-208</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tallahassee Research Institute Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D87A0056-B2CC-4B76-AAFD-59D899B6FB28</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-260</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Maine Research Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B95734DE-C3EF-4084-9948-8285F8E5E887</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-180</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Elizabeth Hospital Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>6D3930CE-DAFE-4B4B-A080-11475AEAD9B1</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-27</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lister Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>71A82F19-B5E4-42AF-8784-3C7B4265324C</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-323</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Houma People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>53CF4C05-1E84-4BED-A8B4-50500A2B17B7</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-418</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xuzhou No.1 People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>1F6D13EF-9E71-44B1-9E83-2E72635989DB</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-220</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedale Maggiore</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>DFE9F10F-64C0-4699-BBED-17571A3B7BEF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-298</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nambour General Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>89C0B264-7708-4F7B-B2E9-9D0CAF71333E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-15</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clinique du Landy</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2D1F5395-CB9F-4163-A633-CF99D7304793</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-124</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aberdeen Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>D4654369-D30B-49E2-A49B-2E7829EE9717</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-295</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>N?stved Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>3EEAA96A-1606-47B0-A459-788C0AAF7D6E</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-162</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shenyang Fourth People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>B2AE05DF-A17F-43CB-8300-340254DE91EE</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-189</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hvidovre Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D560E565-40FC-413C-AA7D-CCDE5E601963</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-145</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset??stfold</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8AA90517-BE16-4937-845F-D0CE828DCB1F</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-247</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cleveland Cardiovascular Research Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1D17F4EF-30BF-4676-856B-0C9A17E8A2EF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-198</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Helier's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>3B8F08FF-6BFD-4610-9496-4C1B86C0C80D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-352</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MultiCare Health System</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Institute of Research &amp; Innovation</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C926D066-93C2-44C4-A734-401EE960B3D4</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-174</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northwick Park Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E58FFEA3-1A58-4E81-81C8-8E997D226529</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-47</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Alberta</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>A4049ADD-6986-4577-A2BE-42CC9FBD1563</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-66</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Perth Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>E508A23F-9DAE-4B39-9B05-6B4302A2A76E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-27</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mid-Valley Cardiology</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>225983E0-79D8-4BAF-A372-A7D948F7E333</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-145</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Third People's Hospital of Dalian</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3BC19684-C3A4-408B-B413-536871B44A89</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-403</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>LeBauer Cardiovascular Research Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>32FB4D0F-A290-4251-BF43-903386726ECA</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-210</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Internistische Gemeinschaftspraxis Alzey</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>00822B47-A099-46FD-8767-495E69A66076</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-165</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Berkshire Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>5A611391-96A7-43C3-99C5-98B6FBD2F1EA</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-73</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Princess Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>94FAE262-EE01-4685-8944-17720434959E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-19</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of North Carolina at Chapel Hill</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>5B5AC2C4-C62F-4782-8C2D-4FDAFE13F037</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-388</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Strakonice Hospital</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>CBD04546-8087-4ADD-B12C-949305F5F008</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-93</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardio Centrum</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>F53E9094-76C5-4E2E-ADB1-F4961511FE87</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-342</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nephrologische Praxis Dr. Meyer Bad Nauheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>7B0B13F5-BE1C-4165-9A56-DB9A27FDAF4B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-194</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>York Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1AA0AA83-87E6-47F4-B22D-AFDF21D77C2B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-360</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>CCBF0B47-1892-4F7B-B55C-1ECE70F7B725</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-51</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Halmstads Sjukhus</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AAE8F7A0-F022-4C71-8A28-0F149A7C93D4</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-90</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Union Medicine Centre</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2DB74928-24CE-4019-A205-DCEAB72B8C94</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-373</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Austin Heart, PLLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BF923FEA-6387-496D-B525-EAA0A11DC73E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-171</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vestfold Hjertesenter AS</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>E5553EF0-34F0-4745-A212-BE73379111BF</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-106</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ladulaas Clinical Studies</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>40A3DFFD-6B37-44EE-9B72-CD1E6F3C0AC3</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-121</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9D985B84-760F-4001-9ABA-9C0BE92EFAFB</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-365</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Westpfalz-Klinikum GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Kaiserslautern</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>DD72FEA3-A244-4AC8-A7D4-EE844914B276</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-215</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Graz</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Division of General Dermatology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>318807AB-AC71-4DB1-AAF7-47286137DD81</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-202</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Munich Hospital</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C80E3F8B-2DD1-44D1-8179-47DD788AABAE</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-186</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedale F. Veneziale Pronto Soccorso</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>7FEE6F7E-C81C-41FC-9E5D-0750C0BC6BE8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-323</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>114DCB57-CE5E-4E0E-846F-3A9271D86BC2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-109</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Affiliated Hospital of China Medical University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0094DAC5-AD5F-480D-BAD8-997B0F50A356</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-190</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shanxi Cardiovascular Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>23218AEA-3456-4BFB-84E8-2787926448FC</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-413</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dayton Heart Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>AFE802C0-97E1-4246-8775-229057F3E167</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-211</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Affiliated Hospital of Medical College Qingdao University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>04469A63-2AC6-48EB-9640-ECC65FBD1DC7</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-226</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Clinical Research, Richmond</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B9F4CA07-2CC4-4054-A288-E79AD8A762C6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-207</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trondheim University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>St.Olavs Hospital</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C8990056-38C6-483A-9DEA-9673B74E11F1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-108</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Derriford Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B9A967BA-0B10-4F58-AAB4-4CBED29213F2</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-1</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Inner Mongolia Autonomous Region People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>05E32AD2-9ED8-4258-B440-F39C8919A08C</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-202</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southampton General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F3A45B1F-F854-48AB-A4AE-15A3039827E9</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-348</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vrinnevisjukhuset in Norrkoping</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>78E1434F-432E-4069-8B63-4E49DE989E6A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-286</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clinical Trials of America, Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9CA4A19D-1135-4AC5-99C0-F4A6B947A1F1</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-138</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xuzhou Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7D123638-C728-45AF-AB45-5CC867960351</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-219</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Alabama Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>8AF0C624-F2D1-4FCD-8EA7-800E9400BA24</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-160</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Suzhou Kowloon Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>86A6EB66-EBD9-41A9-94E8-E36317A55B16</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-364</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Turku University Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1A77E147-6BDE-40E1-B719-3022F369B08A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-113</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northampton General Hospital, Northampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>2401973B-A7C1-4EAA-92B0-A63B4828C884</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-32</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sykehuset Telemark, Skien</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B39EA11F-048E-4D04-8BE1-B5DDC75ED3B4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-246</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum K?ln-Merheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>C2ED5BAE-A82D-4EDE-A3AF-8C12EC9ABC23</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-178</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charles LeMoyne Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>609461A4-20F7-46F1-AA6A-1C11569F5F32</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-44</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Devon and Exeter Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>9827AC35-F3EA-4F2D-9E53-B4EE81FB7C5D</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-341</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Macclesfield District General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D8619DAC-0FD8-40CA-B4BA-ACAB40940B7A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-6</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hoglandssjukhuset Eksjo, Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>2FEF74E9-3798-4E3E-838A-5839D3A8B0D0</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-98</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Paul's Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>DFD307CD-3CEB-47E4-8697-B5B9F568B174</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-62</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum Saarlouis</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>75235C76-491A-4026-93BD-51793C6B6979</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-155</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gemeinschaftspraxis Langenhagen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>8C906DBE-EEE6-4C2D-B268-9C6BD4D88752</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-160</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Johannes Hospital Dortmund</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>D14AED33-D089-41A2-9EF4-BD704F186305</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-333</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. Boniface General Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F9577251-9FC3-4AD8-AF54-F630260563B4</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-59</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nordsj?llands Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>FA0320F5-CF23-4419-B9CF-2EEE577CE74A</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-119</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Herlev Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>9AE7E790-7601-4DDF-BA67-E283B935F01A</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-152</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liaoning Provincial People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>87BBA522-99E6-42A9-9E69-42FEED4DDB10</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-80</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Clinical and Experimental Medicine (IKEM)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>AC242702-3DCF-4638-A7C1-6174DB7EA534</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-91</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nepean Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B1F53CF3-CA93-43ED-A5A7-5EB26535F1D2</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-16</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Inner Mongolia Baogang Staff Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>FCCDE273-B651-467A-BE90-A78808759910</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-72</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charles University</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>58581DC8-02B1-40CC-A1BB-098159A7FFAC</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-88</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Norton Cardiovascular Associates</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>9AD624CB-1ACF-4738-A65A-CFBE8E9D16E6</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-184</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Klinikum der Universit?t Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>91448BE6-3024-48A9-95B1-F7CC6E3DBE22</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-348</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helse Forde HF</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>7114A349-76F6-4C95-BE5D-E59F926C2016</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-139</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mid-Ohio Heart Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>2FBA326E-DDC1-4ED8-ADD6-4990A1AE6923</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-234</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medi 3 ?lesund / MEDI3 Alesund</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>C8D3E22B-8439-4293-BC15-7537EB842D4E</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-104</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit?tsklinikum Schleswig-Holstein - Kiel</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>68FDF955-107E-49B8-95EB-D2064CE3B26B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-212</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oskarshamns Sjukhus</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>B8BD6040-67E1-495F-A2AE-A593E68E9942</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-85</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>VA Ann Arbor Healthcare System</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:department>Department of Development and Regeneration</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>1C9330A4-6384-4552-9AFF-B70F05F1B35E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-391</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Provincial Specialist Hospital No. 4</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2918CF98-B6DA-4AF5-B4F2-B864D6E3D688</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-260</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Raigmore Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>F832C520-5554-40EF-B8EF-0246E6086773</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-338</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shenyang Fourth People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>4CA3D932-EB87-4A11-9197-F9F74A08082E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-84</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Herning Regional Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>A5CDF8B3-D0BC-49E0-936C-17CB7C04E3DB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-116</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pottstown Medical Specialists</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>09B918D6-22B8-4C18-AA5B-B70766515C6B</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-216</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Whiston Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>0DDEA5B1-3D83-4665-8066-56FF187F5574</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-68</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Virginia Tech</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>1B815E2D-C6E0-4843-A66C-97AA8A78329C</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-205</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Haderslev Sygehus, Denmark</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>238AF89D-CC0C-4A10-944D-80E4897FE274</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-156</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SLK-Kliniken Heilbronn GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>28ED6787-151E-49D2-9322-7CB81CB634FB</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-325</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tianjin Third Central Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>E164195D-4FFE-4630-8E8F-F2860A9AF8B2</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-181</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peking University People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>DF8C4A4D-147D-4597-A279-3F1885ACE5C9</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-169</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Worthing Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): Effects of adding niacin to effective statin therapy</gtr:description><gtr:id>D31EF713-99CA-4C98-9579-DBFBDAA06EE0</gtr:id><gtr:impact>THRIVE was published in the New England Journal of Medicine in July 2014 (http://www.nejm.org/doi/full/10.1056/NEJMoa1300955) and clearly showed that niacin did not reduce heart attacks, strokes, or operations to unblock arteries and also had a number of side-effects.</gtr:impact><gtr:outcomeId>542532265e16e8.78474735-14</gtr:outcomeId><gtr:partnerContribution>Local collaborators screen, recruit and follow-up trial participants.</gtr:partnerContribution><gtr:piContribution>HPS2-THRIVE is co-ordinated and run by CTSU and randomised over 25,000 patients with a history of heart attack, stroke or a history of peripheral arterial disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queensland Government</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Princess Alexandra Hospital (Australia)</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>B8485131-B765-4744-B252-A281450D81E8</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-19</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dialysezentrum R?sselsheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2479C4D4-9125-4F96-9B00-EB151BB5134A</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-154</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiovascular Associates of the Delaware Valley (CADV)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>088C72B4-A942-4480-9F67-BCF2036E98A8</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-259</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ostersund Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>111D5A4C-74BE-4974-889B-D1B0CF917441</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-287</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Southampton NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Princess Anne Hospital</gtr:department><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>AD0F083E-1AC6-412E-9A59-4E7AC2692DF3</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-333</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>KfH Nierenzentrum Frankfurt/Oder</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>2C318FB1-7B6C-4F8F-ACE5-614F85672445</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-175</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Affiliated Hospital of Medical College Qingdao University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>70992B93-B48D-4D7D-B12C-54B24C188C76</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-405</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dorset County Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>451D2554-F9D6-4758-912F-D3D8E48EAA56</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-310</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Hospital in Kristianstad</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>3371494C-1726-437B-8A1C-83078CF42648</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-79</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Corusfit Oy</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>480D2B6E-3A1C-4DA2-BFF8-7E178E82D8DD</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-66</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Advanced Neurology Specialists</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>56B634AF-ACC2-4BE2-B8E7-EE5B42ED0235</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-246</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Melbourne Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>264E9D18-21B2-4D11-AF21-70F2BC5C593E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-25</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thunder Bay Regional Health Sciences Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>6FB22628-F9C7-49C1-960B-A8B40310085E</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-65</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Basildon and Thurrock University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SHARP (Study of Heart and Renal Protection): Effects of statin-based LDL-lowering therapy in patients with chronic renal disease</gtr:description><gtr:id>39C0E714-29DE-46A5-B579-B1B9FD5FD07B</gtr:id><gtr:impact>The SHARP study clearly demonstrated the benefits of cholesterol lowering in patient with chronic kidney disease. As a result of this, in 2011 the FDA a change in drug labelling for Vytorin (simvastatin and ezetimibe) to indicate that the SHARP study had provided compelling evidence of the benefits of cholesterol lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>542d2e134a3379.08201066-298</gtr:outcomeId><gtr:partnerContribution>Local participating hospitals recruited and assessed patients during follow-up.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the study which is the largest randomised trial in patients with chronic kidney disease. 9,438 patients were randomised from 380 centres in 18 countries.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shenyang Fourth People's Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Department of Cardiology</gtr:department><gtr:description>REVEAL (Randomised evaluation of the effects of anacetrapib through lipid modification): Effects of adding anacetrapib to statin therapy</gtr:description><gtr:id>BC25281E-15DA-4395-82DC-D72DF4A3410F</gtr:id><gtr:impact>Recruitment of 30,000 participants was completed in September 2013. The results of the trial should be available in the next few years.</gtr:impact><gtr:outcomeId>542298dae6e347.40010014-379</gtr:outcomeId><gtr:partnerContribution>Local participating centres recruit and follow-up patients.</gtr:partnerContribution><gtr:piContribution>CTSU co-ordinates the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient meeting for BEST-D</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EA305A3B-7445-4746-82B9-4E151009610D</gtr:id><gtr:impact>meeting for the Participants of BEST-D in 9 January 2015 in Banbury Town Hall</gtr:impact><gtr:outcomeId>56d6cd7c32d1d6.02397823</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plans for CTSU's REVEAL trial of anacetrapib: Press Release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7428A1E8-AC6B-4BDB-BE61-15B78912C85D</gtr:id><gtr:impact>Press release resulted in following media coverage:

Can new cholesterol drug conquer heart disease? USA Today, 18/11/10 http://www.usatoday.com/news/health/2010-11-17-miracle-cholesterol-drug_N.htm
Cholesterol Drug Advances: Wall Street Journal, 18/11/10
http://online.wsj.com/article/SB10001424052748704648604575620411889854200.html
Merck's New Cholesterol Drug Shows Promise: New York Times (blog), 18/11/10
http://prescriptions.blogs.nytimes.com/2010/11/17/mercks-new-cholesterol-drug-shows-promise/?src=mv
Merck Drug Could Eliminate The Stent Business: Forbes (blog), 18/11/10
http://blogs.forbes.com/robertlangreth/2010/11/17/merck-drug-could-eliminate-the-stent-business/?boxes=businesschannelsections
New drug promising against cholesterol: CNN (blog), 18/11/10
http://pagingdrgupta.blogs.cnn.com/2010/11/17/new-drug-promising-against-cholesterol/
New drug bumps up good cholesterol: Science News, 18/11/10
http://www.sciencenews.org/view/generic/id/65684/title/New_drug_bumps_up_good_cholesterol
Merck &amp;quot;good cholesterol&amp;quot; drug study wows doctors: Reuters, 18/11/10
http://www.reuters.com/article/idUSN1722720220101117
Merck cholesterol drug extremely effective in study: Forexyard, 18/11/10
http://www.forexyard.com/en/news/Merck-cholesterol-drug-extremely-effective-in-study-2010-11-17T140354Z
Major Oxford test to check heart attacks: Zee news (India), 18/11/10
http://www.zeenews.com/news668714.html



Increased public awareness of the value of large simple randomised trials.</gtr:impact><gtr:outcomeId>5433c6778874f2.00932935</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Results of THRIVE trial of niacin reported: Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E18E6B02-BDFC-4356-91DF-D65B945ECC7F</gtr:id><gtr:impact>Press release resulted in following media coverage:

Merck's Discontinued Heart Drug Tredaptive Raised Side Effects: Washington Post, 09/03/2013, via Bloomberg
&amp;quot;Merck's cholesterol drug Tredaptive, which was pulled from the market earlier this year, increased side effects such as bleeding and infections and did not help patients, according to results of a clinical trial by Oxford University. The study of 25,673 patients found Tredaptive failed to reduce the risk of stroke, death, heart attack or the need for surgery in people with vascular diseases. The drug combines the vitamin niacin, which studies suggest can help raise levels of good cholesterol, with the experimental medicine laropiprant, added to reduce a face-flushing effect of the vitamin. The results of the study, called HPS2-THRIVE, could change the use of niacin, which is often used to supplement cholesterol-lowering drugs, said the study's lead investigator. 'Niacin has been used for many years in the belief that it would help patients and prevent heart attack and stroke, but we know now that its adverse side effects outweigh the benefits when used with current treatments,' said Jane Armitage, the study's lead investigator and a professor of clinical trials and epidemiology at the University of Oxford.&amp;quot;
http://washpost.bloomberg.com/Story?docId=1376-MJCND807SXKX01-51VMLRMORHNF7EJ5MJ2JDM9905
Niacin doesn't help heart, may cause harm, study says USA Today, 09/03/2013
http://www.usatoday.com/story/news/nation/2013/03/09/niacin-heart-risk/1974385/
Serious side effects seen with failed Merck niacin drug: Chicago Tribune online, via Reuters, 10/03/2013
http://www.chicagotribune.com/health/sns-rt-us-heart-niacin-merckbre9280g6-20130309,0,7995322.story
Is This The End Of A Widely Used Heart Drug? Forbes (USA) 09/03/2013
http://www.forbes.com/sites/matthewherper/2013/03/09/is-this-the-end-of-a-widely-used-heart-drug/
Serious side effects seen with failed Merck niacin drug study Reuters, 09/03/2013 
http://www.reuters.com/article/2013/03/09/heart-niacin-merck-idUSL1N0C11TX20130309
Merck Heart Drug Tredaptive Raises Side Effects in Study Bloomberg, 09/03/2013
http://www.bloomberg.com/news/2013-03-09/merck-heart-drug-tredaptive-raises-side-effects-in-study.html
ACC: HPS2-THRIVE May Signal the End for Niacin: MedPage Today, 09/03/2013
http://www.medpagetoday.com/MeetingCoverage/ACC/37771
Merck Heart Drug Tredaptive Raises Side Effects in Study: Business Week, 09/03/2013
http://www.businessweek.com/news/2013-03-09/merck-heart-drug-tredaptive-raises-side-effects-in-study
Niacin Won't Help, May Harm Heart Patients: Study: US News and World Report, via HealthDay, 09/03/2013
http://health.usnews.com/health-news/news/articles/2013/03/09/niacin-wont-help-may-harm-heart-patients-study
Failed Merck Drug Reveals Dangers Of Niacin-Based Heart Drugs: RedOrbit (USA), via agencies, 10/03/2013
http://www.redorbit.com/news/health/1112800125/side-effects-health-dangers-failed-merck-drug-031013/
Niacin causes serious unexpected side-effects, but no worthwhile benefits, for at risk patients: The Pharma Letter, 11/03/2013
http://www.thepharmaletter.com/file/120586/niacin-causes-serious-unexpected-side-effects-but-no-worthwhile-benefits-for-at-risk-patients.html
HPS2-THRIVE: A 'Disappointing But Clear' Result: Forbes online, 09/03/2013
http://www.forbes.com/sites/larryhusten/2013/03/09/hps2-thrive-a-disappointing-but-clear-result/
Niacin therapy unhelpful, occasionally harmful: study: AFP, 10/03/2013
http://www.google.com/hostednews/afp/article/ALeqM5iUNxsOjOvCuzjvDqrq45BGDjziTQ?docId=CNG.3462200b35ff9a12806d21e61ef4dca6.2a1


To demonstrate that a commonly prescribed drug, niacin, causes more harm than benefit.</gtr:impact><gtr:outcomeId>5433c8707f8ef6.75462054</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Benefits of LDL-lowering therapy for renal patients: Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EE8FCD53-96EC-470C-8BE5-5B04C3F03947</gtr:id><gtr:impact>Press release resulted in following media coverage:

Study Suggests a Cholesterol Pill Benefits Patients With Kidney Disease: New York Times, blog, 20/11/2010
&amp;quot;Patients with chronic kidney disease who took Vytorin, a cholesterol-lowering pill, had one-sixth fewer heart attacks, strokes or operations to unblock their arteries than patients taking a placebo, according to the results of a new study presented on Saturday. The Sharp trial was coordinated by researchers at Oxford University and financed primarily by Merck.&amp;quot;
http://prescriptions.blogs.nytimes.com/2010/11/20/lowering-bad-cholesterol-reduced-heart-problems-in-kidney-patients-study-shows/?partner=rss&amp;amp;emc=rss
Merck Cholesterol Drug Is Found to Help Kidney Patients: Wall Street Journal, blog, 20/11/2010
http://online.wsj.com/article/SB10001424052748704496104575627002710652936.html
Finally, A Win For Vytorin: Forbes, 20/11/2010
http://blogs.forbes.com/matthewherper/2010/11/20/finally-a-win-for-vytorin/?boxes=businesschannelsections
Merck's Vytorin Safely Cuts Heart Risk in Kidney Patients: Bloomberg Business Week, 20/11/2010
http://www.businessweek.com/news/2010-11-20/merck-s-vytorin-safely-cuts-heart-risk-in-kidney-patients.html
Vytorin Protects Chronic Kidney Disease Patients From Major Vascular Events: Medical News Today, 20/11/2010
http://www.medicalnewstoday.com/articles/208841.php
ASN: Lipid Combo Cuts CV Risk in Kidney Disease: MedPageToday, 20/11/2010
http://www.medpagetoday.com/MeetingCoverage/ASN/23550 
SHARP: Ezetimibe/simvastatin combo cuts atherosclerotic and vascular events in kidney disease patients: TheHeart.org, 20/11/2010
Merck to Seek New Use for Vytorin: Wall Street Journal, p. 34, 22/11/10
http://online.wsj.com/article/SB10001424052748704496104575627002710652936.html
Vytorin lowers heart disease risk in large study of kidney patients: US News and World Report, 09/06/2011
http://health.usnews.com/health-news/family-health/heart/articles/2011/06/09/vytorin-lowers-heart-disease-risk-in-large-study-of-kidney-patients
SHARP published: Ezetimibe/simvastatin reduces risk of atherosclerotic events in CKD patients: TheHeart.Org, 09/06/2011
Lowering LDL Cuts Cardio Events in Renal Disease: MedPage Today, 09/06/2011
http://www.medpagetoday.com/Cardiology/Dyslipidemia/26958
Simvastatin Plus Ezetimibe Effective in Kidney Disease: Doctors Lounge, 09/06/11?
http://www.doctorslounge.com/index.php/news/pb/20784
Statins cut vascular events in kidney disease: GP Online, 16/06/2011
http://www.gponline.com/News/article/1075365/Statins-cut-vascular-events-kidney-disease/


Increased awareness amongst patients and doctors of the benefits of cholesterol lowering in renal patients.</gtr:impact><gtr:outcomeId>5433c549cedff5.04913151</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>99838000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (HPS3)</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>E4400237-9829-498B-8FD1-13486FAB790F</gtr:id><gtr:outcomeId>5432c685ccfff4.00167906</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>371000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>D5637442-071F-4FD4-8DA4-498AA9282DD8</gtr:id><gtr:outcomeId>5432c6d52039f2.90978722</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2003-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2762000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (BHF chair)</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>3EFDD009-F6F2-4CD2-A91D-F792AABF15C0</gtr:id><gtr:outcomeId>545792f37efd49.08036249</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>155000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ASCEND study of cognitive function</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>343448A2-F8E0-4D4E-9B9B-631640FF69AC</gtr:id><gtr:outcomeId>58be9f0c3afb88.89227840</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Excellence Award</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>05655DF1-A132-429F-A3AE-FE73E3787B2B</gtr:id><gtr:outcomeId>5432c788b72849.68792960</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>880220</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (HPS3 Adipose substudy)</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>6770C4C8-553F-44B0-A0D0-4B2AA1F4AB61</gtr:id><gtr:outcomeId>5433a61c6cddf6.19672621</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52772000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (HPS2)</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>C18B2F7D-3426-4EEE-AD7E-350B3EA6EA0F</gtr:id><gtr:outcomeId>5432c60635b669.44729006</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2005-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>39689000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (SHARP)</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>BDF434D0-68C1-4BEF-BE02-7FB9C8178694</gtr:id><gtr:outcomeId>5432c8678564b4.67199716</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2003-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22727000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (SEARCH)</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>535122AF-28F2-4F5C-97BE-147E6E8F85FA</gtr:id><gtr:outcomeId>5432c802459eb3.52924872</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2003-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3286000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (BHF chair)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>A9B3DA14-EB9C-4D74-99C9-F1E80E68A54A</gtr:id><gtr:outcomeId>545792a84e5916.40545857</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>61000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (STICS)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>17052B55-E80F-456C-BDFB-C6A34562B133</gtr:id><gtr:outcomeId>5432c8ccdce0c1.57906971</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US Food and Drug Administration (FDA) change to drug labelling for Vytorin (simvastain and ezetimibe)</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>2D77DA15-9CEF-4A93-BA66-1E2FE59D2CE6</gtr:id><gtr:impact>The results of the SHARP trial resulted in the FDA's Endocrinologic and Metabolic Drugs Advisory Committee approving a change in the drug label for Vytorin to state that there was compelling evidence on the benefit of cholesterol-lowering with the drug in patients with chronic kidney disease.</gtr:impact><gtr:outcomeId>54355d81de1af4.71072868</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.sharpinfo.org/FDA_approval_PR_2012-01-25.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>THRIVE</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EECEBB97-64C7-4B38-B5DE-11E6893EEB8B</gtr:id><gtr:impact>As a result of the results Merck stopped development of the Combined ER niaicn/laropiprant combination drug and the EMA licence for Tredaptive (the marketed name) was withdrawn.</gtr:impact><gtr:outcomeId>56d6d29cbdb8e4.95969126</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D115CA1B-C7EA-4F49-8A53-741500BFB60C</gtr:id><gtr:title>Reply</gtr:title><gtr:parentPublicationTitle>Journal of Vascular Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cceaead22bbd8edd3155d098af00ec8a"><gtr:id>cceaead22bbd8edd3155d098af00ec8a</gtr:id><gtr:otherNames>Bulbulia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>541ae16631a007.65415410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDE8851E-2210-4604-9846-EDC0A2C7CDF4</gtr:id><gtr:title>Pharmacogenomics of statin therapy: any new insights in efficacy or safety?</gtr:title><gtr:parentPublicationTitle>Current opinion in lipidology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/767d8feef3d4136b7e7ee00a2c6e9f3b"><gtr:id>767d8feef3d4136b7e7ee00a2c6e9f3b</gtr:id><gtr:otherNames>Hopewell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0957-9672</gtr:issn><gtr:outcomeId>5463772e58fea6.48716837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>128732B1-2049-4B8A-A78B-D6F72897B8EA</gtr:id><gtr:title>Clinical trials of lipid-modifying agents: design considerations</gtr:title><gtr:parentPublicationTitle>Clinical Lipidology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd8709e9b38dcf0cb16d5d26e22da903"><gtr:id>fd8709e9b38dcf0cb16d5d26e22da903</gtr:id><gtr:otherNames>Bowman L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>541ab545ad2ed2.50589489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46B4D777-51D2-4B0F-8E15-A37A9AD5CCF4</gtr:id><gtr:title>Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.</gtr:title><gtr:parentPublicationTitle>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffd871a732200a1c7d46c59e7a29035f"><gtr:id>ffd871a732200a1c7d46c59e7a29035f</gtr:id><gtr:otherNames>Hin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0937-941X</gtr:issn><gtr:outcomeId>58be972f3dcf29.38272112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0326F185-1ADD-4A2A-A552-88702C12C7EA</gtr:id><gtr:title>Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5aa1058133e6e1.25827123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>191B9197-3B0E-42E4-A990-00115DF92E4A</gtr:id><gtr:title>Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c28a8e3c01a5869f6ea0a4fb7405366d"><gtr:id>c28a8e3c01a5869f6ea0a4fb7405366d</gtr:id><gtr:otherNames>Lp-PLA(2) Studies Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>541c43c0075798.85239636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CAEB92A-3FCD-48C8-9530-A815B03CF22E</gtr:id><gtr:title>Epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases</gtr:title><gtr:parentPublicationTitle>Evidence-based Management of Lipid Disorders. (eds: Vissers M, Kastelein J, Stroes E)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40fbb7ffef7f4341670630851f0537ac"><gtr:id>40fbb7ffef7f4341670630851f0537ac</gtr:id><gtr:otherNames>Armitage, J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>5420029bc4e2d2.21625177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12E56A3D-E046-401E-B172-3AC9F8D10FF1</gtr:id><gtr:title>Evidence for the prevention and treatment of stroke in dialysis patients.</gtr:title><gtr:parentPublicationTitle>Seminars in dialysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0894-0959</gtr:issn><gtr:outcomeId>541af6eeecb4b8.13710945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3953EBE0-4BF9-4686-B8CC-A3E332616C00</gtr:id><gtr:title>No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6e09464ef9ac4d7ccb0d5a34f50d506"><gtr:id>b6e09464ef9ac4d7ccb0d5a34f50d506</gtr:id><gtr:otherNames>Hopewell, J.C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>541adc45d034a8.85310224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D722D2D1-4842-4917-9B6B-66B6F9E47426</gtr:id><gtr:title>Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01a50d6dd425eaa7a6e921ca2fc8a17d"><gtr:id>01a50d6dd425eaa7a6e921ca2fc8a17d</gtr:id><gtr:otherNames>Cholesterol Treatment Trialists' (CTT) Collaborators</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>8472F99027A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91826BB3-4ADD-4D7B-8443-C691FCCA5E97</gtr:id><gtr:title>Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.</gtr:title><gtr:parentPublicationTitle>BMC clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97cc0ac1639d248d300d2f78a3356540"><gtr:id>97cc0ac1639d248d300d2f78a3356540</gtr:id><gtr:otherNames>MRC/BHF Heart Protection Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1472-6904</gtr:issn><gtr:outcomeId>541ab546b25d31.80997185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBE2A8F7-8CAB-4DBA-8DA8-8F994CB5DE8F</gtr:id><gtr:title>The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb63708d9a2c1110053edcafe51ed637"><gtr:id>bb63708d9a2c1110053edcafe51ed637</gtr:id><gtr:otherNames>Hopewell, J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>541c3c899127e3.72829014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>808CC82B-C2FB-4DE3-887F-4137BC40AE86</gtr:id><gtr:title>Commentary: Controversies in NICE guidance on chronic kidney disease.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0580ad7d95d71801683291bd0ac115fc"><gtr:id>0580ad7d95d71801683291bd0ac115fc</gtr:id><gtr:otherNames>Landray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>541af6f2c6f957.81297417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>422A625B-A20D-4010-AE53-B08BA7964A37</gtr:id><gtr:title>Impact of CKD on Household Income</gtr:title><gtr:parentPublicationTitle>Kidney International Reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262d13d32625db31cd4441acd223ed"><gtr:id>78262d13d32625db31cd4441acd223ed</gtr:id><gtr:otherNames>Morton R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa0046e405cb4.65008631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7740F02-AFCF-4631-8F90-A54D7D100EBE</gtr:id><gtr:title>Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e076c6ecf685f11a5d56959e53d3dce0"><gtr:id>e076c6ecf685f11a5d56959e53d3dce0</gtr:id><gtr:otherNames>Armitage J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>542975dea280a2.29379127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38346A82-4892-42F4-92C4-E3EEA8A50314</gtr:id><gtr:title>Monday, 27 August 2012</gtr:title><gtr:parentPublicationTitle>European Heart Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85ddc66d43b0f119a5c4c70821a3b025"><gtr:id>85ddc66d43b0f119a5c4c70821a3b025</gtr:id><gtr:otherNames>Mendes-Ferreira P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>541ab545e1cbc9.08174911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7D2F5DE-4E7E-4B59-BC27-137AE2C37474</gtr:id><gtr:title>Misrepresentation of statin safety evidence</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e076c6ecf685f11a5d56959e53d3dce0"><gtr:id>e076c6ecf685f11a5d56959e53d3dce0</gtr:id><gtr:otherNames>Armitage J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5463772e812494.99056531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46901264-E98A-481E-83E8-33BAC91BECD3</gtr:id><gtr:title>Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5a31e57a07e968.21406493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB537975-2B33-40C5-B527-E8DA6241F0FB</gtr:id><gtr:title>Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>56d962477970a9.20636585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC5C07F9-CFD9-4B66-95F1-FE0C9697F2B6</gtr:id><gtr:title>Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b6ca17d90ff352dcb91babbfaf0a272"><gtr:id>5b6ca17d90ff352dcb91babbfaf0a272</gtr:id><gtr:otherNames>Lewington Sarah</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5a360db14f2e02.49627595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D2C6EE7-0D2B-4D45-9CCE-B5123B559371</gtr:id><gtr:title>European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed258c775de102ad8ed3e251f8b12372"><gtr:id>ed258c775de102ad8ed3e251f8b12372</gtr:id><gtr:otherNames>Perk J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>541aad75b2cd33.12884708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97BD451C-ADEA-4B49-8E29-312CA9814616</gtr:id><gtr:title>Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45e1f44a10cacab8ee373d2181cc2ec7"><gtr:id>45e1f44a10cacab8ee373d2181cc2ec7</gtr:id><gtr:otherNames>Preiss D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-5061</gtr:issn><gtr:outcomeId>5aa00b1312d253.35696072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>984B306D-47D7-4619-9DB2-B86230881FAC</gtr:id><gtr:title>The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.</gtr:title><gtr:parentPublicationTitle>European journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00954130f581451305ebfe461866731f"><gtr:id>00954130f581451305ebfe461866731f</gtr:id><gtr:otherNames>Emerging Risk Factors Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0393-2990</gtr:issn><gtr:outcomeId>pm_13220_10_17876711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB14422C-737F-418B-ACF1-8E4D1AB950B8</gtr:id><gtr:title>Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.</gtr:title><gtr:parentPublicationTitle>Journal of vascular surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d10eeceafe5f86ffbf5d039c9d3335"><gtr:id>14d10eeceafe5f86ffbf5d039c9d3335</gtr:id><gtr:otherNames>Heart Protection Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0741-5214</gtr:issn><gtr:outcomeId>D452626FC88</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CD6539E-2462-4621-B9CE-43D1B1C0E440</gtr:id><gtr:title>A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c58f3c16b86942790305de6c065d992c"><gtr:id>c58f3c16b86942790305de6c065d992c</gtr:id><gtr:otherNames>Mangravite LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>541ab549dba884.33678957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60D8FB8D-899E-4879-81AF-CE7335DFC52C</gtr:id><gtr:title>Major lipids, apolipoproteins, and risk of vascular disease.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00954130f581451305ebfe461866731f"><gtr:id>00954130f581451305ebfe461866731f</gtr:id><gtr:otherNames>Emerging Risk Factors Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>541c43c0a0b4b9.04514721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B844AF2F-3F69-4530-9AD7-99D9BF7984CD</gtr:id><gtr:title>The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>541aad7b3f09c4.13356941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53F41B10-5DAB-47A1-9B0F-E07CDDF9F0FE</gtr:id><gtr:title>Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/767d8feef3d4136b7e7ee00a2c6e9f3b"><gtr:id>767d8feef3d4136b7e7ee00a2c6e9f3b</gtr:id><gtr:otherNames>Hopewell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>541ab54982a4c3.35937516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C826E733-7FD7-4C12-ACBC-EB37C1C88895</gtr:id><gtr:title>Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.</gtr:title><gtr:parentPublicationTitle>American heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8111a639e9193a93340108963069348f"><gtr:id>8111a639e9193a93340108963069348f</gtr:id><gtr:otherNames>SEARCH Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-8703</gtr:issn><gtr:outcomeId>128A9D29222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79D76CA8-02C2-4A95-915F-0D84DD7E8822</gtr:id><gtr:title>Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4660e6a1d6c7ec927ecc2f6e64bb30"><gtr:id>7c4660e6a1d6c7ec927ecc2f6e64bb30</gtr:id><gtr:otherNames>Mafham MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5aa106822f3650.73229888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DFD4B73-2ABE-4814-96E3-6435DBE974F9</gtr:id><gtr:title>Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de0c7acc1b1b788058c085cccf18b134"><gtr:id>de0c7acc1b1b788058c085cccf18b134</gtr:id><gtr:otherNames>Cholesterol Treatment Trialists' (CTT) Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>jweh3Xv6f7z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B12A28D-1B0C-4480-877F-82843A0BF30A</gtr:id><gtr:title>Effects of lowering LDL cholesterol on progression of kidney disease.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32210b6eab29b7812cf339823efba2fd"><gtr:id>32210b6eab29b7812cf339823efba2fd</gtr:id><gtr:otherNames>Haynes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>541aad7b738a44.65992585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A125831-2416-4553-9119-F7D1C1CF5209</gtr:id><gtr:title>[A cross-sectional study on the use of statin among patients with atherosclerotic ischemic stroke in China].</gtr:title><gtr:parentPublicationTitle>Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f75ab2df71120fc67f1ba08556c46a5"><gtr:id>6f75ab2df71120fc67f1ba08556c46a5</gtr:id><gtr:otherNames>Jiang LX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0254-6450</gtr:issn><gtr:outcomeId>541ab5c404c035.52270801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FF16047-4026-4C55-86CC-FAC686D51D95</gtr:id><gtr:title>Effects of Folic Acid Plus Vitamin B
 
 vs Placebo in Myocardial Infarction Survivors-Reply</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e076c6ecf685f11a5d56959e53d3dce0"><gtr:id>e076c6ecf685f11a5d56959e53d3dce0</gtr:id><gtr:otherNames>Armitage J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>541ab54abd5be1.91428340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10BEBEC7-1BBB-46E6-8CD3-6811D4EB2F49</gtr:id><gtr:title>Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d10eeceafe5f86ffbf5d039c9d3335"><gtr:id>14d10eeceafe5f86ffbf5d039c9d3335</gtr:id><gtr:otherNames>Heart Protection Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>541ae031144d32.24962173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00AD229A-E29B-4DDB-9AF7-99A10A11BA9A</gtr:id><gtr:title>Does the benefit from statin therapy extend beyond 5 years?</gtr:title><gtr:parentPublicationTitle>Current atherosclerosis reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cceaead22bbd8edd3155d098af00ec8a"><gtr:id>cceaead22bbd8edd3155d098af00ec8a</gtr:id><gtr:otherNames>Bulbulia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-3804</gtr:issn><gtr:outcomeId>541ab54a930c26.62122429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33D4118E-15F5-435A-A6BD-71A237900AFA</gtr:id><gtr:title>Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86e157b6ca8625708f298dea213390e3"><gtr:id>86e157b6ca8625708f298dea213390e3</gtr:id><gtr:otherNames>Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>541aad77a79c49.46206515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6AB7EB5-A2DD-4850-BAD0-EC7F4D7947F8</gtr:id><gtr:title>Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78bf4acd842867687b701ca1c29e8cd9"><gtr:id>78bf4acd842867687b701ca1c29e8cd9</gtr:id><gtr:otherNames>Staplin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5aa10631547db3.11812158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4966D61A-B0C4-42FE-94E4-841E8925C3E1</gtr:id><gtr:title>Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab7e6264c4efdca8fda553bdf0e56088"><gtr:id>ab7e6264c4efdca8fda553bdf0e56088</gtr:id><gtr:otherNames>Prospective Studies Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_13220_10_18061058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96BD0EC0-8FED-4EC3-9FDD-7B49B14B81A4</gtr:id><gtr:title>Safety and efficacy of statins &amp;acirc;?? Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5079851905ee4c5f671c1e3e5a037c87"><gtr:id>5079851905ee4c5f671c1e3e5a037c87</gtr:id><gtr:otherNames>Collins R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a816a90d8bca8.16249560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F70D723-0DD5-4D85-8799-1B163332FDB4</gtr:id><gtr:title>Analyses of cancer data from three ezetimibe trials.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a00cf5073cfab5fca7f7dbf9c89219a"><gtr:id>9a00cf5073cfab5fca7f7dbf9c89219a</gtr:id><gtr:otherNames>Peto R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>541aad766a0b88.25694590</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65F47ADF-D1FF-4A4F-9743-41AA739B5BBB</gtr:id><gtr:title>Should We Increase GFR with Bardoxolone in Alport Syndrome?</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5aa004df3df8a2.80867913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74F965E9-8A57-4FAA-BA24-E9713182B4C6</gtr:id><gtr:title>Safety of long-term simvastatin discontinuation - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cceaead22bbd8edd3155d098af00ec8a"><gtr:id>cceaead22bbd8edd3155d098af00ec8a</gtr:id><gtr:otherNames>Bulbulia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>541ab54659b495.73377942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6924A0CF-5C1E-4722-BDD0-6741177E1D89</gtr:id><gtr:title>Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/767d8feef3d4136b7e7ee00a2c6e9f3b"><gtr:id>767d8feef3d4136b7e7ee00a2c6e9f3b</gtr:id><gtr:otherNames>Hopewell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1942-3268</gtr:issn><gtr:outcomeId>541ab548643990.24016281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C474D46-DE79-4C6A-B884-3A864B9EBB70</gtr:id><gtr:title>The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3462b794be7390e5ce0a4c570bc9b54"><gtr:id>e3462b794be7390e5ce0a4c570bc9b54</gtr:id><gtr:otherNames>Sever PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>541c43c268aa97.69227339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8213376E-93D5-4E93-A1C2-B35BD1DD2393</gtr:id><gtr:title>Benefits of lowering cholesterol in chronic kidney disease - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>541aad7acea7a3.53307947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF9279F2-0372-4EB9-8E07-C554F81B9E61</gtr:id><gtr:title>Analyses of cancer data from three ezetimibe trials.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d2169f7ff3704c2936655a4e882ff18"><gtr:id>1d2169f7ff3704c2936655a4e882ff18</gtr:id><gtr:otherNames>Nissen SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>541c07954a8cc5.26805612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18CF6416-4C96-4AFE-B3D5-7234C4C36D36</gtr:id><gtr:title>Niacin for reduction of cardiovascular risk.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0580ad7d95d71801683291bd0ac115fc"><gtr:id>0580ad7d95d71801683291bd0ac115fc</gtr:id><gtr:otherNames>Landray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56d9624706ed47.38462582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03A35C64-FEA5-4800-B3AF-8722430D4560</gtr:id><gtr:title>[Current statin use for patients with atherosclerotic cardiovascular disease in 39 large Chinese hospitals].</gtr:title><gtr:parentPublicationTitle>Zhonghua xin xue guan bing za zhi</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/832216c3df80b3e815bce6a592c6f125"><gtr:id>832216c3df80b3e815bce6a592c6f125</gtr:id><gtr:otherNames>Zhang D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0253-3758</gtr:issn><gtr:outcomeId>541ab5c33adec5.76222135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED641968-2F80-424F-9BC2-891C0B5C84C5</gtr:id><gtr:title>Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5aa0137e5d8df7.15848634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C337F319-2F9A-4217-B76D-29086E29022E</gtr:id><gtr:title>Cross-sectional study of statin use among high-risk patients with coronary heart disease in China</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46d7fcaf57546a6311fce404a0457704"><gtr:id>46d7fcaf57546a6311fce404a0457704</gtr:id><gtr:otherNames>Li, J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>541adb99045316.54969261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CFF8A64-715F-4CE6-A0E6-B7A91E1B5F19</gtr:id><gtr:title>LDL cholesterol targets--how low to go?</gtr:title><gtr:parentPublicationTitle>Current opinion in lipidology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cceaead22bbd8edd3155d098af00ec8a"><gtr:id>cceaead22bbd8edd3155d098af00ec8a</gtr:id><gtr:otherNames>Bulbulia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0957-9672</gtr:issn><gtr:outcomeId>541ab548edef93.99330884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC17C68D-85C6-4B4D-BB9D-C4634C6EB311</gtr:id><gtr:title>Cognitive aging and the incidence of cardiovascular events and diabetes: a meta-analysis of the HPS, SEARCH and HPS2-THRIVE studies</gtr:title><gtr:parentPublicationTitle>EUROPEAN HEART JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389fb502641ffd73fbd1b1a8273758b8"><gtr:id>389fb502641ffd73fbd1b1a8273758b8</gtr:id><gtr:otherNames>Parish S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>56d963d5703980.03498522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>838056A5-3570-46D9-9785-924912BBCE50</gtr:id><gtr:title>Management of residual risk after statin therapy.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8150647508a1e4ee538bcba81440d914"><gtr:id>8150647508a1e4ee538bcba81440d914</gtr:id><gtr:otherNames>Reith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>56d962475575e3.86725374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E5E6F30-4074-4546-8396-FA0EBCEF6BF2</gtr:id><gtr:title>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d10eeceafe5f86ffbf5d039c9d3335"><gtr:id>14d10eeceafe5f86ffbf5d039c9d3335</gtr:id><gtr:otherNames>Heart Protection Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_13220_10_12114036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A0AEF2C-BA81-4767-AAB2-C941AE4FCD39</gtr:id><gtr:title>Therapeutic Strategies in Lipid Disorders</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40fbb7ffef7f4341670630851f0537ac"><gtr:id>40fbb7ffef7f4341670630851f0537ac</gtr:id><gtr:otherNames>Armitage, J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:isbn>978 1 84692 034 9</gtr:isbn><gtr:outcomeId>541add8e7ef131.28891152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C718F56-5E3E-4328-B44A-F3BDFB4FCFD2</gtr:id><gtr:title>N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d10eeceafe5f86ffbf5d039c9d3335"><gtr:id>14d10eeceafe5f86ffbf5d039c9d3335</gtr:id><gtr:otherNames>Heart Protection Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>89025DBF7D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30F769A1-4183-4730-AD39-B9CF8EEDD191</gtr:id><gtr:title>Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3095e5f245a9b4155f07a1154b0c7ea"><gtr:id>f3095e5f245a9b4155f07a1154b0c7ea</gtr:id><gtr:otherNames>Patrono C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>5aa00b68dd4ba6.16068490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>815F9576-878E-451D-AAD4-BBCB5A373E4C</gtr:id><gtr:title>Revascularization versus medical therapy for renal-artery stenosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74794858bdafe130aa0196b2d8155fb1"><gtr:id>74794858bdafe130aa0196b2d8155fb1</gtr:id><gtr:otherNames>ASTRAL Investigators</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>egmbHtQt8dC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6063D21A-83DA-45ED-A407-8A2C7A9F2053</gtr:id><gtr:title>ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes</gtr:title><gtr:parentPublicationTitle>American Heart Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd8709e9b38dcf0cb16d5d26e22da903"><gtr:id>fd8709e9b38dcf0cb16d5d26e22da903</gtr:id><gtr:otherNames>Bowman L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a816a9145f1a7.39291657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B01B7568-560A-4896-935B-2E2779C46B03</gtr:id><gtr:title>Greater absolute reductions in LDL cholesterol should yield greater proportional reductions in risk of cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd3c262c9ed0c7ba14ef8ac1308be4a0"><gtr:id>cd3c262c9ed0c7ba14ef8ac1308be4a0</gtr:id><gtr:otherNames>Clarke R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn><gtr:outcomeId>541ab544148692.57549491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56AD8340-FB21-4F5B-AB30-D953EE0F7056</gtr:id><gtr:title>Statin cost-effectiveness in the United States for people at different vascular risk levels.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular quality and outcomes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d10eeceafe5f86ffbf5d039c9d3335"><gtr:id>14d10eeceafe5f86ffbf5d039c9d3335</gtr:id><gtr:otherNames>Heart Protection Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1941-7713</gtr:issn><gtr:outcomeId>541ab546867e27.22447315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5673A73-5E31-469F-B9B3-6C2D03ABE37F</gtr:id><gtr:title>No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/767d8feef3d4136b7e7ee00a2c6e9f3b"><gtr:id>767d8feef3d4136b7e7ee00a2c6e9f3b</gtr:id><gtr:otherNames>Hopewell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>541ab54a68f848.48335936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35F90E06-74B6-4263-8334-FF0A9EC8C4EA</gtr:id><gtr:title>SLCO1B1 variants and statin-induced myopathy--a genomewide study.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9897a594c28de07e7b593b548156475"><gtr:id>d9897a594c28de07e7b593b548156475</gtr:id><gtr:otherNames>SEARCH Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>541ab543d73121.53400495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67B1D27B-AEA5-4BC3-8A9A-A409BF1F4C61</gtr:id><gtr:title>Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial.</gtr:title><gtr:parentPublicationTitle>Maturitas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd3c262c9ed0c7ba14ef8ac1308be4a0"><gtr:id>cd3c262c9ed0c7ba14ef8ac1308be4a0</gtr:id><gtr:otherNames>Clarke R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0378-5122</gtr:issn><gtr:outcomeId>56d962473a2d75.98623961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6480282A-BB13-418B-A59D-A960F2CE26B5</gtr:id><gtr:title>Low use of statins among high-risk patients in China</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8319130e6ee0eb7171b9ae57ce193485"><gtr:id>8319130e6ee0eb7171b9ae57ce193485</gtr:id><gtr:otherNames>Jiang, L.X.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>541af9e9894086.43584973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37A4E9B3-FFC1-4140-BAA5-F84475170A63</gtr:id><gtr:title>HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936b68efa866101ffd6e3c7ca8d1a1a8"><gtr:id>936b68efa866101ffd6e3c7ca8d1a1a8</gtr:id><gtr:otherNames>HPS2-THRIVE Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>541ab54927ad66.98017238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92169930-B253-45F0-B690-C5CF3267AE14</gtr:id><gtr:title>TRIAL OF ATORVASTATIN FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH RA (TRACE RA): A RANDOMIZED TRIAL IN 2986 RA PATIENTS</gtr:title><gtr:parentPublicationTitle>RHEUMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72311aa60e72ab4a2300f59a13967ae3"><gtr:id>72311aa60e72ab4a2300f59a13967ae3</gtr:id><gtr:otherNames>Kitas George D.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>56d963d5917013.13540422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDCAE69F-E366-45A9-BA77-004B17EECFBC</gtr:id><gtr:title>Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d37509308a441b1702c956ab80fc6506"><gtr:id>d37509308a441b1702c956ab80fc6506</gtr:id><gtr:otherNames>Rocca B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>5aa00276e20784.73888399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA156A35-A9D7-4636-95F8-AC0EB4361EE9</gtr:id><gtr:title>Underuse of statins in patients with atherosclerotic ischemic stroke in China.</gtr:title><gtr:parentPublicationTitle>Chinese medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93f8556619f3487d06c35513ec7d86fb"><gtr:id>93f8556619f3487d06c35513ec7d86fb</gtr:id><gtr:otherNames>Li X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0366-6999</gtr:issn><gtr:outcomeId>541ab5c39e1290.17820555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FE6B434-A1F1-49B6-81FC-01B8D2D039A0</gtr:id><gtr:title>Low-density lipoprotein cholesterol as a therapeutic target</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40fbb7ffef7f4341670630851f0537ac"><gtr:id>40fbb7ffef7f4341670630851f0537ac</gtr:id><gtr:otherNames>Armitage, J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>541added22f367.77917704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD6D116A-3FFA-4032-B526-62D4FCB490BD</gtr:id><gtr:title>C-reactive protein in the Heart Protection Study - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d92ef546ea273952a7cfddeb17749e"><gtr:id>27d92ef546ea273952a7cfddeb17749e</gtr:id><gtr:otherNames>Emberson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>541ab54a39b8b0.32905300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F712DD8B-505B-4EB7-A86A-7674BC6E80CD</gtr:id><gtr:title>C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d10eeceafe5f86ffbf5d039c9d3335"><gtr:id>14d10eeceafe5f86ffbf5d039c9d3335</gtr:id><gtr:otherNames>Heart Protection Study Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>541ab543aa9897.55594507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DC5959F-F5DE-4533-90D6-1F66CA02A1A0</gtr:id><gtr:title>Lack of adverse effect of statin therapy on common muscle-related adverse events.</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5079851905ee4c5f671c1e3e5a037c87"><gtr:id>5079851905ee4c5f671c1e3e5a037c87</gtr:id><gtr:otherNames>Collins R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn><gtr:outcomeId>541c43bc13c693.32052979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10D932BC-2EE5-4C56-9811-089190AB621A</gtr:id><gtr:title>Survey of statin usage in 4429 diabetic patients with atherosclerostic cardiovascular disease in China</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8319130e6ee0eb7171b9ae57ce193485"><gtr:id>8319130e6ee0eb7171b9ae57ce193485</gtr:id><gtr:otherNames>Jiang, L.X.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>541af9b70a4d05.97775793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>725C33AD-5EE4-4DFF-8D7F-E0E6F8670B1B</gtr:id><gtr:title>Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ef8974a3ea34f36f0caa0ff4080c8da"><gtr:id>8ef8974a3ea34f36f0caa0ff4080c8da</gtr:id><gtr:otherNames>Kearney P. M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5a36018ea71934.60244971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D2422A3-319D-493E-B877-5587585A71E2</gtr:id><gtr:title>Effect sizes for cardiovascular disease and diabetes outcomes of metabolic risk factors for population-based comparative risk assessment</gtr:title><gtr:parentPublicationTitle>PLos One</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/562501adfd5db195cdc42a87c58d5d03"><gtr:id>562501adfd5db195cdc42a87c58d5d03</gtr:id><gtr:otherNames>Singh, G.M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5420024555a369.51555413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D839E2F8-74BC-40DF-B480-09892C3C2928</gtr:id><gtr:title>Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32210b6eab29b7812cf339823efba2fd"><gtr:id>32210b6eab29b7812cf339823efba2fd</gtr:id><gtr:otherNames>Haynes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>541aaa6a50c254.64326210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9A51F2B-DFC8-47EF-9B86-DCEADBD33482</gtr:id><gtr:title>Lack of effect of higher dose vitamin D supplements on systolic blood pressure and arterial stiffness measure in older people after 12 months of treatment. Results of BEST-D trial</gtr:title><gtr:parentPublicationTitle>EUROPEAN HEART JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31034cea818bae0ed1c2c24c72240d90"><gtr:id>31034cea818bae0ed1c2c24c72240d90</gtr:id><gtr:otherNames>Tomson J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>56d963d536a3c3.88638557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3590CAD-E036-45AF-97DF-6D62895C11FE</gtr:id><gtr:title>Lessons from the controversy over statins - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e076c6ecf685f11a5d56959e53d3dce0"><gtr:id>e076c6ecf685f11a5d56959e53d3dce0</gtr:id><gtr:otherNames>Armitage J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be972ef40ec2.47655458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E15DE9C0-10EA-49D6-B112-D3544C5E0E30</gtr:id><gtr:title>Brenner and Rector's The Kidney</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41805038389027f0c6b95cb76e5ccd1"><gtr:id>a41805038389027f0c6b95cb76e5ccd1</gtr:id><gtr:otherNames>Wheeler D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>9781416061939</gtr:isbn><gtr:outcomeId>541aaf707a79c5.51558766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A7756F6-452A-4E8B-ABF5-05A874752902</gtr:id><gtr:title>Lipids in chronic kidney disease.</gtr:title><gtr:parentPublicationTitle>Journal of renal care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4cd2d1e64a2ab062b297b332b09cae"><gtr:id>3f4cd2d1e64a2ab062b297b332b09cae</gtr:id><gtr:otherNames>Lewis D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1755-6678</gtr:issn><gtr:outcomeId>541af6f1ee91a6.11356099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3B8ADDE-86A4-472A-BDE4-8A41E8FD48AC</gtr:id><gtr:title>Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.</gtr:title><gtr:parentPublicationTitle>American journal of kidney diseases : the official journal of the National Kidney Foundation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0580ad7d95d71801683291bd0ac115fc"><gtr:id>0580ad7d95d71801683291bd0ac115fc</gtr:id><gtr:otherNames>Landray MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0272-6386</gtr:issn><gtr:outcomeId>541aad76cbff05.08056491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0544988-22FF-4600-A568-8EF7BCBC955E</gtr:id><gtr:title>The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>541aad7b0e1c45.38025791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BA478C3-9D7D-45B3-9822-63027A4BA27E</gtr:id><gtr:title>Effects of extended-release niacin with laropiprant in high-risk patients.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936b68efa866101ffd6e3c7ca8d1a1a8"><gtr:id>936b68efa866101ffd6e3c7ca8d1a1a8</gtr:id><gtr:otherNames>HPS2-THRIVE Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>541af6ef312b69.89160611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF63D444-579F-432A-93BE-34783B2E13B6</gtr:id><gtr:title>Serum free light chains and the risk of ESRD and death in CKD.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32210b6eab29b7812cf339823efba2fd"><gtr:id>32210b6eab29b7812cf339823efba2fd</gtr:id><gtr:otherNames>Haynes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>541af6f0e3ea23.66859100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C402EB24-0131-4D7D-BAAE-96B996038009</gtr:id><gtr:title>Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.</gtr:title><gtr:parentPublicationTitle>American heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1caeebec8d88248464e3e018048c8351"><gtr:id>1caeebec8d88248464e3e018048c8351</gtr:id><gtr:otherNames>Sharp Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-8703</gtr:issn><gtr:outcomeId>541aad798986b0.04114022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989B174A-912E-4C2C-9594-76BD463FDA79</gtr:id><gtr:title>Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8364111fa2552ba0254a8837987f5e2"><gtr:id>f8364111fa2552ba0254a8837987f5e2</gtr:id><gtr:otherNames>Parish S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>541ab5483dbb85.16794358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A39E15C2-7054-40E0-80E6-98FF8FDFFC85</gtr:id><gtr:title>Phenotype standardization for statin-induced myotoxicity.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>541ab54a10bb08.04477979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D3333D6-7C90-4034-8BF7-BB3D0292A3C4</gtr:id><gtr:title>Interpretation of the evidence for the efficacy and safety of statin therapy.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5079851905ee4c5f671c1e3e5a037c87"><gtr:id>5079851905ee4c5f671c1e3e5a037c87</gtr:id><gtr:otherNames>Collins R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58be970560e943.11937642</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137686853</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>